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ATR	 Ataxia	telangiectasia	RAD	3	related	
AURKA		 Aurora	Kinase	A	
BAX	 BCL2	associated	protein	
BCL2							 B	cell	/	lymphoma	2	
BER	 Base	excision	repair	
BN										 Boolean	network		
BRAC1			 Breast	cancer	1	
CNA	 CellNetAnalyzer	
CBP	 CREBB	binding	protein		
CDK4	 Cyclin	dependent	kinase	2	
CDKI	 Cyclin	dependant	kinase	inhibitors	
CDKNA1					 p21	
cDNA	 Complementary	DNA	
CHEK	 Checkpoint	kinase	
CRD	 C-terminal	regulatory	domain	
DBD	 DNA	binding	domain	
DMSO				 Dimethyl	Sulfoxide	
DNA	 Deoxyribonucleic	acid	
DNA-PK		 DNA	protein	kinase	
dsDNA	 Double	stranded	DNA	
DUB	 De	ubiquitination	enzymes	
DYRK	 Dual	specificity	tyrosine-phosphorylation-regulated	kinase	
E2F									 E2F	transcription	factor	
EGF	 Epithelial	growth	factor	
ERRB2	 V-erb-b2	erythoblastic	leukaemia	viral	oncogene	homolog	2		
FAS	 Fas	(TNF	receptor	superfamily,	member	8)	
FGF2	 Fibroblast	growth	factor	2	
G1											 Gap	1	
G2											 Gap	2	
GADD45																								Growth	arrest	and	DNA	damage	inducible,	alpha	
HAUSP	 Herpes	virus	associated	USP	
HDM2	 Human	Double	Minute	2	
HIFI	 Hypoxia	inducible	transcription	factor	
IGF1				 Insulin	like	growth	factor	
IL-8									 Interleukin	8	
JNK	 c-Jun	N-terminal	kinases	
KD	 Knockdown	
KO	 Knockout	
Lys	 Lysine	
M	phase		 Mitosis	
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MAP							 Microtubule	associated	protein	
MAPK	 Mitogen	activated	kinase	
MDM2	 Murine	Double	Minute	2	
MDMX	 Murine	Double	Minute	X	(4)	
MMR	 Mismatch	repair	
mRNA	 Messenger	RNA	
MYC																											V-myc-	myleocytomatosis	viral	oncogene	homolog	
NCBI																											National	center	for	biotechnology	information	
NF/KB	 Nuclear	factor	kappa	light		
NHEJ	 Non	homologous	end	joining	
ODE	 Ordinary	differential	equations	
Otub1	 Otubaine	1	
P300	 Protein	300	
p53									 Tumor	protein	p53	
PCNA	 Proliferating	Cell	Nuclear	Antigen	
PIKKs	 phosphatidylinositol	3-kinase	related	kinases		
Pirh2	 Periperin2	
PKT206	 p53	interactome	Kun	Tian	206	Nodes	
PMH260	 p53	interactome	Michelle	Hussain	260	Nodes	
PRD	 Proline	rich	domain	
PNPs	 Potential	novel	predictions	
PTGS2			 Prostaglandin	endoperoxide	synthase	
PTM	 Post	translational	modifications	
PTTG1			 Pituitary	tumor	transforming	1	
q	RT	PCR	 Quantitative	real	time	PCR	
RB	 Retinoblastoma	protein		
ROS	 Reactive	oxygen	species	
S	phase	 DNA	synthesis	
SaOS2	 Human	osteosarcoma	cell	line	p53	null		
SDS	page	 SDS	-	poly	acrylamide	gel	electrophoresis		
Ser	 Serine	
ssDNA	 Single	stranded	DNA	
STRING	 Search	Tool	for	the	Retrieval	of	Interacting	Proteins		
TAD	 Transactivation	domain	
TD	 Tetramerisation	domain	
TF	 Transcription	factor	
TGFB1	 Transforming	growth	factor	beta	1	
Thr	 Threonine	
TopB1	 Topoisomerase	binding	protein		
TP53	 Human	p53	gene	
TSG	 Tumor	supressor	gene	
U20S		 Human	osteosarcoma	cell	line	p53	wildtype	
USP	 Ubiquitin	specific	proteins	
UV	 Ultraviolet	radiation		
WT	 Wildtype	
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3	Abstract		
Cancer	is	a	heterogeneous	pathology	of	cell	and	tissue	type,	involving	multi-
dysregulation	of	pathways	that	govern	fundamental	cellular	processes.	Chemotherapy	
efficacy	is	highly	affected	by	these	molecular	deviations	and	the	majority	of	patients	
are	non-responsive.	The	stress	responsive	transcription	factor,	p53	is	a	powerful	
tumour	suppressor	implicated	in	over	50	%	of	all	human	cancers,	and	the	chemo-
therapeutic	applications	of	p53	have	been	well	described.	However,	the	vast	literature	
base	of	p53	and	complexity	of	its	interactions	makes	it	a	challenging	system	for	
integration	of	this	diverse	information.		
	
Computational	methodologies	are	novel	tools	for	integration	of	diverse	molecular	
information	into	a	coherent	framework.	The	in	silico	Boolean	PKT206	p53–DNA	
damage	model	has	previously	demonstrated	good	predictive	capability	for	p53	
wildtype	and	null	tumours.	Here,	we	have	expanded	PKT206	to	generate	a	more	
clinically	robust	representation	of	p53-cancer	dynamics.	The	Boolean	PMH260	and	
PMH302	p53	models	were	constructed	to	consider	260	nodes	and	980	interactions	
(PMH260)	and	302	nodes	with	1398	interactions	(PMH302).	Processes	of	angiogenesis,	
DNA	repair	and	cell	cycle	arrest	were	amalgamated	into	both	models	with	an	additional	
input	of	hypoxia	included	into	PMH302.	For	greater	representation	we	further	
constructed	a	logical	model	that	was	more	relevant	to	a	specific	cancer	and	integrated	
61	deregulated	genes	considered	as	important	to	mesothelioma	(Meso-PMH61	model),	
and	superimposed	microarray	data	generated	in	our	laboratory	of	mesothelioma	cells	
treated	with	etoposide	and	1	%	O2	oxygen.		
	
We	analysed	all	models,	in	silico,	using	CellNetAnalyzer.	In	silico	knockout	analysis	of	
various	nodes	mimicking	in	vivo	mutations	revealed	98	and	514	potential	novel	
predictions	(PNPs)	for	PMH260	and	PMH302	respectively,	some	were	validated	by	
laboratory	and	literature	verification.	Validation	of	4	PNPs	were	investigated	in	our	
laboratory	using	transient	gene	and	protein	knockdown,	q-PCR	and	western	blot	
analysis.		Of	these,	2	PNPs	were	in	agreement	with	the	models	prediction.		
For	further	validation	we	superimposed	various	human	cancer	transcriptome	in	vitro	
profiles	and	compared	omics	results	to	in	silico	LSSA	data.	Greater	correct	predictions	
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were	achieved	than	the	earlier	p53	logical	models	(PKT206	and	PMH260)	when	using	
the	expanded	p53	interactomes	(PMH302	and	Meso-PMH61)	resulting	in	68.5	-	83	%	
dependant	on	model	and	simulation.	We	further	tested	the	models	capability	to	
predict	gene	expression	changes	on	a	clinical	and	individual	patient	basis,	and	
superimposed	patient	derived	in	vivo	transcriptome	tumour	profiles	with	a	p53	mutant	
and	wild	type	status.	Correct	predictions	were	again	in	the	majority	ranging	between	
57	-	61.5	%	for	NSCLC	and	between	56-63	%	for	biphasic	and	epithelioid	mesothelioma	
tumours.		
	
Gene	expression	analysis	of	individual	tumour	profiles	identified	several	significantly	
over-represented	pathways	and	deregulated	genes	common	and	unique	contributing	
to	these	tumours,	correctly	predicted	by	the	model.	In	particular,	we	highlight	
pathways,	MAPK,	Erbb	and	Ca+	as	contributing	to	non-small	cell	lung	cancer	dependant	
on	patient.	For	malignant	pleural	mesothelioma,	we	highlight	cell	cycle	and	MAPK	
pathways	and	the	cell	cycle	genes;	CCNB1,	CCNB2	along	with	KIF14,	PDGFRB	and	
SULF1.	These	offer	potential	for	further	investigation	that	could	be	exploited	for	
greater	therapeutic	efficacy	in	sarcomatoid,	and	CYP24A1,	HIPK4	and	PEG3	in	biphasic	
p53	(+/+)	malignant	mesothelioma	tumours.	Drug	profile	analysis	of	deregulated	genes	
identified	by	the	model	highlight	the	need	for	individualised	therapeutic	approaches,	
and	we	offer	putative	combined	targeted	therapeutic	suggestions	dependant	on	
tumour	profile.		
	
In	summary,	we	have	generated	the	largest	p53	signalling	model	to	date,	and	have	
successfully	identified	overall	system	attributes	when	compared	to	in	vitro	and	in	vivo	
patient	derived	data.	We	show	the	importance	of	individualised	therapies	and	highlight	
the	enlarged	p53	interactome	as	a	promising	predictive	tool	for	further	investigation	
into	personalised	anti-cancer	therapies	with	clinical	relevance.		
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4	Introduction		
4.1	Systems	biology	
The	advent	of	the	‘omics’	era	(genomics,	proteomics,	transcriptomics	etc.)	and	high	
throughput	methodologies	has	highlighted	the	complexity	of	many	diseases	such	as	
cancer,	and	allowed	for	the	identification	of	numerous	deregulated	genes	and	
perturbed	pathways.	Despite	this,	the	molecular	heterogeneity	displayed	in	diseases	
such	as	cancer,	along	with	the	vast	literature	base	makes	it	a	challenging	system	for	
integration	of	this	diverse	information	into	a	coherent	framework.		This	is	particularly	
true	for	p53,	where	over	80,500	publications	are	linked	with	the	keyword	p53	
(PubMed,	May,	2016).		
	
Systems	biology	may	be	defined	as	the	study	of	complex	interactions	within	biological	
systems	and	the	emergent	properties	that	arise	from	those	interactions.		The	
developing	field	of	systems	biology	in	parallel	with	the	generation	of	high-throughput	
data,	computationally	has	heralded	a	new	era	of	network	analysis	and	medicine.	
Indeed,	network	medicine	is	a	new	term	coined	by	many	cancer	researchers	(Pawson	
et	al.2008).	Systems	biology	teamed	with	traditional	reductionist	approaches	are	novel,	
yet,	promising	tools	to	model	such	complexity.		Indeed,	this	intricacy	cannot	be	
effectively	described	by	traditional	reductionist	approaches	alone	(Wang,	2010).	Thus,	
transforming	the	traditional	reductionism	based	methods	by	combining	with	a	systems	
approach	provides	a	greater	unbiased	opportunity	to	understand	complex	network	
diseases	for	development	of	effective	therapeutic	strategies,	in	particular	for	cancer.		
	
4.1.1	Systems	biology	and	cancer		
Cancer	involves	multivariate	deregulation	of	numerous	pathways	which	govern	
fundamental	cellular	processes	including	proliferation,	differentiation,	migration	and	
death	(Pawson	et	al.	2008).	As	stated,	these	molecular	deviations	have	been	
demonstrated	with	the	advent	of	high-throughput	studies,	highlighting	a	plethora	of	
genes	and	pathways	that	contribute	to	the	malignant	phenotype	(Ngo	et	al.2006).	
Nevertheless,	the	complexity	of	cancer	networks	is	a	challenging	system,	in	particular	
for	chemo-resistance	and	the	development	of	effective	anti-cancer	strategies.		For	
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example,	identification	of	a	specific	deregulated	gene	maybe	insufficient	for	a	targeted	
treatment	due	to	the	complex	signalling	pathways	of	posttranslational	and	
transcriptional	mechanisms	(Luo	et	al.2009).	This	is	further	hampered	by	the	
redundancy	and	cross	talk	within	multiple	signalling	pathways	arising	from	
synchronous	interactions	of	a	single	molecule.	Moreover,	pathways	rarely	operate	in	
isolation.	For	example,	one	may	lead	into	another	directly	by	protein	–	protein	
interactions	or,	indirectly	via	transcriptional	programmes	to	modify	others.	In	addition,	
the	heterogeneity	frequently	observed	in	molecular	signatures	within	different	
tumours	of	the	same	tissue	can	result	in	varying	clinical	responses	in	different	patients	
using	the	same	anti-cancer	treatment.	This	underscores	the	need	for	targeted	
treatment	which	can	address	the	genetic	deregulations	associated	with	a	particular	
individual	for	greater	therapeutic	efficacy.		
	
A	systems	approach	provides	this	opportunity,	to	assimilate	large	-	scale	information	
into	a	coherent	framework	to	address	some	of	these	questions.	It	can	provide	an	
unbiased	approach	to	understand	the	initiation,	progression	and	biological	behaviour	
of	cancer,	addressing	the	different	levels	by	integrative	analysis.		
	
Three	key	aspects	of	cancer	research	are	thought	to	benefit	from	system	biology	
approaches;	discovery	of	drug	responsive	tumour	biomarkers,	the	understanding	of	
network	focused	molecular	mechanisms	of	different	stages	of	cancer	progression,	and	
lastly	personalised	targeted	treatment	(Wang,	2010).	Indeed,	many	studies	have	
started	to	address	these	using	different	mathematical	complexities.	For	example,	
Chand	et	al.	(2012)	investigated	the	association	between	wildtype	genes	involved	in	
breast	carcinoma	by	analysing	their	expression	patterns	using	microarray	data	and	as	a	
result	designed	a	gene	interaction	map	of	both	gene	types	where	function	and	
interactions	were	analysed	by	gene	ontology	of	biological	categories	such	as	molecular	
function.	These	were	statistically	analysed	and	functional	characterisation	of	novel	
genes	were	identified	via	BINGO	an	independent	Cytoscape	platform	(discussed	in	
4.1.2.3	and	section	6)	which	delivers	P	value	for	significant	genes.	Interactions	of	genes	
(CREBB,	CHIK	and	INSR)	were	found	to	be	involved	in	breast	carcinoma	p53	signalling	
pathways	along	with	STS5A	which	had	no	previous	predicted	function	in	breast	
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carcinoma	development	(Chand	et	al.2012).	Whilst,	Faratian	et	al.	(2009)	using	a	
kinetic	model	identified	PTEN	as	a	contributing	factor	to	anti-HER2	therapy	resistance.	
Klinger	et	al.	(2014)	constructed	a	kinetic	model,	and	compared	in	silico	to	in	vitro	data	
to	explore	combinational	therapy	and	found	that	P13K	or	mTOR	inhibition	can	inhibit	
both	AKT	and	ERK	activity.	Lastly,	Tian	et	al.	(2013)	designed	a	predictive	logical	based	
p53	network	model	of	DNA	damage	inducible	pathways	and	identified	58	novel	
changes	during	in	silico	analysis	of	various	knock	out	tests;	this	model	has	shown	
potential	for	targeted	therapies.	This	particular	study	is	discussed	in	section	4.1.2.7.	
	
4.1.2	Computational	techniques		
	
4.1.2.1	Text	mining	approaches	for	protein	–	protein	interaction	analysis	
For	construction	of	cancer	networks,	systematic	integration	of	biological	information	
from	literature	is	fundamental	to	establish	a	robust	model.	This	is	particularly	true	for	
p53	where	the	literature	base	is	extensive.	A	text	mining	approach	is	less	exhaustive.	It	
allows	the	user	to	extract	large	data	via	automated	information	retrieval	and	thus	less	
time	consuming.	To	date,	various	text	mining	approaches	and	tools	exist	for	
information	retrieval.	Text	mining	may	be	applied	to	system	biology	networks	by	
searching	for	genes	/	proteins	and	the	parameters	that	define	their	interactions.	
Parsing	(dividing	words	for	identification	of	each	component,	i.e.	verb,	adjective,	or	
noun)	techniques	are	a	prerequisite	for	describing	more	than	one	biological	
interaction,	and	refer	to	retrieval	of	syntactic	(arrangements	of	words	in	a	sentence)	
relations	from	a	complete	sentence	between	verbs	and	object	(Ananiadou	et	al.	2006;	
2010).	For	example,	ATM	activates	p53,	where	ATM	is	the	object	and	p53	is	the	
sentence	subject.		Commonly	used	text	mining	tools	that	consider	natural	language	
processing	based	upon	syntactic	and	semantic	analysis	are	available	through	several	
biochemical	databases.	For	example;	MEDIE	and	InfoPubMed	(Ohta	et	al.2010).	MEDIE	
retrieves	biochemical	information	and	relations	from	the	complete	Medline	database	
which	contains	a	large	number	of	citations	and	publication	abstracts.		It	allows	the	user	
to	perform	a	semantic	query	for	retrieval	of	the	particular	information,	where	semantic	
refers	to	the	meaning	of	a	word	such	as	a	protein	or	gene,	for	instance	p53	in	the	
above	example.		InfoPubMed	also	uses	full	parsing	to	recognise	various	interaction	
	 16	
types	of	such	as	inhibition,	activation	or	enhance	between	proteins	and	genes	based	
upon	ontology.		Others	include,	PESCADOR	(Platform	for	Exploration	of	Significant	
Concepts	Associated	to	Co-	occurrence	Relationships)	which	extracts	interactions	from	
PUBMED	abstracts	and	can	be	used	to	build	pathways	upon	existing	knowledge.	KEGG	
is	another	commonly	used	database	which	uses	PUBMED	and	MEDLINE.	KEGG	provides	
over-represented	pathway	maps	that	investigate	particular	networks	or	interactions,	
and	similar	to	PESCADOR	is	useful	for	building	upon	existing	knowledge.	Whilst	
informative,	these	databases	are	limited	in	information,	and	confidence	scores	are	not	
assigned	to	interactions	which	may	allow	the	user	to	extract	significant	data.	
Furthermore,	the	information	is	not	as	regularly	updated	or	as	extensive	as	that	of	
STRING	database,	described	hereafter.			
	
4.1.2.2	STRING	database	
A	prerequisite	for	a	systems	level	understanding	of	signalling	pathways	is	to	dissect	and	
annotate	functional	interactions	within	the	system.	The	extensive	and	continual	
research	of	protein	function	and	interactions	make	it	less	amenable	to	collect	the	
diverse	information	using	literature	search	only.	Text	mining	approaches	offer	the	
potential	to	extract	this	information	based	upon	previous	literature	in	an	automated	
manner.		
	
The	Search	Tool	for	the	Retrieval	of	Interacting	Genes	(STRING)	is	a	protein	to	protein	
interaction	database	which	integrates	this	extensive	information	and	aims	to	provide	‘a	
one	stop	shop’	for	all	information	on	protein	links	and	interactions.		STRING	extracts	
protein	information	from	four	main	sources;	high	throughput	experiments,	genomic	
content,	conserved	co	expression	and	previous	literature	knowledge	by	natural	
language	processing.	This	information	links	to	the	PUBMED	database	where	text	
mining	retrieval	is	offered	via	STRING	itself.	Using	this	application,	STRING	provides	
around	50	scientific	publications	in	response	to	the	users’	interaction	query.		
Key	features	of	STRING	is	a	probabilistic	confidence	score	schema	that	is	calculated	
from	the	four	main	sources.	Scores	represent	an	estimate	of	functional	interaction	
between	protein	pairs	in	a	pathway,	which	may	guide	users.	For	example,	STRING	
schema	states	that	a	confidence	score	of	over	0.7	is	considered	as	high.		Interactive	
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protein	interaction	maps	are	user	friendly	and	include	interactions	of	activating	or	
inhibiting.	Whilst,	the	nature	of	the	interaction	is	also	considered	such	as:	post-
translational	modifications,	binding,	or	expression.	It	also	considers	partner	sites	such	
as	Cytoscape	software	where	STRING	data	may	be	imported.	Importantly,	STRING	is	
updated	on	a	regular	basis,	every	6-12	months,	thus	allowing	retrieval	of	novel	
information	outdating	those	previous	(Jenson	et	al.2009;	Szklarcyzk	et	al.2011).		
	
4.1.2.3	Cytoscape	software	
Cytoscape	is	an	open	source	software	platform.	It	allows	for	integrative	analysis	and	
visualisation	of	molecular	interaction	networks	and	biological	pathways	by	
amalgamation	of	large	information	that	can	be	represented	into	a	coherent	framework	
(Shannon	et	al.2003).	Cytoscape	software	allows	the	user	to	link	to	several	databases	
of	functional	annotations,	for	example	STRING	and	KEGG.	Cytoscape	functional	analysis	
is	provided	by	various	plugins	for	version	2.9	and	lower,	nomenclature	however	has	
changed	to	‘apps’	for	versions	of	3.0	or	higher.	These	are	publicly	available	allowing	the	
user	to	perform	network	analyses	and	visualisation	of	pathways.	Moreover,	any	user	
may	develop	these	‘apps’	and	as	such	the	Cytoscape	app	community	is	continually	
increasing	allowing	for	greater	analysis	power	and	network	choice.		Similar	to	STRING,	
Cytoscape	is	capable	of	the	construction	of	molecular	networks	through	these	apps,	for	
example	via	the	Agilentsearchliterature	app.	However,	networks	retrieved	are	limited	
in	size	and	literature	evidence	is	not	available	or	updated	on	a	regular	basis.	Thus,	
Cytoscape	is	more	apt	for	input	of	new	networks	from	independent	manual	
construction	for	functional	analysis.		
	
Unlike	CellNetAnalyzer,	Cytoscape	is	an	independent	platform	and	as	such	is	capable	of	
handling	large	datasets	including	high	throughput	expression	profiles.	With	the	
availability	of	transcriptome	data,	Cytoscape	is	becoming	a	promising	tool	and	may	
provide	better	analyses	for	large	networks.	Indeed,	a	recent	study	termed	the	novel	
signal	transduction	flow	algorithm	(STFSA)	has	been	successfully	used	and	is	publicly	
available	as	a	Cytoscape	app.	STSFA	utilizes	large	scale	‘omics’	data	to	assign	dynamic	
gene	scores	throughout	the	network	from	source	node	to	final	cellular	processes	for	
pathway	analysis.	It	has	demonstrated	good	correlation	with	experimental	
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transcriptome	data	of	ChiPSeq	and	microarray	profiles	to	accurately	predict	multiple	in	
silico	gene	knockouts	(Isik	et	al.2012).	Indeed,	Cytoscape	is	considered	most	powerful	
when	used	in	conjunction	with	large	datasets	(Shannon	et	al.2003).		
	
4.1.2.4	System	biology	approaches	
The	metabolic	nature	of	cellular	pathways	may	be	approached	in	either	a	bottom	up	or	
top	down	directionality	as	depicted	in	a	simplified	diagram	(figure	4).	The	latter	
approach	constitutes	data	processing	from	‘omics’	levels	to	pathways	and	individual	
gene	levels,	whilst	bottom	up	encompasses	automated	tools	and	mathematical	
modelling	(Shahzad	and	Loor,	2012).		Both	directionalities	encompass	different	steps	
for	experimental	hypotheses	and	required	outcome.	Different	levels	of	complexity	are	
later	addressed	by	mathematical	modelling	dependant	on	analysis	required	which	may	
be	quantitative	or	qualitative,	simple	or	complex	(figure	4.1).	
	
4.1.2.4.1	Top	down	approach	
The	top	down	approach	originates	from	experimental	data,	to	identify	and	describe	the	
‘bottom’	biological	interactions	by	network	construction,	via	the	flow	of	information	
occurring	from	the	‘omics’	level.	This	directionality	can	help	to	dissect	interactions	
using	the	‘omics’	data	extracted	from	top	down	methodologies	of	high	throughput	
experiments	(Bruggeman,	2006).	Top	down	aims	to	identify	new	molecular	
mechanisms	of	interactions	recursively	from	initial	experimental	data	of	several	
hypotheses.	Subsequent	data	analysis	and	integration	for	determination	of	correlations	
may	consequently	be	applied	with	the	endpoint	of	a	hypothesis	of	the	co	-	interaction	
and	regulation	of	these	molecule	groups.	Subsequent	hypotheses	may	be	utilised	for	
prediction	of	novel	correlations	for	further	analysis	by	laboratory	based	methodologies	
(Bruggeman	2006).		This	approach	is	useful	for	network	structure	determination	and	
identification	of	novel	cellular	molecular	mechanisms	and	interactions	
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Figure	4	Bottom-up	and	top-	down	methodologies		
Bottom	up	approaches	begin	with	detailed	knowledge	about	individual	components	and	
assemble	these	into	larger	elements,	such	as	pathways	and	networks	for	behaviour.	Top-down	
approaches	start	from	typically	large	data	sets	which	represents	‘omics’	of	a	biological	system	
aiming	to	identify	those	components	that	are	most	responsible	for	the	systems	behaviour	such	
as	phenotype.	
	
	
4.1.2.4.2	Bottom	up	approach		
The	bottom	up	approach	is	aimed	at	constructing	detailed	models	which	may	be	
replicated	under	various	physiological	conditions.	It	combines	all	molecular	specific	
information	into	a	genome	scale	model	providing	an	integrative	in	silico	view	of	
biological	interactions	within	living	systems	and	based	upon	constraint	based	
modelling.	In	contrast	to	a	top	down	approach	the	bottom-up	directionality	builds	
upon	pre-existing	data	for	analysis	of	their	systemic	consequences	for	the	cell	
(Westerhoff	and	Palsson,	2004)	and	utilises	experimental	data	of	steady	state	and	
transient	metabolite	and	flux	data.	Experiments	are	on	the	basis	of	detailed	networks	
for	subsequent	validation	and	improvement	of	the	model	to	investigate	the	hypothesis	
generated	by	in	silico	model	analysis.	After	full	characterisation	of	the	network,	top	
down	approaches	may	also	be	combined	with	bottom	down	systems	biology	at	later	
experimental	stages.	The	two	combined	may	provide	a	strong	framework	for	dissecting	
cellular	molecular	interactions	(Bruggeman,	2006).		
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Figure	4.1	Different	levels	of	complexity	in	System	biology	approaches		
	The	two	system	approaches	of	top	down	and	bottom	up.	b)	Complexity	of	mathematical	
methods	of	regression	analysis	being	the	simplest	approach	for	correlation	identification.	ODE	
models	may	be	utilised	to	describe	kinetic	mechanisms,	whilst	Boolean	models	are	more	
simplistic.	Redrawn	from	(Bachmann	et	al.2011)	
	
4.1.2.5	Mathematical	modelling			
The	most	commonly	applied	mathematical	equations	for	signalling	pathways	are	
ordinary	differential	equations	(ODEs),	and	Boolean	mathematical	modelling.	
Applications	of	continuous	and	discrete	models	are	dependent	upon	the	desired	
output.	Kinetic	modelling	is	more	suitable	for	quantitative	modelling,	i.e.	investigating	
the	treatment	efficacy	of	cancer	models.	For	instance,	Mamat	et	al.	(2013)	used	ODE	
modelling	with	in	silico	simulations	to	investigate	the	effects	of	IL-2	(Interleukin	-2)	and	
INF-α	(Interferon-	α)	on	tumour	cell	dynamics	under	the	influence	of	chemotherapy,	
immunotherapy	and	bio-	chemotherapy	in	ten	patients.	The	study	concluded	that	
these	treatments	played	pivotal	roles	in	remission	and	death	of	tumour	cells.		In	
contrast,	Boolean	models	are	more	sufficient	for	measuring	qualitative	aspects	of	
biological	phenomena	for	example,	steady	state	protein	/	gene	activity	and	knock	
down	or	knock	in	effects	(Bachmann	et	al.2011)	
	
4.1.2.5.1	Ordinary	differential	equations			
Ordinary	differential	equations	(ODEs)	have	been	extensively	used	to	model	molecular	
signalling	pathways	and	considered	the	most	natural	equation	for	translation	of	
detailed	reaction	networks	into	a	model.	Constructions	of	ODEs	are	dependent	upon	a	
single	variable,	such	as	time.		Their	networks	represent	reaction	rates	of	a	particular	
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species	such	as	degradation,	production	and	association	in	terms	of	mass	action	
kinetics	where	the	rates	are	proportional	to	the	reactant	concentrations	(Bachmann,	
2011).	ODE	networks	however	have	limitations.	For	example,	a	large	number	of	
parameters	are	required.	Further	drawbacks	are	network	sizes,	ODE	models	may	only	
describe	a	few	nodes,	whilst	Boolean	models	may	constitute	hundreds	(Mai	and	Liu,	
2009).	
	
4.1.2.5.2	Boolean	modelling	
Boolean	modelling	is	another	commonly	used	approach	for	construction	of	signalling	
pathways.	Boolean	models	were	first	described	by	Kaufmann,	(1969)	as	models	of	
genetic	regulatory	networks.	These	logical	networks	are	simplistic,	yet	effective	in	
capturing	the	dynamics	of	gene	/	protein	signal	flow	networks.	For	example,	described	
by	binary	states	of	ON	or	OFF,	they	can	effectively	recapitulate	signalling	events,	
referring	to	a	gene	transcribed	(ON)	or	non-transcribed	(OFF),	a	protein	activated	(ON)	
or	inhibited	(OFF).		
	
Boolean	logic	has	been	applied	successfully	to	model	various	complex	biological	
phenomena	(Shmulevich	and	Kauffmann,2004).	Boolean	models	are	represented	by	
directed	graphs	where	nodes	represent	genes	or	proteins	and	edges	or	hyper-edges	
represent	the	interactions	between	them.	Boolean	logic	states	that	a	node	is	capable	
of	only	discrete	expression	values	contrasting	the	continuous	value	ranges	in	kinetic	
models	such	as	ODEs.	A	logical	rule	linking	the	inputs	is	assigned	to	each	node	and	as	
such	no	real	parameter	values	are	needed	to	be	adjusted	apart	from	the	applicable	
logical	Boolean	rules	that	describe	the	system.	Each	node	according	to	Boolean	logic	is	
parameterized	by	binary	interactions,	1	or	0	operators	referring	to	activation	or	no	
activation.	Nodes	are	assigned	two	separate	states	of	ON	or	OFF;	where	at	each	time	
point	the	state	of	a	particular	node	is	determined	by	the	state	of	another	node	typically	
upstream	by	transfer	of	Boolean	logical	function.		
	
Klamt	et	al.	(2006)	proposed	two	different	graph	theories	for	Boolean	network	
formation.	The	choice	of	graph	is	dependent	on	the	required	outcome	of	model,	data	
type	and	input.		Biological	processes	and	cellular	signalling	pathways	exhibit	multi-
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lateral	relationships	and	thus	graph	choice	must	represent	such	reactions.	Directed	
logical	hypergraphs	consider	and	facilitate	these	multiple	reactions.	Furthermore,	
biological	cancer	networks	frequently	undergo	feedback	loops	of	both	positive	and	
negative	nature.	Whilst	interaction	graphs	may	represent	such	processes	they	cannot	
incorporate	Boolean	logic	of	OR,	NOT,	AND	operators	(Klamt,	2006).		For	these	
synchronous	connections,	Boolean	logic	must	be	considered	to	represent	a	truer	state	
of	signalling	pathways	and	as	such	depict	a	greater	representation	of	cellular	networks	
whilst	also	providing	confident	in	silico	prediction.	The	AND,	OR,	NOT	relationships	are	
thus	best	represented	by	hyper-graphs	where	directed	hyper-arcs	connect	more	than	
one	node	(Klamt,	2006;	2011).	In	contrast,	multi-lateral	signalling	is	not	possible	using	
interaction	graphs	where	only	the	two	states	exist	and	separate	arcs	of	positive	
pathways	influencing	target	node	fail	to	truly	represent	the	relationship	between	three	
species.	Figure	4.1.1	summarises	differences	between	both	graph	theories.		
	
In	addition	to	the	logical	model	constructed	by	Tian	et	al.	(2013)	discussed	above,	
Boolean	modelling	has	been	utilised	in	several	cancer	studies.	For	example,	a	Boolean	
system	was	constructed	of	96	nodes	of	known	cancer	causing	genes	with	249	edges	
and	five	input	nodes	of	cellular	stresses.	(Fumia	and	Martins,	2013).	The	study	
identified	62	attractors	with	distinct	cellular	cancer	phenotypes	in	response	to	
upstream	inputs.	In	silico	mutations	were	introduced	into	the	network	and,	ten	
proteins	were	identified	as	having	the	capability	to	transform	into	malignant	
phenotypes.	Lastly	this	study	considered	targeted	pathways	of	treatment	of	individual	
nodes	to	block	cancer	pathways.	Inhibition	of	PDK1,	AKT	E2F,	Cyclins	D	and	E,	and	
MDM2	or	activation	of	p53,	RB,	CDK11,	p21,	p27,	and	SMAD4	enhanced	senescent	
phenotypes,	impairing	proliferative	ones.	However,	treatment	was	dependent	on	
cancer	stage	and	type	(Fumia	and	Martins,	2013).		Kirouiac	et	al.	(2013)	successfully	
developed	a	Boolean	predictive	model	of	drug	resistance	in	Erbb2	amplified	breast	
cancer	and	tested	the	in	silico	interactome	prediction	using	in	vitro	and	in	vivo	mouse	
model	systems.			
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Figure	4.1.1	Simplified	illustration	of	graph	theories:	Interaction	and	logical	interaction	
hyper-graph.	a)	Interaction	graph	the	reaction	comprises	two	separate	arcs	of	A	and	B	both	
having	an	effect	on	AB	of	positive	paths	leading	to	D-E.	The	two	positive	paths	of,	both	A	and	B	
(AB)	are	required	for	activation	of	D,	however	removal	of	one	species	for	example,	A	is	
sufficient	to	disrupt	activation	of	D.	Thus,	a	signalling	path	in	an	interaction	graph	will	not	
ensure	a	signal	may	flow	via	this	path.	In	contrast,	b)	Interaction	Hyper-graph	depicts	the	
example	as	a	logical	interaction	hypergraph	in	which	a	hyperarc	connects	A	and	B	by	capturing	
the	AND-connection	between	both	species.	(Redrawn	from	Klamt,	2009).	
	
	
4.1.2.6	CellNetAnalyzer	
CellNetAnalyzer	(CNA)	is	an	independent	graphical	user	interface	for	Matrix	laboratory	
(MATLAB)	(discussed	in	section	6),	that	provides	structural	and	functional	analysis	of	
various	cellular	networks	(Klamt,	2006).	CNA	has	been	designed	with	MATLAB	
nomenclature	enabling	the	user	to	incorporate	MATLAB	algorithms.	In	particular,	for	
analysis	of	in	silico	signalling	networks,	using	distance	and	dependency	matrix	
formalisms	such	as	dependency	relationships,	and	node	state	changes	in	the	network	
arising	from	input	perturbations	using	logical	steady	state	analysis.		
	
CNA	provides	a	comprehensive	independent	platform	for	complex	structural,	
functional	and	qualitative	analysis	of	biochemical,	metabolic,	signalling	and	regulatory	
networks	(Klamt,	2006).	Network	projects	constructed	by	CNA	may	be	represented	and	
analysed	with	either	mass	flow	(stochichometric/metabolic)	or	signal	flow	
(signal/regulatory).	Nomenclature	used	for	network	descriptive	in	both	network	
examples	requires	declaration	of	both	species	and	reactions.		
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For	example,	using	mass	flow	networks	reactions	correspond	to	stoichiometric	reaction	
equation	where:	
	
A	+	B	->	C		
This	equation	states	that	two	reactants	(A	and	B)	are	converted	into	C,	with	A	and	B	
totally	consumed	in	the	process.	In	contrast	signal	flow	networks	are	represented	by	
logical	Boolean	operators	of	true	or	false	expressed	by	the	equation:			
	
	A	->	B	=	C	
	
Where	the	product	(end	node)	is	activated	by	the	reactant	(start	node),	for	example	C	
is	activated	if	A	and	B	are	active.	However,	A	and	B	is	not	consumed	during	the	process.	
For	example,	C	may	be	activated,	if	A	and	B	are	in	an	active	state.			
	
In	both	networks,	declaration	of	species	and	reactions	are	required	with	their	
corresponding	attributes.	Declaration	of	nomenclature	in	both	is	equal	however	both	
have	different	interpretations.	For	example,	and	as	described	above,	in	mass	flow	
networks	reactions	are	defined	by	stoichiometric	conversions,	referring	to	products	
consumed	in	a	single	reaction.	In	contrast,	signal	flow	considers	Boolean	logic	of	AND,	
OR	and	NOT	operators	and	defines	interactions	by	the	end	node	(product)	being	
activated	by	start	node	(reactants).	These	signal	flow	networks	can	be	represented	by	
either	interaction	graphs	or	hyper-	graphs	as	previously	discussed	(figure	4.1.1).	
		
For	any	biological	process,	feedback	loops	and	crosstalk	are	frequent	and	important	
events	in	cellular	signalling	pathways.	CNA	considers	such	reactions	which	are	
represented	within	an	interaction	matrix	of	species	and	reactions	for	analysis	and	also	
may	be	visualised	graphically.		Dependency	relationships	between	species	may	be	
analysed	with	the	construction	of	a	dependency	matrix	defined	as	M	which	displays	all	
pair-wise	node	dependencies.	These	relationships	are	calculated	by	the	shortest	or	
positive	or	negative	pathway	distance	between	node	pairs	and	represented	by	six	
different	colours	or	values	of	1	–	6	indicating	the	different	species	relationships	of:	
weak/strong	activator,	inhibitor,	or	ambivalent	factor	or	non-influencing	node.	
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Furthermore,	positive	or	negative	feedback	loops	are	considered	within	the	matrix..	
These	are	described	in	section	6,	material	and	methods.		
	
Logical	steady	state	analysis	is	a	good	method	for	predictive	behaviour	of	the	input	–	
output	dynamics	of	signalling	networks	(Klamt	et	al.2007).	The	steady	state	between	
node	pairs	can	be	analysed	in	CNA	via	logical	steady	state	analysis,	where	the	state	of	
each	node	is	consistent	with	its	Boolean	function	and	as	such	once	a	node	has	
progressed	into	a	logical	steady	state	it	will	remain.	In	this	logical	steady	state	and	in	
accordance	with	Klamt	et	al.	(2006),	each	node	can	have	three	different	states	of;	0,	
inactivated,	1,	activated	and	NaN,	undetermined.		Exclusion	of	node	(s)	and	its	
interaction	(s)	from	a	network	allow	for	analysis	of	the	interactome	in	response	to	their	
absence.	These	in	silico	knock	outs	can	represent	biological	phenomena	of	in	vivo	
mutations	in	diseased	states	such	as	cancer.		
	
CNA	has	been	utilized	in	several	studies	using	Boolean	logic.	For	example,	a	dynamic	
model	was	constructed	to	analyse	p53	and	NF-kB	pathways	in	response	to	DNA	
damage.	This	study	undertook	in	silico	knock	out	tests	for	prediction	of	novel	gene	
function.	Dependency	matrices	were	also	constructed	to	identify	potential	cancer	
therapy	targets	(Plotz	and	Naumann,	2012).	Whilst	another	more	recent	study	
constructed	a	p53	predictive	interactome	defined	as	PKT206	and	analysed	its	response	
to	DNA	damage	inducible	pathways	via	in	silico	knock	out	tests	(Tian	et	al.2013).	As	
PKT206	is	a	continuum	of	this	study,	a	brief	introduction	is	necessitated,	discussed	in	
the	next	section.		
	
4.1.2.7	The	PKT206	Model		
The	Boolean	p53-	DNA	damage	inducible	model	designated	as	PKT206,	generated	by	
Tian	et	al.	(2013)	was	analysed	in	CNA	and	constructed	via	data	extraction	utilising	the	
STRING	database,	and	additionally	manually	curated	for	model	accuracy.	PKT206	
comprises	five	layers;	the	input	signal	of	DNA	damage,	upstream	nodes	of	p53,	the	
core	p53	and	MDM2,	downstream	nodes	of	p53	and	the	output	signals	of	apoptosis	
and	cellular	senescence.	The	p53	core	comprises	738	interactions	between	206	genes	/	
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nodes	connected	with	p53	as	the	network	hub.	Nodes	represent	genes	or	proteins	with	
edges	representing	the	inhibiting	or	activating	interactions	between	them.		
	
Analysis	of	the	network	by	CNA	identified	thirty	feedback	loops,	of	which	fourteen	
involved	p53,	the	majority	significant	to	p53	regulation	such	as	MDM2	and	MDM4.	
Logical	dependency	relationships	between	nodes	were	calculated	where	23,191	nodes	
were	found	to	have	no	effect,	16,425	ambivalent	factors,	1100,	weak	inhibitors,	1240,	
weak	activators,	20,	strong	inhibitors	and	49	being	strong	activators.	Various	in	silico	
p53	knock	outs	were	constructed	to	investigate	and	predict	the	role	of	p53	and	the	
response	of	the	network	upon	node	deletion.	Of	these	11,	753	nodes	changed	after	
p53	node	deletion	from	the	original	41,616	p53	interactome.	The	majority	of	changed	
nodes	were	ambivalent	factors	arising	from	feedback	loops	within	the	system	also	
highlighting	p53	regulatory	role	within	the	in	silico	network	coinciding	with	known	in	
vivo	p53	effects.		11	of	30	in	silico	node	deletions	demonstrated	major	dependency	
changes	to	wildtype	matrix	proceeding	removal	of	a	specific	node.	58	possible	
predictions	of	change	were	obtained	from	the	11	initial	in	silico	knock	out	tests	and,	of	
which	4	were	validated	via	literature	searches	and	2	via	laboratory	validation.		
	
Microarray	analysis	of	human	osteosarcoma	and	colon	cancer	cell	lines	of	p53	null	and	
wild	type	treated	with	etoposide	induced	DNA	damage	has	highlighted	the	models	
predictive	capability.	Up	to	75	%	of	predictions	were	considered	as	true	when	
compared	to	LSS	in	silico	results.	This	highlights	the	prospective	of	employing	PKT206	in	
a	clinical	setting	as	one	future	direction	in	cancer.	However,	limitations	to	this	is	
network	size,	in	particular	for	p53	where	a	plethora	of	responsive	genes	have	been	
described	(Riley	et	al.	2008).	‘Omics’	data	is	high	throughput	and	as	such	model	size	is	
of	importance	for	superimposition	of	expression	profiles	for	greater	biological	
representation.	Furthermore,	inclusion	of	additional	stresses	or	processes	involved	in	
cellular	fate	should	be	considered.		
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4.1.3 Cancer		
Cancer	is	the	result	of	abnormal	cell	growth	due	to	gene	expression	changes	resulting	
in	dysregulated	cell	proliferation.	Tumours	are	the	outcome	of	a	process	of	clonal	
selection	whereby	multiple	alterations	for	example,	oncogene	activation	or	the	loss	of	
tumour	suppressors,	provide	a	selective	advantage	to	the	cells	that	carry	them.	This	
can	ultimately	progress	into	a	more	invasive	cell	population	which	may	metastasise	
into	adjacent	and	distant	sites	(Ruddon,	2007).		
	
Cancer	has	been	described	as	one	of	the	main	causes	of	deaths	worldwide.	The	most	
recent	statistics	of	all	cancer	incidences	in	the	UK	was	more	than	324,500	in	2011,	with	
a	mortality	rate	of	7.6	million	cancer	combined	deaths	globally	(Cancer	Research	UK).	
Various	chemotherapies	are	employed	for	treatment	with	efficacy	reported	as	25	%	by	
Glaxo	Smith	Kline.	In	addition,	chemo-resistance	is	frequent	problem,	and	different	
molecular	signatures	exist	dependant	on	the	individual.	Thus	more	effective	anti-
cancer	strategies	are	necessitated,	in	particular	focusing	upon	the	molecular	deviations	
that	govern	a	particular	tumour.		
	
The	biological	features	of	cancer	progression	to	tumour	formation	has	been	coined	by	
Hanahan	et	al.	(2000)	of	six	tumour	phenotypes	required	for	full	malignancy;	self-
sufficiency	of	growth	signals	in	oncogenes,	insensitivity	to	anti-growth	signals,	evasion	
of	apoptosis,	sustained	angiogenesis,	limitless	replicative	potential	and	lastly	tissue	
evasion	and	metastasis.	Two	further	emerging	phenotypes	have	recently	been	
described;	deregulated	cellular	epigenetics	of	reprogrammed	cellular	energy	
metabolism	and	immunological	evasion	(Hanahan	and	Weinberg,	2011).				
	
Genetic	changes	of	human	cancers	are	typically	due	to	two	distinct	types;	gain	of	
function	proto	oncogene	mutations	resulting	in	oncogenic	transformation	and	
activation,	thereby	promoting	cell	growth,	and	loss	of	function	mutations	in	tumour	
suppressor	genes	resulting	in	failure	of	functions	such	as	activation	of	anti-proliferative	
programs	and	maintenance	of	DNA	replication	and	integrity	resulting	in	genomic	
instability.	The	tumour	suppressor	p53	protein	for	example	has	a	crucial	role	as	it	is	
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mutated	in	over	half	of	all	human	cancers.	More	than	26,000	mutations	of	p53	are	
recorded	within	the	International	agency	for	cancer	research	(Suzuki	and	Matsubara,	
2011).	In	this	form,	loss	of	function	results	in	failure	of	p53	tumour	suppressive	
activities.	Indeed,	p53	is	considered	pivotal	to	tumour	development	and	as	such	has	
been	the	focus	of	extensive	research	for	its	role	in	both	cancer	development	and	
therapeutic	strategies,	in	particular	for	reactivation	of	its	regulatory	pathways	(Lane,	
2010).		
	
4.1.3.1	p53	overview		
The	p53	protein	was	first	described	in	(1979)	by	Levine	et	al.	as	an	oncogene	which	
accrued	within	cancerous	cells	nuclei.	Later	studies	on	wildtype	p53	however	
confirmed	its	definitive	function	as	a	tumour	suppressor,	and	transcription	factor	with	
a	crucial	role	in	cancer,	maintaining	genomic	integrity	and	as	such	is	termed	as	‘the	
guardian	of	the	genome’	(Levine,	1997).	Since	then	the	complexity	of	p53	within	its	
intricate	network	has	unravelled	with	over	85,000	publications	to	date	(May,	2016),	
linked	with	the	keyword	p53	pathways	and	more	than	several	hundred	p53	responsive	
genes	described	(Riley	et	al.2008).	The	significance	of	p53	as	a	tumour	suppressor	is	
highlighted	by	the	fact	that	over	50	%	of	human	cancers	comprise	p53	gene	mutations	
or	defects	within	p53	regulatory	pathway.		
	
p53	protein	is	a	stress	responsive	transcription	factor,	stabilised	and	activated	in	
response	to	cellular	stresses	of	a	genotoxic	and	non-genotoxic	nature	including;	DNA	
damage,	hypoxia,	nutrient	deprivation	and	oncogenic	activation	(Levine,	2009).	Once	
activated,	p53	initiates	a	transcriptional	program	via	a	complex	network	of	multiple	
signalling	layers	to	promote	cellular	homeostasis	and	genomic	integrity.	This	may	result	
in	several	biological	outcomes	dependant	on	stress	type,	severity	and	cellular	/	tissue	
context	that	include	cellular	senescence,	apoptosis,	cell	cycle	arrest,	and	angiogenesis	
(Anderson	and	Appella,	2009).		
	
The	vast	amount	of	literature	on	p53	and	interacting	proteins	has	made	it	less	
amenable	to	a	greater	understanding	of	p53	pathways	involved	in	tumorigenesis.	Thus,	
dissecting	these	pathways	that	govern	p53	is	fundamental.		
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4.1.3.2	The	tumour	suppressor	p53	–	role	in	cancer		
p53	is	a	powerful	tumour	suppressor	protein,	with	various	anti-proliferative	roles	in	
response	to	aberrant	cellular	stresses	(Anderson	and	Appella,	2001).	p53	displays	all	
the	characteristics	of	a	tumour	suppressor	gene	(TSG):	
	
i. TSGs	are	recessive	and	undergo	biallellic	inactivation	in	tumours	(loss	of	both	
alleles)	(although	p53	is	considered	a	recessive	TSG,	several	studies	have	shown	
a	profound	effect	from	loss	of	one	allele	or	inactivation	via	a	single	mutation	
ii. Inheritance	of	a	single	mutant	allele	accelerates	tumour	susceptibility	formation	
iii. The	same	gene	is	frequently	inactivated	in	sporadic	cancers	
iv. It	has	a	powerful	anti-proliferative	role	
	
Under	homeostatic	conditions,	a	latent	form	of	p53	exists	at	low	concentrations.	
However,	in	response	to	stresses	such	as	DNA	damage,	increased	p53	levels	result	in	its	
stabilisation	from	attenuation	of	its	negative	regulator	E3	ligase	Murine	double	minute	
2	(MDM2)	or	HDM2	in	human.		Consequently,	p53	initiates	an	anti-proliferative	
program	transcriptionally	activating	or	repressing	target	genes.	Abrogation	of	this	
pathway	or	its	components,	specifically	p53	has	been	shown	to	contribute	to	tumour	
formation	and	cancer	(Vousden	and	Lane,	2007).		
	
The	fundamental	role	of	p53	and	its	network	is	highlighted	by	the	rare	familial	Li-
Fraumeni	syndrome,	a	dominant	inherited	disease	arising	from	germline	mutations	
where	individuals	are	predisposed	with	premature	onset	to	leukaemia,	breast	cancer	
and	osteosarcomas	arising	from	abrogation	of	apoptotic	and	senescence	programs	by	
DNA	damage	checkpoint	defects	(Malkin	et	al.	1990).	p53	mutations	or	inactivation	are	
present	in	over	half	of	all	human	cancers,	with	the	non-mutated	allele	typically	lost.	
Indeed,	p53	gene	null	mice	are	tumour	prone	and	susceptible	to	neoplastic	disease	
(Reinhart	et	al.2012).			
	
Mutations	are	variable	between	tumour	types,	with	p53	mutation	hot	spots	typically	
located	in	its	central	DNA	binding	domain	(figure	4.1.2),	and	include	cancers	of	skin,	
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bladder,	lung,	liver,	breast,	colon	and	more.	Mutations	are	largely	missense	(80%),	with	
aberrant	modifications	imposing	several	diverse	effects	on	gene	activity	dependant	on	
locality.	For	example,	mutations	within	the	promoter	region	may	result	in	cellular	p53	
decrease	or	absence,	whilst	those	within	the	protein	coding	region	may	impact	gene	
expression	or	protein	activity.	Furthermore,	a	mutation	type	may	dictate	different	
elements	of	p53	signalling	pathways.	For	example,	some	p53	mediated	responses	may	
be	lost,	whilst	other	p53	mutations	may	confer	gain	of	wild	type	function	directly	
enhancing	cancer	progression,	and	include	interactions	with	related	p63/p73	(Goh	et	
al.	2012).	Lastly,	mutated	components	of	the	pathway	may	directly	affect	p53	activity	
such	as	mutated	ATM,	which	causes	ataxia	telangiectasia	(Malkin	et	al.	1990).	This	
highlights	not	only	the	importance	of	p53	in	cancer,	but	that	a	fully	functional	and	
regulated	level	of	p53	is	fundamental	to	maintain	a	tightly	co-ordinated	network	and	
response	for	genomic	integrity.		
	
Recent	studies	have	highlighted	the	importance	of	p53	in	other	pathologies	including	
longevity,	diabetes	mellitus	and	myocardial	infarction	(Reinhardt	et	al.2012).	Taken	
together,	these	studies	demonstrate	the	comprehensive	role	of	p53	in	numerous	
processes	including	cancer	and	inflammation.	
	
4.1.3.3	TP53	gene	and	structure		
p53	is	a	nuclear	protein	encoded	by	a	20kb	gene,	comprising	11	exons	and	10	introns	
located	on	the	short	arm	of	chromosome	17.	p.13.	Wild	type	p53	contains	393	amino	
acids	composed	of	several	structural	and	five	functional	domains	crucial	for	mediating	
interactions	(figure	4.1.2).	The	N-	terminal	domain	(1-43)	constitutes	two	adjacent	
transactivation	domains;	TAD1	and	TAD2	where	the	majority	of	phosphorylation	
occurs.	This	is	typically	in	response	to	DNA	damage.	TAD2	overlaps	the	proline	rich	
region	(63-97)	with	important	roles	in	apoptosis,	transcriptional	activation	and	
repression	(Lin	et	al.	1994)	and	p53	activation	as	shown	proceeding	gamma	irradiation	
(Campbell	et	al.	2013).	Redundancy	is	observed	at	the	N-	terminus,	where	a	single	site	
may	be	phosphorylated	by	several	kinases,	conversely	a	single	kinase	may	
phosphorylate	multiple	sites.	The	DNA	binding	domain	(DBD)	(102-292)	constitutes	the	
core	site	specific	DNA	binding	site	of	p53,	ensuring	p53	function	as	a	transcription	
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factor,	regulating	expression	of	target	genes.	The	majority	of	human	mutations	(90%)	
occur	within	the	DBD	corresponding	to	highly	conserved	II	–	V	regions.	These	result	in	
loss	of	wildtype	function	and	thus	the	inability	to	bind	to	the	consensus	sequences	
within	promoters	of	p53	responsive	genes	(Sigal	and	Rotter,	2000).	The	C-	terminal	
region	(323-393)	constitutes	the	tetramerisation	domain	(TD)	and	C-terminal	
regulatory	region	(CRD).	Here	sequences	are	involved	in	nuclear	localisation,	regulation	
and	tetramerisation.	The	formation	of	p53	tetramer	is	pivotal	to	p53	dependant	trans-
activation	and	suppression	(Kruse,	2009).		This	regulatory	region	comprises	a	non-
specific	DNA	binding	domain	that	binds	to	damaged	DNA	and,	undergoes	several	post	
translational	modifications	crucial	to	p53	activity	and	control	(Loughery	and	Meek,	
2013).	
	
4.1.3.4	Regulation	and	control	of	the	stress	responsive	transcription	factor	p53	
The	tumour	suppressor	p53	is	a	stress	responsive	transcription	factor,	mediating	the	
expression	of	a	plethora	of	target	genes	via	interactions	with	numerous	co-factors.		As	
such,	p53	activity	must	be	tightly	regulated	and	maintained	at	steady	state	levels.		
Adverse	effects	of	decreased	or	increased	p53	activity	have	been	demonstrated	in	
various	mouse	models	of	altered	p53	levels	using	gene	manipulation	studies	(Tyner	et	
al.	2002:	Dumble	et	al.	2007).	p53	null	mice	were	largely	tumour	prone,	in	contrast	p53	
⁺/⁺	mice	were	less	tumour	susceptible,	yet	displayed	other	pathologies	that	were	age	
related.	
	
In	its	latent	state	the	half-life	of	p53	is	limited	to	minutes	and	its	function	repressed	by	
MDM2	(Kruse	and	Gu,	2009).	In	response	to	stress,	the	attenuated	p53	–	MDM2	
complex	stabilises	p53	with	its	half-life	prolonged	to	hours.		Accumulated	p53	is	subject	
to	extensive	post	translational	modifications	in	response	to	genotoxic	stress.	PTMs	are	
crucial	to	p53	modification	and	as	such	its	activation,	regulation	and	control	(Toledo	
and	Wahl,	2006).	These	include	ubiquitination,	phosphorylation	and	acetylation	
amongst	others.		
	
	 32	
	
	
Figure	4.1.2		Functional	and	structural	domains	of	p53	relating	to	the	various	anti-	
proliferative	roles.	Functional	domains:	comprising	transactivation	and	proline	rich	domain	
within	the	N-terminus,	the	core	DNA	binding	domain	and	the	C	–terminus	of	tetrmerisation	
and	regulatory	regions.	These	correspond	to	highly	conserved	domains	of	I,	II	–	V	respectively	
and	highlighted	by	the	same	colour.	Once	activated	p53	exerts	its	anti	proliferative	function	by	
growth	arrest,	apoptosis,	cellular	senescene	and	angiogenisis	inhibition	with	the	functional	p53	
domains	responsible	indictated	by	arrows.	TAD,	transactivation	domain,	PRD,	proline	rich	
domain,	DBD,	DNA	binding	domain,	TET,	tetramesaristion	domain	and	CRD,	C	terminal	
regulatory	domain.		
	
	
4.1.3.5	Post	translational	modifications	of	p53	
	
4.1.3.5.1	Phosphorylation		
Phosphorylation	simply	defined	refers	to	the	addition	of	a	phosphate	group	to	the	one	
side	of	an	amino	acid	chain	of	a	protein.	Due	to	the	negative	charge	of	phosphates,	
their	addition	results	in	modification	of	protein	characteristics,	typically	
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conformational.	The	organisation	of	kinases	in	response	to	a	particular	signal	induces	
phosphorylation	cascades.	This	reaction	is	reversible	via	de-phosphorylation	catalysed	
by	phosphatases	allowing	the	protein	to	conform	back	to	its	original	structure	upon	
phosphate	removal.		Conformational	modifications	can	induce	subtle	activity	changes	
to	the	protein	with	phosphorylation	typically	activating.	Phosphorylation	events	are	
catalysed	by	kinases	where	hydroxyl	groups	(-OH)	of	serine,	threonine,	tyrosine	amino	
acid	side	chains	the	most	important.	TP53	has	23	different	phosphorylation	and	de-	
phosphorylation	sites	typically	within	N	and	C-terminal	regions.		Following	DNA	
damage	p53	is	phosphorylated	by	a	plethora	of	kinases	resulting	in	its	stabilisation.	
Numerous	kinases	involved	in	phosphorylation	have	been	described,	some	highlighted	
in	figure	4.1.3.			
	
Figure	4.1.3	p53	post	translational	modifications:	phosphorylation,	ubiquitination	and	
acetylation.		
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Specific	PTMs	are	shown	corresponding	to	p53	domains	of	TAD,	transactivation	domain,	PRD,	
proline	rich	domain,	DNA	binding	domain,	TD,	transactivation	domain	and	CRD,	C	terminus	
regulatory	domain.	Modifying	PTM	enzymes	are	shown	on	the	right,	but	not	limited	too.	
Compare	this	figure	with	figure	4.1.2	for	anti-proliferative	programs	corresponding	to	
functional	domains.	For	example,	Ser46	in	DB	is	crucial	for	apoptosis	induction.	P	–	
phosphorylation,	U	–	ubiquitination	and	A	representing	acetylation.		
	
Typically	induced	by	DNA	damage,	phosphorylation	of	p53	is	crucial	for	protein	–	
protein	interactions	and	potentially	regulates	target	gene	selectivity.	For	example,	
phosphorylation	by	Chk1	and	Chk2	at	Ser20,	ATR	and	ATM	on	Ser15,	and	Thr32	by	JNK	(c-
Jun	N-terminal)	kinases	in	response	to	DNA	damage	is	crucial	for	disrupting	and	
reducing	the	affinity	of	p53-MDM2	interaction,	enabling	a	tighter	association	with	co	
factors	and	nuclear	accumulation	(Buschmann	et	al.	2001:	Anderson	and	Appella,	
2001).	Other	phosphorylation	events	resulting	in	attenuation	of	p53	–	MDM2	
interaction	are	highlighted	in	figure	4.1.	4.	For	example,	p16/ARF	induced	oncogenic	
stress	inhibits	MDM2.	Indeed,	the	importance	of	phosphorylation	on	these	sites	for	
apoptosis	has	been	demonstrated.	Transgenic	mice	expressing	mutated	Ser	15	and	Ser20	
residues	displayed	decreased	p53	stability	and	an	abrogated	apoptotic	response	(Chao	
et	al.	2006).	Whilst	Ser46	phosphorylation	by	DYRK2	(Dual	specificity	tyrosine-
phosphorylation-regulated	kinase)	is	pivotal	for	the	induction	of	pro-apoptotic	gene	
p53AIP1	and	p53	dependent	apoptosis	evidenced	by	p53	knock	in	mouse	(Tiara	et	al.	
2007).		
	
4.1.3.5.2	Acetylation		
Acetylation	refers	to	the	addition	of	an	acetyl	group	(CH3CO).	Similar	to	
phosphorylation,	acetylation	is	a	reversible	process	via	the	action	of	HDACs	(histone	
deacetylases).	HATs	are	a	well	characterised	acetyltransferase	group	(Histone	
acetyltransferases)	due	to	their	histone	targets.	HATs	transfer	an	acetyl	group	from	
acetyl	CoA	to	the	terminal	amino	side	chain	of	lysines	(Legube	and	Trouche,	2003).	
Similar	to	phosphates,	the	addition	and	conversion	of	the	+ve	charged	lysine	to	acetyl	–	
lysine	results	in	modification	of	protein	conformation	and	trans-activities.	For	instance,	
histone	acetylation	typically	results	in	the	recruitment	of	co-factors,	regulates	
transcription	factors.	This	results	in	increased	transcriptional	activity,	thus	has	a	major	
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role	in	cellular	fate.	HATs	in	addition	to	histone	chromatin	opening	also	target	
transcription	factors	such	as	p53	to	modulate	their	transcriptional	activity.	
Acetylation	is	thus	an	important	protein	modification	which	correlates	with	increased	
p53	transcriptional	activity	(Kouzarides,	2000).	The	importance	of	p53	acetylation	is	
three-fold:	1)	promoting	p53	stabilisation	by	eliminating	ubiquitination	on	the	same	
site,	2)	it	attenuates	MDM2/MDMX	complex	on	target	gene	promoters	and	lastly,	3)	
recruits	co-factors	for	activation	of	p53	transcriptional	activity.		
	
Various	studies	have	reported	how	DNA	damage	pathways	activate	p53	acetylation	via	
acetyltransferases,	or	induce	them	via	p53	phosphorylation.	The	C	–	terminus	
comprises	six	lysines	that	are	targeted	for	acetylation	by	HATs	and	p53	transcriptional	
co	factors.	For	example,	p300	and	CBP	which	include	lysine	sites:	K305,	K370,	K372,	
K381,	K382	and	K386	(Meek	and	Anderson,	2009).	MDM2	also	targets	the	same	C	–	
terminal	sites	for	ubiquitination.	Therefore,	a	key	function	of	acetylation	is	inhibition	of	
ubiquitination	and	p53	downregulation	(Li	et	al.2002).	Acetylation	also	opposes	MDMX	
and	MDM2	recruitment,	attenuating	MDM2/MDMX	–	p53	complexes,	resulting	in	
transcriptional	activation	(Li	et	al.	2002).		Acetylation	of	K320	in	the	TET	domain	by	
PCAF	promotes	activation	of	p53	responsive	cell	cycle	arrest	genes	(figure	4.1.3)	thus	
favouring	cell	survival	over	apoptosis	(Knights	et	al.2006).	In	parallel,	another	study	
using	mice	expressing	p53	(317	residue)	lysine	–	arginine	substitution	(K320	in	human)	
exhibited	enhanced	p53	dependant	apoptosis	following	DNA	damage	(Chao	et	al.	
2006).	Furthermore,	human	cell	lines	expressing	lysine	–	arginine	substitution	failed	to	
induce	apoptosis	and	cell	cycle	arrest	by	non-expression	of	pro	apoptotic	genes,	yet	
retained	the	ability	to	mediate	MDM2	expression	(Tang	et	al.2008).	This	study	
concludes	that	non-	acetylated	p53	is	able	to	sustain	a	negative	feedback	loop,	
however	acetylation	is	a	prerequisite	for	p53	function.		Collectively,	these	studies	
indicate	that	acetylation	is	important	PTM	for	p53	activities.	
	
4.1.3.5.3	Ubiquitination	
Ubiquitination	refers	to	the	process	of	covalent	conjugation	of	one	or	more	ubiquitin	
molecules	to	a	specific	protein	substrate.	Typically	resulting	in	protein	degradation.		
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This	requires	interactions	of	three	enzymes:	E1	ubiquitin	activating,	E2	ubiquitin	
conjugating	and	E3	ubiquitin	ligating	enzyme.	TP53	comprises	20	lysine	sites	clustered	
around	three	locations:	one	within	TAD,	five	at	the	N-	terminus	within	the	DBD,	the	
remainder	located	within	C	-	terminus.	Ubiquitination	is	pivotal	to	p53	stabilization,	
activation	and	localization.	One	of	the	most	important	ubiquitination	events	of	protein	
–	protein	interactions	is	the	p53-MDM2	affiliation	which	lies	at	the	core	of	the	p53	
network.		
	
4.1.3.6	The	p53-MDM2-MDMX	relationship		
As	previously	described,	p53	expression	must	be	tightly	regulated	and	maintained	at	
steady	state	levels	for	genomic	integrity.	Perturbation	of	this	system	may	result	in	
aberrant	proliferation	and	malignant	cellular	phenotypes.	This	regulation	is	maintained	
through	p53’s	primary	negative	regulator,	oncoprotein	RING	finger	type	E3	ligase	
MDM2,	and	to	a	lesser	extent,	MDMX	(MDM4).		
	
p53	is	maintained	at	low	cellular	concentrations	through	MDM2	26S	mediated	
proteasome	degradation	and	ubiquitination	(Ringshausen	et	al.2006).	This	occurs	on	
several	lysine	residues	within	p53	C-terminus	as	demonstrated	in	vivo;	K101,	K120,	
K132,	K139,	K370,	K372,	K373,	K381,	K382,	and	K386	(Feng	et	al.	2005)	(figure	4.1.3).	
Mono	and	poly	ubiquitination	adds	complexity	to	p53	regulation	involving	other	key	
players.	High	levels	of	MDM2	induce	p53	poly	-	ubiquitination,	leading	to	degradation,	
with	co	factors	E4	ligases	CBP/p300	mediating	this	process.	Lower	levels	induce	mono-	
ubiquitination	leading	to	p53	nuclear	exportation	and	cytoplasmic	translocation	(Li	et	
al.	2003).	Mono-ubiquitination	typically	occurs	on	several	lysine	residues	in	the	C-	
terminus	as	above.	However,	a	recent	study	using	spectrometry	analysis	has	identified	
the	central	p53	domain	as	the	dominant	acceptor	sites	for	MDM2	and	E3	ligase	PirH2	
(Shloush	et	al.2012).		
	
MDM2	expression	is	transcriptionally	regulated	by	p53	within	an	auto	regulatory	
feedback	loop.	MDM2	binds	directly	to	p53	N	-	terminal	transactivation	domain,	
termed	BOX-1	via	negative	feedback	mechanisms	inhibiting	phosphorylation,	p53	
stabilisation	and	trans-activation	function.	The	relevance	of	this	feedback	mechanism	
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has	been	demonstrated	in	early	studies	of	MDM2	null	mice	which	displayed	embryonic	
lethality	arising	from	over	expressed	p53,	rescued	only	by	simultaneous	deletion	of	p53	
(Montes	et	al.1995).	Furthermore,	dysfunction	of	this	loop	results	in	tumour	prone	
cells.	For	example,	mice	over	expressing	MDM2	inhibit	p53	function	promoting	
tumorigenesis	(Montes	et	al.	1995).	Taken	together	these	studies	indicate	MDM2	as	
p53’s	primary	negative	regulator. 	
	
Another	important	negative	regulator,	non	E3	ligase	MDMX,	a	MDM2	homolog,	also	
binds	to	p53	trans-activation	domain	inhibiting	p53	stabilisation	and	transcriptional	
activity,	however	with	less	efficiency	than	MDM2.		MDMX	contains	a	RING	domain	
structurally	similar	to	MDM2,	however	does	not	possess	E3	activity	(Jackson	et	al.2000;	
Stad	et	al.2001).	Even	so,	MDMX	has	been	shown	to	be	as	fundamentally	important	for	
p53	regulation.	Similar	to	MDM2,	loss	of	MDMX	in	mice	models	results	in	embryonic	
lethality	and	rescued	only	by	p53	gene	deletion	(Zhang	et	al.2014).	This	feedback	loop	
is	therefore	a	key	signalling	pathway	within	the	p53	network.	The	above	summarises	a	
modest	version	of	p53-MDM2	relationship.	Indeed,	this	core	loop	is	embedded	within	
an	intricate	network	of	p53	responsive	genes	which	converge	onto	the	p53	/	
MDM2/MDMX	axis	providing	additional	layers	of	complexity	and	regulation	to	the	p53-
MDM2	pathway	and	network.	
	
4.1.3.7	The	p53	network		
p53	along	with	its	upstream	regulators	and	downstream	effectors	comprise	a	complex	
network	of	multiple	signalling	layers.		As	previously	stated,	dysfunction	of	this	pathway	
arising	from	deregulation	of	its	components,	specifically	p53	may	result	in	tumour	
formation.	Indeed,	majority	of	human	cancers	acquire	mutations	which	abrogate	p53	
network.	This	complex	network	may	be	divided	into	several	layers	as	highlighted	in	
figure	4.1.4	of	a	simple	model	comprising	upstream	and	downstream	events	and	the	
network	core-	p53	and	MDM2.	
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4.1.3.7.1	Upstream	events		
p53	activation	typically	manifests	in	three	distinct	steps;	stabilisation,	sequence	specific	
DNA	binding	and	transcriptional	activation	or	repression	of	target	genes	in	response	to	
genotoxic	and	non-genotoxic	stresses	that	include;	ultraviolet,	ionising	radiation	or	
oncogenic	stress	and	hypoxia	respectively.		Activation	and	induction	of	p53	are	
important	steps	for	initiating	the	anti-proliferative	program,	however	many	questions	
remain	unanswered	regarding	pathways	and	upstream	signals	that	initiate	p53	activity,	
highlighting	the	complexity	of	the	network	(Loughery	and	Meek,	2013).	Whilst	both	
genotoxic	and	non-genotoxic	stresses	are	important	processes	for	tumorigenesis,	this	
report	focuses	upon	upstream	genotoxic	stresses	of	DNA	damage	only.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.1.4	A	simplified	model	of	the	p53	network		
The	p53	pathway	is	complex.	At	least	50	different	proteins	can	modify	p53s	stability,	cellular	
location	or	activity.	The	above	image	depicts	a	minority	of	these.	Five	layers	of	regulation	are	
observed;	Cellular	stresses	including	DNA	damage,	and	oncogenic	activation.	Upstream	
regulators	that	activate	p53,	the	p53-MDM2	core	for	p53	stabilisation,	lastly	p53	responsive	
downstream	effectors	which	elicit	the	different	responses	dependant	on	stress	severity	and	
type.	A	single	effector	may	regulate	different	processes.	For	example,	E2F1	and	p21	can	exert	
effect	on	both	cell	cycle	arrest	and	senescence.		
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4.1.3.7.2	DNA	damage	
The	integrity	and	fidelity	of	DNA	is	crucial	for	accurate	hereditary	genetic	replication.	
DNA	is	continually	exposed	to	endogenous	and	exogenous	stresses	including	reactive	
oxygen	species	arising	from	metabolic	processes,	ionising	radiation,	ultraviolet	lights,	
and	chemicals	respectively.	A	tightly	controlled	and	competent	DNA	damage	response	
arising	from	DNA	lesions	and	chromosomal	damage	is	pivotal,	allowing	for	DNA	repair,	
genomic	integrity	and	thus	inhibition	of	tumorigenesis		
	
Dependant	on	DNA	damage	type	and	severity,	p53	regulatory	pathways	may	initiate	
cell	cycle	arrest	or	apoptosis	for	repair	or	cell	death	respectively.	For	example,	
moderate	DNA	damage	induces	a	slight	increase	in	p53	levels	resulting	in	transient	cell	
cycle	arrest,	whilst	severe	and	irreparable	damage	results	in	highly	increased	p53	levels	
and	apoptosis	(Vousden	and	Liu,	2003).	Severe	DNA	damage	such	as	in	transcription-
coupled	repair	defects	appears	to	display	constitutive	DNA	damage	signalling,	however	
a	loss	of	DNA	damage	downstream	effectors	appears	to	display	a	tumour	susceptible	
phenotype.	Indeed,	p53	gene	null	mice	are	tumour	prone	and	susceptible	to	neoplastic	
disease	(Jacks	et	al.1994).	The	severity	of	DNA	damage	also	impacts	p53	dynamics	of	a	
bimodal	switch	function	in	U20S	and	A549	etoposide	treated	cell	lines	in	a	dose	
dependant	manner	which	shifted	cell	profile	fate.	Mild	DNA	damage	induced	at	lower	
etoposide	concentrations	resulted	in	periodic	oscillations	of	p53	activity	and	cell	cycle	
arrest,	whereas,	at	higher	levels	of	etoposide	(100	μmol/l)	strong	monotonic	increases	
of	p53	where	observed	with	a	cell	profile	shift	to	apoptosis.	Moreover,	this	DNA	
damage	dose	dependant	bimodal	switch	was	induced	by	differential	MDM2	
upregulation	with	higher	levels	allowing	continuous	accumulation	of	p53,	conversely,	
lower	levels	dictated	cellular	fate	(Chen	et	al.2013).	Indeed,	this	coincides	with	p53	
activity,	for	example	prolonged	p53	stabilisation	leads	to	expression	of	pro	apoptotic	
genes	(Jackson	and	Bartek,	2009).		
	
	
4.1.3.7.3	Hypoxia	
Hypoxia	results	from	an	insufficient	oxygen	supply	that	compromises	biologic	
processes.	Along	with	cancer,	tissue	hypoxia	is	implicated	in	various	pathologies	
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including	those	of	pulmonary,	cardiovascular	and	inflammatory	origin	(Airley	et	
al.2000).		
Hypoxia	is	a	characteristic	state	in	solid	tumours	(Vaupel	and	Mayer,	2007)	arising	from	
the	oxygen	deprivation	in	the	tumour	microenvironment,	and,	along	with	ischemia	
initiates	the	various	processes	associated	with	tumour	angiogenesis	(Ching	et	al.2010).	
Tumour	hypoxia	can	be	defined	dependant	on	severity	typically	being	a	reduction	of	
oxygen	consisting	of	less	than	10	–	15	mm	Hg	partial	pressure	of	internal	oxygen	(pO2)	
or,	severe	hypoxia	pO2	<0.33%,	2.5	mmHg	(Khan	et	al.	2012).		
Hypoxia	is	associated	with	tumour	aggressiveness,	progression	and	a	poor	patient	
survival	rate	(Chang	et	al.2011).	Low	oxygen	levels	in	tumour	cells	reduce	the	efficacy	
of	anti-cancer	treatments	resulting	in	a	resistant	tumour.	This	is	largely	due	to	the	fact	
that	specific	anti-cancer	drugs	or	ionising	radiation	require	oxygen	free	radicals	to	
effectively	destroy	cells.	Additional	drug	resistance	arises	from	the	low	oxygen	levels	
that	reduce	cell	proliferation	and	enhance	growth	arrest.	This	is	problematic	as	anti-
cancer	drugs	typically	target	high	proliferating	cells.	Moreover,	the	reduced	oxygen	
level	results	in	ineffective	drug	delivery	to	the	intended	hypoxic	region.	Thus,	
elucidating	the	molecular	mechanisms	of	hypoxic	regulation	is	of	central	importance	to	
effective	cancer	strategies.		
The	biological	and	molecular	signatures	of	hypoxic	tumours	to	normal	tissues	are	
distinct.	The	insufficient	vasculature	in	a	solid	tumour	mass	results	in	a	heterogeneous,	
dynamic	micro	-	environment	of	perturbed	molecular	signatures,	promoting	genomic	
instability	via	point	mutations,	gene	amplification	or	inhibition,	and	chromosomal	
rearrangements	and	low	pH	and	glucose	concentrations.			
The	transcription	factor	HIF-1a	is	well	postulated	as	the	main	hypoxia	inducible	gene.	
Under	normoxic	conditions	the	tumour	suppressor,	VHL	ubiquitinates	and	degrades	HIF	
–	1a	conversely,	under	low	oxygen	levels	this	interaction	is	inhibited	(Ziello	et	al.2007).	
It	is	well	established	that	hypoxia	promotes	angiogenesis,	a	situation	created	from	the	
metabolic	demands	of	the	proliferative	tumour.	HIF-1a	dependant	induction	of	VEGFA	
is	central	to	this	process	inducing	endothelial	cell	migration	and	tumour	survival	and	is	
highlighted	by	the	fact	that	HIF-	1a	levels	correlate	with	tumour	grade	(ZagZag	et	
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al.2000).	Upon	activation,	HIF-1a	regulates	a	plethora	of	target	genes	involved	in	
proliferation,	vascularisation	and	glucose	metabolism.			
Even	though	in	the	majority	of	tumours,	p53	pathways	are	inactive	and	hypoxia	
tolerance	can	result	from	the	loss	of	p53,	hypoxia	at	0.02	%	O2	can	activate	p53	and	its	
apoptotic	pathways	independent	of	HIF	–	1a	(Soussi	and	Beroud,	2001;	Hammond	and	
Giaccia,	2005).	However,	the	activity	of	p53	and	its	resultant	induction	of	typical	target	
genes	differ	to	those	induced	by	DNA	damage.		It	has	been	postulated	that	this	is	due	
to	the	failure	of	CBP	and	p300	co	factor	recruitment	to	p53	promoters	(Hammond	et	
al.2006).		Additionally,	under	these	hypoxic	conditions,	p53	activity	is	typically	trans-	
repressive	rather	than	trans	-	activating.	For	example,	p53	acetylation	by	PCAF	at	K320	
is	decreased	under	low	oxygen	conditions.	The	acetylation	of	this	residue	has	been	
determined	as	crucial	for	the	induction	of	p53	target	genes	(Xenaki	et	al.2008).	
Moreover,	hypoxia	induced	p53	has	also	been	shown	to	interact	with	the	
transcriptional	corepressor	mSin3A	in	place	of	its	traditional	co	activator	p300	
(Koumenis	et	al.2001).	Only	a	few	hypoxia	regulated	p53	dependant	inhibited	genes	
have	been	described	such	as	BIRC3	and	p21	(Long	et	al.1997;	Liu	et	al.2007).	With	this	
in	mind,	uncovering	the	hypoxic	pathways	that	govern	p53	is	of	importance.		
	
4.1.3.8	Downstream	events	
In	response	to	stresses,	activated	p53	protein	functions	as	a	transcription	factor	
inducing	a	transcriptional	program	reflecting	the	stress	signal	and	corresponding	
proteins	and	their	modifications.	Upon	activation,	p53	represses	or	activates	its	
downstream	target	genes	binding	mainly	to	a	specific	21	nucleotide	DNA	sequence	
termed	the	responsive	element	(El-Deiry	et	al.	1992).	These	effector	genes	which	work	
in	concert	may	initiate	various	independent	anti-	proliferative	outcomes,	discussed	
below.		
	
4.1.3.8.1	Cell	cycle	arrest	
The	cell	cycle	constitutes	several	important	phases;	S	phase	(DNA	synthesis),	M	phase	
(mitosis)	and	the	gap	phases	GO	and	G1/2.	In	response	to	various	stresses	such	as	DNA	
damage,	cells	may	undergo	growth	arrest	at	the	various	checkpoints	for	prevention	of	
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DNA	mutations	prior	to	replication.	Checkpoints	are	important	stages	which	ensure	
fidelity	and	accuracy	of	cell	division	during	each	phase	prior	to	proceeding	to	
replication.	The	various	checkpoints	are	regulated	by	various	cyclins	(cell	cycle	
proteins),	CDKs	(Cyclin	dependant	kinases)	and	their	inhibitors,	CDKIs	(Cyclin	
dependant	kinase	inhibitors).	Negative	modulators	of	the	cell	cycle,	CDKIs	constitute	
two	families;	KIP/CIP	(p21,	p⁵⁷ᴷᴵᴾᴵᴵ	and	p²⁷ᴷᴵᴾᴵᴵ)	and	INK4	(p¹⁹ᴵnk,	p¹⁸ᴵnk	and	pᴵ⁶ink).	These	are	
highlighted	in	figure	4.1.5.		
	
	
Figure	4.1.5	Cell	cycle	phases	and	the	corresponding	CDKs	and	CDKIs		
The	four	different	phases	are	shown.	Cell-cycle	checkpoints	G1/S	and	G2/M	control	cell-cycle	
transitions,	ensuring	the	critical	events	(DNA	replication	and	chromosome	segregation)	are	
completed	correctly	pre	progression.	The	major	cell-cycle	restriction	point	(R)	is	located	the	
end	of	the	G1	phase.	After	this	point,	they	will	complete	cell	cycle.	Progression	through	M	is	via	
CDKs	and	their	activating	cyclin	subunits.	CDK	activity	is	suppressed	by	CDKIs:	INK4	family	
which	selectively	inhibits	CDK4/6,	and	the	CIP/KIP	family	which	displays	a	wider	CDK	inhibitory	
activity	range.		
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In	response	to	DNA	damage,	p53	trans-activates	these	downstream	effectors	to	
promote	cell	cycle	arrest.	Many	key	upstream	regulators	and	downstream	p53	
effectors	have	been	extensively	described,	some	highlighted	in	figure	4.1.6	of	DNA	
damage	utilising	the	p53/p21/pRB/E2F	pathway.	Feedback	loops	exist,	specifically	RB,	
E2F1	and	CDK2	(retinoblastoma	protein,	E2F	transcription	factor	1,	cyclin	dependant	
kinase	2)	(Yi	et	al.2013).			The	upstream	ATM/ATR	pathway	has	shown	to	be	pivotal	for	
p53	activation	and	subsequent	expression	of	downstream	targets	for	G1	arrest	as	
shown	in	murine	embryo	fibroblasts	in	response	to	DNA	damage.		Disruption	of	the	
p21	gene	has	demonstrated	abrogation	of	the	G1/S	checkpoint	in	MEFs	which	extended	
their	lifespan	displaying	a	proliferative	phenotype;	as	such	G1	arrest	through	this	
pathway	is	primarily	induced	via	p53	-	p21	(Deng	et	al.	2005).	The	trans-activation	of	
p21	by	p53	can	inhibit	CDK2/cyclin	E	as	such	retinoblastoma	(RB)	cannot	be	
phosphorylated.	Activated	RB	leads	to	E2F1	inhibition	and	as	a	result,	cells	undergo	
proliferation	arrest	for	DNA	damage	repair	with	failure	of	cell	cycle	completion	(Dulic	et	
al.1994).	Moreover,	p53	downstream	target	p21	has	shown	to	be	a	key	player	with	
various	effector	functions	in	cell	cycle	regulation.	For	example,	p21	induces	inhibition	
of	CDK4	and	PCNA	(Proliferating	Cell	Nuclear	Antigen)	preventing	DNA	synthesis	in	
response	to	DNA	damage	(Rousseau	et	al,	1999).	Other	important	checkpoint	arrests	
induced	by	p53	in	response	to	DNA	damage	include	for	example:	G2/M	arrest	from	
repression	of	mitosis	promoting	phosphatase	cdc25c	and	also	14-3-3a	(St	Clair	and	
Manfredi,	2006).		
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Figure	4.1.6	DNA	damage	response	utilising	the	p53/p21/pRB/E2F	pathway.		
	The	INK4a/ARF	locus	encodes	both	ARF	/	p16	protein.	ARF	stimulates	and	activates	p53	
through	inhibition	and	degradation	of	MDM2,	in	turn	trans	-activating	p21.		p21,	which	inhibits	
CDK2/cyclin	E	with	the	consequent	inhibition	of	CDK2-dependent	phosphorylation	of	Rb.	Un	
phosphorylated	RB	suppresses	the	function	of	the	G1/S	phase-promoting	factor,	E2F,	resulting	
in	proliferation	arrest	and	DNA	damage	repair.	Similarly,	p16	may	inhibit	CDK4-6/cyclin	D	
complex	thereby	reducing	Rb	phosphorylation	and	subsequent	downstream	signal	
transduction	pathways,	resulting	in	G1	arrest.	Bmi1	has	a	inhibitory	role	on	ROS	(reactive	
oxygen	species).		
	
	
	
4.1.3.8.2	Cellular	senescence		
Senescence	is	a	permanent	form	of	cell	cycle	arrest,	first	described	in	human	fibroblast	
cells	(Hayflick,	1965).	Senescent	cells	are	relatively	stable,	lack	proliferation	yet	retain	
metabolic	activity,	contrasting	cancerous	cells	which	are	invasive	with	uncontrolled	
proliferation	and	resistant	to	apoptotic	signals.	The	importance	of	senescence	in	
repression	of	tumorigenesis	has	been	highlighted	with	senescence	gene	mutations	
frequently	associated	with	tumour	progression.	Indeed,	senescent	cells	have	been	
identified	in	various	pre	malignant	human	tumours	(Chen	et	al.2005).	The	RAF	/	MEK	
pathway	downstream	of	oncogene	Ras	seems	to	be	the	most	important	in	activating	
the	senescence	program	(Loughery	and	Meek,	2013).		
	
Senescence	cellular	phenotypes	are	distinct;	morphologically	larger	and	flatter	
comprising	intracellular	particles.	In	normal	cell	growth,	replicative	senescence	is	
induced	upon	maximum	telomere	length	and	thus	cell	proliferation	halted	(Herbig	et	
al.	2004).	DNA	damaged	induced	premature	senescence	however	is	via	oncogene	
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induced	replicative	stress,	or	oxidative	stress	(Bartek	et	al.2008),	utilising	different	
pathways.	For	example,	premature	senescence	is	signalled	by	either	downstream	
p53/p21/pRb/E2F	or	p16/p21/pRb/E2F	pathways,	along	with	anti	-proliferative	mir-34.		
In	contrast	regulators	of	replicative	senescence	are	induced	by	p53/p21/pRb/E2F	solely	
(Campisi	et	al.2005).	As	such	senescence	markers	include	β-galactosidase,	p53INK4b	
and	p53INK4a	cyclin	kinase	inhibitors	(Campisi	et	al.2007).	A	link	between	both	p53	
and	RB	have	recently	been	described	for	the	E421	transcription	factor	functioning	as	a	
direct	p53	target	for	senescence,	inducing	repression	of	several	E2F	target	genes	
promoting	cell	cycle	arrest	and	tumorigenesis	development	(Aksoy	et	al.2013).	This	
highlights	the	importance	of	p53	as	core	regulator,	p21	as	a	key	player	and	
retinoblastoma	protein	for	the	tumour	suppressor	pathway	consistent	with	senescence	
being	a	permanent	form	of	cell	cycle	arrest.		
	
4.1.3.8.3	Apoptosis		
The	role	of	p53	and	apoptosis	was	first	described	in	p53	wildtype	leukemic	cells	which	
displayed	apoptotic	characteristics	such	as	chromatin	condensation	and	fragmented	
nuclei	(Yonish-Rouach	et	al.	1991).	Later	studies	shortly	thereafter	revealed	that	p53	
dependant	apoptosis	contributed	to	chemotherapeutic	induced	cell	death	against	DNA	
damaging	stresses	(Lowe	and	Ruley,	1993).	Indeed,	p53	inactivation	in	lymphoma	
mouse	model	demonstrated	accelerated	tumour	development	with	increased	
invasiveness	(Eiscen	et	al.1999:	Schmitt	et	al.	2003).	The	apoptotic	program	is	complex	
and	regulated	at	multiple	levels.	It	operates	by	two	main	pathways	of	intrinsic	and	
extrinsic	referring	to	cell	death	receptor	pathway	and	intrinsic	mitochondrial	activity	
respectively.	p53	is	a	master	regulator	of	both,	however	p53	–	dependent	apoptosis	
typically	follows	the	mitochondrial	pathway.		
	
I. Extrinsic	Pathways		
p53	–	dependant	apoptosis	involves	both	transcription	dependant	and	
independent	p53	mechanisms	in	concert.	The	extrinsic	pathway	as	stated	is	also	
p53	regulated,	however	less	is	understood	regarding	the	overall	program	
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leading	to	apoptosis	than	intrinsic.	FAS	/	CD95,	DR5	death	receptor	and	TNFSF6	
the	gene	encoding	FAS	loci	are	all	direct	p53	targets	inducing	expression	of	
FADD	and	TRADD	(Fas	–TNFRSF6-associated	via	death	domain	and	TNFRSF1A-
associated	death	domain	respectively).	These	in	turn	initiate	a	caspase	cascade	
via	caspase-8	orchestrating	the	apoptotic	program.	Conversely,	p53	may	induce	
apoptosis	via	repression	of	anti-apoptotic	genes,	further	promoting	caspase	
expression	(Hoffman	et	al.2002).	Considerable	cross	talk	exists	within	the	
caspase	cascade	between	both	signalling	pathways	including	p53s	ability	to	
trans-activate	BID,	further	facilitating	the	crosstalk	between	intrinsic	and	
extrinsic	pathways,	(Sax	et	al.	2002).	Similarly,	apoptotic	inhibitors	such	as	the	
candidate	therapeutic	target	-	IAP	protein	(Vucic	and	Fairbrother,	2007)	was	
also	observed	in	both	pathways	functioning	to	prevent	apoptosis,	maintaining	
tumour	survival.	Either	way,	p53	can	sensitise	cells	to	death	receptor	ligands	
enhancing	the	apoptotic	program.	
	
II. Intrinsic	pathway		
At	the	mitochondria	p53	tran-sactivates	various	pro-apoptotic	genes	of	intrinsic	
pathway	in	response	to	various	cell	death	signals	such	as	DNA	damage	
including;	PIG3,	perp,	Killer/DR5	and	members	of	the	Bcl-2	family,	such	as	BAX,	
Puma	and	NOXA	(Riley	et	al.2008).	Gene	targeting	studies	in	mice	models	and	in	
various	cell	lines	have	demonstrated	the	importance	of	p53	inducing	these	
downstream	effectors	during	apoptosis	for	repression	of	Bcl-2	members.	For	
example,	Bax	null	mice	embryo	fibroblasts	are	desensitised	to	p53	oncogene	
induced	apoptosis	resulting	in	enhanced	tumorigenesis	in	vivo	and	in	vitro	(Yin	
et	al.	1997).	Bcl2	members	down	regulate	pro-apoptotic	genes	BAK	and	BAX,	
which	in	turn	release	cytochrome	c	enhancing	apoptosis	via	the	caspase	
cascade.	Whilst	puma	knockout	mice	display	decreased	apoptosis	with	NOXA	
contributing	to	this	outcome	(Jeffers	et	al.2003).	Even	so,	the	complexity	of	p53	
pathways	is	highlighted	in	this	study	that	Puma	null	mice	were	not	overly	
tumour	susceptible,	thus	signifying	the	requirement	of	various	p53	effector	
targets	for	inducing	tumorigenesis.	This	complexity	is	further	evidenced	by	
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cross	talk	within	the	p53	network	of	a	particular	effector	comprising	more	than	
one	function.	For	example,	p21	functions	in	cell	cycle	arrest,	however	has	the	
capability	to	attenuate	apoptosis	(Seonane	et	al.2002),	similarly	for	the	
described	miR34	mRNA	family	(He	et	al.2007).		
	
The	existence	of	feedback	loops,	pathway	cross	talk	and	synchronous	effector	
functions	with	various	gene	deletion	studies	creating	phenotypes	of	a	particular	
effector	loss,	yet	p53	and	other	effector	functions	remain	intact;	highlight	the	
complexity	of	the	p53	signalling	network	holistically	as	a	tumour	suppressive	program.	
Therefore,	dissecting	the	p53	network	and	its	components	are	crucial	to	gain	a	better	
understanding	of	its	role	in	cancer	and	development	of	effective	therapies.		
	
	
4.1.3.8.4	Angiogenesis	
Angiogenesis	may	be	defined	as	the	formation	of	new	blood	vessels	and	vasculature.	
This	is	a	complex	process	requiring	the	synchronised	activity	of	various	cell	and	
vascular	components;	endothelial	cells	division	and	later	migration,	with	vascular	
basement	membrane	and	surrounding	extracellular	matrix	degradation	(Folkman,	
2002).	In	adults,	angiogenesis	is	involved	in	many	normal	physiological	processes	
including	wound	repair,	ischemia	and	embryogenesis	(Ching	et	al.	2010).	Its	role	in	
cancer	pathogenesis	has	been	well	defined.	Both	tumour	growth	and	metastasis	are	
dependent	on	angiogenesis	and	lymphangiogenesis.		Indeed,	angiogenesis	is	
characterised	as	one	of	the	hallmarks	of	cancer	(Hanahan	and	Weinberg,	2011)	where	
quiescent	endothelial	cells	display	a	proliferative	phenotype	in	response	to	pro	
angiogenic	signals.		
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Hypoxia	is	a	characteristic	state	in	solid	tumours	(Voupel	and	Mayer,	2007).	This	arises	
from	oxygen	deprivation	in	the	tumour	microenvironment	that	initiates	various	
processes	associated	with	tumour	angiogenesis	(Ching	et	al.2010).	Other	stimulus	
includes	mechanical	stress	and	hypoglycaemia	(Ferrara,	2004).	The’	angiogenic	switch’	
whereby	tumours	progress	exponentially	to	propagate	past	their	primary	location	from	
unbalanced	equilibrium	of	pro	and	anti	angiogenic	factors	has	been	observed	in	both	
human	tumour	and	experimental	models	(Folkman,	2002).	These	various	studies	have	
led	to	the	characterisation	of	a	plethora	of	angiogenic	factors	involved	in	tumour	
angiogenesis.	In	particular,	VEGFA,	a	potent	pro	angiogenic	factor	(Ferrara	2009).		
	
Under	normal	physiological	processes,	the	angiogenic	network	is	tightly	controlled.	
Conversely,	in	tumour	angiogenesis	perturbation	of	this	controlled	network	is	typical	
due	to	an	upregulated	state	arising	from	the	shift	‘switch’	between	pro	and	anti	
angiogenic	factors	(Folkman,	2002).	Hypoxia	is	the	most	well	studied	stimuli	for	tumour	
angiogenesis.	This	hypoxic	micro-environment	stimulates	the	angiogenic	network	
resulting	in	sprouting	angiogenesis	(sprouting	of	blood	vessels)	from	adjacent	tissues	
into	the	tumour	(Folkman,	2002).	Growth	of	the	tumour	at	this	stage	around	2	mm	in	
diameter	is	typical.	Angiogenesis	pathology	may	be	defined	by	a	change	in	endothelial	
cell	phenotype	to	that	of	invasive	and	proliferative	with	atypical	tumour	vasculature	
morphology	arising	from	structural	abnormalities	of	venules,	capillaries	and	arterioles.	
The	typically	tight	vasculature	becomes	leaky	due	to	the	loose	EC	monolayer.		
	
The	angiogenic	signalling	network	involved	in	tumour	pathogenesis	is	both	complex	
and	dynamic.	It	comprises	a	plethora	of	pro	and	angiogenic	signals	including	
angiopoietins,	endothelial	and	oxygen	sensors,	growth	factors	and	integrins,	in	addition	
to	various	others	described	in	detail	in	(Ferrara,	2004).	Numerous	studies	in	vivo	and	in	
vitro	have	uncovered	numerous	key	pro	angiogenic	factors	involved	in	this	process;	
VEGF,	TGFβ,	IL-8,	angiogenin	and	growth	factors:	endothelial,	placental,	hepatocyte	
and	epidermal,	probably	the	most	significant	(Nishida	et	al.2006).	In	particular,	the	
VEGF	family	(A-D),	(Ribatti,	2008).	Each	has	varying	angiogenic	roles	differing	in	their	
receptor	binding	specificity	dependant	on	function	and	tissue.	VEGF	C	and	D	are	
typically	involved	in	lymphanogenesis,	whilst	the	role	of	VEGFB	is	less	defined	(Nishida	
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et	al.2006).	VEGFA	however	is	a	well	characterised	pro	angiogenic	stimulator	inducing	
various	independent	angiogenic	cascades.		This	heparin	binding	glycoprotein	
constitutes	six	isoforms	as	a	consequence	of	alternative	mRNA	splicing	(Stalmans	et	
al.2002).	Figure	4.1.7	depicts	a	simplified	view	of	hypoxia	induced	VEGFA	angiogenic	
pathways.			
	
VEGFA	expression	is	highly	regulated	by	the	HIF	family	members,	particularly	HIF-1a	
(Ribatti	et	al.1999).	However,	hypoxia	induced	VEGF	expression	may	also	be	via	HIF	
independent	mechanisms	(Mizukami	et	al.2007).		EGF,	TGFβ	cytokines	along	with	p53	
are	also	pivotal	in	inducing	VEGF	expression	by	several	different	mechanisms	(Dvorak	
et	al.1999).	VEGFA	is	the	most	studied	member	and	its	increased	expression	is	
correlated	with	poor	patient	prognosis.	VEGFA	intra-tumoral	expression	has	been	
observed	in	various	tumours	including	breast,	lung,	ovarian	and	bladder	(Ferrara,	
2004). VEGFA	mechanism	of	action	is	exerted	via	interaction	with	tyrosine	kinase	
receptors;	VEGFR-1/2,	resulting	in	perturbed	effects	to	vascular	ECs	and	an	aggressive	
tumour	phenotype.	This	is	characterised	by	extracellular	matrix	degradation,	increased	
vascular	permeability	and	enhancement	of	EC	survival	via	opposing	apoptosis	(Ferrara,	
2004),	thereby	allowing	tumour	formation	and	progression.	These	various	different,	
yet	overlapping	independent	angiogenic	pathways	are	challenging.		Indeed,	numerous	
anti	angiogenic	therapies	targeting	VEGF	have	low	efficacy	with	limited	clinical	success.	
Some	has	even	shown	to	promote	cancer	progression	by	increased	invasion	and	
metastasis	(Ribatti,	2010).	This	inefficacy	is	probably	as	a	result	of	such	complexity	and	
resistance.	Even	systematic	approaches	have	been	used	to	dissect	angiogenic	network	
dynamics	for	effective	single	and	multi-combined	angiogenic	therapies	(Montanez	et	
al.2011).		
	
Given	this,	elucidating	the	role	of	pro	and	anti	angiogenic	factors,	identifying	effective	
markers	and	targeting	these	pro-proliferative	processes	is	pivotal	to	implementation	of	
successful	anti-cancer	therapy.	
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Figure	4.1.7	A	simplified	view	of	the	hypoxia	induced	angiogenic	pathway	via	VEGF		
VEGFA	activation	via	VEGFR	induces	several	pathways	to	induce	angiogenesis	via	cell	
proliferation,	survival	migration	and	vascular	permeability.	Signalling	via	RAS/MEK.ERK	induces	
expression	and	proliferation.	Signalling	via	PLC	activates	PKC	which	results	in	increased	
intracellular	Ca+	inducing	vascular	permeability	by	Nitric	oxide	(NO)	production	and	also	
prostaglandin	(Not	shown).	FAK	(focal	adhesion	kinase)	signalling	results	in	cell	migration.	
VEGFA	induction	of	p38	results	in	MAP2/3	and	hsp27	activation	and	subsequent	cell	migration.	
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p38	further	induces	p53	with	p21	activation,	however	hsp27	inhibits	p21	affecting	cell	cycle	
arrest.	The	p13K	pathway	ensures	cell	survival	via	PI3K	activated	conversion	of	PIP2	to	PIP3.	
This	results	in	cellular	membrane	translocation	and	activation	of	AKT	which	also	induces	
endothelial	NO	synthase	further	affecting	vascular	permeability,	however	in	parallel	inhibits	
caspase	9	and	BAD	(Pro	apoptotic	genes)	thus	maintaining	cell	survival.		Other	angiogenic	
inducers;	αv	integrins,	(transmembrane	receptors	which	bind	EM	proteins	promote	sprouting),	
cytokines	such	as	IL6,	and	growth	factors	including	FGF2	and	PDGFRB.		
	
	
4.1.3.8.5	DNA	repair		
Genotoxic	and	non-genotoxic	insults	arising	from	endogenous	and	exogenous	sources	
continually	challenge	genome	integrity.	Over	10,000	estimated	DNA	damaging	insults	
are	thought	to	impose	on	each	human	cell	per	year	(Lindahl	and	Barnes,	2000).		These	
can	impinge	upon	all	normal	cellular	functional	aspects	with	severe	consequence	to	cell	
homeostasis.	Transcription	and	replication	may	affect	cell	viability,	whilst	DNA	lesions	
arising	from	DNA	damage	may	induce	mutations	contributing	to	aging	or	diseases	such	
as	cancer	(Lindhall	and	Barnes,	2000).	DNA	repair	mechanisms	are	pivotal	for	reversal	
and	elimination	of	intrinsic	and	extrinsic	damage.	The	DNA	damage	response	(DDR)	is	a	
controlled	cascade	of	signal	transduction	events	that	has	evolved	to	maintain	genomic	
integrity	and	cell	survival	during	replication	by	DNA	damage	sensing	and	inducement	of	
various	repair	factors	(Harper	and	Elledge,	2007).	This	response	can	exert	its	effect	via	
several	different	mechanisms,	dependant	on	damage	severity	and	type.	For	example;	
transcriptional	activation,	inducing	cell	cycle	arrest,	senescence	for	DNA	repair	prior	to	
replication,	or	apoptosis	arising	from	irreparable	or	severe	damage	(Zhou	and	Elledge,	
2000).	The	importance	of	this	and	a	fully	functional	DDR	are	underscored	by	several	
diseases,	in	particular	cancer	or	neurological	pathologies	such	as	ataxia	telangiectasia	
from	mutated	ATM,	and	Fanconi	anemia	as	a	result	from	mutations	in	5	genes	which	
regulate	removal	of	inter-strand	DNA	cross	links	mainly	through	homologous	repair	
and	non-end	joining	pathways.	Briefly,	at	the	core	of	this	response	are	ATM	and	ATR	
DDR	kinases,	activated	by	DNA	damage	of	dsDNA	and	ssDNA	breaks	by	interaction	with	
regulators	MRN	and	ATRIP	complexes	respectively.	Activation	of	these	kinases	induces	
a	signalling	cascade	by	phosphorylation	of	a	plethora	of	downstream	responsive	genes	
including	the	well	characterised	CHK1	and	CHK2	and	later	BRCA1	/	2.	Matsukoa	et	al.	
(2007)	has	described	over	900	phosphorylation	sites	of	over	700	ATM/ATR	responsive	
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proteins	phosphorylated	from	the	DDR	on	consensus	sites	by	high	throughput	
proteomic	analysis.	Other	well	defined	DDR	regulators	include	CDK	and	DNA-PK.	Five	
major	types	of	DNA	repair	mechanisms	exist	and	are	discussed	briefly	These	events	are	
simplified	and	illustrated	in	Figures	4.1.8.	-	4.1.9.		
	
Base	excision	repair		
BER	is	responsible	for	repair	of	damaged	DNA	base	modifications,	which	are	the	most	
common	form	of	endogenous	damage	(Kim	and	Wilson,	2012).	Typical	insults	include	
excising	of	incorrect,	damaged	bases	from	deamination	(cytosine	and	5-
methylcytosine)	which	results	in	uracil	and	thymine	mispaired	with	guanine,	
respectively,	and	C-G --> T-A	mutation,	or	oxidation	(8-oxoG).	8-oxoG	tends	to	pair	with	
adenine,	resulting	in	G-C	-->	T-A	mutation.	Two	pathways	constitute	this	mechanism:	
short	and	long	patch	being	repair	of	a	single	or	more	than	two	nucleotide	bases	
respectively	(Robertson	et	al.2009).		
	
	
Mismatch	repair	
This	repair	mechanism	(MMR),	in	addition	to	mismatched	bases	also	involves	post	
replication	repair	of	incorrect	intercalated	bases	from	error	prone	activities	of	DNA	
polymerases	such	as	slippage	during	repair	or	incorrect	base	recognition.	Elevated	and	
mutation	prone	phenotypes	are	observed	in	MMR	deficient	cells,	from	MMR	
inactivation,	whilst	germline	MMR	mutations	are	cancer	prone,	in	particular	for	non-
polyposis	cancer	(Zhang	et	al.2005).		Furthermore,	MMR	is	pivotal	to	many	anti-tumour	
processes	such	as	DNA	damaged	induced	apoptosis	(Wu,	1999).	The	MMR	pathway	
comprises	three	major	steps;	1)	recognition	of	mis-paired	bases,	2)	excision	of	the	
error-containing	strand	resulting	in	a	gap,	and	3)	repair	synthesis,	by	gap	filling	
processes.		
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Figure	4.1.8.	Base	excision	repair	–	Short	patch	and	mismatch	repair	pathways		
A)	Base	mutation	(red)	arising	from	DNA	damage	(U>G	mismatch	for	eg	with	UNG)	and	
mismatch	base	recognised	by	b)	Mutsa	and	DNA	glycosylase	(UNG)	induces	BER	pathway,	by	
recognition	of	and	binding	to	the	base	lesion.	After	base	binding	(uracil	for	UNG),	the	base	is	
flipped	out	of	the	helix	by	bending	of	the	DNA	and	into	catalytic	pocket	of	UNG	where	it	is	
targeted	for	a	subsequent	nucleophilic	attack	to	the	N	glycosidic	bond.	In	c)	an	AP	site	is	
produced	as	a	result	of	base	release	by	UNG	and	for	MMR;	MutLα	nicks	the	3'	or	5'	of	the	
mismatched	base	on	the	discontinuous	strand.	This	incision	by	MutLα	requires	MutSα,	RFC,	
PCNA,	and	also	ATP	(Not	shown)	d)	For	BER,	this	site	is	further	processed	by	AP-endonuclease,	
APE-1,	which	cleaves	the	phosphate	backbone	5’	to	the	AP	site,	producing	a	3’OH	and	a	
5’deoxyribose-phosphate	moiety	(5’dRP)	and	for	MMR,	the	resulting	DNA	is	excised	by	EXO1	a	
5'->3'	exonuclease	in	cooperation	with	RPA	ssDNA-binding	protein.The	5’dRP	is	hydrolysed	by	
PolB	who	fills	in	the	single	nucleotide	gap	in	the	5>3	direction	ligated	and	sealed	by	DNA	ligase	
III,	and	supported	by	XRCC1	a	scaffold	protein	to	restore	the	original	base	sequence.	The	
position	of	the	helix	moves	from	90	C	angle	to	around	35	C	from	a	–	d.	Whilst	the	resultant	
error	free	DNA	strand	is	re	synthesised	by	DNA	polymerase	δ	and	ligated	by	DNA	ligase	(DP)	
shown	in	e	of	MMR.		
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Nucleotide	excision	repair		
NER	is	considered	to	be	the	most	versatile	of	all	DNA	repair	mechanisms.	This	pathway	
responds	to	and	repairs	a	plethora	of	unrelated	DNA	lesions.	It	removes	lesions	which	
may	distort	the	DNA	helix,	base	pairing	interference	and	also	blocks	DNA	transcription	
and	replication.	The	most	commonly	responded	to	lesions	by	NER	are:	cyclobutane	
pyrimidine	dimers	(CPDs)	and	6-4	photoproducts	(6-4	PPs).	These	are	formed	between	
adjacent	pyrimidines,	constituting	the	two	major	types	of	UV	induced	lesions.		The	
other	most	typical	is	bulky	distorted	helix	lesions	induced	by	chemical	agents	(Leiber	et	
al.2010).	such	as	cigarette	smoke	arising	from	aromatic	hydrocarbons,	and	inter-strand	
cross	linkage	induced	by	chemo	therapeutic	agents	such	as	etoposide	and	cisplatin (de	
Boer	and	Hoijemaker,	2000).		
	
The	NER	program	comprises	two	pathways	which	differ	in	the	recognition	stage	and	
whether	DNA	is	transcribed	or	not.	The	global	genome	repair	(GGR)	repairs	
transcriptional	inactive	genomic	lesions	(Reidel	et	al.2003),	whilst	transcription	coupled	
repair	(TCR)	focuses	upon	actively	transcribed	DNA	lesions	(Hanawalt	and	Spivak,	
2008).	(Sagasawa	et	al.2008).	The	importance	of	the	NER	repair	system	is	highlighted	
by	several	clinical	pathologies	linked	to	recessive	defects	in	NER	proteins	or	pathways.	
At	least	eleven	mutations	out	of	the	total	28	NER	genes	have	been	linked	with	rare	
genetic	diseases	comprising	at	least	8	overlapping	phenotypes.		Examples	include:	
Cockayene	syndrome,	xeroderma	pigmentosum	and	trichothiodystrophy.	These	are	
linked	to	photo	sensitivity	as	a	result	of	NER	errors	which	typically	respond	to	sun	
damage.	As	such,	these	individuals	are	pre	disposed	to	skin	cancer	(Kraemer	et	
al.2007).		
	
Double	stranded	DNA	breaks		
Double	stranded	DNA	breaks	(dsDNA)	are	considered	the	most	damaging	lesions	to	
genomic	integrity.	This	may	impinge	upon	critical	cellular	process	such	as	replication	
and	transcription.	Conversely,	highly	controlled	dsDNA	breaks	are	thought	to	be	
beneficial	in	some	instances.	For	example,	immune	system	development	and	during	
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meiosis	(Maizels	et	al.2005;	Loidl	et	al.		2016).	Different	repair	mechanisms	are	
employed	dependant	on	type	of	damage	and	DNA	termini	break.	dsDNA	breaks	are	
induced	in	response	to	DNA	damage	insults	such	as	ionising	radiation	(IR),	which	are	
responded	to	by	ATM	triggering	a	cascade	of	downstream	events.	Other	sources	are	
aberrant	enzymatic	or	endonuclease	activity	such	as	topoisomerase	activity,	or	those	
endogenous	such	as	reactive	oxygen	species	(ROS).	These	may	promote	carcinogenesis	
by	genomic	rearrangements	(Hoijemakers,	2001).	Two	different	repair	mechanisms	
respond	to	this	type	of	insult;	homologous	recombination	(HR)	and	non-homologous	
DNA	end	joining	(NHEJ).	Both	mechanisms	can	respond	to	dsDNA	breaks	however,	one	
end	termini	break	frequently	observed	during	replication	are	repaired	by	HR	typically	in	
S	phase	of	cell	division.	Two	stranded	breaks	are	responded	to	by	the	continually	cell	
cycle	active	NHEJ	repair	pathway.	Both	pathways	are	shown	in	figure	4.1.9.	
	
HR	is	induced	if	the	damage	is	not	repaired	pre-	replication	by	homologous	pairing.	HR	
similar	to	single	strand	annealing	simply	defined	is	whereby	homologous	information	
within	a	secondary	intact	DNA	duplex	of	a	homologous	chromosome	serves	as	
template	to	maintain	repair	fidelity.	The	HR	pathway	is	highly	conserved.	HR	only	
functions	during	S	phase	and	if	sequence	homology	is	apt.	For	example,	at	least	100	
homologous	bp	are	required	for	this	repair	mechanism	to	operate	(Leiber	et	al.2010).	
Conversely,	NHEJ	does	not	require	this	specific	sequence	homology	and	can	function	at	
any	given	time	being	active	in	all	cell	cycle	stages.	NHEJ	thus,	may	re-join	damaged	
DNA	incorrectly.	Indeed,	NHEJ	error	is	typically	always	mutagenic	(Van	De	Bosch,	
2002).		Translocation	is	a	common	example	of	this	process,	arising	from	the	incorrect	
joining	of	independent	chromosomes.	This	occurs	due	to	two	different	breaks	which	
may	occur	on	separate	chromosomes	thus	giving	rise	to	two	DNA	termini	at	each	break	
(Lieber	et	al.1998).		The	importance	of	this	is	seen	in	lymphomas	and	leukaemia	where	
translocations	induce	oncogene	activation	arising	from	aberrant	NHEJ	events	(Gelb	and	
Mederios,	2009).	This	highlights	the	importance	of	error	free	joining	in	maintain	
genomic	stability.			
	 56	
	
Figure	4.1.9	dsDNA	break	repair	by	homologous	recombination	and	non-homologous	end	
joining.	HR:	Black	and	red	lines	represent	dsDNA	homologous	sequence.	DNA	lesions	are	
recognised	by	the	MRN	complex	recruited	to	the	lesion	(black),	nucleoytically	processed	
forming	the	3’	ssDNA,	bound	by	RPA-RAD51/52	which	subsequently	invades	homologous	intact	
sequences	(blue).	DNA	strand	exchange	results	in	a	joint	molecule	of	damaged	and	non	-	
damaged	DNA.	Missing	sequence	information	at	the	lesion	is	restored	via	DNA	re-synthesis	
(red).	Interconnected	molecules	are	processed	(grey	arrows)	by	DNA	ligation.	NHEJ:	Following	
dsDNA	breaks,	lesions	are	sensed	by	Ku70/80	complex	to	recruit	the	DNA-PK.	This	enhances	
XRCC4-Ligase-Artemis-XLF	recruitment	and	activity	facilitating	re-joining,	and	direct	ligation.	
Sequence	homology	is	not	required.	dsDNA	breaks	may	be	joined	accurately,	however	typically	
translocations	of	indels	are	generated.	
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5	Aims	and	hypothesis		
This	study	is	a	continuum	of	previous	research	conducted	by	(Tian,	K,	PhD	Thesis,	
University	of	Manchester,	2013).	The	overall	aim	of	this	study	is	to	generate	a	model	
which	is	more	representative	of	p53	cancer	dynamics.	By	this,	our	main	aim	to	expand	
upon	the	Tian,	K.	(2013)	study,	to	enlarge	the	initial	PKT206	-	p53	-	DNA	damage	
model,	increasing	network	size	using	data	mining	and	extensive	literature	curation	
approaches.		By	inclusion	of	more	in	and	outputs	into	the	expanded	models,	we	
hypothesise	that	the	expanded	p53	models	will	be	have	increased	predictive	potential,	
provide	a	greater	representation	of	p53	signalling	pathways	and	its	role	in	cancer.	We	
further	hypotheses	that	the	expanded	model	will	have	promising	clinical	relevance	for	
use	in	a	personalised	therapeutic	approach.	For	this,	we	will	undertake	several	
approaches.		
	
i) 	We	aim	to	undertake	a	systems	biology	approach	using	Boolean	logic	to	establish	if	
larger	Boolean	models	can	be	successfully	simulated,	and	identify	overall	system	
attributes	of	p53	-	cancer	dynamics.	After	expansion	of	the	model,	we	aimed	to	
undertake	several	computational	logical	based	approaches	using	in	silico	knockout	
comparative	scenarios	to	mimic	in	vivo	processes,	identify	network	perturbations	
and	derive	potential	predictions	in	response	to	these	in	silico	conditions.		
	
ii) We	aimed	to	validate	these	in	silico	predictions	by	various	approaches	including	
extensive	literature	curation,	laboratory	methodologies	and	superimposition	of	
high	-	throughput	transcriptome	in	vitro	data.	We	further	aimed	to	explore	the	
models	predictive	capability	to	predict	gene	changes	on	a	clinical	basis.	By	this,	we	
aim	to	superimpose	in	vivo	patient	derived	tumour	profiles	of	various	cancers	and	
compare	it	to	in	silico	generated	results.			
	
iii) We	further	aimed	to	construct	a	Boolean	model	which	is	more	relevant	to	specific	
cancer	by	addition	of	cancer	specific	genes	and	test	the	models	potential	to	predict	
gene	changes	in	a	particular	cancer	by	comparison	to	in	vitro	and	in	vivo	generated	
data	of	the	same	cancer.		
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iv) Lastly,	we	will	use	the	clinically	derived	in	vivo	data	to	highlight	the	predictive	
potential	of	the	p53	logical	model	to	correctly	identify	genetic	perturbations	on	an	
individual	basis,	and	suggest	personalised	targeted	treatment	dependant	on	
tumour.		
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6	Material	and	Methods	
	
6.1	Systems	biology	and	computational	methodologies		
Matrix	Laboratory	(MATLAB)	software	was	the	base	platform	used	for	computational	
methodologies	here	and	as	such	is	briefly	described.	All	analyses	including	statistical	
analysis	were	undertaken	using	Minitab,	Graphpad	software	and	excel	functions.		
	
6.1.1	MATLAB		
MATLAB	Is	a	high	performance	language	software	for	scientific	computing.	MATLAB	
integrates	numerical	computation,	visualisation	and	programming	where	formalisms	
are	expressed	in	mathematical	notations	using	MATLAB	commands.	Toolboxes	are	
comprehensive	collections	of	MATLAB	functions	(M-Files)	which	use	logical	Boolean	
operators	of	AND,	OR,	NOT.		Analysis	is	in	the	form	of	numerical	matrices	referred	to	as	
scalars	(a	single	number	represented	by	a	1	x	1	matrix)	and	vectors	(a	one	dimensional	
array	of	numbers	represented	by	n	x	1	column	vector,	or	a	1	x	n	vector	of	n	elements).	
Matlab	(v.8.30)	was	downloaded	from	Mathworks	Inc.	available	at:	
(https://www.mathworks.co.uk/downloads/web_downloads)	and	used	for	all	software	
extension	platforms;	CellNetAnalyzer	and	Cytoscape	both	described	in	below	and	in	
section	4,	literature	review.		
	
6.1.2	Generation	of	all	p53	models	
	
6.1.2.1	Retrieval	of	protein	-	protein	interaction	evidence	using	STRING	database		
Tian	et	al.	(2013),	previously	conducted	extensive	screening	of	over	30	protein	–	
protein	interaction	databases,	identifying	the	The	Search	Tool	for	the	Retrieval	of	
Interacting	Genes	(STRING)	database	as	the	most	suitable	for	model	generation	(Tian	K,	
PhD	Thesis,	University	of	Manchester,	2013).	The	STRING	database	is	a	protein	to	
protein	interaction	database	that	integrates	extensive	information	of	protein	links	and	
interactions	from	four	main	sources	described	in	detail	in	section	4	of	this	report.	An	
example	screenshot	of	STRING	interaction	evidence	is	shown	in	image	6,	between	p53	
and	MDM2.		
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Image	6	STRING	interaction	evidence	for	p53	–	MDM2	derived	from	the	four	main	sources	
Screenshot	example	of	interaction	evidence	derived	from	STRING,	assigned	by	the	confidence	
schema	shown	as	combined	score	above	(0.999).		
	
A	total	of	81,000	interactions	were	extracted	from	STRING	using	ULTRAEDIT,	a	text	
editor	programme	capable	of	handling	large	datasets,	available	at:	
(http://www.ultraedit.com/products).	Interactions	with	a	confidence	scores	over	0.7	a	
high	confidence	schema	assigned	by	STRING	were	only	considered.	Key	identifiers	
assigned	by	STRING	were	used	for	extraction	of	target	data.	For	example,	in	STRING	the	
identifier	of	p53	is	‘ENSP00000269305’.	This	identifier	was	input	into	ULTRAEDIT	and	
filtered	to	direct	interactions	with	p53	only.	These	interactions	were	considered	as	
direct	to	p53.	To	close	and	complete	all	models,	evidence	was	extracted	from	STRING	
to	include	interactions	between	other	nodes.	For	example,	considering	two	
interactions	included	in	the	p53	model	linking	directly	to	p53:	p53	activates	CDKN1A	
and	p53	activates	PRKG1.	These	are	direct	and	referred	to	as	the	first	layer	of	the	
model.	However	for	interactions	between	other	nodes	(as	an	example	here		PRKG1	
activates	CDKN1A)	were	referred	to	as	the	second	layer	of	the	model.		This	was	
performed	for	all	nodes	in	the	p53	models	using	the	same	confidence	score	of	over	0.7.	
The	nature	of	all	interactions	(post	translational	modification,	activation,	inhibition	or	
binding)	were	also	extracted.	Activation	and	inhibition	were	the	key	interactions	
considered	which	refer	to	the	state	of	gene	transcription	if	a	gene	is	transcribed	or	not	
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transcribed	respectfully,	or	if	protein	was	activated	or	inactivated	by	other	means	such	
as	protein	degradation,	subcellular	localisation	or	post	-	translational	modifications.		
	
Due	to	several	issues	of	STRING	reporting	incorrect	interactions	(discussed	in	section	8,	
final	discussion),	all	interactions	extracted	were	additionally	manually	curated	by	
literature	evidence	for	model	accuracy.	This	was	undertaken	initially	utilising	the	
STRING	text	mining	tool	which	links	to	PUBMED.	For	example,	image	6.1	depicts	the	
STRING	text	mining	evidence	between	p53	and	MDM2	linking	to	the	PUBMED	
database.		In	addition	to	the	STRING	text	mining	tool,	manual	curation	of	interactions	
was	also	performed	using	other	literature	sources;	Google,	Google	Scholar	and	
additional	PUBMED	searches.	Further	validation	for	all	interactions	in	all	p53	models	
were	also	confirmed	by	supervisor	to	ensure	accuracy	of	model.		At	least	one	
documented	scientific	publication	was	used	for	a	confirmed	interaction,	some	
described	by	more.			
	
Image	6.1	Predicted	evidence	from	STRING	text	mining	application	for	p53-MDM2	
In	 the	 above	 example,	 text	mining	 evidence	 shows	 that	 p53	 induces	 (activates)	MDM2	with	
corresponding	link	to	the	PUBMED	source.			
	
	
	
6.1.2.2	Construction	of	all	p53	models		
All	p53	models	were	generated	by	expansion	of	the	PKT206	model	generated	by	Tian	
et	al.	(2013).	The	Boolean	PKT206	model	was	also	constructed	using	the	STRING	
database.	Briefly	PKT206	comprises	783	interactions	of	inhibition,	activation	or	
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ambivalent	factor	amongst	203	internal	nodes.	An	input	of	DNA	damage	and	two	
outputs	of	cellular	senescence	and	apoptosis	were	also	considered	in	PKT206.	For	
consistency	we	used	the	same	methodology	as	applied	by	Tian	et	al.	(2013)	and	
extracted	all	protein	information	from	the	STRING	database	as	described	above.	All	
confirmed	interactions	from	manual	curation	and	validation	were	incorporated	into	the	
relevant	models	(PMH260,	PMH302	and	Meso-PMH61).		The	Meso-PMH61	model	was	
constructed	by	integration	of	nodes	representing	genes	considered	as	important	to	
malignant	mesothelioma,	obtained	from	Melaiu	et	al.	(2015).	For	consistency	we	
followed	the	same	principle	(6.1.2.1)	and	input	the	total	119	genes	into	the	STRING	
(v9.1)	database	to	extract	information	for	mesothelioma	genes	that	interact	with	genes	
in	the	PMH302	model.		
	
6.1.2.3	Addition	of	biological	outputs	and	input	to	the	p53	models	
Three	additional	biological	outputs	were	initially	integrated	into	PMH260;	
angiogenesis,	cell	cycle	arrest	and	DNA	repair,	an	additional	input	of	hypoxia	was	
further	included	into	the	PMH302	model.	Dependant	on	their	biological	processes	that	
they	regulate,	all	nodes	within	the	relevant	models	were	linked	to	these	three	
additional	outputs	and	one	input	by	their	edge	function	of	inhibition,	activation	or	
ambivalent	factor.	This	was	primarily	undertaken	using	the	Gene	Ontology	(GO)	
database	available	at	(http://geneontology.org/).	The	GO	database	provides	a	list	of	
defined	gene	terms	considering,	biological	processes,	molecular	function	and	cellular	
components.	Additional	literature	search	was	also	undertaken	for	model	accuracy	to	
confirm	these	interactions	using;	PUBMED,	Google	and	Google	Scholar.		As	PKT206	did	
not	consider	these	additional	3	outputs	(DNA	repair,	angiogenesis	and	cell	cycle	arrest)	
PKT206	internal	nodes	(n	=	203)	were	also	linked	to	their	relevant	outputs.	All	
additional	nodes	included	to	generate	the	larger	three	models	were	also	linked	to	the	
PKT206	outputs	of	apoptosis	and	cellular	senescence	and	to	the	input	of	DNA	damage.		
	
6.1.3	Cytoscape		
Cytoscape	available	at	(http://www.cytoscape.org)is	an	open	source	platform	used	
with	MATLAB	for	viewing	and	constructing	interaction	networks	and	biological	
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pathways.	Cytoscape	allows	for	integration	of	these	networks	with	annotations,	gene	
expression	and	other	state	data	analyses.	Cytoscape	(v.3.1)	was	utilised	for	the	p53	
interactome	models	serving	two	main	purposes;	visualisation	of	all	p53	models	and	
functional	analysis	of	PKT206	by	application	of	STSFA	described	in	6.4.			
	
6.1.3.1	Visualisation	of	networks		
For	visualisation	of	p53	models,	tab.	delimited	files	were	constructed	in	accordance	
with	Kline	et	al.	(2007).	A	new	network	was	declared	and	relevant	files	imported	into	
Cytoscape.	Source	interaction,	interaction	type	and	target	interaction	were	
subsequently	declared	generating	the	visual	networks	for	all	models.	For	example,	
source	interaction	may	be	defined	as	p53,	target	interaction	as	MDM2	and	interaction	
type	given	as	activation.	The	network	/	model	style	may	be	modified	accordingly	with	
the	user’s	requirement	using	the	Vizmapper	tool.	
	
6.2	In	silico	analyses	of	the	p53	models	
	
6.2.1	Functional	network	analysis	using	CellNetAnalyzer	
CellNetAnalyzer	(CNA)	is	discussed	in	section	4	of	this	report.			
All	p53	models	(PMH260,	PMH300	and	Meso	–	PMH61)	were	constructed	via	retrieval	
of	protein	–	protein	interaction	information	derived	from	STRING	and	imported	into	
CNA	(v.2013.1).	All	Confirmed	interaction	records	were	input	into	tab	delimited	text.	
file	and	processed	to	a	node	and	reaction	transcript	readable	by	CNA	as	described	by	
Klamt	et	al.	(2007).		A	new	signal	flow	network	project	was	declared	and	data	files	of	
species/nodes	and	their	edges/interactions	were	uploaded.	Two	approaches	facilitated	
by	CNA	were	used	for	various	in	silico	knock	out	tests	and	comparative	in	silico	
simulations;	dependency	matrix	calculations	and	logical	steady	state	analysis	(LSSA)	
described	below	(6.2.1.2).	
	
6.2.1.1	Application	of	dependency	matrices	to	the	p53	models	
CNA	facilitates	construction	and	calculation	of	dependency	matrices	within	a	given	
network.	The	dependency	matrix	represents	the	effects	between	node	pairs	by	
calculation	of	positive	and	negative	pathways	between	them	and	considers	the	
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presence	of	feedback	loops	within	the	system.	Two	nodes	may	be	represented,	i	and	j	
with	six	dependency	effects	observed	in	a	matrix:	Strong	activator,	weak	activator,	
strong	inhibitor,	weak	inhibitor,	ambivalent	factor	and	no	effect	defined	by:	
	
1. If	no	negative	or	positive	path	exists	between	node	i	and	node	j,	then	I	will	have	
no	effect	on	node	j	
2. If	both	a	positive	and	negative	path	exists	between	node	i	to	node	j,	then	i	is	an	
ambivalent	factor	of	node	j	
3. If	only	negative	paths	exist	between	node	i	to	node	j,	with	only	negative	
feedback	loops	present	in	these	paths,	then	node	i	is	a	weak	inhibitor	of	node	j	
4. If	only	positive	paths	exist	between	node	i	to	node	j	with	negative	feedback	
loops	present	in	these	positive	paths,	then	node	i	is	a	weak	activator	of	node	j	
5. If	only	negative	paths	exist	between	node	i	to	node	j	with	negative	feedback	
loops	absent	in	these	paths,	then	node	i	is	a	strong	inhibitor	of	node	j	
6. If	only	positive	paths	exist	between	node	i	to	node	j	with	negative	feedback	
loops	absent	in	positive	paths,	then	node	i	is	a	strong	activator	of	node	j.		
	
The	connectivity	of	all	nodes	was	determined	using	Cytoscape	(v.	3.1)	and	the	most	
highly	connected	nodes	of	the	network	deleted	to	generate	an	in	silico	knockout	
simulation.	The	particular	nodes	deleted	were	dependant	on	model	being	analysed.		
For	all	models,	ASCII	files	were	generated	and	imported	into	CNA	in	accordance	with	
the	format	described	in	(Klamt	et	al.2007).		For	the	deleted	node,	default	values	of	
‘NaN’	given	as’	#’	in	species	files	were	altered	to	‘0’	in	the	network	composer.	Shortest	
paths	and	species	dependencies	were	calculated	using	approximate	algorithm	for	each	
knockout	(KO)	scenario	by	declaration	of	exclusion	of	any	given	species/node	defined	
as	‘0’.		Dependency	matrices	were	subsequently	calculated	where	the	6	possible	
relationships	may	be	derived	as	defined	above.	Result	files	of	data	corresponding	to	
the	values	of	1	–	6	defining	the	above	relationships	were	exported	as	raw	data	in	tab	
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delimited	format	and	subsequently	converted	into	a	readable	format	accepted	by	excel	
for	analysis	by	comparison	to	the	default	model.			
	
	
6.2.1.2	Application	of	logical	steady	state	analysis	to	the	p53	models	
LSSA	is	a	method	for	predictive	input	and	output	relationships	in	signalling	networks.	
Interaction	hypergraphs	supported	in	CNA	are	used	to	represent	signalling	events	that	
allow	for	a	synchronous	interaction	targeting	the	same	node(s)	to	be	combined,	
referring	to	the	relationship	operators	of	AND,	OR,	NOT	(Klamt	et	al.	2007).	The	logical	
behaviour	of	node	states	within	a	Boolean	network	can	be	analysed	by	LSSA	in	
response	to	various	in	silico	perturbations	of	different	input	and	knock	out	tests.		
	
In	LSSA,	each	scenario	is	defined	by	declaration	of	the	value	of	input	signals.	For	
example,	declaring	the	values	below	where:	
	
‘0’	represents	inactivated	
‘1’	represents	activated	
‘NaN’	represents	undetermined		
	
The	state	of	some	nodes	may	remain	undetermined	if	several	logical	steady	states	are	
possible	(NaN).	Proceeding	declaration	of	each	scenario	from	the	given	values,	CNA	
calculates	the	steady	state	of	each	node	and	its	interactions	within	a	network	by	logical	
operation	(above).	Resultant	node	and	interaction	states	for	each	scenario	are	
returned	by	CNA	which	can	be	compared	to	default	model	for	investigation	of	network	
perturbations.		
	
ASCII	files	of	interactions	were	generated	for	all	models	in	accordance	with	(Klamt	et	
al.2007).	Four	different	scenarios	were	constructed	for	application	of	LSSA	which	can	
represent	or	mimic	in	vivo	processes	such	as	loss	of	p53	function	arising	from	mutation	
(p53	deletion	from	the	network)	in	the	presence	or	absence	of	DNA	damage	or	
hypoxia.	DNA	damage	and	p53	simulations	are	summarised	in	table	6	for	PMH260,	
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PMH300	and	Meso-	PMH61	models	and	table	6.1	for	hypoxia	and	p53	simulations	
(PMH302	and	Meso	–	PMH61	models).		
	
Table	6	Four	in	silico	scenarios	generated	for	LSSA	of	DNA	damage	ON/OFF	in	the	presence	/	
absence	of	p53	
Scenario	No.	 Input	signal	 Model	background	
1	 DNA	damage	ON	 p53	knockout	
2	 DNA	damage	OFF	 p53	knockout	
3	 DNA	damage	ON	 p53	wildtype	
4	 DNA	damage	OFF	 p53	wildtype	
	
Table	6.1	Four	in	silico	scenarios	generated	for	LSSA	of	hypoxia	ON/OFF	in	the	presence	/	
absence	of	p53	
Scenario	No.	 Input	signal	 Model	background	
1	 Hypoxia	ON	 p53	knockout	
2	 Hypoxia	OFF	 p53	knockout	
3	 Hypoxia	ON	 p53	wildtype	
4	 Hypoxia	OFF	 p53	wildtype	
	
To	mimic	loss	of	p53,	deletion	of	p53	from	the	network	was	via	total	node/	species	
deletion	from	the	network	composer	and	all	associated	edges	were	removed	to	
generate	a	p53	knockout	scenario.	For	construction	of	a	p53	wild	type	background,	the	
p53	node	was	switched	to	1	in	CNA	network	composer.		The	DNA	damage	or	hypoxia	
input	was	switched	to	‘0’	referring	to	hypoxia	or	DNA	damage	OFF	or	‘1’	referring	to	
hypoxia	or	DNA	damage	ON	for	the	various	scenarios	as	described	above	in	table	6	and	
table	6.1.		
	
Each	scenario	was	subsequently	imported	and	computed	separately	by	CNA	and	
compared	against	the	default	model	for	investigation	of	the	network	response	to	p53,	
DNA	damage	or	hypoxia	presence	or	absence.		Results	obtained	from	CNA	in	tab	
delimited	format	were	subsequently	converted	and	imported	into	excel	files	for	
analysis.		
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Four	comparative	scenarios	of	different	DNA	damage,	hypoxia	and	p53	statuses	were	
additionally	constructed	to	investigate	network	perturbations	in	response	to	the	
different	in	silico	stresses.	In	particular	node	state	changes	of	angiogenic	and	apoptotic	
nodes	were	explored.	The	various	in	silico	scenarios	simulated	are	summarised	in	
tables	6.2	and	6.3	for	DNA	damage	and	hypoxia	respectively.		
	
Table	6.2	List	of	four	different	scenario	comparisons	for	in	silico	simulations	using	LSSA	for	
DNA	damage	
	 In	silico	simulation		
Scenario	No.	
1	
	
p53	wildtype	DNA	damage	ON	vs.	p53	knockout	DNA	damage	OFF	
2	 p53	wildtype	DNA	damage	OFF	vs.	p53	knockout	DNA	damage	OFF	
3	 p53	wildtype	DNA	damage	OFF	vs.	p53	wildtype	DNA	damage	ON	
4	 p53	knockout	DNA	damage	OFF	vs.	p53	knockout	DNA	damage	ON	
	
	
Table	6.3	List	of	four	different	scenario	comparisons	for	in	silico	simulations	using	LSSA	for	
hypoxia	
	 In	silico	simulation		
Scenario	No.	
1	
	
p53	wildtype	hypoxia	ON	vs.	p53	knockout	hypoxia	OFF	
2	 p53	wildtype	hypoxia	OFF	vs.	p53	knockout	hypoxia	OFF	
3	 p53	wildtype	hypoxia	OFF	vs.	p53	wildtype	hypoxia	ON	
4	 p53	knockout	hypoxia	OFF	vs.	p53	knockout	hypoxia	ON	
	
6.3	Genome	wide	validation	of	the	p53	interactome	models	
To	evaluate	the	predictive	strength	of	all	models	on	a	genome	wide	level,	in	silico	
predictions	of	LSSA	generated	as	described	in	6.2.1.2	were	compared	to	various	
experimental	gene	expression	profiles	as	described	below.	LSSA	provides	a	steady	state	
in	each	scenario	where	differential	gene	expression	states	can	be	compared	between	
model	predictions	and	experimental	data	in	accordance	with	Christensen	et	al.	(2009).		
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6.3.1	Model	validation	using	transcriptome	profiles		
To	evaluate	the	predictive	strength	of	all	models	generated;	PMH260,	PMH302	and	
Meso-PMH61,	in	silico	results	derived	from	the	four	in	silico	LSSA	scenarios	of	different	
p53	backgrounds,	DNA	damage	and	hypoxia	input	signals	(tables	6	–	6.3)	were	
compared	to	several	gene	expression	in	vitro	and	in	vivo	profiles	of	various	human	
cancers;	osteosarcoma	U2OS	p53	+/+	and	SaOS2	p53	-/-	cell	lines	with	and	without	10	
µM	etoposide	treatment	for	24	hr	(Tian	et	al.2013),	untreated	HTC116	p53	null	and	
wildtype	colon	cancer	cell	lines	available	from	the	gene	expression	omnibus	ID:	
GSE10795	and	(Wilhelm	et	al.2008),		non-small	cell	lung	cancer	profiles	(Peifer	et	al.	
2012)	and	microarray	profiles	generated	in	our	laboratory	of	malignant	mesothelioma	
Mero-14	cell	lines	untreated	and	treated	with	10	µM	etoposide	for	24	h.	For	
comparison	of	in	silico	hypoxia	to	experimental	hypoxic	conditions,	Mero	–	14	cells	
were	exposed	to	hypoxic	conditions	of	1	%	O2	for	24	hr	compared	to	untreated	
maintained	at	37	⁰	C	with	5%	CO₂ for	24	h.	All	transcriptome	profiles	described	above	
were	superimposed	to	the	p53	models	for	investigation	of	model	predictive	capability.		
Comparison	of	in	vitro	and	in	vivo	data	to	in	silico	data	was	undertaken	in	accordance	
with	the	formula	described	by	(Christensen	et	al.2009)	and	(Tian	et	al.	2013)	using	the	
dynamic	threshold.	This	is	defined	by	the	predicted	state	of	a	variable	Emod	where	a	
node	given	as	(i)	is	defined	as	S(i)wt	and	S	(i)mu	for	p53	wildtype	and	p53	knockout	
respectively.	For	any	given	state,	both	could	take	any	three	values	defined	as;		
	
0	representing	downregulated		
1	representing	upregulated	
NaN	representing	unchanged		
	
The	variable	Emod	represents	the	predicted	change	of	gene	state	from	p53	wild	type	to	
knockout	where:		
	
Emod	=	0,	if	S(i)wt	=	1	and	S(i)mu	=	1	
Emod	=	0,	if	S(i)wt	=	0	and	S(i)mu	=	0	
Emod	=	0,	if	S(i)wt	=	NaN	and	S(i)mu	=	NaN	
Emod	=	1,	if	S(i)wt	=	0	and	S(i)mu	=	1	
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Emod	=	1,	if	S(i)wt	=	0	and	S(i)mu	=	NaN	
Emod	=	1,	if	S(i)wt	=	NaN	and	S(i)mu	=	1	
Emod	=	-1,	if	S(i)wt	=	1	and	S(i)mu	=	0	
Emod	=	-1,	if	S(i)wt	=	1	and	S(i)mu	=	NaN	
Emod	=	-1,	if	S(i)wt	=	NaN	and	S(i)mu	=	0	
	
The	differential	expression	level	of	a	gene	(i)	derived	from	experimental	validation	was	
defined	by	the	parameter	Eexp	where:		
	
If	the	expression	level	of	a	gene	was	upregulated,	Eexp	=	1	
If	the	expression	level	of	a	gene	was	downregulated,	Eexp	=	-1	
If	the	expression	level	of	a	gene	was	unchanged,	Eexp	=	0	
	
The	log10	fold	change	(FC)	between	experimental	and	simulated	data	was	subsequently	
calculated	for	each	gene	/	node	also	in	accordance	with	(Christensen	et	al.2009),	
defined	by	the	equation:		
	FC(𝑖) = 𝑀1(𝑖)𝑀2	(𝑖)	
	
	
Where	M1(i)	is	the	median	of	expression	values	in	the	target	condition	and,	M2(i)	the	
median	of	expression	values	in	the	source	condition	Threshold	values	defined	as	(θ),		
the	mean	as	(𝑥)	and	standard	deviation	as	(σ)	were	applied	to	normalise	expression	
profile	distributions	of	(θmax	and	θmin),	defined	as:		
	
θmax	=	𝑥		+	σ	
θmin	=	𝑥	-	σ.	
	
Gene	activity	was	further	determined	for	both	datasets,	where:		
	
If	Log10	=	FC	>	𝑥		+	σ	=	gene	(i)	upregulated	
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If	Log10	FC	<	𝑥	-	σ	=gene	(i)	downregulated	
If-	σ	<=	log10	FC	<=	+	σ	=	gene	(i)	was	unchanged	
	
	
The	differences	between	experimental	and	predicted	simulations	were	defined	as	(Emod	
–	Eexp),	which	could	take	one	of	three	values	given	below	where:		
	
‘0’	represents	a	correct	prediction	where	both	outcomes	of	experimental	and	in	silico	
results	were	the	same	
‘1’	represents	a	small	error	prediction	between	experimental	and	in	silico	results	where	
one	outcome	was	‘no	change’	and	the	other	‘up	or	downregulated’.			
‘2’	represents	a	large	error	prediction	between	experimental	and	in	silico	results	where	
one	outcome	was	‘upregulated	‘and	the	other	‘downregulated’.		
	
6.4	Functional	analysis	of	the	PKT206	network		
Original	construction	and	analysis	of	the	PKT206	p53	interactome	is	described	in	detail	
elsewhere	(Tian	et	al.2013).		
	
STSFA	utilizes	transcriptome	data	for	node	score	generation,	and	is	provided	as	a	
Cytoscape	app/plugin	for	versions	above	2.7.	Node	and	edge	attributes	were	assigned	
to	the	network	in	accordance	with	Isik	et	al.	(2012),	and	imported	into	Cytoscape	
(v.3.1.).	Gene	expression	profiles	of	HTC116	p53	null	and	wildtype	colon	cancer	cell	
lines	were	analyzed	available	from	GSE10795	and	(Tian	et	al.2013).	Experimental	
results	were	compared	to	in	silico	data	generated	from	LSSA.		
	
To	overcome	high	background	noise	typically	associated	with	microarray	data,	the	
median	score	of	each	gene	in	the	network	was	taken	as	its	expression	value.	Expression	
scores	generated	from	microarray	data	were	imported	in	a	3	tab-delimited	.txt	file	in	
accordance	with	Isik	et	al.	(2012)	and	imported	into	Cytoscape.	However,	as	PKT206	
comprises	an	extremely	high	number	of	nodes	downstream	to	p53	(n=154),	scores	
traversed	to	these	were	low	and	often	negative.	This	would	suggest	that	p53	has	little	
influence	on	its	downstream	target	nodes,	when	in	reality	it	is	the	hub	of	the	network.	
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To	overcome	this,	log2	microarray	scores	were	scaled	up	by	a	factor	of	100.		For	
HTC116	transcriptome	data,	expression	scores	were	extremely	low,	and	raw	
microarray	scores	were	additionally	scaled	up	by	the	same	factor.	This	allowed	for	an	
increased	score	in	p53	for	downstream	signals,	whilst	leaving	network	ratios	of	edge	
and	nodes	unaffected.			
	
6.5	Laboratory	based	methodologies	and	materials	
	
6.5.1	Mammalian	cell	culture	
	
6.5.1.1	Cell	line	maintenance				
Three	main	cell	lines	were	used;	human	adherent	mesothelioma	cell	line,	Mero	–	25	
and	human	osteosarcoma	adherent	cell	lines	U2OS	p53	(⁺/⁺)	and	SaOS2	p53	(¯/¯).	All	
cell	lines	were	maintained	at	37	⁰	C	with	5%	CO₂	(Wolf	Laboratories,	Galaxy	S).	Cell	
culture	procedures	were	performed	in	Laminar	flow	Class	II	culture	cabinets	(Esco	Class	
II	Biological	Safety	Cabinet)	under	strict	aseptic	conditions.	Mero	–	25	and	U2OS	cell	
lines	were	cultured	in	T75	cm²	culture	flasks	with	Dulbecco’s	Modified	Eagles	Medium	
(DMEM)	(Sigma,	UK)	supplemented	with	10	%	(v/v)	Foetal	Bovine	Serum	(FBS),	
0.05U/ml	penicillin	and	0.05U/ml	of	streptomycin.		SaOS2	cell	lines	were	cultured	in	T75	
cm2	flasks,	maintained	with	Dulbecco’s	Modified	Eagles	Medium	4	(DMEM4)	(Sigma,	
UK),	supplemented	with	above	described	antimicrobial	agents	and	15	%	(v/v)	FBS.		
	
6.5.1.2	Passage	of	cell	lines	
All	cell	lines	were	passaged	every	2-3	days	to	avoid	over	confluence.		Sub	culture	of	cell	
lines	was	performed	when	cells	reached	80	%	confluence,	typically	in	a	1:4	or	1:2	ratios	
for	human	osteosarcoma	cell	lines	U20S	and	SaOS2	respectively	and	1:3	ratios	for	
malignant	mesothelioma	mero	–	14	cells.		Specific	media,	1x	phosphate	buffered	saline	
(PBS)	and	Trypsin-Ethylenediaminetetraacetic	acid	(trypsin)	(Sigma,	UK)	were	pre	
warmed	at	37⁰C	for	5	mins,	existing	media	was	aspirated	and	cells	washed	in	7	ml	of	1	
X	PBS	for	removal	of	any	dead	cells.	1	x	PBS	was	subsequently	aspirated,	prior	to	
addition	of	1ml	of	trypsin	for	detachment	of	adherent	cells	and	incubated	for	3	min	at	
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37⁰C.	Trypsinised	cells	were	removed	from	incubator	and	7.5	ml	of	fresh	media	was	
added.	2.5	ml	of	suspension	was	aliquoted	to	the	new	flasks	making	a	total	volume	of	
10	ml	media	and	incubated	at	37	°C	(1:4	ratio).		
	
6.5.1.3	Freezing	of	cell	lines		
Once	fully	confluent	or	to	a	specific	cell	count,	typically	1	x	106,	cells	were	pelleted	by	
centrifugation	at	1,200	rpm	for	3	min	(Meadowrose	Scientific	Ltd	HERMLE	Z	400),	and	
resuspended	in	1	ml	FBS	/	20	%	Dimethyl	Sulfoxide	(DMSO)	solution	for	prevention	of	
intracellular	ice	crystal	formation.	FBS/DMSO	solution	was	added	slowly	in	a	drop	wise	
fashion	to	ensure	avoidance	of	osmotic	cell	shock.	Resultant	cell	suspension	was	
transferred	into	cryovials	and	transferred	to	-	80⁰C	for	24h,	prior	to	storage	in	liquid	
nitrogen	-196⁰C.	This	slow	freezing	process	avoids	shock	to	cells.		
	
6.5.1.4	Thawing	of	cell	lines	
Cells	were	rapidly	thawed	at	37⁰C	and	transferred	quickly	for	recovery	to	7	ml	of	pre	
warmed	medium	in	T25	cm²	flasks.		Rapid	thawing	ensures	the	reduction	and/or	
prevention	of	ice	crystals	within	the	cells	during	rehydration	which	are	damaging	to	the	
cells.	Cells	were	later	pelleted	by	centrifugation	to	remove	DMSO	at	1,200	for	3	mins	
prior	to	re-suspension	in	specific	growth	medium.	Cells	were	transferred	to	T75	cm²	
flasks	once	70%	confluence	was	reached	in	10	ml	of	specific	media.		
	
	
6.5.2	Immuno	-	detection	of	proteins		
	
6.5.2.1	Preparation	of	whole	cell	extract		
U2OS	and	SaOS2	cells	were	seeded	at	106	in	100mm	culture	plates	and	incubated	
overnight	at	37	⁰C.	10µM	of	etoposide	was	added	24	hr	pre	extraction.	Etoposide	is	a	
chemotherapeutic	agent	which	induces	DNA	double	strand	breaks	(dsDNA)	via	
inhibition	of	topoisomerase	II	and	therefore	is	a	good	choice	when	studying	DNA	
damage (Zhou	et	al,	1999). Media	was	subsequently	removed	from	plates	and	cells	
washed	twice	with	cold	1	x	PBS,	prior	to	cell	scraping	on	ice	with	addition	of	125	µl	(six	
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well	plates)	250	µM	(100	mm	plate)	of	high	salt	lysis	buffer	(HSLB)	(45mM	Hepes,	
400mM	NaCl,	1mM	EDTA,	10	%	glycerol,	0.5	%	IgePal,	phosphatase	inhibitors;	2mM	
sodium	orthovanadate,	5mM	NaPPi,	and	20mM	β	glycerol	phosphate)		and	1	µg	/ml	
protease	inhibitor	cocktail	comprising	aprotinin,	leupeptin,	pepstain	A,	1mM	DTT,	and	
1mM	PMSF	was	added	fresh.	Resultant	extracts	were	collected	in	a	fresh	1.5	ml	
eppendorf	tube	and	rotated	at	4	⁰C	for	20	mins	on	a	miniroller	(Mini	LabrollerTM,	
Labnet	Inc),	followed	by	centrifugation	(GenFuge	24D,	Progen	Scientific)	at	4⁰C	for	20	
mins	at	13,000rpm.	Pellets	were	discarded	and	supernatant	transferred	to	fresh	1.5	ml	
eppendorf	tubes	kept	on	ice.	
	
6.5.2.2	Protein	concentration	determination	
Protein	concentration	of	whole	cell	extract	was	determined	using	the	Bio-Rad	protein	
assay	reagent,	which	relies	upon	colour	changes	of	Coomassie	Brilliant	Blue	dye	from	
the	binding	to	arginyl	and	lysyl	protein	residues	(Bradford,	1976).		
	
Bio	–	Rad	stock	solution	was	diluted	1:5	with	distilled	water	prepared	in	a	1.6	ml,	1	cm	
path	visible	cuvette.	2	µl	of	bio-rad	mixture	was	used	to	calibrate	the	
spectrophotometer	(Jenway,	G305).	2	µl	of	extract	was	transferred	to	the	bio-rad	
working	solution,	incubated	at	room	temperature	(RT)	for	5	mins	prior	to	absorbance	
measurement	at	595	nm.	Protein	concentration	was	performed	in	duplicates	and	the	
average	taken	as	value.	This	was	determined	using	a	relative	method	defined	by	the	
equation	below:		
	 𝐿𝑜𝑤𝑒𝑠𝑡	𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 40µl	
𝐸𝑥𝑡𝑟𝑎𝑐𝑡	𝑣𝑜𝑙𝑢𝑚𝑒	 = 𝐿𝑜𝑤𝑒𝑠𝑡	𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒	×	40	×	2𝑛𝑑	𝑙𝑜𝑤𝑒𝑠𝑡	𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒			
	
	
	
The	resultant	extracts	were	transferred	to	fresh	eppendorf	tubes	mixed	with	3X	
Sodium	dodecyl	sulphate	sample	buffer	(187	mM	Tris,	30%	Glycerol,	6%	SDS,	2-
Mercaptoethanol,	0.01%	bromophenol	blue)	and	stored	at	-20⁰C	if	not	used	on	day.		
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6.5.2.3	SDS	gel	electrophoresis		
SDS-	poly	acrylamide	(SDS	–	page)	gel	electrophoresis	is	the	primary	stage	of	
immunoblotting	and	relies	upon	the	principle	of	electrophoresis	where	
macromolecules	are	separated	according	to	their	molecular	weight.	A	polyacrylamide	
gel	serves	as	the	supporting	medium,	whilst	the	SDS	acts	to	denature	the	proteins.			
Two	gels	were	used;	resolving	of	a	basic	pH	8.8	with	a	higher	acrylamide	concentration	
comprising	smaller	pores	allowing	for	easier	migration	of	smaller	proteins.	The	stacking	
gel	is	slightly	acidic	(pH	6.8)	with	a	lower	acrylamide	content	constituting	a	porous	gel	
aiding	protein	alignment.	During	electrophoresis	the	denatured	proteins	possess	a	
negative	charge	and	therefore	migrate	towards	the	positive	electrode	upon	voltage.		
	
SDS	-	PAGE	was	performed	using	either	a	7.5	%	or	12.5	%	polyacrylamide	gel	
dependant	on	protein	size.		The	resolving	gel	was	prepared	as	described	in	Table.	6.4	
and	poured	into	the	casting	apparatus	(Mini-Protean	3	–	Bio-Rad,	UK)	Ammonium	
persulfate	(APS)	and	N,	N,	N,	N-	Tetramethylethylenediamine	(TEMED)	was	added	last	
to	the	gel	solution	to	ensure	gel	solidification	did	not	occur	rapidly.	500	µl	isopropanol	
was	later	added	to	ensure	absence	of	air	bubbles.	After	gel	solidification,	isopropanol	
was	removed	and	the	stacking	gel	added	(table	6)	prior	to	insertion	of	1.5	mm	well	
combs.	Proceeding	solidification,	the	stacking	gel	was	removed	from	the	casting	
apparatus	and	placed	into	an	electrophoresis	mini	buffer	tank	(Bio-Rad)	filled	with	1X	
SDS	PAGE	running	buffer	(0.25M	Tris,	1.9M	glycine,	and	30mM	SDS)	and	combs	
subsequently	removed.		
	
Protein	samples	were	incubated	at	95⁰C	for	3	mins	on	a	heating	block	(Techne	Dri-
Block,	DB-2P)	then	centrifuged	for	1	min	at	13,000rpm	(GenFuge	24D,	Progen	
Scientific).	Sample	volumes	were	loaded	accordingly	to	direct	equation	above	and	5µl	
of	PageRuler	protein	ladder	(26616,	Fermentas,	UK)	into	respective	wells	using	a	fine	
microsyringe.	Samples	were	subsequently	run	at	80	volts	for	20	mins	so	samples	may	
enter	resolving	gel,	then	120	volts	for	1.5	h.	
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6.5.2.4	Western	transfer		
The	resolved	protein	gel	sample	was	removed	from	the	buffer	tank	for	transfer	using	
western	transfer	apparatus	(Bio-Rad,	UK).		Polyvinyllidene	fluoride	(PVDF)	membranes	
(Millipore,	UK)	were	used	for	protein	transfer.	PVDF	membranes	provide	greater	
mechanical	support	than	nitrocellulose	and	allows	for	membrane	re	use	(Mahmood	
and	Yang,	2012).	Components	of	the	apparatus	were	set	up	accordingly	and	
transferred	to	a	universal	buffer	tank	(Bio-Rad,	UK)	filled	with	western	transfer	buffer	
(150mM	Glycine,	25mM	Tris-	HCl,	ph	8.3,	and	20%	methanol).	A	magnetic	stirrer	and	
ice	pack	was	placed	within	the	buffer	tank	and	the	transfer	run	at	0.4	amp	for	2	h,	with	
ice	pack	renewal	every	hour.		
	
After	transfer,	the	membrane	was	blocked	in	5	%	dried	milk	in	1X	PBS	for	1	hr	at	RT	
prior	to	incubation	with	specific	primary	antibody	(Santa	Cruz,	Biotechnology)	in	2.5	%	
milk	/	PBS/0.1%	Tween	solution	on	a	roller	overnight	at	4	⁰C.	Primary	antibody	volume	
added	were	as	per	supplier	instructions	for	optimum	concentration.	After	incubation,	
membranes	were	washed	three	times	for	10	min	intervals	with	10	ml	PBS/0.1%	Tween	
and	incubated	with	corresponding	secondary	anti	–	mouse	or	anti	–	rabbit	IgG	
horseradish	antibody	(Amersham,	GE	Healthcare)	in	2.5	%	/	PBS/	0.1%	Tween	for	1	hr	
at	RT	on	a	rocking	platform	(Stuart	Platform	Rocker,	STR6).	
	
Table	6.4	Different	%	composition	of	SDS	polyacrylamide	gel		 	
	 																													7.5%	gel	 															10	%	gel	
Solutions	 Resolving	 Stacking	 Resolving	 Stacking	
Distilled	water	 13.3	ml	 6.73	ml	 10.94	ml	 6.73	ml	
Acrylamide	 7	ml	 1.67	ml	 9.33	ml	 1.67	ml	
1.5M	Tris	pH	8.95	 7	ml	 -	 7	ml	 -	
1M	Tris	pH	6.95	 -	 1.25	ml	 -	 1.25	ml	
0.2M	EDTA	 280	µl	 100	µl	 280	µl	 100	µl	
10%	SDS	 280	µl	 100	µl	 280	µl	 100	µl	
10%	APS	 157	µl	 157	µl	 157	µl	 157	µl	
TEMED	 17	µl	 17	µl	 17	µl	 17	µl	
	
Membranes	were	further	washed	three	times	at	10	min	intervals	with	PBS/0.1%	Tween	
at	RT	on	a	rocking	platform	prior	to	immuno-detection.		Membranes	were	removed	
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from	washing	solution	and	dependant	on	protein	size	or	detection	method	used	either	
1	ml	of	SuperSignal	West	Pico	chemiluminescent	substrate	(ThermoScientific,	UK)	was	
added	for	3	min	at	RT	or	750	µl	of	femto	chemiluminescent	substrate	
(ThermoScientific,	UK)	added	for	1	min	at	RT	prior	to	viewing.		
For	the	X	ray	method,	the	membrane	was	placed	into	a	X-ray	cassette	wrapped	with	
cling	film,	exposed	to	medical	X	ray	film	(Fujifilm,	UK)	and	developed	using	X-ray	film	
processor	(AFP,	X-ray	film	processor,	mini	medical	series)	or	viewed	directly	using	the	
Syngene	G:BOX	XT4:	Chemiluminescence	and	Fluorescence	Imaging	System.		
	
6.5.2.5	Membrane	stripping		
The	membrane	was	stripped	prior	to	secondary	detection	if	molecular	weights	of	
protein	were	similar.	Membranes	were	incubated	in	stripping	buffer	(100mM	2-
Mercaptoethanol,	2%	SDS,	62.5	mM	Tris-HCl	pH6.7)	for	30	min	at	55⁰C	and	washed	
three	times	in	10	ml	of	PBS/0.1%	Tween	at	10	min	intervals.	The	membrane	was	
subsequently	blocked	in	5%	milk/PBS	for	1	hr	at	RT,	prior	to	incubation	with	the	
specific	primary	antibody.		
	
6.6	Quantitative	Real	Time	PCR		
Quantitative	RT	–	PCR	(q	PCR)	is	a	powerful	and	sensitive	method	for	gene	expression	
analysis	where	cDNA	levels	correspond	to	mRNA	content	of	target	gene.	It	allows	for	
continuous	data	logging	in	real	time	for	each	DNA	amplification	cycle.	Different	
fluorescence	dyes	may	be	utilised	where	the	fluorescence	signal	is	directly	proportional	
to	the	number	of	amplified	copies	(Arya,	2005).		
	
6.6.1	Total	RNA	isolation		
For	investigation	of	target	mRNA	expression	in	response	to	DNA	damage	and	the	
absence	and	presence	of	p53,	human	osteosarcoma	cells	U2OS	(p53	+/+)	and	SaOS2	
p53	null	were	used.	1	x	106	U2OS	and	SaOS2	cells	were	seeded	and	incubated	in	6	well	
plates.	The	chemo	therapeutic	agent	Etoposide	(10	µM)	was	introduced	24	h	pre	RNA	
isolation	to	induce	DNA	damage.			
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Total	RNA	was	extracted	from	both	cell	lines	using	RNeasy	plus	mini	kit	(Qiagen,	UK).	
This	was	performed	in	sterile	conditions.	The	method	was	performed	in	accordance	
with	manufacturer’s	instructions	utilising	the	direct	isolation	method.		Briefly,	cells	
were	washed	twice	with	1X	PBS	and	RLT	buffer.	Cell	lysates	were	added	to	Qiashredder	
spin	columns	and	centrifuged	for	2	mins	at	13,000rpm.	Subsequent	homogenised	
lysates	were	transferred	to	gDNA	eliminator	columns	for	removal	of	genomic	DNA	and	
centrifuged	for	30	sec	at	13,000rpm.	Cell	lysates	were	further	transferred	to	a	fresh	
RNase	free	eppendorf	tube	and	one	volume	of	70%	ethanol	added	to	flow	through	
columns.	Total	RNA	bound	on	spin	columns	were	washed	with	RW1	and	RPE	buffer,	
prior	to	elution	with	30µl	of	RNase	free	H₂O.	RNA	concentration	and	purity	was	
determined	post	isolation	using	a	NanoDrop	(NanoDrop	2000,	ThermoScientific)	at	
260/280	nm	and	260/230	nm	with	the	ratio	of	1.8	is	generally	accepted	as	‘pure’	for	
DNA	and	a	ratio	of	2.0	‘pure’	for	RNA.		Lower	ratios	are	indicative	of	protein,	phenol	or	
other	contaminants	which	absorb	strongly	at	280	nm.	260/230	values	are	typically	
higher	for	nucleic	acids	as	a	measure	of	purity.	Generally,	2.0-2.2	is	acceptable.	Each	
reading	was	performed	three	times	and	the	mean	taken	as	exact	concentration	and	
normalised	for	subsequent	cDNA	synthesis.	Isolated	RNA	was	stored	at	-	80⁰C.		
	
6.6.2	Reverse	transcription	for	cDNA	synthesis	
cDNA	was	transcribed	from	total	isolated	mRNA	by	reverse	transcription.	Eukaryotic	
mRNA	comprises	poly-A	tail	located	at	3’	end	of	mRNA	sequence,	and	as	such	a	poly-T	
oligonucleotide	is	utilised	as	primer	in	the	reaction	annealing	to	3’end	of	mRNA,	
allowing	for	primer	extension	by	reverse	transcriptase	enzyme	using	target	mRNA	
strand	as	template.		
Reverse	transcription	was	performed	using	Tetro	cDNA	synthesis	kit	(Qiagen,	UK)	
followed	in	accordance	with	instructions.	Synthesised	cDNA	concentration	was	
determined	using	NanoDrop	and	normalised	as	required	using	the	mean	value	of	three	
readings.	Synthesised	cDNA	was	subsequently	used	for	gene	expression	analysis	in	qRT	
PCR	with	specific	oligonucleotide	primers	designed	for	amplification	of	target	genes.	
cDNA	concentration	was	ascertained	using	a	nanodrop	at	260/280	nm.	cDNA	not	used	
on	day	was	stored	at	-20⁰C.	
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6.6.3	Oligonucleotide	primer	design		
Target	gene	sequences	were	obtained	from	National	Center	for	Biotechnology	(NCBI)	
database	and	primers	ordered	from	Eurofins	or	PrimerDesign	(PrimerDesign	LTD,	UK).	
The	full	mRNA	coding	sequences	were	converted	to	fasta	formats	and	input	into	Basic	
alignment	tool	(BLAST)	for	alignment	and	similarity	against	other	sequences.		GC	clamp	
presence,	absence	of	hairpin	loop,	similar	Tm	and	GC	%	content,	and	less	than	four	
polynucleotide	runs	where	ensured.		Sequences	were	input	into	Primer3	for	specificity	
of	target	gene,	available	at	(http://www.ncbi.nlm.nih.gov/tools/primer-blast)	Primer	
sequences	and	NCBI	data	(table	6.5).	
Table	6.5	Primer	sequences	and	results	for	target	genes	
Primers	 Sequence	(5’->	3’)	 Tm	 GC	%	 Self	3’	
FGF2	 Forward	 GCTGAAGACAATGGTGAGCCG	
	
60.12	 57.14	 2.00	
	 Reverse	 GGATTTGCCTCTAGAAGGGCG	
	
60.99	 57.14	 2.00	
CDK4	 Forward	 GCGTTCCGCGGATTGCATTAC	
	
60.50	 57.14	 4.00	
	 Reverse	 CTTCGACAGAAGGTCAGTGGC	
	
60.19	 57.14	 3.00	
E2F1	 Forward	 AAATGCCCATTCTCCACTTC	
	
54.00	 45.00	 1.8	
	 Reverse	 GAGGCTGACCTTTCTTCGAG	
	
54.20	 50.00	 1.8	
RPL19	 Forward	 GTTAGACCCAATGAGACCAATG	
	
57.8	 47.8	 3.0	
	 Reverse	
GTCACAGGCTTGCGGATGA	
58.1	 57.9	 3.5	
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6.6.4	Quantitative	Real	Time	PCR	to	determine	mRNA	expression	levels	of	target	genes	
Synthesised	cDNA	was	used	for	qRT	PCR	as	a	2-	step	protocol	for	target	gene	
expression	analysis	(MJ	Research	Opticon	2	monitor,	BIORAD).	SYBR	Green	SensiFAST	
SYBR	Lo-ROX	kit	(Bioline,	UK)	and	PrecisionPlus	SYBR	green	master	mix	(PrimerDesign	
LTD,	UK)	were	used	in	accordance	with	manufactures	instructions.	SYBR	Green	dye	
intercalates	specifically	to	dsDNA,	with	an	emission	maxima	and	excitation	of	494	nm	
and	521	nm	respectively	(Amaya,	2005).		For	SYBR	Green	SensiFAST	SYBR	Lo-ROX	kit	
(Bioline,	UK),	a	total	volume	reaction	of	20	µl	was	used	comprising;	4µl	(25	ng)	target	
cDNA,	10µl	sensiFAST	SYBR	Lo-ROX	kit	(1X),	4.4µl	Rnase/Dnase	free	H₂O,	0.8µl	(400nM)	
FGF2	and	CDK4	primer	sequences.		
	
For	the	protocol	using	PrimerDesign	SYBR	master	mix,	a	20	µl	total	volume	reaction	
was	used	comprising;	10	µl	of	PrecisionPlus	master	mix,	1.2	µl	(6	pmols)	of	target	
primer	and	5	µl	(10	ng)	of	target	cDNA	made	up	to	the	total	volume	with	3.8	µl	
Rnase/Dnase	free	H₂O.	Samples	were	run	in	triplicate	wells	twice	or	duplicate	wells	
three	times	for	determination	of	relative	gene	expression	compared	against	
endogenous	gene	RPL19.	Primer	sequences	are	provided	in	table	6.5.		
	
Cycling	parameters	are	described	in	table	6.6	for	gene	expression	analysis	using	SYBR	
Green	SensiFAST	SYBR	Lo-ROX	kit	(Bioline,	UK).		Cycling	parameters	using	PrecisionPlus	
SYBR	green	master	mix	(PrimerDesign	LTD,	UK)	are	summarised	in	table	6.7.	mRNA	
expression	analysis	was	performed	using	the	Opticon	system	Monitor	3.1,	BIORAD.		
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Table	6.6	Cycling	conditions	for	q	RT	PCR	using	SYBR	Green	SensiFAST	SYBR	Lo-ROX	kit	(Bioline,	
UK)	A	2-	step	protocol	was	undertaken	using	cDNA	of	target	genes.		
.		
Parameters	 Time	 Temperature	(ᵒC)	 Cycles	
Enzyme	activation	 10	min	 95	 1	
2	–	step	cycling		 	 	 	
Denaturation	 15	sec	 95	 40	
Annealing	
Extension	
30	sec	
5	min	
60	
72	
	
Melt	curve	analysis		 15secs	 60	–	90	 1	
	
Table	6.7	Cycling	conditions	for	q	RT	PCR	using	PrecisionPlus	master	mix	(PrimerDesign)	
A	2-	step	protocol	was	undertaken	using	cDNA	of	target	genes.	No	final	extension	phase	was	
used	for	this	particular	protocol	as	per	manufacturer’s	guidance	
Parameters	 Time	 Temperature	(ᵒC)	 Cycles	
Enzyme	activation	 2	min	 95	 1	
2	–	step	cycling		 	 	 	
Denaturation	 15	sec	 95	 50	
Annealing	 60	sec	 60	 	
Melt	curve	analysis		 30	secs	 72	–	90	 1	
	
	
6.7	Small	interfering	RNA	(siRNA)	method	
The	term	RNAi	(RNA	interference)	was	coined	by	Fire	and	Coll	(1998)	describing	the	
phenomenon	of	introduction	of	dsRNA	into	a	cell	typically	due	to	dsRNA	activated	
protein	kinase	R	from	anti-viral	response	(Williams,	1999).	This	process	triggers	non-
specific	silencing	of	transcription	and	translation	(Moselin	and	Preovenzano,	2004).		
Small	interfering	RNAs	(siRNAs)	thus	occur	naturally	at	the	cellular	level	as	a	
component	of	the	post-transcriptional	gene	silencing	mechanism.	dsRNA	nucleotides	
termed	siRNAs	can	suppress	mammalian	gene	expression	in	a	specific	manner	resulting	
in	gene	silencing	and	gene	knock	down	as	opposed	to	gene	knock	out.		siRNA	
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mechanism	of	action	is	a	multi-step	process	shown	as	a	schematic	in	figure	6	and	
briefly	described:	Long	dsRNAs	are	initially	processed	by	the	functional	RNAse	III	
enzyme	Dicer	constituting	helicase,	dsRNA	binding,	and	PAZ	(piwi,	argonaute,	and	
zwille	proteins)	domains.	The	former	two	domains	are	important	for	dsRNA	unwinding	
and	mediation	of	protein-RNA	interactions.	Dicer	produces	21–23	nucleotide	dsRNA	
fragments	with	two	nucleotides	3'	end	overhangs,	i.e.	siRNAs.	RNAi	is	mediated	by	the	
RNA-induced	silencing	complex	(RISC)	guided	by	the	siRNA,	it	recognises	homologous	
mRNA	to	the	siRNA	sequence.	RISC	subsequently	cleaves	the	mRNA	in	the	middle	of	
the	homologous	region.		Thus,	gene	expression	is	specifically	inactivated	at	a	post-
transcriptional	(mRNA)	level.		Commercially	available	siRNA	systems	are	available	
which	use	the	above	principle	also	resolving	the	issue	of	anti-viral	response	discussed	
in	detail	in	(Williams,	1999).	This	is	achieved	by	generation	of	synthetic	siRNA	from	
segmenting	long	dsRNAs	or	dicing	small	hairpin	RNA	with	two	base	overhangs	which	
are	mRNA	specific.	These	can	be	subsequently	introduced	into	the	cell	via	transfection	
for	target	gene	silencing/knock	down.			
 
 
6.7.1	siRNA	transfection	for	knockdown	of	target	genes	
For	transient	protein	or	mRNA	knockdown	of	target	genes;	E2F1	and	FGF2,	2	x	105	
U2OS	p53	(+/+)	cells	were	seeded	into	6	well	plates	in	2	ml	antibiotic	free	DMEM	media	
supplemented	with	10	%	FBS,	and	incubated	at	37	°	C	for	24	h.	siRNA	transfection	for	
target	gene	silencing	was	performed	using	the	commercially	available	siRNA	
transfection	system	from	(SantaCruz	Biotechnology	Inc).	The	protocol	was	followed	in	
accordance	with	manufacturer’s	instructions.		
	
	
For	optimum	transient	knockdown	of	target	genes	at	the	mRNA	level	a	series	of	
concentrations	in	increments	of	20	pmols	was	performed	as	follows	to	make	following	
solutions;	Solution	A;	for	20	pmols;	2	µl	(20	pmols)	of	target	siRNA	duplex	was	added	to	
100	µl	of	siRNA	transfection	medium	(SantaCruz,	sc:	36868).	For	40	pmols;	4	µl	(40	
pmols)	of	target	siRNA	duplex	was	added	to	100	µl	of	siRNA	transfection	medium.	For	
60	pmols;	6	µl	(60	pmols)	of	target	siRNA	duplex	was	added	to	100	µl	of	siRNA	
transfection	medium.		
	 82	
	
	
For	each	transfection	and	to	prepare	Solution	B;	2	µl	(20	pmols)	of	transfection	reagent	
(SantaCruz,	sc	–	29528)	was	added	to	100	µl	of	siRNA	transfection	medium	(SantaCruz,	
sc	-36868).	For	40	pmols;	4	µl	(40	pmols)	of	transfection	reagent	was	added	to	100	µl	of	
siRNA	transfection	medium.	For	60	pmols;	6	µl	(60	pmols)	of	transfection	reagent	was	
added	to	100	µl	of	siRNA	transfection	medium.	Solution	A	was	directly	added	to	the	
siRNA	transfection	Solution	B	prior	to	incubation	at	RT	for	45	min.	For	each	
transfection,	a	non-coding	scramble	control	was	included	(SantaCruz	sc:	37007)	to	
ascertain	successful	transfection	and	for	comparison	against	target	mRNA	level.		
Scramble	concentrations	were	prepared	in	exactly	the	same	manner	as	Solution	A	and	
B	above	substituting	scramble	for	siRNA	duplex	using;	2	µl	(20	pmols),	4	µl	(40	pmols)	
and	6	µl	(60	pmols)	of	scramble	instead	of	target	siRNA	duplex.	The	non-coding	control	
contains	a	scrambled	sequence	which	will	not	lead	to	specific	degradation	of	any	
cellular	mRNA.	
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Figure	6	RNAi	mechanism	of	action	
dsRNA	introduced	into	a	cell	for	subsequent	cleavage	by	DICER	which	binds	and	cleaves	into	
short	nucleotide	pairs	around	20	bp	resulting	in	siRNA.	In	turn	this	RISC	silencing	complex	
utilises	one	siRNA	strand	to	bind	to	homologous	sequence	of	mRNA.	RISC	in	turn	degrades	the	
mRNA	thus	silencing	the	expression	of	the	target	gene.	This	principle	may	be	used	in	
experimental	settings	to	knock	down	target	genes.		
	
	
Proceeding	45	min	incubation	of	both	siRNA	duplex	and	scramble	solutions	all	cells	
were	washed	with	1	ml	of	transfection	medium	and	aspirated.	0.8	ml	of	siRNA	
transfection	media	was	added	to	both	siRNA	duplex	and	scramble	solutions	and	mixed	
gently	with	a	pipette	prior	to	overlaying	onto	the	washed	cells.	Cells	were	further	
incubated	for	7	hr	at	37	°	C.	After	incubation,	1	ml	of	DMEM	media	supplemented	with	
2	x	FBS	(20	%)	and	2	x	Penicillin	streptomycin	(2	%)	was	added	to	each	well	without	
removal	of	transfection	mixture	prior	to	incubation	at	37	°	C	for	24h	for	mRNA	and	72h	
for	protein.		
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Proceeding	incubation	(24	or	72	h),	the	media	was	aspirated	from	all	wells	and	
replaced	with	1	x	normal	DMEM	media	containing	10	%	FBS	and	1	%	P/S	and	incubated	
for	a	further	24	hr	37	°	C	prior	to	RNA	isolation.	RNA	isolation	was	performed	as	in	
6.6.1	using	the	exact	RNA	isolation	kit	(QIAGEN,	UK).	qRT	PCR	was	subsequently	
performed	to	ensure	successful	transfection	via	quantification	of	mRNA	levels	of	target	
knockdown	by	comparison	to	controls	of	scrambled	sequence.	qRT	PCR	was	performed	
as	described	in	6.6	using	the	exact	same	cycling	parameters	and	conditions	as	set	out	in	
table	6.7	and	analysed	using	the	Opticon	monitor	3.1,	BIORAD.	For	protein	isolation,	
methods	were	performed	exactly	as	in	6.5.2.1.	Protein	concentration	was	determined	
by	the	relative	method	described	in	6.5.2.2.	Western	blot	analysis	was	subsequently	
performed	to	ensure	successful	transfection	via	analysis	of	protein	levels	and	by	
comparison	to	controls	of	scrambled	sequence	as	described	in	6.5.2.		
	
6.7.2	Fluorescein	isothiocyanate	based	measurement	for	transfection	efficiency		
Fluorescein	isothiocyanate	(FITC)	was	performed	to	investigate	transfection	efficiency.	
Fluorescein	is	a	light	reactive	dye	for	visual	fluorescent	microscopy	which	can	be	used	
to	assess	transfection	efficiency.	Fluorescein	has	an	absorption	maximum	of	490	nm	
and	emission	maximum	of	514	nm.	Control	siRNA	Fluorescein	Conjugate	A	(SantaCruz,	
sc	–	36869)	a	non-coding	scrambled	sequence	was	used	to	measure	transfection	
efficiency	for	the	above	mentioned	transfections	described	in	6.7.1.	
U2OS	cells	were	seeded	at	2	x	105	and	incubated	for	24	hr	as	in	6.7.1.	The	FITC	protocol	
was	performed	as	per	manufacturer’s	guidelines	(SantaCruz	Biotechnology	INC.).	To	
measure	optimum	transfection	efficiency,	a	series	of	FITC	control	concentrations	in	
increments	of	20	pmoles	was	used	as	follows;	20	pmols	of	siRNA	Fluorescein	Conjugate	
A	was	added	to	100	µl	of	siRNA	transfection	medium	(SantaCruz,	sc:	36868),	40	pmols	
of	siRNA	Fluorescein	Conjugate	A	was	added	to	100	µl	of	siRNA	transfection	medium	
and	60	pmols	of	siRNA	Fluorescein	Conjugate	A	added	to	100	µl	of	siRNA	transfection	
medium.		
	
Solution	A	and	solution	B	containing	FITC	was	prepared	exactly	as	described	above	in	
6.7.1	Analysis	of	transfection	efficiency	was	performed	using	adobe	and	with	the	kind	
help	of	Dr	Geoff	Parr	of	Salford	Analytical	Services.		
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6.8	MTT	assay	
A	standard	5	day	MTT	[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	bromide]	
assay	was	used	to	determine	the	inhibitory	concentration,	50	%	(IC:50)	of	etoposide,	
gemcitabine	and	doxycycline	on	malignant	mesothelioma	Mero-14	cell	lines.	The	IC:50	
may	be	defined	as	is	the	concentration	of	drug	that	is	required	for	50	%	inhibition	in	
vitro.		
	
Mero-14	cells	were	detached	as	described	in	6.5.2.1	and	4.5	ml	of	fresh	media	was	
added	to	isolated	cells	in	a	10	ml	conical	test	tube.	10	µl	of	cell	suspension	was	
transferred	to	a	hemocytometer	for	cell	count	to	establish	2000	cells	/	well	and	a	total	
of	100	µl	cell	suspension	was	seeded	into	MTT	96	flat	well	–	plates		
	
Serial	dilutions	of	decreasing	drug	concentrations	were	undertaken	in	10	ml	conical	
test	tubes	supplemented	with	DMEM	media	and	the	relevant	drug	concentration	
added	to	each	96	well	in	triplicate.	100	µM	cisplatin	was	used	as	control	also	serially	
diluted	and	added	to	relevant	well	in	triplicate.		Proceeding	the	plate	set-up,	cells	were	
incubated	for	five	days	maintained	at	37	⁰	C	with	5%	CO₂.	Following	incubation,	50	µl	of	
MTT	[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	bromide)	reagent	was	added	
to	each	well	using	a	multi-channel	pipette	and	incubated	for	3	h	maintained	at	37	⁰	C	
with	5%	CO₂.	Following	this,	MTT	solution	was	aspirated	from	each	well	and	200	µl	
DMSO	was	added	to	each	well	using	a	multi-channel	pipette.	Results	were	read	on	a	
MTT	plate	reader	using	ascent	software	which	measures	the	difference	between	540	
and	690	absorbance.	690	is	a	background	reading	providing	a	default	to	compare	with	
540	which	shows	cell	viability.	The	IC:50	of	each	drug	was	determined	using	ascent	
software.		
6.9	Microarray		
Microarray	technique	is	a	high-throughput	technology	allowing	for	parallel	gene	
expression	analysis	on	a	genome	wide	level.	Microarrays	allow	for	the	identification	of	
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many	differentially	expressed	genes	that	have	an	established	or	redundant	function	in	
the	specific	area	of	interest.		
Microarray	methodology	works	on	the	principle	of	hybridization	probing	using	
fluorescently	labelled	nucleic	molecules	to	detect	complementary	sequences	
(immobilized	target	DNA	and	mobile	probe	DNA,	mRNA	or	cDNA).	Proceeding	mRNA	
isolation,	cDNA	probes	are	fluorescently	labelled,	if	complementary	hybridizing	of	the	
sample	to	the	immobile	target	occurs.	Image	acquisition	and	data	analysis	is	
undertaken	using	specialist	software	that	detects	fluorescent	labels	of	cDNA	(probe)	
bound	to	each	target	spot	on	the	hybridization	plate.	This	is	typically	of	a	green	to	red	
ratio	intensity,	where	green	represents	genes	upregulated	compared	to	control,	red	
represents	those	downregulated	compared	to	control.	Yellow	typically	represents	
genes	of	equal	abundance	between	experimental	and	control	samples.		
6.9.1	The	Affymetrix	Human	Genome	U133	plus	2.0	Array	
The	Affymetrix	Human	Genome	U133	plus	2.0	Array	(Eurofins,	UK)	was	chosen	as	it	
provides	complete	coverage	of	the	human	genome	U133	set	plus	an	additional	6.500	
genes	for	analysis	of	over	47.000	transcripts	with	accuracy	and	reproducibility.		
6.9.2	Preparation	of	microarray	samples		
Human	malignant	mesothelioma	adherent	Mero-14	cell	lines	were	seeded	at	10	6	cells	
and	treated	with	10	µM	etoposide,	1	µM	gemcitabine	(SIGMA,	UK)	and	50	µM	
doxycycline	(SIGMA,	UK)	for	24	h	with	a	control	of	untreated.	To	expose	cells	to	low	
oxygen	conditions	to	mimic	hypoxia,	Mero-14	cells	were	placed	in	a	hypoxic	chamber	
with	1	%	oxygen	for	24h	with	a	control	of	untreated	cells	that	were	maintained	at	37	⁰	
C	with	5%	CO₂	for	24	h.		This	was	performed	in	duplicate	as	biological	replicates.	
Proceeding	24	h	treatment	and	in	accordance	with	Eurofins	genomics	UK,	cells	were	
washed	twice	with	1X	PBS	and	collected	using	RLT	buffer	on	ice,	and	centrifuged	at	
1500	RPM	for	4	mins.	Cell	pellets	were	collected	in	a	fresh	Eppendorf	tube	containing	
RLT	buffer	and	shipped	on	dry	ice	to	Eurofins	genomics	(AROS,	Denmark).	RNA	
extraction	and	microarray	procedure	were	performed	by	Eurofins,	AROS,	Denmark.	
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6.9.2.1	Microarray	analysis		
In	order	for	gene	expression	levels	to	be	comparable	across	microarrays,	normalization	
procedures	have	to	be	undertaken	(Smyth	and	Speed,	2003).	Normalization	tries	to	
take	into	account	variations	arising	from	background	noise,	sample	preparation	and	
technology	variation	
On	an	array,	an	individual	gene	is	represented	by	different	oligonucleotide	probes.	
Each	probe	pair	consists	of	a	perfect	match	(PM)	oligonucleotide	and	a	mismatch	(MM)	
oligonucleotide.	The	PM	probe	contains	an	exact	sequence	complimentary	to	the	
target	gene,	thus	measuring	gene	expression.	The	MM	probe	differs	from	the	PM	
probe	arising	from	a	single	base	substitution	which	disrupts	the	binding	of	the	target	
gene	transcript.	This	helps	to	determine	the	background	and	nonspecific	hybridization	
that	contributes	to	the	signal	measured	for	the	perfect	match	oligonucleotide.	Two	
algorithms	are	typically	used	for	normalization	of	microarray	data,	Mas5	and	RMA.	The	
Mas5	algorithm	considers	mismatch	probes	(MM)	and	calculates	an	average	of	the	
logged	perfect	match	–	mismatch	probes	(PM-MM)	as	such	increased	variation	is	noted	
at	low	signal	strength	arising,	in	part	from	the	extra	noise	by	subtraction	of	MM	values	
from	PM	values.	This	can	result	in	false	positives.	Robust	multi-array	(RMA)	in	contrast	
is	a	quantile	normalization,	ignoring	MM	values	and	as	such	do	not	suffer	from	this	
variation	(Izarry	et	al.	2003).	Thus,	the	RMA	was	used	for	background	correction,	
quantile	normalization	of	gene	expression	data	and	subsequent	analysis.		
All	gene	expression	analysis	using	RMA	CEL.	files	were	undertaken	using	the	Affymetrix	
expression	console	software,	and	in	Bioconductor	available	in	R.	Tests	were	performed	
as	one-way	ANOVA	comparisons.	and	statistically	differentially	expressed	genes	were	
determined	by	log	fold	changes	>	1.5	and	<	-	1.5,	Anova,	P	<	0.05	and	adjusted	Q	value.	
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7	Results		
7.1	Application	of	the	signal	transduction	score	flow	algorithm	to	PKT206	
	
The	Boolean	p53	model	(PKT206)	(discussed	in	section	4	and	6)	and	in	detail	in	(Tian	et	
al.2013)	has	been	shown	as	a	promising	predictive	interactome	for	investigating	
network	perturbations	of	p53	–	DNA	damage	pathways,	highlighting	its	potential	in	
anti-cancer	strategies.	Correct	predictions	of	52-	71	%	were	obtained	using	Boolean	
PKT206	from	various	in	silico	KO	tests	and	comparison	to	various	human	microarray	
datasets	revealing	several	potential	novel	predictions.	Even	so,	greater	predictive	ratios	
are	required	to	represent	biological	phenomena	for	future	clinical	relevance.		
	
Boolean	models	whilst	informative	are	often	limited	in	their	ability	to	truly	depict	the	
system	providing	an	approximate	representation.	As	discussed	in	section	4,	discrete	
modelling	approaches	which	consider	only	binary	states	are	advantageous;	they	allow	
for	the	construction	of	large	scale	networks	due	to	their	simplification,	therefore	are	
computationally	more	efficient.	This	is	in	contrast	to	continuous	models	such	as	
ordinary	differential	equations	(Albert	et	al.2008).	However,	these	simplifications	have	
drawbacks,	they	cannot	fully	describe	system	dynamics	frequently	observed	in	
diseased	states	or	biological	phenomena.	Characteristically,	genes	may	be	assigned	as	
either	‘ON’/transcribed	or	‘OFF’/not	transcribed	and	as	such	Boolean	models	are	
competent	for	such	representation.	However,	consideration	must	be	given	to	the	
complexity	of	the	cellular	interactome	and	its	accompanying	dynamics.	Indeed,	
differential	gene	expression	exhibits	considerable	inherent	stochasticity	and	ambiguity	
which	cannot	always	be	described	sufficiently	by	only	two	states.		Therefore,	a	
quantitative	approach	was	undertaken	to	refine	PKT206	for	a	more	robust	in	silico	
model	to	clinical	data	and	investigate	the	potential	and	use	of	a	quantitative	method.			
	
The	novel	Signal	Transduction	Score	Flow	Algorithm	(STSFA),	described	in	detail	in	(Isik	
et	al.2012)	depicted	as	a	schematic	in	figure	7,	has	demonstrated	good	correlation	with	
transcriptome	profiles.	STSFA	quantitatively	evaluates	biological	activities	of	a	cyclic	
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cellular	network,	and	stimulates	cell	signalling	flow	on	cyclic	pathway	topology,	as	
opposed	to	the	Boolean	binary	states	of	on	or	off	in	Boolean.	Moreover,	STSFA	is	
capable	of	handling	large	data	sets	typically	infeasible	in	extensive	models.		Using	large	
scale	‘omics’	driven	data,	STSFA	assigns	dynamic	gene	scores	throughout	the	network	
from	source	node	to	final	cellular	processes	for	pathway	analysis,	incorporating	crucial	
topological	signalling	information	such	as	feedback	cycles	and	node	stoichiometry,	
often	lacking	in	logical	models.	Thus	application	of	STSFA	to	PKT206	may	provide	a	
better	representation	of	the	complex	p53	system.			
	
7.1.1	Application	of	STSFA	to	the	PKT206	model		
The	logical	PKT206	model	was	constructed	and	described	in	detail	by	Tian	et	al.	(2013)	
through	text	mining	approaches	and	manual	curation	using	the	STRING	database.		
Although	PKT206	is	a	simplified	view	of	the	p53	system,	it	has	established	overall	
system	attributes	with	good	predictive	ratios.	Whilst	extensive,	the	Boolean	model	
remains	qualitative.	Both	greater	predictive	ratios	with	a	quantitative	view	are	required	
for	a	more	robust	p53	network	and	truer	representation	of	the	biological	system	for	
clinical	significance.	The	STSFA	has	demonstrated	as	a	promising	method	for	a	
quantitative	view	of	large	scale	transcriptional	networks.	As	such	the	STSFA	was	
applied	to	the	p53	interactome	for	investigation	of	p53	interactome	performance	to	
accurately	stimulate	experimental	conditions	using	microarray	data	of	human	
osteosarcoma	SaOS2	(p53	-/	-),	U2OS	(p53	+/+)	untreated	and	treated	with	DNA	damage	
inducing	etoposide	and,	untreated	human	colon	HCT116	p53	null	and	wildtype	cells.		
These	results	were	further	compared	to	the	LSSA	analysed	model	for	evaluation	of	p53	
model	performance.		
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Figure	7	The	signal	transduction	score	flow	algorithm	principle.	The	initial	score	is	shown	in	
the	square	node	of	DNA	damage.		The	score	is	subsequently	transmitted	downstream.	For	
example,	ATM	and	ATR,	the	sum	of	these	is	10	therefore,	6/15	of	protein	ATM	raw	score	is	
transmitted	downstream	to	CHK1,	and	4/10	is	transferred	to	ATR.	These	scores	subsequently	
transmit	to	p53	which	receives	the	total	score	of	36	(2+20+14).	This	transmits	to	both	VEGFA	
and	p21.	However,	p53	to	VEGFA	edge	is	inhibitory,	thus	the	score	outcome	is	-34	and	
therefore	considered	inactive.	Conversely,	p21	is	active	with	a	score	of	8.		
	
7.1.2	Validation	of	the	STSFA	p53	interactome	using	genome	wide	analysis	
To	compare	experimental	to	in	silico	model	data,	the	log10	fold	change	(FC)	(section	6)	
in	gene	expression	scores,	between	experimental,	and	in	silico	conditions	for	each	
simulation	were	calculated,	summarised	in	table	7,	defined	by	the	thresholds	given	in	
section	6	for	each	comparison.	Figure	7.1	shows	the	frequency	distribution	of	the	log10	
FC	in	STSFA	gene	activity	scores	between	experimental	and	simulated	conditions.		
	
The	STSFA	model	accurately	predicted	gene	activity	changes	between	both	conditions	
of	DNA	damage	and	p53	knockdown	for	the	majority	of	genes,	with	correct	predictions	
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derived	73.5	-	82%,	considered	highly	statistically	significant	(P=<1x10-16)	(table	7.1).	
Considering	this	accuracy,	comparison	of	the	STFSA	model	against	the	Boolean	model	
performance	and	predictions	was	further	evaluated.		
	
7.1.3	Comparison	of	STSFA	and	LSSA	for	model	performance	and	prediction	to	
experimental	data		
Distributions	of	correct,	small	error	and	large	error	predictions	were	compared	across	
all	conditions	(figure	7.1.1).	The	STSFA	consistently	demonstrated	a	higher	proportion	
of	correct	predictions	than	LSSA,	with	average	percentage	of	all	U20S	p53	+/+	and	
SaOS2	p53	-/-	simulations	between	LSSA	(61%)	and	STSFA	(75%)	considered	very	highly	
significant,	(P	<	0.005).	Similar	results	were	also	observed	for	untreated	HTC116	p53	
wildtype	and	null	simulations	of	STSFA	correct	predictions	(79%)	and	LSSA	(52%),	with	
over	a	two-fold	increase	of	small	errors,	and	a	two	-	fold	increase	in	large	error	
predictions	observed	for	LSSA	than	the	STSFA	model	respectively.	For	every	condition,	
the	proportion	of	correct	predictions	were	considered	significantly	significant		
(P,	<	1x10-16).		
	
	
	
Figure	7.1	Frequency	distribution	of	the	log10	FC	in	STSFA	gene	activity	scores	of	experimental	
and	simulated	conditions.	Two	thresholds	are	shown	for	each	condition,		𝑥	-	σ	(blue	bars)	and		𝑥	±	σ	(red	bars).	Genes	whose	log10	FC	of	gene	activity	score	fell	between	these	values	were	
classified	as	‘no	change’,	those	above	and	below	threshold	values	were	‘upregulated’	or	
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‘downregulated’,	respectively.	A)	p53	wt	DNA	damage	on	vs	p53	wt	DNA	damage	off	B)	p53	
null	DNA	damage	on	vs	p53	null	DNA	damage	off	C)	p53	wt	DNA	damage	on	vs	p53	null	DNA	
damage	on	D)	p53	wt	DNA	damage	off	vs	p53	null	DNA	damage	off	E)	p53	wt	DNA	damage	off	
vs	p53	null	DNA	damage	on	F)	p53	wt	DNA	damage	on	vs	p53	null	DNA	damage	off.		
	
Taken	together,	these	results	demonstrate	the	STSFA	accurately	predicts	gene	activity	
changes	between	transcriptome	data	and	in	silico	simulations.	Moreover,	the	STSFA	
model	is	consistently	more	accurate	than	the	logical	p53	model	providing	a	semi	-
quantitative	representation	of	the	PKT206	model.		
	
	
Table	7	STSFA	model	performance	by	distribution	of	PKT206	and	HTC116	predictions	for	each	
condition.	Model	predictive	performance	was	evaluated	with	various	gene	expression	profiles.	
Gene	activity	changes	between	experimental	and	simulated	conditions	were	analysed	using	the	
approach	given	in	section	6.		Results	were	considered	significant	(P<1x10-16)	for	all	conditions.	
wt	=	wild	type.		
	
Condition		
																															Prediction	
True														Small	error											Large	error	
p53	wt	DNA	damage	off	vs.	p53	wt	DNA	
damage	on		
159	(77%)		 44	(21%)	 4	(2%)		
	
p53	wt	DNA	damage	on	vs.	p53	null	DNA	
damage	on	
	
158	(77%)	
	
	
47	(22%)	
	
2	(1%)	
	
p53	wt	DNA	damage	off	vs.	p53	null	DNA	
damage	off	
p53	wt	DNA	damage	off	vs.	p53	null	DNA	
damage	on		
p53	null	DNA	damage	on	vs.	p53	null	DNA	
damage	off	
p53	wt	DNA	damage	on	vs.	p53	null	DNA	
damage	off		
	
158	(77%)	
	
152	(73.5%)	
156	(75%)	
	
170	(82%)	
	
43	(20%)	
	
52	(25%)	
49	(24%)	
	
35	(17%)	
	
6	(3%)	
	
3	(1.5%)	
2	(1%)	
	
2	(1%)	
	
HTC116	p53	wt	DNA	damage	off	vs.	p53	
null	DNA	damage	off	
137	(79%)	 32	(19%)	 3	(1.7%)	
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A)																																							
  
	
	
	
	
	
	 	
	
	
	
	
B)																																							
	
	
	
	
	
	
	
	
Figure	7.1.1	The	STSFA	p53	interactome	is	able	to	correctly	predict	the	response	to	DNA	
damage	and	p53	knockout,	and	is	more	accurate	than	LSSA.	A)	The	distribution	of	predictions	
made	in	each	comparison	(table	7),	defined	by	the		𝑥	±	σ	threshold.	B)	Comparison	of	mean	
percentage	of	correct	predictions	for	each	PKT206	SaOS2	p53	-/-	and	U20S	p53	+/+	simulations	
from	Table.3	(Unpaired	T	Test,	P	=	<0.005),	(𝑥			±	SEM).	
	
7.1.4	In	silico	knock	out	analysis	of	anti-apoptotic	genes		
Given	the	high	level	of	accuracy	demonstrated	by	the	STSFA	p53	model,	in	silico	knock	
out	analysis	of	potent	anti-apoptotic	genes	were	simulated.	Apoptosis	is	well	studied	
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and	the	most	clinically	relevant	anti-proliferative	program,	thus	identification	of	novel	
drug	candidates	targeting	apoptosis	is	pivotal	to	effective	therapies.		
	
Genes	chosen	were	those	who	had	direct	apoptotic	effects,	with	fewest	off	target	
effects	on	the	rest	of	the	network.	CKS2,	IER3,	C12orf5,	WWP1,	PSEN1,	EPHB4	and	
PRSS50	were	investigated	as	a	result	(figure	7.1.2	and	7.1.3).	Knock	out	analysis	
demonstrated	increased	apoptotic	log10	FC	scores	in	target	gene	deletion	backgrounds	
than	that	of	wildtype	(figure	7.1.2)	with	little	effect	on	the	rest	of	the	network,	
indicative	of	the	prospective	of	these	as	novel	drug	targets.		
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Figure	7.1.2	The	Log10	fold	change	of	STSFA	activity	scores	for	apoptosis	and	the	x	+	σ	
threshold	for	each	in	silico	gene	knockout.	Increased	apoptotic	scores	were	observed	in	target	
gene	deletion	backgrounds	than	in	wildtype.		
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Anti-apoptotic	genes	
	 	
Anti-apoptotic	genes	ONLY	
BCL2	 	 C12orf5	
BCL3	 	 CKS2	
C12orf5	 	 EPHB4	
CDKN1A	 	 GSTP1	
CKS2	 	 IER3	
EPHB4	 	 MCL1	
EZH2	 	 PRSS50	
FHL2	 	 PSEN1	
GSTP1	 	 WWP1	
IER3	 	 	
IGF1R	 	 	
MCL1	 	 	
PDGFRB	 	 	
PRSS50	 	 	
PSEN1	 	 	
SFN	 	 	
SGK	 	 	
TCF7L2	 	 	
TGFA	 	 	
VEGFA	 	 	
WWP1	 	 	
Figure	7.1.3	CKS2,	IER3,	C12orf5,	WWP1,	PSEN1,	EPHB4	and	PRSS50	are	potential	targets	for	
inhibitory	anti-cancer	therapeutics.	A	flow	diagram	highlighting	the	selection	of	the	
identification	of	anti-apoptotic	genes	(highlighted	in	grey)	from	the	PKT206	network,	genes	
with	the	least	effect	on	the	network	node	population	were	chosen.		
	
7.1.5	Conclusion	
Here	we	have	applied	a	novel	algorithm	recently	described	(Isik	et	al.2012)	to	the	
PKT206	p53	interactome	utilising	raw	expression	data	of	U2OS	p53	+/+	and	SaOS2	p53	-
/-,	and	untreated	HTC116	colon	cancer	p53	null	and	wildtype	cell	lines	(Tian	et	al.2013)	
to	investigate	overall	STSFA	model	enactment	and,	finally	compare	in	silico	prediction	
of	experimental	data	to	the	PKT206	logical	model.		
	
Dynamic	biological	phenomena	such	as	cancer	and	p53	networks	display	system	
complexity,	involving	multivariate	dysregulation	of	signalling	pathways	governing	
fundamental	cellular	processes	(Hornberg	et	al.2006).	Thus,	in	silico	representations	
must	encode	mathematical	models	of	a	quantitative	nature	for	true	representation	
(Wilkinson	et	al.2000:	Bachmann	et	al.2011).	The	STSFA	p53	interactome	described	
Gene	
knockout	
Number	of	other	
genes	affected	
MCL1	 14	
GSTP1	 12	
PRSS50	 5	
EPHB4	 4	
C12orf5	 3	
CKS2	 3	
IER3	 3	
PSEN1	 3	
WWP1	 2	
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here	has	accurately	predicted	overall	system	attributes	in	response	to	p53	–	DNA	
damage	inducible	pathways	when	compared	to	transcriptome	in	vitro	experimental	
data.	These	results	provided	a	semi	quantitative	representation	of	the	p53	system	as	
opposed	to	the	qualitative	Boolean	approach.	Furthermore,	to	investigate	potent	anti-
apoptotic	candidates,	we	mimicked	in	vivo	mutations	of	anti-apoptotic	nodes	using	in	
various	in	silico	knock	out	backgrounds.	Here	we	describe,	WWP1,	CKS2	and	EPHB4	as	
putative	cancer	drug	targets.		
	
Slightly	greater	predictive	ratios	were	obtained	utilising	STSFA	than	LSSA	(73.5	-	82	%)	
(table	7),	achieved	by	incorporation	of	stoichiometric	processes	during	signal	flow	
pathway	analysis	not	considered	in	LSSA.	Deterministic	qualitative	models	such	as	
Boolean	often	fail	to	capture	the	heterogeneity	and	stochasticity	associated	with	large	
‘omics’	driven	biochemical	networks.	Boolean	logic	assigns	static	gene	states	only,	of	
(“ON/1”)	and	(“OFF/0”)	referring	to	genes	expressed	or	non-expressed	respectively,	
thus	are	limited	for	true	system	representation.	Discrete	models	provide	good	
approximation	of	the	qualitative	behaviour	of	the	system	(Kauffman	et	al.1969:	Albert	
et	al.2008).	These	networks	may	be	represented	by	directed	graphs	or	hypergraphs	
where	transfer	states	of	edges	are	derived	using	logical	operators	of;	AND,	OR	and	NOT	
(Klamt	et	al.2009).	In	naïve	Boolean	models	no	reaction	rates	are	incorporated	in	
transfer	functions,	thus	no	kinetic	parameters	are	required.	This	simplicity	allows	for	
large	scale	modelling,	which	has	been	applied	successfully	to	cancer	networks	(Schlater	
et	al.2009;	Sridhoron	et	al.2012;	Rodrigeuz	et	al.2012).	However,	Boolean	models	have	
limitations.	Differential	gene	expression	exhibits	considerable	inherent	stochasticity	
and	ambiguity,	which	cannot	be	described	sufficiently	by	only	two	states.	Therefore,	
poor	predictive	accuracy	may	be	a	consequence	of	the	inference	of	deterministic	
functions.	Indeed,	many	of	these	simplistic	approaches	appear	robust	when	analysed	in	
silico,	however	display	considerably	reduced	enactment	once	applied	to	experimental	
‘omics’	datasets	and	can	only	be	used	for	approximates	and	statistical	based	system	
analysis	rather	than	experimental	representation	(Soranzo	et	al.2007;	Zhongxing	et	
al.2008).	The	score	flow	algorithm	however,	captures	such	gene	dynamics	applying	an	
empirical	approach	utilising	‘omics’	data	driven	gene	enrichment	of	a	particular	
pathway.	It	incorporates	stoichiometric	processes	as	score	partitions,	stimulating	
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cellular	signal	flow	on	cyclic	pathway	topology	rather	than	static	binary	node	states.	
Thus	is	more	apt	for	genome	wide	data	analysis	and	in	silico	representation.	
	
The	STSFA	p53	interactome	has	revealed	several	anti-	apoptotic	genes	which	may	offer	
therapeutic	potential.	These	had	little	effect	on	the	rest	of	the	network,	and	as	such	
were	considered	good	candidates	(figure	7.1.3).		Moreover,	downstream	nodes	which	
were	affected	by	the	target	gene	KO	were	also	of	interest.	For	example,	deletion	of	
EPHB4	resulted	in	downregulation	of	the	potent	pro	angiogenic	factor	VEGFA.	Those	
considered	as	putative	drug	candidates	are	briefly	described.		
	
CKS2	(essential	for	cyclin	dependent	kinase	function)	expression	is	upregulated	in	
several	tumour	types	and	associated	with	poor	prognosis.	CSK2	knockdown	resulted	in	
increased	apoptosis	and	tumorigenic	loss	in	prostate	cancer	cells	(Lan	et	al.2008),	
whilst	its	overexpression	results	in	a	loss	of	S	phase	checkpoint	and	continuation	of	cell	
cycle	progression	(Liberal	et	al.2012).	The	E3	ubiquitin	ligase,	WWP1	role	in	cancer	is	
less	defined.	However,	its	upregulation	is	associated	with	cell	proliferation	in	breast	
cancer	cells	promoting	growth.	Conversely,	this	study	also	revealed	that	decreased	
WWP1	expression	had	a	worse	prognosis	than	in	WWP1	wt	tumours	in	another	breast	
cancer	tumour	type.	Thus,	WWP1	may	be	tissue	specific	(Zhi	and	Chen,	2012),	and	may	
be	promising	for	novel,	targeted	cancer	therapeutics.		
	
The	receptor	tyrosine	kinase		EPHB4	is	also	a	pro	angiogenic	factor,	overexpressed	in	
several	cancers	(Chen	et	al.2013;	Hasina	et	al.2013;	Li	and	Zhao,	2013).	A	recent	study	
blocking	EPHB4	function	resulted	in	decreased	tumour	growth		(Krasnoperov	et	al.	
2010).	Therefore,	this	protein	seems	to	be	a	promising	target	for	novel,	broad	range	
cancer	therapeutics.	
	
Even	though	the	STSFA	p53	model	identified	overall	system	attributes,	limitations	were	
observed	of	several	incorrectly	predicted	genes.	Those	identified	were	in	the	majority	
connected	only	to,	and	downstream	of	p53.	Considering	the	plethora	of	upstream	
genes	influencing	p53	activity	(71	nodes),	this	is	not	surprising,	with	any	small	error	
within	these	nodes	traversing	to	p53.	This	could	be	challenging	as	the	network	
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increases.	One	factor	to	consider	is	that	p53	has	nine	isoforms	differing	at	the	N	and	C	
termini	arising	from	the	presence	of	a	second	promoter	in	intron	one,	alternative	
mRNA	splicing	and	an	alternative	translation	initiation	site	at	AUG40	(Courtois	et	
al.2002;	Bourdon	et	al.2005;	Khoury	et	al.2010).	As	such	the	p53	node	in	PKT206	
represents	all	gene	isoforms.	Different	isoforms	have	distinct	roles	and	binding	
partners,	thus	amalgamation	into	one	node	may	compromise	its	ability	to	simulate	the	
response	of	signalling	pathways	to	changes	in	experimental	conditions.		Therefore,	
consideration	of	integration	of	these	isoforms	into	the	network,	may	resolve	such	
network	limitations.	Another	factor	to	consider	is	that	PKT206	is	a	global	cancer	model.		
Downstream	responses	by	p53	are	both	cell	type	dependant	and	also	governed	by	the	
differentiation	state	of	the	cell	(Marcel	and	Hainaut,	2005).	Thus,	constructing	cell	/	
tissue	specific	models	may	overcome	this	issue.	Lastly,	a	sole	input	of	DNA	damage	and	
output	of	apoptosis	are	only	described	by	PKT206,	where	in	fact	p53	initiates	several	
anti-proliferative	downstream	programs	and	is	also	induced	by	various	other	stresses	
in	addition	to	DNA	damage,	for	example,	hypoxia.	Indeed,	even	DNA	damage	has	
different	forms	of	ssDNA	and	dsDNA	break	which	influence	downstream	nodes.	
Possible	addition	of	this	diversity	in	the	model	should	be	explored.		
	
Nevertheless,	and	in	conclusion,	the	STSFA	PKT206	model	described	here	has	provided	
a	semi	quantitative	representation	of	the	p53	interactome	producing	a	promising	
platform	for	a	fully	quantitative,	predictive	transcriptional	p53	model.		
	
7.2	Generation	of	the	PMH260	model	
	
Both	quantitative	(Hussain	et	al.	2014)	(section	7.1)	and	the	qualitative	p53	DNA	–	
damage	model	(Tian	et	al.	2013)	have	shown	good	predictive	potential	for	dissecting	
p53	network	dynamics,	both	deriving	over	70	%	average	correct	predictions	when	
compared	to	various	human	in	vitro	generated	microarray	profiles.	This	has	provided	a	
promising	platform	for	further	studies	using	predictive	logical	models	for	personalised	
anti-cancer	strategies.		
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Nevertheless,	the	network	complexity	of	p53	and	its	regulatory	pathways	with	the	vast	
literature	base	makes	it	a	challenging	system.	Although	over	85,	000	PubMed	
publications	are	linked	with	the	keyword	p53	(PubMed,	May,	2016),	we	are	still	far	
from	fully	elucidating	the	role	of	p53	and	its	associated	pathways	governing	
tumorigenesis.		In	order	to	gain	an	increased	understanding	of	p53	regulatory	
networks,	information	at	the	molecular	level	must	be	integrated	into	a	coherent	
framework,	and	computational	methodologies	are	novel	tools	to	depict	the	
heterogeneity	of	disease	networks	such	as	cancer.		
	
Cancer	systems	biology	is	a	relatively	novel,	yet	promising	field	that	can	utilize	high-
throughput	data	to	analyse	intracellular	network	perturbations	(Wang,	2010).	These	
integrative	approaches	can	offer	potential	to	systematize	and	predict	molecular	
deviations	of	the	cancer	phenotype.	Predictive	models	can	be	of	both	clinical	and	
pharmaceutical	relevance	for	the	development	of	novel	effective	therapies.	Indeed,	
several	computational	studies	of	different	mathematical	complexities	have	already	
been	developed	in	an	effort	to	address	this,	including	the	modelling	of	p53	(Kreeger	
and	Lafenberger,	2010).		
	
Even	though	the	quantitative	model	(Hussain	et	al.2014)	has	successfully	simulated	
overall	system	attributes,	Boolean	networks	are	a	promising	predictive	framework	for	
cancer	modelling.	The	most	simplistic	of	models	defining	binary	states	of	ON	or	OFF	to	
represent	gene	activation	or	inhibition,	can	effectively	recapitulate	gene	expression	in	
silico,	allowing	for	larger	scale	modelling.	Logical	networks	have	been	applied	
successfully	to	model	various	biological	phenomena	(Shmulevich	and	Kauffman,	2004;	
Schaltter	et	al.2009	and	Tian	et	al.2013).		
	
Even	though	Boolean	PKT206	has	demonstrated	overall	system	attributes,	the	p53	
network	is	extensive.	In	fact,	over	1000	p53	responsive	genes	have	been	previously	
described	(Riley	et	al.2008),	and	previous	attempts	to	superimpose	microarray	data	to	
PKT206	were	problematic	due	to	network	size	(unpublished	data,	Tian	et	al.2013).		In	
addition,	for	greater	representation	of	cancer	dynamics,	predictive	models	must	
incorporate	and	depict	the	heterogeneity	of	diseased	states	and	the	processes	that	
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govern	them.	For	example,	defined	as	hallmarks	of	cancer,	angiogenesis	and	apoptosis	
are	pivotal	properties	to	the	tumour	environment	(Hanahan	and	Weinberg,	2011).	
Further,	it	is	well	established	that	perturbed	apoptotic	pathways	are	a	major	cause	of	
chemo-resistance	(Fulda,	2009).	Therefore,	consideration	of	such	processes	are	crucial	
to	correctly	represent	tumour	dynamics	(Wang,	2010),	in	particular	for	discovery	of	
potential	anti-cancer	strategies	
	
With	this	in	mind,	we	have	expanded	PKT206	to	generate	a	larger,	more	robust	model	
for	elucidation	of	p53	–	cancer	dynamics.	We	have	incorporated	three	additional	
outputs	(angiogenesis,	cell	cycle	arrest	and	DNA	repair)	allowing	for	processes	involved	
in	p53	governed	tumorigenesis	to	be	modelled	and	analysed	systematically,	and	
ascertain	if	the	expanded	Boolean	model	can	correctly	predict	overall	system	attributes	
in	response	to	network	perturbations	by	comparison	to	transcriptome	data.		
	
	
7.2.1	Results		
	
7.2.1.1	Generation	of	the	PMH260	model	
The	generation	of	PKT206	is	described	in	detail	elsewhere	(Tian	et	al.	2013),	also	
discussed	here	(section	4).		
	
The	PMH260	model	was	generated	by	expansion	of	PKT206	which	originally	comprised	
206	nodes	with	738	interactions.	Given	the	fact	that	STRING	was	identified	as	the	best	
source	for	p53	information	from	over	30	databases	(Tian,	K,	PhD	thesis,	University	of	
Manchester,	2013)	for	construction	of	the	PMH260	network,	we	followed	the	same	
principle	for	consistency	in	accordance	with	PKT206	generation	(Tian	et	al.2013).	
Additional	interactions	direct	to	p53	were	extracted	from	the	STRING	database	(v9.1)	
(Szklocyk,	2011).	Interactions	were	only	considered	if	their	confidence	score	was	high,	
set	at	0.7	by	a	STRING	schema.	This	resulted	in	a	possible	81,000	STRING	interactions	
described	for	p53.		
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Interactions	were	filtered	according	to	the	nature	of	their	interaction	(post	
translational	modification,	binding,	expression,	activation	and	inhibition)	and	any	
duplicated	information	removed	arising	from	the	value	of	direction.	This	resulted	in	a	
total	of	12,545	possible	interactions	from	81,000.	Additional	filtering	was	undertaken	
to	separate	the	first	and	second	layer	of	the	network,	referring	to	proteins	that	directly	
interact	with	p53	and	proteins	which	interact	with	each	other	respectively.	For	
example,	both	ATM	and	CHK1	activate	p53,	these	are	direct	and	considered	as	the	first	
layer,	whilst,	ATM	activates	CHK1,	this	defines	interactions	which	are	independent	of	
p53	and	refers	to	the	second	layer	of	the	model.		This	resulted	in	a	total	of	967	possible	
interactions	direct	to	p53	for	manual	curation.		
	
As	we	initially	aimed	to	expand	the	model	slightly	to	test	if	the	model	could	
successfully	simulate	and	predict	overall	system	attributes,	we	created	a	preliminary	
model	and	considered	54	additional	internal	nodes.	This	resulted	in	an	extra	242	
interactions	between	existing	(PKT206	nodes)	and	new	nodes	(n	=	54).	Manual	curation	
for	validation	of	these	interactions	were	also	undertaken	for	model	accuracy	and	
additionally	confirmed	with	the	kind	help	of	supervisor,	Prof.	M.	Demonacas.	At	least	
one	documented	scientific	publication	was	used	for	an	interaction,	some	described	by	
more.		
	
Three	additional	outputs	were	also	included	into	PMH260	(cell	cycle	arrest,	DNA	repair	
and	angiogenesis)	and	all	internal	nodes	(n	=	254)	were	linked	to	the	biological	
processes	that	they	regulate	or	are	regulated	by	(DNA	damage)	via	their	edge	function	
of	inhibition,	activation	or	ambivalent	factor.	These	links	were	initially	selected	based	
upon	their	GO	annotations	via	the	Gene	Ontology	(GO)	database,	and	additionally	
manually	curated	by	scientific	literature	for	confirmation	of	interactions.	As	the	PKT206	
model	did	not	consider	the	three	additional	outputs,	all	internal	nodes	(n	=	203)	of	the	
PKT206	network	were	linked	to	these	outputs	(cell	cycle	arrest,	DNA	repair	and	
angiogenesis).		
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7.2.1.2	PMH260	network	topology		
The	PMH260	model	comprises	a	network	considering	260	nodes	(including	1	input	and	
5	outputs)	with	980	interactions	of	activation	or	inhibition.	A	total	of	42	nodes	were	
regulated	by	the	single	input	to	the	model	(DNA	damage)	which	serves	as	
environmental	stress.	Of	these,	37	were	activated	by	DNA	damage,	5	inhibited.	
Amongst	the	five	outputs;	118	nodes	regulated	apoptosis,	42	regulated	angiogenesis,	
68	regulated	cellular	senescence,	28	regulated	DNA	repair,	and	62	regulated	the	cell	
cycle	arrest	output.		
	
Of	the	internal	nodes	linked	to	p53,	117	nodes	were	located	upstream	of	p53,	with	164	
downstream,	27	nodes	were	considered	as	ambivalent	factors	(activating	and	
inhibiting).		34	feedback	loops	were	identified	in	the	model,	of	these	p53	participated	
in	over	50	%	(n	=	18).	Tables	7.2.1	–	7.2.6	summarise	all	nodes	and	their	links	to	the	
single	input	or	five	outputs.	Image	7.2	depicts	the	different	layers	of	the	PMH260	
model,	generated	in	Cytoscape	(v.28).		
	
Table	7.2	Total	interaction	list	of	all	nodes	in	the	PMH260	model.		
Table	includes	interactions	of	activation	or	inhibition	(excludes	GO	annotations).	Some	
interactions	are	described	by	more	than	one	literature	source.	PMID	AND	PMC	IDs	are	
supplied.	For	some	sources,	PMID/PMCs	were	not	available,	thus	links	or	DOIs	are	provided.	
Interactions	derived	from	Tian	et	al.	(2013)	are	also	included.		
Source		 Interaction	 Target	 PMID/PMC	
AATF	 Activates	 p53	 20708154	
AATF	 Activates	 CDK5	 18388733	
APP	 Inhibits	 p53	 10377452	
AR	 Inhibits	 MMP1	 8798622	
ASPP1	 Activates	 p53	 11684014	
ASPP1	 Activates	 p53	 22552744	
ASPP2	 Activates	 p53	 22552744	
ATF3	 Inhibits	 MMP2	 11792711	
ATF3	 Activates	 CCND1	 11375399	
ATF3	 Inhibits	 IL6	 16688168	
ATM	 Activates	 p53	 10608806	
ATM	 Activates	 CHEK2	 16936775	
ATM	 Activates	 ATR	 17088261	
ATM	 Activates	 AATF	 17157788	
ATM	 Inhibits	 BCL6	 18346918	
ATM	 Activates	 BRCA1	 12082091	
ATM	 Activates	 DYRK2	 19965871	
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ATM	 Inhibits	 MDM2	 16943424	
ATM	 Inhibits	 MDM4	 16943424	
ATR	 Activates	 p53	 16557269	
ATR	 Activates	 CHEK1	 16557269	
ATR	 Activates	 AATF	 17157788	
ATR	 Activates	 BRCA1	 12082091	
ATR	 Inhibits	 MDM2	 16943424	
AURKA	 Inhibits	 p53	 14702041	
AXIN1	 Activates	 p53	 19513548	
AXIN1	 Inhibits	 CCND1	 11739413	
AXIN1	 Inhibits	 TCF7L2	 17768662	
BAIAP2L1	 Inhibits	 p53	 21887275	
BAIP2L1	 Inhibits	 p53	 PMC3160901	
BCCIP	 Activates	 p53	 15539944	
BCL2	 Activates	 MMP2	 19258038	
BCL2	 Activates	 CCND1	 11313702	
BCL2	 Activates	 FOS	 15326476	
BCL2	 Activates	 VEGFA	 12205045	
BCL2	 Activates	 SLC2A1	 15120582	
BCL2	 Activates	 RAS	 15326476	
BCL3	 Activates	 EGFR	 17881446	
BCL6	 Activates	 p53	 18524763	
BCL6	 Inhibits	 p53	 15577913	
BCL6	 Inhibits	 CDKN1B	 10981963	
BRCA1	 Activates	 p53	 11371136	
BRCA1	 Activates	 CCND1	 17278098	
BTG2	 Activates	 p53	 11814693	
BTG2	 Inhibits	 CCND1	 15378000	
CCAR1	 Activates	 p53	 PMC2562329	
CCNA	 Inhibits	 CKM	 8995365	
CCNA	 Activates	 CDC25A	 10926775	
CCNA	 Inhibits	 FEN1	 12853968	
CCNA	 Inhibits	 E2F1	 7838523	
CCNA	 Activates	 AXIN1	 15063782	
CCND1	 Inhibits	 THBS1	 17020778	
CCND1	 Activates	 HSPA4	 9121772	
CCND1	 Activates	 E2F1	 10504464	
CD44	 Inhibits	 CCND1	 17296798	
CDC25A	 Inhibits	 EGFR	 11912208	
CDK2	 Activates	 p53	 11078726	
CDK2	 Activates	 CDC25A	 10926775	
CDK2	 Inhibits	 CDKN1B	 8622855	
CDK2	 Activates	 E2F1	 7969176						
CDK2	 Activates	 AXIN1	 15063782	
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CDK2	 Activates	 CCNA	 10652300	
CDK2	 Inhibits	 MDM2	 21278451	
CDK4	 Activates	 CCND1	 9099745	
CDK4	 Activates	 BRCA1	 10660629	
CDK4	 Inhibits	 BRCA1	 17334399	
CDK5	 Activates	 p53	 17591690	
CDK5	 Activates	 MYC	 18408012	
CDK5	 Activates	 ERBB2	 16203963	
CDK5	 Activates	 CDKN1B	 16341208	
CDK9	 Activates	 p53	 16741955	
CDKN1A	 Inhibits	 CDK2	 8756624	
CDKN1B	 Inhibits	 BCL2	 14676836	
CDKN1B	 Inhibits	 CCNA	 8547220	
CDKN1B	 Inhibits	 CDK2	 18354415	
CDKN2A	 Inhibits	 CCND1	 15205322	
CDKN2A	 Inhibits	 MDM2	 20523835	
CDKN2A	 Activates	 MDM4	 15907800	
CDKN2A	 Inhibits	 MDM4	 16492744	
CHEK1	 Activates	 p53	 10673501	
CHEK1	 Inhibits	 CDC25A	 12759351	
CHEK1	 Inhibits	 MDM4	 16511572	
CHEK2	 Activates	 p53	 10673500	
CHEK2	 Activates	 MYC	 19812253	
CHEK2	 Inhibits	 CDC25A	 12759351	
CHEK2	 Activates	 BRCA1	 14701743	
CHEK2	 Activates	 E2F1	 12717439	
CHEK2	 Activates	 AATF	 17157788	
CHEK2	 Inhibits	 MDM4	 16943424	
CIAPIN1	 Inhibits	 p53	 16410721	
CIAPIN1	 Inhibits	 BAX	 16410721	
CIAPIN1	 Inhibits	 BCL2	 18059532	
CSNK2	 Activates	 FOS	 1915270	
CSNK2	 Activates	 p53	 9244359	
CSNK2	 Activates	 MDM2	 16335531	
CSNK2	 Inhibits	 MDM2	 21769452	
CSNK2	 Activates	 TCF7L2	 11711551	
CSNK2	 Activates	 PTEN	 11035045	
CSNK2	 Activates	 MYC	 2663470	
CSNK2	 Activates	 MYCN	 1425701	
CSNK2	 Activates	 NCL	 3190709	
CSNK2	 Activates	 HDAC1	 11602581	
CUL7	 Inhibits	 p53	 17586686	
CUL7	 Inhibits	 p53	 17229476	
CUL7	 Inhibits	 p53	 16547496	
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CXCR4	 Activates	 VEGFA	 17559806	
CXCR4	 Activates	 TNFRSF10B	 15990565	
DAP	 Activates	 p53	 11146619	
DAXX	 Activates	 p53	 12482984	
DAXX	 Inhibits	 p53	 15364927	
DAXX	 Inhibits	 p53	 15339933	
DAXX	 Activates	 p53	 17210684	
DDX20	 Inhibits	 p53	 22335944	
DDX5	 Activates	 p53	 15660129	
DKK1	 Activates	 TGFB1	 20019166	
DNMT3A	 Inhibits	 p53	 16131836	
DUSP5	 Inhibits	 MAPK1	 8221888	
DYRK2	 Activates	 p53	 17349958	
DYRK2	 Activates	 p53AIP1	 17349958	
E2F1	 Activates	 p53	 12625370	
E2F1	 Inhibits	 MDM2	 20837136	
E2F1	 Activates	 HIC1	 19491197	
E2F1	 Activates	 SIVA1	 15105421	
E2F1	 Activates	 APAF1	 18056406	
E2F1	 Inhibits	 MCL1	 11857079	
E2F1	 Inhibits	 AR	 17178887	
E2F1	 Activates	 PCNA	 12468739	
E2F1	 Activates	 MYCN	 14645238	
E2F1	 Activates	 CHEK2	 15024084	
E2F1	 Activates	 SIAH1	 20187294	
E2F1	 Activates	 EZH2	 19893569	
EGFR	 Activates	 CCND1	 19935697	
EGFR	 Activates	 PTGS2	 15781636	
EGFR	 Inhibits	 NOTCH1	 18604200	
EGFR	 Activates	 VEGFA	 21074412	
EGFR	 Activates	 ESR1	 19470835	
EIF2AK2	 Activates	 p53	 19210572	
ELAVL1	 Activates	 p53	 12821781	
ELAVL1	 Inhibits	 CDKN1B	 18354415	
ELAVL1	 Activates	 PTGS2	 14633672	
ELAVL1	 Inhibits	 MYC	 19574298	
ERBB2	 Inhibits	 p53	 8700512	
ERBB2	 Activates	 CCND1	 17483350	
ERBB2	 Activates	 CXCR4	 15542424	
ERBB2	 Inhibits	 CDKN1B	 16951165	
ERBB2	 Activates	 PTGS2	 11901151	
ESR1	 Activates	 LTF	 15525592	
ESR1	 Activates	 CCND1	 15544931	
ESR1	 Inhibits	 IL6	 16043358	
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ESR1	 Inhibits	 EGFR	 9269899	
ESR1	 Activates	 CKB	 11746525	
ESR1	 Activates	 MYC	 19661132	
EZH2	 Inhibits	 RAD51	 16331887	
FAS	 Activates	 p53	 9358752	
FGF2	 Activates	 MMP2	 19107653	
FGF2	 Activates	 CDK4	 11889462	
FGF2	 Activates	 THBS1	 15927970	
FGF2	 Activates	 ABCB1	 17620438	
FGF2	 Activates	 FOS	 8783257	
FGF2	 Activates	 MMP1	 19107653	
FGF2	 Activates	 BCL2	 11380405	
FGF2	 Activates	 PTGS2	 9920767	
FGF2	 Activates	 VEGFA	 15485645	
FGF2	 Activates	 PCNA	 17003443	
FHL2	 Inhibits	 MAPK1	 14729955	
FOS	 Activates	 CCND1	 9710644	
FOS	 Activates	 MMP1	 21344389	
FOS	 Activates	 BCL2	 19079363	
FOXM1	 Activates	 MMP2	 17804744	
FOXM1	 Activates	 VEGFA	 17804744	
FOXM1	 Activates	 CCNB1	 11682060	
GAPDH	 Activates	 SIAH1	 15951807	
H2AFZ	 Inhibits	 p53	 17671089	
HDAC1	 Inhibits	 p53	 12426395	
HF1A	 Activates	 CDKN1B	 19342889	
HIF1A	 Activates	 CXCR4	 19212630	
HIF1A	 Activates	 IL6	 20600219	
HIF1A	 Activates	 MMP1	 17335808	
HIF1A	 Activates	 VEGFA	 17919812	
HIF1A	 Activates	 SLC2A1	 17387384	
HIF1A	 Activates	 PLAUR	 17335808	
HIPK2	 Inhibits	 MDM2	 16212962	
HIPK2	 Inhibits	 HIF1A	 19046997	
HIPK2	 Inhibits	 POU4F1	 15492043	
HIPK2	 Activates	 p53	 16601678	
HIPK4	 Activates	 p53	 18022393	
HOXA10	 Activates	 p53	 15044858	
HOXA11	 Inhibits	 p53	 19372592	
HOXA5	 Activates	 p53	 12490103	
HOXA5	 Inhibits	 p53	 12490102	
HSP90AB1	 Inhibits	 MMP13	 18593760	
HSPA4	 Activates	 p53	 17278883	
HSPA4	 Activates	 p53	 17278883	
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HSPA4	 Inhibits	 FOS	 11189444	
HTATIP2	 Activates	 p53	 18519672	
HTATIP2	 Inhibits	 MMP2	 19349353	
HTATIP2	 Inhibits	 VEGFA	 19349353	
HTATIP2	 Inhibits	 MYC	 15073177	
iASPP	 Inhibits	 p53	 22552744	
iASPP	 Inhibits	 p53	 12524540	
ICAM1	 Activates	 FOS	 12097408	
ID3	 Inhibits	 p53	 19618124	
IFNA1	 Activates	 p53	 15254403	
IFNA1	 Activates	 MDM2	 15580300	
IFNA1	 Activates	 CXCR4	 18202009	
IFNA1	 Activates	 IL6	 12434062	
IFNA1	 Inhibits	 FGF2	 9485039	
IFNA1	 Activates	 ICAM1	 11593644	
IFNA1	 Inhibits	 ABCB1	 17331344	
IFNA1	 Activates	 EGFR	 1718587	
IFNA1	 Activates	 TLR3	 16087162	
IFNA1	 Activates	 FOS	 15970516	
IFNA1	 Inhibits	 BCL2	 12881711	
IFNA1	 Activates	 PTGS2	 16685393	
IFNA1	 Activates	 FAS	 14616354	
IFNA1	 Inhibits	 MYC	 11798827	
IFNA1	 Activates	 MYC	 10068671	
IFNA1	 Activates	 TNFRSF10B	 12642868	
IFNA1	 Inhibits	 E2F1	 10208422	
IFNA1	 Activates	 EIF2AK2	 15254208	
IFNA1	 Activates	 PRKCA	 17988665	
IGF1R	 Activates	 p53	 8710868	
IGF1R	 Activates	 MDM2	 17846171	
IGF1R	 Activates	 RAS	 19174523	
IGFBP7	 Inhibits	 PTGS2	 19374835	
IGFBP7	 Inhibits	 VEGFA	 19374835	
IL6	 Activates	 MMP2	 16934628	
IL6	 Activates	 CXCR4	 9933168	
IL6	 Activates	 EGFR	 9459124	
IL6	 Inhibits	 BAX	 12101271	
IL6	 Activates	 TGFA	 11892999	
IL6	 Activates	 FOS	 11713282	
IL6	 Activates	 MMP1	 16934628	
IL6	 Activates	 MMP13	 15601621	
IL6	 Activates	 PTGS2	 16837651	
IL6	 Activates	 MYC	 20974848	
ING4	 Activates	 p53	 12750254	
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ING4	 Activates	 p53	 3742747	
ING5	 Activates	 p53	 12750254	
JUN	 Inhibits	 p53	 10072388	
KLF4	 Activates	 p53	 19696146	
KLF4	 Inhibits	 p53	 16244670	
KLF4	 Inhibits	 CCNB1	 14627709	
LATS2	 Activates	 p53	 17015431	
LTF	 Inhibits	 CCND1	 18697201	
MAPK1	 Activates	 CCND1	 9618377	
MAPK1	 Activates	 p53	 11409876	
MAPK1	 Activates	 NR2C1	 18682553	
MAPK1	 Activates	 YBX1	 16198352	
MAPK1	 Activates	 RAF1	 1730637	
MAPK14	 Activates	 MMP2	 15677464	
MAPK14	 Activates	 SGK	 12488318	
MAPK14	 Activates	 p53	 18265945	
MAPK8	 Activates	 TGFB1	 12760970	
MAPK8	 Activates	 MMP2	 16672691	
MAPK8	 Activates	 CCND1	 21135252	
MAPK8	 Activates	 ICAM1	 15389584	
MAPK8	 Activates	 FOS	 17085440	
MAPK8	 Activates	 ATF3	 18377912	
MAPK8	 Activates	 PTGS2	 15546960	
MAPK8	 Activates	 p53	 11057897	
MAPK8	 Activates	 BAX	 16709574	
MAPK8	 Activates	 BCL2	 11323415	
MAPK8	 Inhibits	 E2F1	 10075927	
MAPK9	 Activates	 PTGS2	 9786861	
MAPK9	 Activates	 p53	 17525747	
MCTS1	 Inhibits	 p53	 17416211	
MCTS1	 Activates	 CCND1	 11709712	
MDM2	 Inhibits	 p53	 21423613	
MDM2	 Activates	 ABCB1	 8883415	
MDM2	 Activates	 HIF1A	 15024078	
MDM2	 Inhibits	 VEGFA	 18199551	
MDM2	 Inhibits	 MDM4	 16557269	
MDM2	 Inhibits	 DYRK2	 19965871	
MDM4	 Activates	 MDM2	 16557269	
MDM4	 Inhibits	 p53	 16557269	
MMP2	 Activates	 BAX	 16857167	
MTA2	 Inhibits	 p53	 17914590	
MTA2	 Inhibits	 p53	 12920132	
MUC1	 Inhibits	 p53	 15710329	
MUC1	 Activates	 CCND1	 14688481	
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MUC1	 Activates	 EGFR	 16082192	
MYC	 Activates	 p53	 9839551	
MYC	 Activates	 MMP2	 19258038	
MYC	 Activates	 CCND1	 7526316	
MYC	 Activates	 MSH2	 15814658	
MYC	 Activates	 HSPA4	 1459202	
MYC	 Activates	 CDC25A	 10205150	
MYC	 Inhibits	 BCL2	 11438662	
MYC	 Activates	 BRCA1	 21668996	
MYC	 Inhibits	 GADD45A	 15021909	
MYC	 Activates	 VEGFA	 15580293	
MYC	 Inhibits	 CDKN1A	 12408820	
MYC	 Activates	 NME1	 11960382	
MYC	 Activates	 TNFRSF10A	 17881904	
MYC	 Activates	 E2F1	 17784791	
MYC	 Activates	 CDK2	 8157956	
MYCN	 Activates	 p53	 20145147	
MYCN	 Activates	 ABCC1	 14737110	
MYCN	 Activates	 ABCB1	 12819037	
MYCN	 Inhibits	 CD44	 11035936	
MYCN	 Inhibits	 MYC	 7529553	
MYCN	 Inhibits	 CDKN1B	 18198336	
MYST4	 Activates	 p53	 19001415	
NCL	 Inhibits	 p53	 16213212	
NCL	 Inhibits	 MDM2	 16751805	
NCL	 Activates	 BCL2	 21048921	
NME1	 Activates	 PTGS2	 16415009	
NME1	 Activates	 MYC	 19170058	
NOTCH1	 Activates	 ESR1	 19838210	
NOTCH1	 Activates	 EGFR	 18359760	
NOTCH1	 Activates	 PTGS2	 19290049	
NOTCH1	 Inhibits	 CCNA	 14678992	
NOV	 Activates	 MMP1	 15611078	
NTN1	 Inhibits	 p53	 18922894	
p53	 Inhibits	 CA9	 480909	
p53	 Inhibits	 CA9	 18815219	
p53	 Inhibits	 OP18	 11072234	
p53	 Inhibits	 OP18	 10557083	
p53	 Inhibits	 APP	 19049493	
p53	 Inhibits	 APP	 23942195	
p53	 Activates	 S100B	 9632811	
p53	 Activates	 S100B	 10490652	
p53	 Activates	 PML	 1151544	
p53	 Inhibits	 EXPORTIN	1	 21683812	
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p53	 Activates	 UNC5A	 20372800	
p53	 Activates	 TFAP2A	 16636674	
p53	 Activates	 TFAP2C	 16636674	
p53	 Activates	 ABCC1	 12647018	
p53	 Inhibits	 BCL3	 12808109	
p53	 Activates	 GSTP1	 18505928	
p53	 Inhibits	 PDRG1	 20453924	
p53	 Activates	 ESR1	 15012604	
p53	 Inhibits	 BDKRB1	 11400161	
p53	 Activates	 MMP2	 9343394	
p53	 Activates	 CKM	 7488858	
p53	 Activates	 CD82	 11212267	
p53	 Inhibits	 CCND1	 12808109	
p53	 Activates	 GAPDH	 18552833	
p53	 Inhibits	 ECT2	 16778203	
p53	 Activates	 MSH2	 10984493	
p53	 Activates	 CD58	 11812190	
p53	 Activates	 DUSP4	 16778175	
p53	 Inhibits	 CXCR4	 17130833	
p53	 Activates	 RRM2B	 19010910	
p53	 Activates	 EDA2R	 20434500	
p53	 Inhibits	 SLC6A6	 16734743	
p53	 Inhibits	 XAF1	 20198350	
p53	 Activates	 DDB2	 12509284	
p53	 Inhibits	 CDK4	 7851794	
p53	 Activates	 MDM2	 11313969	
p53	 Inhibits	 IL6	 11830554	
p53	 Activates	 NOV	 18418052	
p53	 Activates	 THBS1	 12609716	
p53	 Inhibits	 THBS1	 9849855	
p53	 Inhibits	 PDGFRB	 18697203	
p53	 Activates	 ARID3A	 12136662	
p53	 Activates	 KAT2B	 15153330	
p53	 Inhibits	 FGF2	 11313915	
p53	 Activates	 ICAM1	 15247038	
p53	 Inhibits	 WWP1	 16924229	
p53	 Activates	 ABCB1	 17666793	
p53	 Inhibits	 ABCB1	 11920581	
p53	 Inhibits	 IGF1R	 10023442	
p53	 Inhibits	 NR2C1	 8663350	
p53	 Activates	 EGFR	 19597475	
p53	 Inhibits	 EGFR	 18391986	
p53	 Activates	 IGFBP1	 18056423	
p53	 Inhibits	 CD44	 18614011	
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p53	 Activates	 CDKN1A	 17585201	
p53	 Inhibits	 PRKCA	 15563462	
p53	 Activates	 DUSP2	 16474395	
p53	 Activates	 FDXR	 12370809	
p53	 Activates	 BAX	 18949380	
p53	 Activates	 KRT8	 8615594	
p53	 Activates	 TGFA	 7651386	
p53	 Activates	 IFI16	 18974396	
p53	 Activates	 TLR3	 18779317	
p53	 Inhibits	 CKB	 7969181	
p53	 Activates	 Tp53I13	 14767535	
p53	 Inhibits	 RECQL4	 15674334	
p53	 Inhibits	 MGMT	 19846904	
p53	 Inhibits	 SP7	 16380437	
p53	 Inhibits	 HSPA4	 8418500	
p53	 Activates	 HSPA4	 20180806	
p53	 Inhibits	 CDC25A	 17001315	
p53	 Activates	 FEN1	 16103874	
p53	 Inhibits	 FOS	 1946467	
p53	 Activates	 DDIT4	 19210572	
p53	 Inhibits	 CDC20	 17873905	
p53	 Inhibits	 IQCB1	 16322217	
p53	 Activates	 MAP4K4	 15958553	
p53	 Activates	 HIC1	 7585125	
p53	 Activates	 SEMA3B	 11922394	
p53	 Activates	 RPRM	 11313928	
p53	 Inhibits	 EZH2	 15208672	
p53	 Inhibits	 MMP1	 11850838	
p53	 Inhibits	 PSEN1	 18374905	
p53	 Activates	 PEG3	 11679586	
p53	 Inhibits	 PRSS50	 17283160	
p53	 Inhibits	 IFITM2	 19544527	
p53	 Activates	 SIVA1	 19240372	
p53	 Inhibits	 HSP90AB1	 15284248	
p53	 Inhibits	 BCL2	 11313951	
p53	 Activates	 PCBP4	 11313928	
p53	 Inhibits	 HIF1A	 18815219	
p53	 Activates	 DFNA5	 16897187	
p53	 Inhibits	 MMP13	 11850838	
p53	 Activates	 CD59	 11812190	
p53	 Inhibits	 FOXM1	 19806025	
p53	 Inhibits	 HNF4A	 16895524	
p53	 Activates	 Tp53INP1	 12438758	
p53	 Activates	 FHL2	 17352216	
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p53	 Activates	 CCNG1	 21447558	
p53	 Inhibits	 TCF7L2	 14990988	
p53	 Inhibits	 BRCA1	 12802282	
p53	 Inhibits	 EPHB4	 16205642	
p53	 Activates	 CASP8	 12376477	
p53	 Inhibits	 HMMR	 18971636	
p53	 Activates	 CDKN1B	 12376477	
p53	 Activates	 COL18A1	 15958553	
p53	 Activates	 BBC3	 18657356	
p53	 Activates	 APAF1	 11559530	
p53	 Inhibits	 MAP4	 10521394	
p53	 Activates	 BAK1	 15105295	
p53	 Activates	 NLRC4	 15580302	
p53	 Inhibits	 PRC1	 15531928	
p53	 Activates	 GTSE1	 11313928	
p53	 Activates	 CALD1	 19349302	
p53	 Inhibits	 KRT19	 7515894	
p53	 Activates	 ATF3	 17108111	
p53	 Activates	 PTGS2	 15608668	
p53	 Inhibits	 PTGS2	 15921850	
p53	 Activates	 RGS16	 16405749	
p53	 Activates	 SGK	 16619268	
p53	 Activates	 S100A2	 18388131	
p53	 Inhibits	 S100A6	 18714402	
p53	 Inhibits	 MCL1	 18208354	
p53	 Activates	 DUSP5	 12944906	
p53	 Activates	 IER3	 9781666	
p53	 Activates	 GADD45A	 18350249	
p53	 Activates	 NOTCH1	 17534448	
p53	 Activates	 FAS	 9841917	
p53	 Activates	 PTEN	 11729185	
p53	 Inhibits	 VEGFA	 11559575	
p53	 Inhibits	 SLC2A1	 21862591	
p53	 Activates	 AIFM2	 15273740	
p53	 Activates	 CDKN1A	 17585201	
p53	 Activates	 DKK1	 15668788	
p53	 Activates	 PRKG1	 19955367	
p53	 Inhibits	 AR	 18084622	
p53	 Inhibits	 TFDP1	 9556576	
p53	 Inhibits	 CKS2	 17336302	
p53	 Activates	 NME1	 12669312	
p53	 Inhibits	 NME1	 12669312	
p53	 Inhibits	 MYC	 8479742	
p53	 Activates	 PCNA	 11682006	
	 113	
p53	 Inhibits	 PCNA	 8570655	
p53	 Activates	 C13orf15	 17146433	
p53	 Activates	 ISG15	 11462054	
p53	 Activates	 BNIP3L	 15607964	
p53	 Inhibits	 SLC2A4	 20729871	
p53	 Inhibits	 CCNB1	 11162602	
p53	 Activates	 TNFRSF10A	 15289308	
p53	 Activates	 TNFRSF10B	 10942251	
p53	 Activates	 IGFBP7	 19638426	
p53	 Activates	 LATS2	 19855428	
p53	 Inhibits	 RAD51	 19942681	
p53	 Activates	 SERPINB5	 15578720	
p53	 Activates	 RAS	 11574421	
p53	 Inhibits	 CCNA	 8270002	
p53	 Activates	 C12orf5	 16557269	
p53	 Activates	 PERP	 16557269	
p53	 Activates	 SIAH1	 16557269	
p53	 Activates	 LRDD	 16557269	
p53	 Activates	 p53AIP1	 16557269	
p53	 Activates	 SESN2	 16557269	
p53	 Activates	 SFN	 16557269	
p53	 Inhibits	 CDKN2A	 9774662	
p53	 Activates	 ZMAT3	 19805223	
p53	 Activates	 KLF4	 19826046	
p53	 Activates	 PPM1D	 18265945	
p53	 Inhibits	 PPM1D	 20093361	
p53	 Activates	 COL1A2	 9764819	
p53	 Activates	 PPID	 	PMC3383624	
PAD4	 Inhibits	 p53	 2493360	
PADI4	 Inhibits	 p53	 18499678	
PARK2	 Inhibits	 p53	 19801972	
PDGFRB	 Activates	 CCND1	 10688905	
PHF20	 Activates	 p53	 22334668	
PIAS2	 Inhibits	 p53	 19901969	
PITX1	 Activates	 p53	 17762884	
PLAUR	 Inhibits	 p53	 17110957	
PML	 Activates	 p53	 12810724	
PML	 Activates	 p53	 14992722	
POU4F1	 Activates	 p53	 10329733	
POU4F1	 Activates	 BCL2	 9722627	
POU4F1	 Activates	 BRCA1	 11470235	
PPARG	 Activates	 p53	 16887883	
PPM1A	 Activates	 p53	 12514180	
PPM1D	 Inhibits	 p53	 15870257	
	 114	
PPM1D	 Inhibits	 CHEK1	 15870257	
PPM1D	 Activates	 MDM4	 19808970	
PPM1D	 Inhibits	 MAPK14	 18265945	
PRAK	 Activates	 p53	 17254968	
PREP1	 Activates	 p53	 2887940	
PREP1	 Activates	 p53	 20587415	
PRKCA	 Inhibits	 CCND1	 20141613	
PRKCA	 Activates	 IL6	 9523575	
PRKCA	 Inhibits	 ABCB1	 9823967	
PRKCA	 Activates	 HSPA4	 17208995	
PRKCA	 Activates	 MMP1	 16368506	
PRKCA	 Activates	 VEGFA	 1511446	
PRKCA	 Inhibits	 MYC	 20141613	
PRKCA	 Activates	 ERBB2	 17545611	
PRKCA	 Activates	 ABCB1	 15563462	
PRKCA	 Activates	 RAF1	 8321321	
PRKD1	 Activates	 PTGS2	 19794144	
PRKD1	 Activates	 p53	 12628923	
PRKDC	 Activates	 p53	 11042698	
PRKG1	 Activates	 CDKN1A	 18593937	
PRKG1	 Activates	 CDKN1B	 18593937	
PRKG1	 Inhibits	 MAPK14	 16990590	
PSMD10	 Inhibits	 p53	 19287195	
PTEN	 Inhibits	 CCND1	 16849370	
PTEN	 Inhibits	 HIF1A	 18158893	
PTEN	 Inhibits	 EPHB4	 15930280	
PTEN	 Inhibits	 VEGFA	 16527906	
PTEN	 Inhibits	 PCNA	 17826033	
PTGS2	 Activates	 CXCR4	 20110411	
PTGS2	 Activates	 ABCB1	 17510421	
PTGS2	 Inhibits	 EGFR	 19671676	
PTGS2	 Activates	 CD44	 12393872	
PTGS2	 Activates	 HSPA4	 14717913	
PTGS2	 Activates	 FOS	 16685273	
PTGS2	 Activates	 MCL1	 16000874	
PTGS2	 Activates	 VEGFA	 18533784	
PTGS2	 Inhibits	 CDKN1B	 14587561	
PTTG1	 Activates	 p53	 15242522	
PTTG1	 Inhibits	 p53	 19477929	
PTTG1	 Activates	 MMP2	 19433493	
PTTG1	 Activates	 FGF2	 21858218	
PTTG1	 Activates	 BAX	 15242522	
PTTG1	 Activates	 MYC	 11115508	
RAF1	 Activates	 p53	 10732786	
	 115	
RAS	 Activates	 GSTP1	 11606500	
RAS	 Activates	 MAPK14	 15677464	
RAS	 Inhibits	 CKM	 3600660	
RAS	 Activates	 CCND1	 10201372	
RAS	 Inhibits	 CCND1	 12081197	
RAS	 Activates	 CD44	 8453616	
RAS	 Activates	 FOS	 7917786	
RAS	 Activates	 PTGS2	 19903783	
RAS	 Inhibits	 PTEN	 19000654	
RAS	 Activates	 VEGFA	 11507052	
RAS	 Activates	 CDKN1A	 19440234	
RAS	 Activates	 CCNA	 15737994	
RAS	 Activates	 CDKN1B	 14504289	
RAS	 Activates	 RAF1	 9020159	
RAS	 Activates	 MAPK1	 9020159	
RB1CC1	 Inhibits	 p53	 21775823	
RFC	 Inhibits	 p53	 10910354	
RREB1	 Activates	 p53	 19558368	
S100A2	 Inhibits	 PTGS2	 16908593	
S100B	 Inhibits	 p53	 15572370	
SERPINB5	 Inhibits	 VEGFA	 19374835	
SERPINF1	 Activates	 p53	 17651710	
SERPINF1	 Inhibits	 VEGFA	 16901919	
SET	 Inhibits	 p53	 3245910	
SFN	 Activates	 MMP1	 19533306	
SFN	 Inhibits	 CCNB1	 17573669	
SFN	 Inhibits	 CDK2	 10767298	
SFN	 Activates	 CDKN1B	 20642839	
SGK	 Inhibits	 p53	 19756449	
SIAH1	 Activates	 HIF1A	 15210114	
SLC2A1	 Activates	 MMP2	 12122099	
SOX4	 Activates	 p53	 19234109	
STAT3	 Inhibits	 p53	 1190305	
SUB1	 Activates	 p53	 21586571	
SUMO2	 Activates	 p53	 21900752	
SUMO2	 Inhibits	 p53	 17012228	
TCF7L2	 Activates	 MYC	 9727977	
TFAP2A	 Inhibits	 p53	 16288208	
TFDP1	 Activates	 EZH2	 20565746	
TGFA	 Activates	 CCND1	 9407106	
TGFA	 Activates	 FOS	 8783257	
TGFA	 Activates	 PTGS2	 12930301	
TGFA	 Activates	 MYC	 10839631	
TGFB1	 Activates	 p53	 11741524	
	 116	
TGFB1	 Activates	 IL6	 2265243	
TGFB1	 Inhibits	 IL6	 2265243	
TGFB1	 Activates	 THBS1	 11955611	
TGFB1	 Inhibits	 ICAM1	 14500551	
TGFB1	 Activates	 PRKCA	 14749204	
TGFB1	 Inhibits	 MMP1	 16911716	
TGFB1	 Inhibits	 MMP13	 9009143	
TGFB1	 Activates	 CCNG1	 9696022	
TGFB1	 Inhibits	 KRT19	 14732924	
TGFB1	 Activates	 PTGS2	 10935498	
TGFB1	 Inhibits	 PTEN	 19940030	
TGFB1	 Activates	 VEGFA	 12615726	
TGFB1	 Activates	 CDKN1A	 7696178	
TGFB1	 Inhibits	 MYC	 12628347	
THBS1	 Activates	 TGFB1	 11021838	
TIAF1	 Activates	 p53	 14965474	
TLR3	 Inhibits	 CXCR4	 19652552	
Tp53BP1	 Activates	 p53	 9748285	
Tp53RK	 Activates	 p53	 16600182	
TPT1	 Activates	 p53	 24067374	
UBE2A	 Activates	 p53	 22083959	
UBE2A	 Inhibits	 p53	 22083959	
UCHL1	 Activates	 p53	 20395212	
UCHL1	 Activates	 p53	 22279545	
VEGFA	 Inhibits	 TGFB1	 19180561	
VEGFA	 Activates	 SERPINF1	 12670505	
VEGFA	 Inhibits	 SERPINF1	 16901919	
VEGFA	 Activates	 MMP2	 16584583	
VEGFA	 Activates	 CXCR4	 19391039	
VEGFA	 Activates	 CD44	 9242547	
VEGFA	 Activates	 FOS	 14741347	
VEGFA	 Activates	 BCL2	 11895790	
VEGFA	 Activates	 PTGS2	 21273371	
VEGFA	 Activates	 DUSP5	 19741200	
VEGFA	 Activates	 NOTCH1	 12482957	
VEGFA	 Activates	 ID3	 15494533	
VRK1	 Activates	 p53	 15542844	
YBX1	 Inhibits	 p53	 12835324	
YBX1	 Activates	 p53	 11175333	
YBX1	 Activates	 MMP2	 9278454	
YBX1	 Activates	 ABCB1	 17038319	
YBX1	 Activates	 EGFR	 1967130	
YBX1	 Inhibits	 MMP13	 17822788	
YY1	 Inhibits	 p53	 15295102	
	 117	
YY1	 Activates	 p53	 PMC231595	
ZMAT3	 Activates	 p53	 12196512	
ZNF307	 Inhibits	 p53	 17910948	
	
	
Table	7.2.1	Nodes	regulating	apoptosis	in	the	PMH260	model.		
A	total	of	118	apoptotic	nodes	are	considered.	Of	these;	73	are	pro-	apoptotic	and	45	are	anti-
apoptotic.	Some	links	to	apoptosis	were	not	obtained	via	their	GO	annotations	and	were	
additionally	searched	by	literature	evidence.	PMIDs	and	PMCs	are	supplied.	Reference	links	are	
also	supplied	if	no	PMID	is	available.		Apoptotic	nodes	described	in	Tian	et	al.	(2013)	are	also	
supplied.		
Source	 Interaction	 Target	 GO	Term	 GO	ID	 PMID/PMC	
AIFM2	 Activates	 apoptosis	 induction	of	apoptosis	 GO:0006917	 21943319	
APAF1	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 10791976	
APP	 Activates	 apoptosis	 Neuron	apoptotic	process	 GO:0051402	 19225519	
AR	 Activates	 apoptosis	 	 	 16479009	
AR	 Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 21815189	
ASPP1	 Activates	 apoptosis	 Negative	regulation	of	
cell	cycle	
GO:0045786	 11684014	
ASPP1	 Activates	 apoptosis	 	 	 14729977	
ASPP1	 Activates	 apoptosis	 	 	 14729977	
ASPP1	 Activates	 apoptosis	 Intrinsic	apoptotic	
signalling	pathway	by	p53	
class	mediator	
GO:0072332	 11684014	
ASPP2	 Activates	 apoptosis	 	 	 14729977	
ASSP2	 Activates	 apoptosis	 	 	 14729977	
ASSP2	 Activates	 apoptosis	 	 	 11684014	
ATF3	 Activates	 apoptosis	 	 	 18755691	
ATF3	 Inhibits	 apoptosis	 	 	 12392999	
BAK1	 Activates	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 20460378	
BAX	 Activates	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 19672311	
BBC3	 Activates	 apoptosis	 activation	of	pro-
apoptotic	gene	products	
GO:0008633	 11572983	
BCL2	 Inhibits	 apoptosis	 anti-apoptosis	 GO:0006916	 8617294	
BCL2	 Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 8617294	
BCL2	 Inhibits	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 8617294	
BCL3	 Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 20800578	
BNIP3L	 Activates	 apoptosis	 positive	regulation	of	
apoptotic	process	
GO:0043065	 10381623	
C12orf
5	
Inhibits	 apoptosis	 	 	 16839880	
	 118	
CASP8	 Activates	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 15029256	
CCNG1	 Activates	 apoptosis	 	 	 10467405	
CCNG1	 Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 18497347	
CD44	 Activates	 apoptosis	 	 	 6208414	
CD44	 Inhibits	 apoptosis	 	 	 17045821	
CDC25
A	
Activates	 apoptosis	 	 	 20368335	
CDC25
A	
Inhibits	 apoptosis	 	 	 11416155	
CDKN1
A	
Inhibits	 apoptosis	 induction	of	apoptosis	by	
intracellular	signals	
GO:0008629	 21815189	
CDKN1
A	
Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 21815189	
CDKN1
B	
Activates	 apoptosis	 	 	 10208428	
CDKN1
B	
Inhibits	 apoptosis	 	 	 10050878	
CDKN2
A	
Activates	 apoptosis	 induction	of	apoptosis	 GO:0006917	 9403064	
CKS2	 Inhibits	 apoptosis	 	 	 18498131	
COL18
A1	
Activates	 apoptosis	 	 	 11158588	
CUL7	 Inhibits	 apoptosis	 	 	 17229476	
CXCR4	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 15705741	
DAP	 Activates	 apoptosis	 Apoptotic	process	 GO:0006915	 7828849	
DAP	 Activates	 apoptosis	 Positive	regulation	of	
apoptotic	process	
GO:0043605	 9118961	
DAP	 Activates	 apoptosis	 Regulation	of	apoptotic	
process	
GO:0042981	 11709549	
DAXX	 Activates	 apoptosis	 Extrinsic	apoptotic	
signalling	pathway	via	
death	domain	receptors	
GO:0008625	 9215629	
DAXX	 Activates	 apoptosis	 Positive	regulation	of	
apoptotic	signalling	
pathway	
GO:2001235	 11193028	
DAXX	 Activates	 apoptosis	 Apoptotic	signalling	
pathway	
GO:0097190	 11003656	
DAXX	 Activates	 apoptosis	 	 	 12407442	
DAXX	 Activates	 apoptosis	 	 	 11773067	
DAXX	 Activates	 apoptosis	 	 	 12407442	
DAXX	 Inhibits	 apoptosis	 	 	 19017466	
DAXX	 Inhibits	 apoptosis	 	 	 16088932	
DDIT4	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 18796435	
DDIT4	 Inhibits	 apoptosis	 apoptotic	process	 GO:0006915	 19221489	
DDX20	 Activates	 apoptosis	 Positive	regulation	of	
apoptotic	process	
GO:0043065	 16153597	
DFNA5	 Activates	 apoptosis	 	 	 21522185	
	 119	
DKK1	 Activates	 apoptosis	 	 	 20549706	
DUSP2	 Activates	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 9501207	
DUSP2	 Inhibits	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 9501207	
DUSP2	 Inhibits	 apoptosis	 	 	 12673251	
DUSP4	 Activates	 apoptosis	 	 	 20124482	
DUSP4	 Inhibits	 apoptosis	 	 	 20860659	
ECT2	 Activates	 apoptosis	 	 	 12787561	
EGFR	 Activates	 apoptosis	 	 	 11226409	
EGFR	 Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 15277479	
EPHB4	 Inhibits	 apoptosis	 	 	 20133814	
ESR1	 Activates	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 17615152	
ESR1	 Inhibits	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 9118519	
EZH2	 Inhibits	 apoptosis	 	 	 19079346	
EZH2	 Inhibits	 apoptosis	 	 	 19893569	
FAS	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 7536620	
FDXR	 Activates	 apoptosis	 	 	 12370809	
FGF2	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 20081577	
FGF2	 Inhibits	 apoptosis	 apoptotic	process	 GO:0006915	 15856005	
FHL2	 Inhibits	 apoptosis	 	 	 21377781	
FOS	 Activates	 apoptosis	 	 	 8524298	
FOS	 Inhibits	 apoptosis	 	 	 19255142	
GADD
45A	
Activates	 apoptosis	 apoptotic	process	 GO:0006915	 17474084	
GSTP1	 Inhibits	 apoptosis	 	 	 21637416	
HNF4A	 Activates	 apoptosis	 	 	 19835622	
HOXA
10	
Activates	 apoptosis	 	 	 	
IER3	 Inhibits	 apoptosis	 anti-apoptosis	 GO:0006916	 14688131	
IFI16	 Activates	 apoptosis	 DNA	damage	response,	
signal	transduction	by	
p53	class	mediator	
resulting	in	induction	of	
apoptosis	
GO:0042771	 14990579	
IFITM2	 Activates	 apoptosis	 	 	 19544527	
IGF1R	 Inhibits	 apoptosis	 anti-apoptosis	 GO:0006916	 14726697	
IGF1R	 Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 14726697	
IGF1R	 Inhibits	 apoptosis	 positive	regulation	of	
anti-apoptosis	
GO:0045768	 14726697	
IGFBP
7	
Activates	 apoptosis	 	 	 18267069	
	 120	
IL6	 Activates	 apoptosis	 negative	regulation	of	
cysteine-type	
endopeptidase	activity	
involved	in	apoptotic	
process	
GO:0043154	 12714376	
IL6	 Activates	 apoptosis	 neutrophil	apoptosis	 GO:0001781	 12714376	
IL6	 Activates	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 12714376	
IL6	 Inhibits	 apoptosis	 negative	regulation	of	
cysteine-type	
endopeptidase	activity	
involved	in	apoptotic	
process	
GO:0043154	 11751424	
IL6	 Inhibits	 apoptosis	 neutrophil	apoptosis	 GO:0001781	 11751424	
IL6	 Inhibits	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 11751424	
ING4	 Activates	 apoptosis	 Negative	regulation	of	
growth	
GO:0045926	 16387653	
ING5	 Activates	 apoptosis	 Positive	regulation	of	
apoptotic	signalling	
pathway	
GO:2001235	 	
JUN	 Activates	 apoptosis	 	 	 1169773	
KAT2B	 Activates	 apoptosis	 	 	 PMC3847488	
LATS2	 Activates	 apoptosis	 	 	 15265683	
LRDD	 Activates	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 9403064	
MAP4
K4	
Activates	 apoptosis	 	 	 15958553	
MAP4
K4	
Inhibits	 apoptosis	 	 	 21196414	
MCL1	 Inhibits	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 18550749	
MSH2	 Activates	 apoptosis	 negative	regulation	of	
neuron	apoptosis	
GO:0043524	 10097137	
NLRC4	 Activates	 apoptosis	 positive	regulation	of	
apoptotic	process	
GO:0043065	 11374873	
NOTC
H1	
Activates	 apoptosis	 positive	regulation	of	
apoptotic	process	
GO:0043065	 12815466	
NOTC
H1	
Inhibits	 apoptosis	 negative	regulation	of	cell	
death	
GO:0060548	 10227380	
P53AIP
1	
Activates	 apoptosis	 apoptotic	process	 GO:0006915	 9403064	
PCBP4	 Activates	 apoptosis	 DNA	damage	response,	
signal	transduction	
resulting	in	induction	of	
apoptosis	
GO:0008630	 20817677	
PDGFR
B	
Inhibits	 apoptosis	 	 	 21954875	
PEG3	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 10681424	
PERP	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 10733530	
	 121	
PITX1	 Activates	 apoptosis	 	 	 17762884	
PITX1	 Activates	 apoptosis	 	 	 20563669	
PML	 Activates	 apoptosis	 	 	 14663483	
PML	 Activates	 apoptosis	 Positive	regulation	of	
apoptotic	process	
involved	in	mammary	
gland	involution	
G0:0060058	 11080164	
PREP1	 Inhibits	 apoptosis	 	 	 PMC2643814	
PRKCA	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 10825394	
PRKCA	 Inhibits	 apoptosis	 apoptotic	process	 GO:0006915	 DOI:10.1007/97
8-1-59745-199-
4_2	
PRSS5
0	
Activates	 apoptosis	 	 	 21086474	
PSEN1	 Inhibits	 apoptosis	 anti-apoptosis	 GO:0006916	 10805794	
PSEN1	 Inhibits	 apoptosis	 apoptotic	process	 GO:0006915	 10805794	
PSEN1	 Inhibits	 apoptosis	 negative	regulation	of	
neuron	apoptosis	
GO:0043524	 10805794	
PTEN	 Activates	 apoptosis	 induction	of	apoptosis	 GO:0006917	 11159942	
PTGS2	 Activates	 apoptosis	 	 	 16544098	
PTGS2	 Inhibits	 apoptosis	 	 	 11046152	
RBC1C
C1	
Inhibits	 apoptosis	 Negative	regulation	of	
apoptotic	process	
GO:0006916	 2064504	
RBC1C
C1	
Inhibits	 apoptosis	 Negative	regulation	of	
extrinsic	apoptotic	
signalling	pathway	
GO:2001237	 PMC2064504	
SEMA
3B	
Activates	 apoptosis	 	 	 15273288	
SERPI
NB5	
Activates	 apoptosis	 	 	 15713631	
SFN	 Inhibits	 apoptosis	 apoptotic	process	 GO:0006915	 10654934	
SFN	 Inhibits	 apoptosis	 DNA	damage	response,	
signal	transduction	
resulting	in	induction	of	
apoptosis	
GO:0008630	 15857577	
SGK	 Inhibits	 apoptosis	 	 	 12488318	
SIAH1	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 9403064	
SIAH1	 Activates	 apoptosis	 neuron	apoptosis	 GO:0051402	 9403064	
SIAH1	 Activates	 apoptosis	 :	positive	regulation	of	
apoptotic	process	
GO:0004306
5	
9403064	
SIVA1	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 20727854	
STAT3	 Inhibits	 apoptosis	 Negative	regulation	of	
cell	death	
GO:0060548	 20562100	
STAT3	 Inhibits	 apoptosis	 Negative	regulation	of	
cell	death	
GO:0060548	 16540667	
STAT3	 Inhibits	 apoptosis	 Cell	proliferation	 GO:0008283	 11171987	
TCF7L
2	
Inhibits	 apoptosis	 	 	 21965303	
	 122	
TCF7L
2	
Inhibits	 apoptosis	 	 	 21357677	
TFAP2
A	
alpha	
Activates	 apoptosis	 Negative	regulation	of	
cell	proliferation	
GO:0008285	 20607706	
TFAP2
A	
alpha	
Activates	 apoptosis	 	 	 14551210	
TFAP2
A	
alpha	
Activates	 apoptosis	 	 	 12654297	
TFAP2
C	
Activates	 apoptosis	 	 	 14573793	
TFAP2
C	
Activates	 apoptosis	 	 	 21779369	
TGFA	 Inhibits	 apoptosis	 anti-apoptosis	 GO:0006916	 16079309	
TGFA	 Inhibits	 apoptosis	 negative	regulation	of	
neuron	apoptosis	
GO:0043524	 16079309	
TLR3	 Activates	 apoptosis	 positive	regulation	of	
apoptotic	process	
GO:0043065	 16585585	
TNFRS
F10A	
Activates	 apoptosis	 induction	of	apoptosis	 GO:0006917	 21785270	
TNFRS
F10A	
Activates	 apoptosis	 induction	of	apoptosis	via	
death	domain	receptor	
GO:0008625	 21785270	
TNFRS
F10B	
Activates	 apoptosis	 activation	of	pro-
apoptotic	gene	products	
GO:0008633	 22046379	
TNFRS
F10B	
Activates	 apoptosis	 apoptotic	process	 GO:0006915	 22046379	
TNFRS
F10B	
Activates	 apoptosis	 induction	of	apoptosis	via	
death	domain	receptor	
GO:0008625	 22046379	
TNFRS
F10B	
Activates	 apoptosis	 regulation	of	apoptotic	
process	
GO:0042981	 22046379	
TP53I
NP1	
Activates	 apoptosis	 induction	of	apoptosis	 GO:0006917	 21219856	
TP53R
K	
Inhibits	 apoptosis	 	 	 20647325	
TPT1	 Inhibits	 apoptosis	 Negative	regulation	of	
intrinsic	apoptotic	
signalling	pathway	in	
response	to	DNA	damage	
GO:1902230	 11598139	
TPT1	 Inhibits	 apoptosis	 Negative	regulation	of	
apoptotic	process	
GO:0043066	 16130169	
TPT1	 Inhibits	 apoptosis	 Regulation	of	apoptotic	
process	
G0:0049281	 15162379	
TPT1	 Inhibits	 apoptosis	 	 	 12149273	
TPT1	 Inhibits	 apoptosis	 	 	 15262975	
UCHL1	 Activates	 apoptosis	 	 	 18949367	
UCHL1	 Activates	 apoptosis	 	 	 18949367	
UCHL1	 Activates	 apoptosis	 	 	 24155778	
VEGFA	 Inhibits	 apoptosis	 anti-apoptosis	 GO:0006916	 11891765	
	 123	
VEGFA	 Inhibits	 apoptosis	 negative	regulation	of	
apoptotic	process	
GO:0043066	 11891765	
WWP1	 Inhibits	 apoptosis	 	 	 18806757	
XAF1	 Activates	 apoptosis	 apoptotic	process	 GO:0006915	 21788101	
	
	
Table	7.2.2	Nodes	regulating	angiogenesis	in	the	PMH260	model.		
A	total	of	42	angiogenic	nodes	are	considered.	Of	these;	27	are	pro-	angiogenic	and	15	are	anti-
angiogenic.	Some	links	to	angiogenesis	were	not	obtained	via	their	GO	annotations	and	were	
additionally	searched	by	literature	evidence.	PMIDs	and	PMCs	are	supplied.	Reference	links	are	
also	supplied	if	no	PMID	is	available.			
Source	 Interaction	 Target	 GO	Term	 GO	ID	 PMID/PMC	
BBC3	 Activates	 Angiogenesis	 	 	 23122957	
BCL2	 Activates	 Angiogenesis	 	 	 18490895	
BCL2	 Activates	 Angiogenesis	 	 	 11280784	
BDKRB
1	
Activates	 Angiogenesis	 	 	 21835216	
CALD1	 Activates	 Angiogenesis	 Angiogenesis	 	 18980955	
CALD1	 Activates	 Angiogenesis	 Vasculogenesis	 	 15161654	
CALD1	 Activates	 Angiogenesis	 Blood	vessel	endothelial	
cell	migration	
	 15161654	
CCND1	 Activates	 Angiogenesis	 	 	 PMC1986788	
CD44	 Activates	 Angiogenesis	 	 	 1698758	
CDK2	 Activates	 Angiogenesis	 	 	 23042366	
CDK4	 Activates	 Angiogenesis	 	 	 20603602	
CDK5	 Activates	 Angiogenesis	 	 	 20826806	
EGFR	 Activates	 Angiogenesis	 	 	 23856030	
ELAVL
1	
Activates	 Angiogenesis	 	 	 25422430	
ELAVL
1	
Activates	 Angiogenesis	 	 	 23516604	
ELAVL
1	
Activates	 Angiogenesis	 	 	 25422430	
EPHB4	 Activates	 Angiogenesis	 Cell	migration	involved	
in	sprouting	
angiogenesis	
GO:0002042	 12734395	
EPHB4	 Activates	 Angiogenesis	 Angiogenesis	 GO:0001525	 10518221	
EPHB4	 Activates	 Angiogenesis	 Angioblast	cell	
migration	involved	in	
selective	angioblast	
sprouting	
GO:0035475	 19815777	
EPHB4	 Activates	 Angiogenesis	 	 	 15930280	
FGF2	 Activates	 Angiogenesis	 Positive	regulation	of	
angiogenesis	
GO:0045766	 14702107	
FGF2	 Activates	 Angiogenesis	 Cell	migration	involved	
in	sprouting	
angiogenesis	
GO:0002042	 17187775	
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FGF2	 Activates	 Angiogenesis	 Positive	regulation	of	
blood	vessel	endothelial	
cell	migration	
GO:0043536	 23856030	
HIF1A	 Activates	 Angiogenesis	 Positive	regulation	of	
vascular	endothelial	
growth	factor	receptor	
signaling	pathway	
GO:0030949	 18658046	
HIF1A	 Activates	 Angiogenesis	 positive	regulation	of	
angiogenesis	
GO:0045766	 8756616	
HIF1A	 Activates	 Angiogenesis	 positive	regulation	vascular	endothelial	
growth	factor	production	
12958148	
HIF1A	 Activates	 Angiogenesis	 Angiogenesis	 GO:0001525	 18037992	
HIF1A	 Activates	 Angiogenesis	 Positive	regulation	of	
vasculogenesis	
GO:2001214	 17636018	
HSPA4	 Activates	 Angiogenesis	 Positive	regulation	of	
angiogenesis	
GO:00045766	 22098710	
HSPA4	 Activates	 Angiogenesis	 	 	 15994930	
HSPA4	 Activates	 Angiogenesis	 	 	 PMC3980608	
JUN	 Activates	 Angiogenesis	 Angiogenesis	 GO:0001525	 25083991	
MMP1	 Activates	 Angiogenesis	 	 	 7512058	
MMP1
3	
Activates	 Angiogenesis	 	 	 22992737	
NTN1	 Activates	 Angiogenesis	 	 	 23824572	
NTN1	 Activates	 Angiogenesis	 	 	 20080097	
PDGFR
B	
Activates	 Angiogenesis	 Fibroblast	growth	factor	
receptor	signaling	
pathway	
GO:0008543	 18827023	
PDGFR
B	
Activates	 Angiogenesis	 positive	regulation	of	
cell	proliferation	by	
VEGF-activated	platelet	
derived	growth	factor	
receptor	signaling	
pathway	
GO:0038091	 17470632	
PDGFR
B	
Activates	 Angiogenesis	 Cell	migration	involved	
in	coronary	
angiogenesis	
GO:0060981	 18555217	
PDGFR
B	
Activates	 Angiogenesis	 Cell	migration	involved	
in	vasculogenesis	
GO:0035441	 14998491	
PRKCA	 Activates	 Angiogenesis	 Positive	regulation	of	
angiogenesis	
GO:0045786	 11909826	
PRKCA	 Activates	 Angiogenesis	 Angiogenesis	 GO:0001525	 11909826	
PRKCA	 Activates	 Angiogenesis	 Positive	regulation	of	
endothelial	cell	
proliferation	
GO:0001938	 11909826	
PTGS2	 Activates	 Angiogenesis	 Positive	regulation	of	
cell	migration	involved	
in	sprouting	
angiogenesis	
GO:0090050	 9630216	
PTGS2	 Activates	 Angiogenesis	 Positive	regulation	
vascular	endothelial	
GO:0010575	 9630216	
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growth	factor	
production	
PTGS2	 Activates	 Angiogenesis	 Positive	regulation	of	
fibroblast	growth	factor	
production	
GO:0090271	 9630216	
S100B	 Activates	 Angiogenesis	 	 	 23719262	
SGK	 Activates	 Angiogenesis	 	 	 24265802	
SGK	 Activates	 Angiogenesis	 	 	 20568246	
STMN
1	
Activates	 Angiogenesis	 	 	 15031128	
TGFA	 Activates	 Angiogenesis	 Angiogenesis	 GO:0001938	 14998491	
TGFA	 Activates	 Angiogenesis	 	 	 19481589	
VEGFA	 Activates	 Angiogenesis	 Angiogenesis	 GO:0001525	 11427521	
VEGFA	 Activates	 Angiogenesis	 Positive	regulation	of	
endothelial	cell	
proliferation	
GO:0001938	 2575835	
VEGFA	 Activates	 Angiogenesis	 Tube	formation	 GO:0035148	 21245381	
VEGFA	 Activates	 Angiogenesis	 vascular	endothelial	
growth	factor	receptor	
signalling	pathway	
GO:0048010	 16109918	
VEGFA	 Activates	 Angiogenesis	 Positive	regulation	of	
vascular	permeability	
GO:0043117	 20497126	
VEGFA	 Activates	 Angiogenesis	 Positive	regulation	of	
endothelial	cell	
chemotaxis	by	VEGF-
activated	vascular	
endothelial	growth	
factor	receptor	
signalling	pathway	
G0:0038033	 16489009	
VEGFA	 Activates	 Angiogenesis	 Cellular	response	to	
vascular	endothelial	
growth	factor	stimulus	
GO:0035924	 12714610	
VEGFA	 Activates	 Angiogenesis	 Growth	factor	activity	 GO:0008083	 9202027	
VEGFA	 Activates	 Angiogenesis	 Positive	regulation	of	
cell	migration	involved	
in	sprouting	
angiogenesis	
GO:0090050	 18577655	
VEGFA	 Activates	 Angiogenesis	 Positive	regulation	of	
angiogenesis	
GO:0045766	 18440775	
VEGFA	 Activates	 Angiogenesis	 Cell	migration	involved	
in	sprouting	
angiogenesis	
GO:0002042	 20497126	
VEGFA	 Activates	 Angiogenesis	 Blood	vessel	
remodelling	
GO:0001974	 20551324	
VEGFA	 Activates	 Angiogenesis	 Patterning	of	blood	
vessels	
GO:0001569	 7929439	
VEGFA	 Activates	 Angiogenesis	 	 	 17470632	
VEGFA	 Activates	 Angiogenesis	 	 	 18440775	
VEGFA	 Activates	 Angiogenesis	 	 	 20660291	
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VEGFA	 Activates	 Angiogenesis	 	 	 19033661	
	
	
Table	7.2.3	Nodes	regulating	DNA	repair	in	the	PMH260	model.			
A	total	of	28	nodes	that	regulate	DNA	repair	are	described.	Of	these;	20	and	8	are	positive	and	
negative	regulators	of	DNA	repair	respectively.	Some	links	to	DNA	repair	were	not	obtained	via	
their	GO	annotations	and	were	additionally	searched	by	literature	evidence.	PMIDs	and	PMCs	
are	supplied.	Reference	links	are	also	supplied	if	no	PMID	is	available.			
Source	 Interaction	 Target	 GO	Term	 GO	ID	 PMID/PMC	
ATM	 Activates	 DNA	repair	 DNA	repair	 GO:0006281	 doi:10.1038/nc
omms4347	
ATR	 Activates	 DNA	repair	 	 	 PMC4176976	
BCCIP	 Activates	 DNA	repair	 DNA	repair	 GO:0006281	 17947333	
BRCA1	 Activates	 DNA	repair	 	 	 14636569	
CD44	 Activates	 DNA	repair	 	 	 16263582	
CDKN1A	 Activates	 DNA	repair	 	 	 22735704	
DDB2	 Activates	 DNA	repair	 UV-damage	
excision	repair	
GO:0070914	 22334663	
FEN1	 Activates	 DNA	repair	 Double-strand	
break	repair	
GO:0006302	 8131753	
FGF2	 Activates	 DNA	repair	 	 	 22732006	
FGF2	 Activates	 DNA	repair	 	 	 20681019	
GADD45
A	
Activates	 DNA	repair	 DNA	repair	 GO:0006281	 7973727	
HSPA4	 Activates	 DNA	repair	 	 	 14627201	
IFI16	 Activates	 DNA	repair	 	 	 18472023	
KLF4	 Inhibits	 DNA	repair	 	 	 PMC3750599	
MCL1	 Activates	 DNA	repair	 	 	 20647761	
MDM2	 Inhibits	 DNA	repair	 	 	 18541670	
MDM4	 Inhibits	 DNA	repair	 	 	 24608433	
MGMT	 Activates	 DNA	repair	 DNA	
dealkylation	
involved	in	
DNA	repair	
GO:0006307	 1554415	
MSH2	 Activates	 DNA	repair	 DNA	repair	 GO:0006281	 8942985	
MSH2	 Activates	 DNA	repair	 Mismatch	
repair	
GO:0006298	 1334021	
MSH2	 Activates	 DNA	repair	 Mismatch	
repair	
GO:0006298	 11555625	
MSH2	 Activates	 DNA	repair	 Post	
replication	
repair	
GO:0006301	 17715146	
MYC	 Inhibits	 DNA	repair	 	 	 23308051	
NME1	 Activates	 DNA	repair	 	 	 25017017	
PCNA	 Activates	 DNA	repair	 Positive	
regulation	of	
DNA	repair	
GO:0006281	 16227586	
PPM1D	 Inhibits	 DNA	repair	 	 	 15327777	
	 127	
PRKDC	 Activates	 DNA	repair	 Double-strand	
break	repair	
via	
homologous	
recombination	
GO:0000724	 11418067	
PTTG1		 Inhibits	 DNA	repair	 GO:0006281	 DNA	repair	 	
RAD51	 Activates	 DNA	repair	 	 GO:0000150	 PMC2430071	
SERPINE
1	
Inhibits	 DNA	repair	 	 	 23111469	
SIAH1	 Inhibits	 DNA	repair	 	 	 20682032	
YY1	 Activates	 DNA	repair	 Double	strand	
break	repair	
via	
homologous	
recombination	
GO:0000724	 18026119	
	
	
Table	7.2.4	Nodes	regulating	cellular	senescence	in	the	PMH260	model.			
A	total	of	68	nodes	that	regulate	cellular	senescence	are	described.	Of	these;	32	and	36	are	
positive	and	negative	regulators	of	senescence	respectively.	Some	links	were	not	obtained	via	
their	GO	annotations	and	were	additionally	searched	by	literature	evidence.	PMIDs	and	PMCs	
are	supplied.	Reference	links	are	also	supplied	if	no	PMID	is	available.		Table	includes	links	to	
cellular	senescence	as	described	in	Tian	et	al.	(2013).		
Source	 Interaction	 Target	 GO	Term	 GO	ID	 PMID/PMC	
APAF1	 Inhibits	 Cellular	senescence	 	 	 17652622	
APP	 Activates	 Cellular	senescence	 	 	 24232259	
AR	 Activates	 Cellular	senescence	 	 	 22403609	
ARID3A	 Inhibits	 Cellular	senescence	 	 	 22010578	
BAK1	 Activates	 Cellular	senescence	 	 	 19747230	
BAK1	 Inhibits	 Cellular	senescence	 	 	 11557285	
BCL2	 Activates	 Cellular	senescence	 	 	 12670482	
BCL2	 Inhibits	 Cellular	senescence	 	 	 19855432	
BRCA1	 Inhibits	 Cellular	senescence	 	 	 12533509	
C12orf5	 Activates	 Cellular	senescence	 	 	 19710698	
CD59	 Activates	 Cellular	senescence	 	 	 22918646	
CD59	 Inhibits	 Cellular	senescence	 	 	 17188915	
CDK4	 Inhibits	 Cellular	senescence	 	 	 12435633	
CDKN1A	 Activates	 Cellular	senescence	 Cellular	
senescence	
GO:009039
8	
15149599	
CDKN1B	 Activates	 Cellular	senescence	 	 	 21795702	
CDKN2A	 Activates	 Cellular	senescence	 Cellular	
senescence	
GO:009039
8	
14966292	
CDKN2A	 Activates	 Cellular	senescence	 Positive	
regulation	of	
cellular	
senescence	
GO:200077
4	
14966292	
CKB	 Inhibits	 Cellular	senescence	 	 	 21980054	
CUL7	 Inhibits	 Cellular	senescence	 	 	 18498745	
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DAXX	 Inhibits	 Cellular	Senescence	 	 	 23542781	
DDB2	 Activates	 Cellular	senescence	 	 	 23109835	
DDIT4	 Inhibits	 Cellular	senescence	 	 	 22629318	
DKK1	 Activates	 Cellular	senescence	 	 	 22927647	
DKK1	 Inhibits	 Cellular	senescence	 	 	 21712954	
EGFR	 Inhibits	 Cellular	senescence	 	 	 21852385	
ELAVL1	 Inhibits	 Cellular	senescence	 	 	 23028944	
EZH2	 Inhibits	 Cellular	senescence	 	 	 15208672	
EZH2	 Inhibits	 Cellular	senescence	 	 	 21383005	
FGF2	 Inhibits	 Cellular	senescence	 	 	 17532297	
FGF2	 Inhibits	 Cellular	senescence	 	 	 21990129	
FHL2	 Inhibits	 Cellular	senescence	 	 	 19018287	
FOXM1	 Inhibits	 Cellular	senescence	 	 	 23262037	
GADD45A	 Activates	 Cellular	senescence	 	 	 16951155	
GADD45A	 Inhibits	 Cellular	senescence	 	 	 21986581	
GAPDH	 Activates	 Cellular	senescence	 	 	 22847419	
GAPDH	 Inhibits	 Cellular	senescence	 	 	 21749859	
HIF1A	 Inhibits	 Cellular	senescence	 	 	 18645006	
HNF4A	 Inhibits	 Cellular	senescence	 	 	 21385945	
IFI16	 Activates	 Cellular	senescence	 	 	 15208661	
IFITM2	 Activates	 Cellular	senescence	 	 	 19071156	
IGF1R	 Activates	 Cellular	senescence	 	 	 18216278	
IGFBP7	 Activates	 Cellular	senescence	 	 	 21997538	
IL6	 Activates	 Cellular	senescence	 	 	 22374671	
LATS2	 Activates	 Cellular	senescence	 	 	 21498571	
MCL1	 Inhibits	 Cellular	senescence	 	 	 22451485	
MSH2	 Activates	 Cellular	senescence	 	 	 18986375	
MSH2	 Inhibits	 Cellular	senescence	 	 	 23213348	
MYC	 Activates	 Cellular	senescence	 	 	 20027199	
MYC	 Inhibits	 Cellular	senescence	 	 	 17664422	
NME1	 Inhibits	 Cellular	senescence	 	 	 20713695	
NOTCH1	 Activates	 Cellular	senescence	 	 	 23078884	
PCBP4	 Inhibits	 Cellular	senescence	 	 	 20817677	
PML	 Activates	 Cellular	senescence	 Negative	
regulation	of	
telomere	
maintenance	
via	
telomerase	
GO:003221
1	
10950866	
PML	 Activates	 Cellular	senescence	 Negative	
regulation	of	
telomere	
maintenance	
via	
telomerase	
GO:003221
1	
10910364	
PML	 Activates	 Cellular	senescence	 	 	 12093737	
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PPM1D	 Inhibits	 Cellular	senescence	 	 	 22201816	
PRAK	 Activates	 Cellular	senescence	 	 	 17254968	
PRKCA	 Activates	 Cellular	senescence	 	 	 18162471	
PSEN1	 Activates	 Cellular	senescence	 	 	 19181896	
PTEN	 Activates	 Cellular	senescence	 	 	 23314408	
PTEN	 Inhibits	 Cellular	senescence	 	 	 21072054	
PTGS2	 Activates	 Cellular	senescence	 	 	 23328527	
RAS	 Activates	 Cellular	senescence	 Cellular	
senescence	
GO:009039
8	
15489886	
RRM2B	 Inhibits	 Cellular	senescence	 	 	 23139867	
S100A6	 Inhibits	 Cellular	senescence	 	 	 23095053	
SESN2	 Inhibits	 Cellular	senescence	 	 	 20606249	
SFN	 Activates	 Cellular	senescence	 	 	 19642975	
SGK	 Inhibits	 Cellular	senescence	 	 	 15068796	
TFDP1	 Inhibits	 Cellular	senescence	 	 	 15716376	
TGFA	 Activates	 Cellular	senescence	 	 	 12593448	
VEGFA	 Inhibits	 Cellular	senescence	 	 	 21618508	
WWP1	 Inhibits	 Cellular	senescence	 	 	 22051607	
WWP1	 Inhibits	 Cellular	senescence	 	 	 21795702	
	
	
	
Table	7.2.5	Nodes	regulating	cell	cycle	arrest	in	the	PMH260	model.			
A	total	of	62	nodes	that	regulate	cell	cycle	arrest	are	described.	Of	these;	34	and	28	are	
positive	and	negative	regulators	of	cell	cycle	arrest	respectively.	Some	links	were	not	obtained	
via	their	GO	annotations	and	were	additionally	searched	by	literature	evidence.	PMIDs	and	
PMCs	are	supplied.	Reference	or	DOI	links	are	also	supplied	if	no	PMID	is	available.			
Source	 Interaction	 Target	 GO	Term	 GO	ID	 PMID/PMC	
APAF1	 Inhibits	 Cell	cycle	arrest	 	 	 18309324	
APAF1	 Inhibits	 Cell	cycle	arrest	 	 	 18042457	
AR	 Inhibits	 Cell	cycle	arrest	 	 	 16877366	
AR	 Inhibits	 Cell	cycle	arrest	 	 	 6483690	
AR	 Inhibits	 Cell	cycle	arrest	 	 	 9685369	
ATF3	 Activates	 Cell	cycle	arrest	 	 	 12386811	
ATF3	 Inhibits	 Cell	cycle	arrest	 Positive	
regulation	of	
cell	proliferation	
GO:0008284	 15990869	
ATM	 Activates	 Cell	cycle	arrest	 cell	cycle	arrest	 GO:0007050	 11721054	
ATR	 Activates	 Cell	cycle	arrest	 	 	 11721054	
AURKA	 Inhibits	 Cell	cycle	arrest	 	 	 24841948	
BRCA1	 Activates	 Cell	cycle	arrest	 Positive	
regulation	of	
cell	cycle	arrest	
GO:0071158	 21102443	
BRCA1	 Activates	 Cell	cycle	arrest	 	 	 10644742	
BRCA1	 Activates	 Cell	cycle	arrest	 	 	 10644742	
BRCA1	 Activates	 Cell	cycle	arrest	 	 	 7954448	
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BTG2	 Activates	 Cell	cycle	arrest	 DNA	repair	 GO:0006281	 10669755	
CCNA	 Inhibits	 Cell	cycle	arrest	 	 	 25615569	
CCNB1	 Inhibits	 Cell	cycle	arrest	 	 	 2570636	
CCNB1	 Inhibits	 Cell	cycle	arrest	 	 	 1717476	
CCNB1	 Inhibits	 Cell	cycle	arrest	 	 	 8797586	
CDK2	 Inhibits	 Cell	cycle	arrest	 	 	 19445729	
CDK5	 Activates	 Cell	cycle	arrest	 Regulation	of	
cell	cycle	arrest	
GO:0071156	 21473899	
CDKN1B	 Activates	 Cell	cycle	arrest	 Cell	cycle	arrest	 GO:0007050	 12093740	
CDKN1B	 Activates	 Cell	cycle	arrest	 G1/S	transition	
of	mitotic	cell	
cycle	
GO:0000082	 10208428	
CDKN1B	 Activates	 Cell	cycle	arrest	 Mitotic	cell	
cycle	
GO:0000278	 19266349	
CDKN1B	 Activates	 Cell	cycle	arrest	 Negative	
regulation	of	
cyclin-
dependent	
protein	
serine/threonin
e	kinase	activity	
GO:0045736	 15374880	
CDKN1B	 Activates	 Cell	cycle	arrest	 DNA	damage	
response,	signal	
transduction	by	
p53	class	
mediator	
resulting	in	cell	
cycle	arrest	
GO:006977	 8033213	
CDKN1B	 Activates	 Cell	cycle	arrest	 Response	to	G1	
DNA	damage	
checkpoint	
signalling	
GO:0072432	 8033213	
CDKN2A		 Activates	 Cell	cycle	arrest	 Cell	cycle	arrest	 GO:0007050	 23238983	
CDKN2A		 Activates	 Cell	cycle	arrest	 positive	
regulation	of	
cell	cycle	arrest	
GO:0071158	 9529249	
CHEK1	 Activates	 Cell	cycle	arrest	 	 	 21034966	
CHEK2	 Activates	 Cell	cycle	arrest	 	 	 PMC316357	
CKS2	 Inhibits	 Cell	cycle	arrest	 	 	 1862572	
CUL7	 Inhibits	 Cell	cycle	arrest	 	 	 18498745	
DKK1	 Activates	 Cell	cycle	arrest	 	 	 20549706	
DKK1	 Activates	 Cell	cycle	arrest	 	 	 12740383	
DUSP5	 Activates	 Cell	cycle	arrest	 	 	 12944906	
E2F1	 Activates	 Cell	cycle	arrest	 	 	 9766435	
EPHB4	 Inhibits	 Cell	cycle	arrest	 	 	 15930280	
EXPORTI
N1	
Activates	 Cell	cycle	arrest	 	 	 23615632	
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EXPORTI
N1	
Activates	 Cell	cycle	arrest	 	 	 22832492	
GADD45
A	
Activates	 Cell	cycle	arrest	 Regulation	of	
cell	cycle	
GO:0051726	 12124778	
GADD45
A	
Activates	 Cell	cycle	arrest	 Cell	cycle	arrest	 GO:0007050	 10747892	
GADD45
A	
Activates	 Cell	cycle	arrest	 G2/M	transition	
of	mitotic	cell	
cycle	
GO:0000086	 11964479	
HDAC1	 Inhibits	 Cell	cycle	arrest	 	 	 20194438	
HOXA10	 Activates	 Cell	cycle	arrest	 	 	 2731304	
HOXA5	 Activates	 Cell	cycle	arrest	 	 	 25590986	
ID3	 Activates	 Cell	cycle	arrest	 	 	 21498546	
IER3	 Inhibits	 Cell	cycle	arrest	 	 	 11311240	
IGFBP7	 Activates	 Cell	cycle	arrest	 	 	 23388612	
ING4	 Activates	 Cell	cycle	arrest	 Cell	cycle	 	 15251430	
ING5	 Inhibits	 Cell	cycle	arrest	 Negative	
regulation	of	
cell	proliferation	
GO:0008285	 12750254	
ISG15	 Inhibits	 Cell	cycle	arrest	 	 	 PMC4226694	
JUN	 Inhibits	 Cell	cycle	arrest	 Positive	
regulation	of	
fibroblast	
proliferation	
GO:0048146	 1171114	
KAT2B	 Activates	 Cell	cycle	arrest	 Negative	
regulation	of	
cell	proliferation	
GO:000825	 8684459	
KAT2B	 Activates	 Cell	cycle	arrest	 	 G0:0006915	 20809119	
KLF4	 Activates	 Cell	cycle	arrest	 	 	 PMC3750599	
MAPK1	 Activates	 Cell	cycle	arrest	 	 	 11821415	
MCL1	 Inhibits	 Cell	cycle	arrest	 	 	 22378300	
MUC1	 Inhibits	 Cell	cycle	arrest	 DNA	damage	
response,	signal	
transduction	by	
p53	class	
mediator	
resulting	in	cell	
cycle	arrest	
GO:0006977	 15710329	
MYC	 Inhibits	 Cell	cycle	arrest	 Cell	cycle	arrest	 GO:0007050	 10962037	
MYCN		 Inhibits	 Cell	cycle	arrest	 	 	 17495526	
MYST4	 Activates	 Cell	cycle	arrest	 	 	 19001415	
PAD4	 Activates	 Cell	cycle	arrest	 	 	 16502257	
PARK2		 Activates	 Cell	cycle	arrest	 	 	 24793136	
POU4F1		 Activates	 Cell	cycle	arrest	 	 	 18421303	
PPARG	 Activates	 Cell	cycle	arrest	 	 	 15916743	
PRAK	 Inhibits	 Cell	cycle	arrest	 	 	 DOI:	
10.1007/s11684
-009-0073-y	
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PTGS2	 Activates	 Cell	cycle	arrest	 Negative	
regulation	of	
cell	cycle	
GO:0045786	 10567385	
PTGS2	 Activates	 Cell	cycle	arrest	 	 	 11606477	
RAD51	 Inhibits	 Cell	cycle	arrest	 	 	 19140342	
RAF1	 Activates	 Cell	cycle	arrest	 	 	 10022606	
RAS	 Activates	 Cell	cycle	arrest	 	 	 3510745	
RAS	 Activates	 Cell	cycle	arrest	 	 	 3049071	
RB1CC1	 Activates	 Cell	cycle	arrest	 Cell	cycle	 GO:0007049	 16061648	
RGS16	 Inhibits	 Cell	cycle	arrest	 	 	 16405749	
S100A6	 Inhibits	 Cell	cycle	arrest	 Positive	
regulation	of	
fibroblast	
proliferation	
GO:0048146	 12577318	
S100A6	 Inhibits	 Cell	cycle	arrest	 	 	 20013795	
S100A6	 Inhibits	 Cell	cycle	arrest	 	 	 23095053	
SIVA1	 Inhibits	 Cell	cycle	arrest	 	 	 23462994	
SLC2A1	 Inhibits	 Cell	cycle	arrest	 	 	 	
STMN1	 Activates	 Cell	cycle	arrest	 	 	 15368352	
STMN1	 Activates	 Cell	cycle	arrest	 	 	 15031128	
TFAP2C	 Activates	 Cell	cycle	arrest	 	 	 16867219	
UBE2A	 Inhibits	 Cell	cycle	arrest	 Positive	
regulation	of	
cell	proliferation	
GO:0008284	 1748683	
VRK1	 Inhibits	 Cell	cycle	arrest	 	 	 18286197	
YBX1	 Inhibits	 Cell	cycle	arrest	 	 	 20398058	
	
	
Table	7.2.6	Nodes	that	are	regulated	by	DNA	damage	in	the	PMH260	model.			
A	total	of	42	nodes	are	regulated	by	DNA	damage.	Of	these;	37	are	activated	by	DNA	damage,	
5	are	inhibited.	Some	links	were	not	obtained	via	their	GO	annotations	and	were	additionally	
searched	by	literature	evidence.	PMIDs	and	PMCs	are	supplied.	Reference	or	DOI	links	are	also	
supplied	if	no	PMID	is	available.		Table	includes	DNA	damage	nodes	described	in	Tian	et	al.	
(2013).		
Source	 Interaction	 Target	 GO	Term	 GO	ID	 PMID/PMC	
DNA	
damage	
Activates	 APP	 	 	 18421302	
DNA	
damage	
Activates	 ATM	 	DNA	damage	
response,	signal	
transduction	resulting	
in	induction	of	
apoptosis	
GO:0008630:	 15279774	
DNA	
damage	
Activates	 ATM	 	response	to	ionizing	
radiation	
GO:	0010212	 15322239	
DNA	
damage	
Activates	 ATR	 cellular	response	to	
UV	
GO:0034644	 15322239	
DNA	
damage	
Activates	 ATR	 	response	to	DNA	
damage	stimulus	
GO:0006974	 15322239	
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DNA	
damage	
Inhibits	 AURKA	 	 	 21099343	
DNA	
damage	
Activates	 BTG2	 	response	to	DNA	
damage	stimulus	
GO:0006974	 8944033	
DNA	
damage	
Activates	 CCAR1	 	 	 12816952	
DNA	
damage	
Activates	 CDK5	 	 	 19151707	
DNA	
damage	
Activates	 CUL7	 	 	 17586686	
DNA	
damage	
Activates	 DAP	 	 	 15608685	
DNA	
damage	
Activates	 DAXX	 	 	 23539629	
DNA	
damage	
Activates	 ERBB2	 	 	 19406993	
DNA	
damage	
Activates	 FAS	 	 	 9660938	
DNA	
damage	
Activates	 HTATIP2	 	 	 21376742	
DNA	
damage	
Activates	 ICAM1	 Response	to	ionizing	
radiation	
G0:0010212	 7963663	
DNA	
damage	
Activates	 ING5	 	 	 23576563	
DNA	
damage	
Activates	 JUN	 	 	 16733206	
DNA	
damage	
Activates	 MAPK8	 induction	of	apoptosis	
by	extracellular	signals	
GO:0008624	 15696159	
DNA	
damage	
Activates	 MAPK8	 induction	of	apoptosis	
by	intracellular	signals	
GO:0008629	 	
DNA	
damage	
Activates	 MAPK8	 	response	to	UV	 O:000941	 	
DNA	
damage	
Activates	 MAPK9	 	 	 17306896	
DNA	
damage	
Activates	 MCTS1	 response	to	DNA	
damage	stimulus	
GO:0006974	 17016429	
DNA	
damage	
Inhibits	 MDM2	 	Positive	regulation	of	
cell	cycle	arrest	by	
p53-mediated	DNA	
damage	response.	
GO:0006977	 11960904	
DNA	
damage	
Inhibits	 MDM2	 	 	 16227609	
DNA	
damage	
Activates	 MYC	 cellular	response	to	
UV	
GO:0034644	 2687769	
DNA	
damage	
Activates	 MYC	 response	to	DNA	
damage	stimulus	
GO:0006974	 	
DNA	
damage	
Inhibits	 MYC	 	cellular	response	to	
UV	
GO:003464	 12761495	
DNA	
damage	
Inhibits	 MYC	 	response	to	DNA	
damage	stimulus	
GO:0006974	 12761495	
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DNA	
damage	
Activates	 MYST4	 	 	 19001415	
DNA	
damage	
Activates	 NCL	 	 	 12000845	
DNA	
damage	
Activates	 PHF20	 	 	 PMC3454513	
DNA	
damage	
Activates	 PITX1	 	 	 20563669	
DNA	
damage	
Activates	 PML	 	 	 PMC156140	
DNA	
damage	
Activates	 PRKD1	 	 	 16911582	
DNA	
damage	
Activates	 PRKDC	 	 	 16908529	
DNA	
damage	
Inhibits	 PTTG1	 	 	 18047793	
DNA	
damage	
Activates	 RFC	 	 	 11336696	
DNA	
damage	
Activates	 RFC	 	 	 18245774	
DNA	
damage	
Activates	 RFC	 	 	 PMC87010	
DNA	
damage	
Activates	 SOX4	 DNA	damage	
response,	detection	of	
DNA	damage	
GO:0042769	 19234109	
DNA	
damage	
Activates	 STAT3	 	 	 20456494	
DNA	
damage	
Inhibits	 STMN1	 	 	 16909102	
DNA	
damage	
Activates	 SUB1	 	 	 19047459	
DNA	
damage	
Activates	 TFAP2A	 	 	 8962096	
DNA	
damage	
Activates	 TGFB1	 	 	 15652459	
DNA	
damage	
Activates	 TP53BP1	 	 	 14695167	
DNA	
damage	
Activates	 TP53BP1	 	 	 PMC150747	
DNA	
damage	
Activates	 TP53RK	 	 	 20647325	
DNA	
damage	
Activates	 UBE2A	 Response	to	UV	 GO:0009411	 1717990	
DNA	
damage	
Activates	 UBE2A	 	 	 23525009	
DNA	
damage	
Activates	 YBX1	 regulation	of	
transcription,	DNA-
dependent	
GO:0006355	 12080043	
DNA	
damage	
Activates	 YY1	 Cellular	response	to	
UV	
GO:0034644	 18026119	
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DNA	
damage	
Activates	 YY1	 Cellular	response	to	
DNA	damage	stimulus	
GO:0006974	 18026119	
	
	
	
Image	7.2	The	PMH260	p53-DNA	damage	model		
Five	layers	are	observed	in	accordance	with	node	function;	the	input	signal	of	DNA	damage	
(green),	upstream	of	p53	(yellow),	the	network	hub,	p53	(red)	contained	within	the	crucial	
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feedback	loop	with	MDM2	(red),	downstream	of	p53	(turquoise)	and	five	downstream	outputs	
(orange).	Red	lines	signify	inhibition,	blue	activation.	
	
7.2.2	Analysis	and	validation	of	the	PMH260	model	
One	of	the	main	aims	was	to	generate	a	larger	model	and	ascertain	if	the	extended	
model	could	correctly	predict	overall	system	attributes	in	response	to	network	
perturbations	by	comparison	to	experimental	data.	To	investigate	network	
perturbations	of	the	PMH260	interactome	in	response	to	in	silico	manipulation	of	
different	node	states	and	inputs,	two	methods	were	undertaken;	Logical	Steady	State	
Analysis	(LSSA)	and	dependency	matrix	calculations,	both	provided	in	CellNetAnalyzer	
(v.2015.1)	(CNA).	The	PMH260	network	was	established	in	CNA	in	accordance	with	
Klamt	et	al.	(2006)	discussed	in	detail	in	material	and	methods,	section	6.2.1.2.		
	
7.2.2.1	Logical	steady	state	analysis	of	PMH260	
The	DNA	damage	input	serves	as	environmental	stress	to	the	model.	The	in	silico	
manipulation	of	this	input	can	represent,	for	example,	DNA	damaging	
chemotherapeutic	agents	such	as	etoposide.		To	investigate	network	perturbations	
from	loss	of	p53	and	different	DNA	damage	inputs	(ON	or	OFF),	we	created	four	
different	in	silico	scenarios	(section	6,	table	6.2)	and	investigated	the	LSS	of	nodes	in	
the	PMH260	network	as	a	result	of	these	different	conditions.		
	
Under	these	conditions	and	globally,	the	majority	of	node	states	were	determined	in	
p53	wildtype	backgrounds	(78.5	%	for	p53	wild	type	with	DNA	damage	OFF)	(78.8	%	for	
p53	wildtype	with	DNA	damage	ON)	compared	to	node	states	in	the	p53	deleted	
backgrounds.	In	fact,	over	half	of	all	nodes	switched	to	an	undetermined	state	when	
p53	was	deleted	from	the	network	(57	%	for	DNA	damage	ON)	(57.1	%	for	DNA	damage	
OFF).			
	
In	the	presence	of	p53,	a	greater	number	of	upregulated	nodes	were	observed	
compared	to	p53	KO	backgrounds:	164	(63	%)	when	DNA	damage	was	ON	in	the	
presence	of	p53,	compared	to	101	(39	%)	when	p53	was	deleted	with	DNA	damage	ON	
(compare	lanes	1	and	7,	fig.	7.2).		Nearly	a	4-fold	increase	was	observed	in	the	number	
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of	down-regulated	nodes	when	DNA	damage	was	switched	ON	in	the	presence	of	p53,	
41	(15.7	%),	when	comparing	to	p53	KO,	11	(4	%),	(compare	lanes	2	and	8,	fig.	7.2).	A	2-
fold	increase	in	the	number	of	down-regulated	nodes	was	seen	when	DNA	damage	was	
OFF	in	the	presence	of	p53,	56	(21.5	%),	compared	to	when	DNA	damage	was	OFF	in	
p53	KO	background,	30	(11.6	%),	(compare	lanes	5	and	11,	fig.	7.2).	All	output	signals	
remained	active	across	all	scenarios.		Table	7.2.7	provides	a	global	list	off	all	node	state	
changes	in	response	to	the	four	in	silico	conditions.		
	
Figure	7.2	Global	distribution	of	all	PMH260	nodes	under	LSSA	
Global	distribution	of	node	state	changes	in	response	to	the	four	in	silico	scenarios	generated	
of	different	DNA	damage	(DD)	and	p53	statuses:		WT:	Wild	type.	KO:	Knockout.			
	
Several	nodes	were	exclusively	in	silico	DNA	damage	responsive	regardless	of	p53	
status	and	some,	unsurprisingly	upregulated	when	the	DNA	damage	input	was	
switched	ON,	downregulated	when	OFF	(ATM,	ATR,	JUN,	DAXX,	BTG2,	CCAR1,	DAP,	
HTATIP2,	MAPK9,	MYST4,	PITX1,	PRKD1,	SOX4	and	UBE2A).	Other	nodes	were	
differentially	regulated	dependant	on	p53	in	silico	status.	For	example,	GADD45A	was	
downregulated	in	p53	deletion	backgrounds,	conversely	upregulated	when	p53	was	
present.	As	highlighted	in	table	7.2.6	many	nodes	remained	up	or	downregulated	
across	all	simulations,	regardless	of	p53	status	or	DNA	damage	input.		
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Table	7.2.7	Global	list	of	node	state	changes	under	LSSA	in	the	PMH260	model	in	response	to	
different	DNA	damage	and	p53	scenarios.	Distribution	of	all	nodes	(n	=	260)	in	PMH260	under	
LSSA	in	response	to	the	four	different	simulations	of	different	p53	(WT=wild	type,	
KO=knockout),	and	DNA	damage	(DD)	statuses	(section	6,	material	and	methods).	In	
accordance	with	CNA,	three	states	exist;	1	=	upregulated,	0	=	downregulated,	NaN	=	
undetermined.		
Node	ID	 p53	WT	with	DD	
ON	
p53	WT	with	DD	
OFF	
p53	KO	with	DD	
ON	
p53	KO	with	DD	
OFF	
AATF	 1	 1	 1	 1	
ABCB1	 1	 1	 1	 1	
ABCC1	 1	 1	 1	 1	
AIFM2	 1	 1	 NaN	 NaN	
Angiogenesis	 1	 1	 1	 1	
APAF1	 1	 1	 1	 1	
Apoptosis	 1	 1	 1	 1	
APP	 NaN	 NaN	 NaN	 NaN	
AR			 0	 0	 0	 0	
ARID3A	 1	 1	 NaN	 NaN	
ASPP1	 NaN	 NaN	 NaN	 NaN	
ASPP2	 NaN	 NaN	 NaN	 NaN	
ATF3	 1	 1	 1	 1	
ATM			 1	 0	 1	 0	
ATR			 1	 0	 1	 0	
AURKA	 NaN	 NaN	 NaN	 NaN	
AXIN1	 1	 1	 1	 1	
BAIA2PL1	 NaN	 NaN	 NaN	 NaN	
BAIAP2L2	 NaN	 NaN	 NaN	 NaN	
BAK1	 1	 1	 NaN	 NaN	
BAX			 1	 1	 1	 1	
BBC3	 1	 1	 NaN	 NaN	
BCCIP	 NaN	 NaN	 NaN	 NaN	
BCL2	 1	 1	 1	 1	
BCL3	 0	 0	 NaN	 NaN	
BCL6	 0	 1	 0	 1	
BDKRB1	 0	 0	 NaN	 NaN	
BNIP3L	 1	 1	 NaN	 NaN	
BRCA1	 1	 1	 1	 1	
BTG2	 1	 0	 1	 0	
C12orf5	 1	 1	 NaN	 NaN	
C13orf15	 1	 1	 NaN	 NaN	
CA9	 0	 0	 NaN	 NaN	
CALD1	 1	 1	 NaN	 NaN	
CASP8	 1	 1	 NaN	 NaN	
CCAR1	 1	 0	 1	 0	
CCNA	 1	 1	 1	 1	
CCNB1	 0	 0	 NaN	 NaN	
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CCND1	 1	 1	 1	 1	
CCNG1	 1	 1	 1	 1	
CD44	 1	 1	 1	 1	
CD58	 1	 1	 NaN	 NaN	
CD59	 1	 1	 NaN	 NaN	
CD82	 1	 1	 NaN	 NaN	
CDC20	 0	 0	 NaN	 NaN	
CDC25A	 1	 1	 1	 1	
CDK2	 1	 1	 1	 1	
CDK4	 NaN	 1	 NaN	 1	
CDK5	 1	 NaN	 1	 1	
CDK9	 NaN	 1	 NaN	 NaN	
CDKN1A	 1	 1	 1	 1	
CDKN1B	 1	 1	 1	 1	
CDKN2A	 0	 0	 NaN	 NaN	
Cell	Cycle	
Arrest	
1	 1	 1	 1	
Cellular	
Senescence	
1	 1	 1	 1	
CHEK1	 1	 0	 1	 NaN	
CHEK2	 1	 1	 1	 1	
CIAPIN1	 NaN	 NaN	 NaN	 NaN	
CKB			 1	 1	 1	 1	
CKM			 1	 1	 0	 0	
CKS2	 0	 0	 NaN	 NaN	
COL18A1	 1	 1	 NaN	 NaN	
COL1A2	 1	 NaN	 NaN	 NaN	
CSNK2	 NaN	 NaN	 NaN	 NaN	
CUL7	 1	 0	 1	 1	
CXCR4	 1	 1	 1	 1	
DAP	 1	 0	 1	 0	
DAXX	 1	 0	 1	 0	
DDB2	 1	 1	 NaN	 NaN	
DDIT4	 1	 1	 NaN	 NaN	
DDX20	 NaN	 NaN	 NaN	 NaN	
DDX5	 NaN	 NaN	 NaN	 NaN	
DFNA5	 1	 1	 NaN	 NaN	
DKK1	 1	 1	 NaN	 NaN	
DNA	damage	 1	 0	 1	 0	
DNA	repair	 1	 1	 1	 1	
DNMT3A	 NaN	 NaN	 1	 NaN	
DUSP2	 1	 1	 NaN	 NaN	
DUSP4	 1	 1	 NaN	 1	
DUSP5	 1	 1	 1	 0	
DYRK2	 1	 0	 1	 1	
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E2F1	 1	 1	 1	 NaN	
ECT2	 0	 0	 NaN	 NaN	
EDA2R	 1	 1	 NaN	 1	
EGFR	 1	 1	 1	 NaN	
EIF2AK2	 NaN	 NaN	 NaN	 NaN	
ELAVL1	 1	 1	 1	 0	
EPHB4	 0	 0	 1	 NaN	
ERBB2	 1	 1	 1	 1	
ESR1	 1	 1	 NaN	 1	
EXPORTIN1	 0	 1	 0	 1	
EZH2	 1	 1	 1	 1	
FAS			 1	 1	 1	 NaN	
FDXR	 1	 1	 NaN	 NaN	
FEN1	 1	 1	 NaN	 0	
FGF2	 NaN	 1	 0	 1	
FHL2	 1	 1	 NaN	 NaN	
FOS			 1	 1	 1	 1	
FOXM1	 0	 0	 NaN	 NaN	
GADD45A	 1	 1	 0	 0	
GAPDH	 1	 1	 NaN	 NaN	
GSTP1	 1	 1	 1	 1	
GTSE1	 1	 1	 NaN	 NaN	
H2AFZ	 NaN	 NaN	 NaN	 NaN	
HDAC1	 NaN	 NaN	 NaN	 NaN	
HIC1	 1	 1	 1	 1	
HIF1A	 1	 1	 1	 1	
HIPK2	 NaN	 NaN	 NaN	 NaN	
HIPK4	 NaN	 NaN	 NaN	 NaN	
HMMR	 0	 0	 NaN	 NaN	
HNF4A	 0	 0	 NaN	 NaN	
HOXA10	 NaN	 NaN	 NaN	 NaN	
HOXA11	 NaN	 NaN	 NaN	 NaN	
HOXA5	 NaN	 NaN	 NaN	 NaN	
HSP90AB1	 0	 0	 NaN	 NaN	
HSPA4	 1	 1	 1	 1	
HTATIP2	 1	 0	 1	 0	
IASPP	 NaN	 NaN	 NaN	 NaN	
ICAM1	 1	 1	 1	 1	
ID3			 1	 1	 1	 1	
IER3	 1	 1	 NaN	 NaN	
IFI16	 1	 1	 NaN	 NaN	
IFITM2	 0	 0	 NaN	 NaN	
IFNA1	 NaN	 NaN	 NaN	 NaN	
IGF1R	 0	 0	 NaN	 NaN	
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IGFBP1	 1	 1	 NaN	 NaN	
IGFBP7	 1	 1	 NaN	 NaN	
IL6			 1	 1	 1	 1	
ING4	 NaN	 NaN	 NaN	 NaN	
ING5	 NaN	 NaN	 1	 NaN	
IQCB1	 0	 0	 NaN	 NaN	
ISG15	 1	 1	 NaN	 NaN	
JUN	 1	 0	 1	 0	
KAT2B	 1	 1	 NaN	 NaN	
KLF4	 1	 1	 NaN	 NaN	
KRT19	 0	 0	 0	 NaN	
KRT8	 1	 1	 NaN	 NaN	
LATS2	 1	 1	 NaN	 NaN	
LRDD	 1	 1	 NaN	 NaN	
LTF	 1	 1	 1	 1	
MAP4	 0	 0	 NaN	 NaN	
MAP4K4	 0	 1	 1	 NaN	
MAPK1	 1	 1	 1	 1	
MAPK14	 1	 1	 1	 1	
MAPK8	 1	 1	 1	 1	
MAPK9	 1	 0	 1	 0	
MCL1	 1	 1	 1	 1	
MCTS1	 1	 0	 1	 0	
MDM2	 1	 1	 NaN	 1	
MDM4	 1	 1	 NaN	 1	
MGMT	 0	 0	 NaN	 NaN	
MMP1	 0	 1	 1	 1	
MMP13	 1	 1	 1	 1	
MMP2	 1	 1	 1	 1	
MSH2	 1	 1	 1	 1	
MTA2	 NaN	 NaN	 NaN	 NaN	
MUC1	 NaN	 NaN	 NaN	 NaN	
MYC			 1	 1	 1	 1	
MYCN	 1	 1	 1	 1	
MYST4	 1	 0	 1	 0	
NCL			 1	 NaN	 1	 NaN	
NLRC4	 1	 1	 NaN	 NaN	
NME1	 1	 1	 1	 1	
NOTCH1	 1	 1	 1	 1	
NOV			 1	 1	 NaN	 NaN	
NR2C1	 1	 1	 1	 1	
NTN1	 NaN	 NaN	 NaN	 NaN	
OP18	 0	 0	 NaN	 NaN	
p53	 1	 1	 0	 0	
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p53AIP1	 1	 1	 NaN	 NaN	
PAD4	 NaN	 NaN	 NaN	 NaN	
PADI4	 NaN	 NaN	 NaN	 NaN	
PARK2	 1	 0	 NaN	 0	
PCBP4	 1	 1	 NaN	 NaN	
PCNA	 1	 1	 1	 1	
PDGFRB	 0	 0	 1	 0	
PDRG1	 0	 0	 NaN	 NaN	
PEG3	 1	 1	 NaN	 NaN	
PERP	 1	 1	 NaN	 NaN	
PHF20	 NaN	 NaN	 NaN	 NaN	
PIAS2	 NaN	 NaN	 NaN	 NaN	
PITX1	 1	 0	 1	 0	
PLAUR	 1	 1	 1	 1	
PML	 1	 1	 1	 0	
POU4F1	 NaN	 NaN	 NaN	 NaN	
PPARG	 NaN	 NaN	 NaN	 NaN	
PPID	 NaN	 NaN	 NaN	 NaN	
PPM1A	 NaN	 NaN	 NaN	 NaN	
PPM1D	 1	 1	 NaN	 NaN	
PRAK	 0	 1	 0	 1	
PRC1	 0	 0	 NaN	 NaN	
PREP1	 NaN	 NaN	 NaN	 NaN	
PRKCA	 1	 1	 NaN	 NaN	
PRKD1	 1	 0	 1	 0	
PRKDC	 1	 0	 1	 0	
PRKG1	 1	 1	 NaN	 NaN	
PRSS50	 0	 0	 NaN	 NaN	
PSEN1	 1	 1	 1	 1	
PSMD10	 NaN	 NaN	 NaN	 NaN	
PTEN	 1	 1	 NaN	 NaN	
PTGS2	 1	 1	 1	 1	
PTTG1	 0	 1	 0	 1	
RAD51	 0	 0	 0	 0	
RAF1	 1	 1	 1	 1	
RAS			 1	 1	 1	 1	
RB1CC1	 NaN	 NaN	 NaN	 NaN	
RECQL4	 0	 0	 NaN	 NaN	
RFC	 NaN	 NaN	 NaN	 NaN	
RGS16	 1	 1	 NaN	 NaN	
RPRM	 1	 1	 NaN	 NaN	
RREB1	 NaN	 NaN	 NaN	 NaN	
RRM2B	 1	 1	 NaN	 NaN	
S100A2	 1	 1	 NaN	 NaN	
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S100A6	 0	 0	 NaN	 NaN	
S100B	 NaN	 NaN	 NaN	 NaN	
SEMA3B	 1	 1	 NaN	 NaN	
SERPINB5	 1	 1	 NaN	 NaN	
SERPINF1	 1	 1	 1	 1	
SESN2	 1	 1	 NaN	 NaN	
SET	 NaN	 NaN	 NaN	 NaN	
SFN			 1	 1	 NaN	 NaN	
SGK			 1	 1	 1	 1	
SIAH1	 1	 1	 1	 1	
SIVA1	 1	 1	 1	 1	
SLC2A1	 1	 1	 1	 1	
SLC2A4	 0	 0	 NaN	 NaN	
SLC6A6	 0	 0	 NaN	 NaN	
SOX4	 1	 0	 1	 0	
SP7			 0	 0	 NaN	 NaN	
STAT3	 NaN	 NaN	 NaN	 NaN	
STMN1	 0	 1	 0	 1	
SUB1	 NaN	 NaN	 NaN	 NaN	
SUMO2	 NaN	 NaN	 NaN	 NaN	
TCF7L2	 NaN	 NaN	 NaN	 NaN	
TFAP2A	 1	 1	 1	 0	
TFAP2C	 1	 1	 NaN	 NaN	
TFDP1	 0	 0	 NaN	 NaN	
TGFA	 1	 1	 1	 1	
TGFB1	 1	 1	 1	 1	
THBS1	 1	 1	 1	 1	
TIAF1	 NaN	 NaN	 NaN	 NaN	
TLR3	 1	 1	 NaN	 NaN	
TNFRSF10A	 1	 1	 1	 1	
TNFRSF10B	 1	 1	 1	 1	
TP53BP1	 1	 0	 NaN	 NaN	
TP53I13	 1	 1	 NaN	 NaN	
TP53INP1	 1	 1	 NaN	 NaN	
TP53RK	 NaN	 NaN	 NaN	 NaN	
TPT1	 1	 1	 NaN	 NaN	
UBE2A	 1	 0	 1	 0	
UCHL1	 NaN	 NaN	 NaN	 NaN	
UNC5A	 1	 1	 1	 0	
VEGFA	 1	 1	 1	 1	
VRK1	 NaN	 NaN	 NaN	 NaN	
WWP1	 0	 0	 NaN	 NaN	
XAF1	 0	 0	 NaN	 NaN	
YBX1	 1	 1	 NaN	 1	
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YY1	 NaN	 NaN	 NaN	 NaN	
ZMAT3	 1	 1	 NaN	 NaN	
ZNF307	 NaN	 NaN	 NaN	 NaN	
	
	
7.2.2.2	Genome	wide	analysis	and	validation	of	the	PMH260	model		
The	Boolean	PKT206-	DNA	damage	model	has	generated	good	predictive	ratios	when	
compared	to	transcriptome	data	(Tian	et	al.2013).	Thus,	we	investigated	the	predictive	
potential	of	the	expanded	logical	model	(PMH260)	to	predict	differential	gene	changes	
when	compared	to	the	exact	transcriptome	data	as	applied	in	Tian	et	al.	(2013)	using	
node	expression	results	generated	from	in	silico	LSSA	of	PMH260	(table	7.2.7).		
	
Microarray	profiles	of	untreated	and	etoposide	(10	µM)	treated	human	osteosarcoma	
cell	lines;	SaOS2	(p53	-/-)	and	U2OS	(p53	+/+)	available	in	(Tian	et	al.2013)	and	
untreated	HCT116	(p53	wild	type	and	null)	colon	cancer	cell	lines	from	the	Gene	
Expression	Omnibus	(GSE10795)	were	compared	against	the	PMH260	interactome.	The	
fold	change	and	expression	profiles	of	both	transcriptomes	in	vitro	and	in	silico	LSS	
data	were	calculated	in	accordance	with	Christensen	et	al.	(2009)	and	Tian	et	al.	(2013).	
This	formula	is	discussed	in	detail	in	material	and	methods,	section	6.3.1.		
A	total	of	202	genes	were	filtered	from	osteosarcoma	and	172	from	HCT116	colon	
cancer	transcriptome	profiles.	Comparing	osteosarcoma	in	vitro	to	in	silico	LSSA	
expression	results,	correct	predictions	were	in	the	majority	ranging	between	55	to	71	%	
dependant	on	simulation,	with	an	average	of	61.2	%	when	considering	all	simulations.	
Large	errors	occupied	the	minority,	resulting	in	less	than	5	%	for	all	predictions	
(average,	2.9	%).	Small	errors	comprised	35	%	when	considering	all	simulations.		Less	
correct	predictions	were	derived	for	HCT116	simulation	(55	%	correct).	Table	7.2.8	and	
figure	7.2.1	summarise	the	total	number	and	percentage	of	all	predictions	respectively.		
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Table	7.2.8	Total	number	of	all	predictions	from	comparison	of	in	silico	data	to	in	vitro	
microarray	profiles.	Correct	predictions	were	in	the	majority	across	all	simulations	with	large	
errors	occupying	a	small	percentage	of	results	when	comparing	osteosarcoma	transcriptome	
profiles	to	in	silico	data	under	LSSA.	Table	represents	total	numbers	from	osteosarcoma	(n	=	
202)	HCT116	(n=	172).		
Experimental	
Source	
Experimental	
Target	
Model	LSSA	in	silico	
simulation		 Correct	
Small	
error	 Large	error	
	   
	
Total	number	
U2OS	cells	with	
DNA	damage	
SaOS2	cells	with	
DNA	damage	
p53	wild	type	DNA	
damage	ON	vs.	p53	KO	
DNA	damage	ON	 111	 82	 9	
U2OS	cells	no	
DNA	damage	
SaOS2	cells	no	
DNA	damage	
p53	wild	type	DNA	
damage	OFF	vs.	p53	KO	
DNA	damage	OFF	 117	 75	 10	
U2OS	cells	no	
DNA	damage	
U2OS	cells	with	
DNA	damage	
	p53	wild	type	DNA	
damage	OFF	vs.	p53	
wild	type	DNA		damage	
ON	 142	 59	 1	
SaOS2	cells	no	
DNA	damage	
SaOS2	cells	with	
DNA	damage	
	p53	KO	DNA	damage	
OFF	vs.	p53	KO	DNA	
damage	OFF	 136	 64	 2	
HCT116	p53	
(+/+)	no	DNA	
damage	
HCT116	p53	
(+/+)	no	DNA	
damage	
p53	WT	DNA	damage	
OFF	vs.	p53	KO	DNA	
damage	OFF		 94.5	 72.5	 5	
	
	
Figure	7.2.1	Percentage	of	all	predictions	from	comparison	of	in	silico	data	to	in	vitro	
osteosarcoma	microarray	profiles.		
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The	differential	gene	expression	changes	in	human	osteosarcoma	cells	untreated	and	
treated	with	10	µM	etoposide	(24	h)	were	further	explored.		In	general,	the	majority	of	
genes	remained	unchanged	across	all	three	simulations.		Of	the	‘no	changes’,	the	
model	predicted	the	majority	as	correct.	Several	genes	that	were	correctly	predicted	
were	belonging	to	the	growth	factor	family	or	growth	factor	regulated	genes,	such	as	
FGF2	and	EPHB4,	and	along	with	PTGS2,	IGF1R	and	PDGFRB,	and	were	differentially	
expressed	dependant	on	cell	type	and	p53	status.	For	example,	FGF2	was	
downregulated	in	SaOS2	(p53	-/-)	cells,	conversely,	anti-apoptotic	genes,	PDGFRB,	
IGF1R,	EPHB4	and	PTGS2	were	all	upregulated	in	SaOS2	cells.	However,	the	input	of	
differentially	expressed	genes	into	the	DAVID	functional	annotation	tool	derived	no	
significant	over	represented	pathways	of	interest	for	each	experimental	condition.	
Table	7.2.9	summarises	differential	gene	expression	changes	in	osteosarcoma	
transcriptome	profiles	using	the	formula	in	accordance	with	Christensen	et	al.	(2009).		
	
Table	7.2.9	Global	list	of	genes	differentially	expressed	in	untreated	and	etoposide	treated	
human	osteosarcoma	cell	lines.	In	accordance	with	Christensen	et	al.	(2009),	three	different	
changes	were	possible;	upregulated,	downregulated	or	unchanged	between	in	vitro	to	in	silico	
data.		
Experimental	condition	 Upregulated	 Downregulated	 Unchanged	
U2OS	cells	with	DNA	damage	vs.	
SaOS2	cells	with	DNA	damage	
Total	number	
	 19	 21	 162	
	 AR	 ABCB1	 AATF	
	 CDKN2A	 BTG2	 ABCC1	
	 CKM	 C12orf5	 AIFM2	
	 COL18A1	 CCND1	 APAF1	
	 DDIT4	 CD44	 ARID3A	
	 DKK1	 CDKN1A	 ATF3	
	 DYRK2	 DDB2	 ATM	
	 HIPK2	 DFNA5	 ATR	
	 ID3	 DUSP2	 AURKA	
	 IFITM2	 FAS	 AXIN1	
	 IGF1R	 FDXR	 BAK1	
	 IGFBP7	 FGF2	 BAX	
	 ISG15	 FHL2	 BBC3	
	 KLF4	 MGMT	 BCL2	
	 RPRM	 PEG3	 BCL3	
	 SEMA3B	 RRM2B	 BCL6	
	 SOX4	 S100A2	 BDKRB1	
	 147	
	 SP7	 SERPINF1	 BNIP3L	
	 TNFRSF10A	 SFN	 BRCA1	
	 	 THBS1	 C13orf15	
	 	 TNFRSF10B	 CALD1	
	 	 	 CASP8	
	 	 	 CCNA	
	 	 	 CCNB1	
	 	 	 CCNG1	
	 	 	 CD58	
	 	 	 CD59	
	 	 	 CD82	
	 	 	 CDC20	
	 	 	 CDC25A	
	 	 	 CDK2	
	 	 	 CDK4	
	 	 	 CDK5	
	 	 	 CDK9	
	 	 	 CDKN1B	
	 	 	 CHEK1	
	 	 	 CHEK2	
	 	 	 CIAPIN1	
	 	 	 CKB	
	 	 	 CKS2	
	 	 	 CSNK2	
	 	 	 CXCR4	
	 	 	 DDX5	
	 	 	 DUSP4	
	 	 	 DUSP5	
	 	 	 E2F1	
	 	 	 ECT2	
	 	 	 EDA2R	
	 	 	 EGFR	
	 	 	 EIF2AK2	
	 	 	 ELAVL1	
	 	 	 EPHB4	
	 	 	 ERBB2	
	 	 	 ESR1	
	 	 	 EZH2	
	 	 	 FEN1	
	 	 	 FOS	
	 	 	 FOXM1	
	 	 	 GADD45A	
	 	 	 GAPDH	
	 	 	 GSTP1	
	 148	
	 	 	 GTSE1	
	 	 	 H2AFZ	
	 	 	 HDAC1	
	 	 	 HIC1	
	 	 	 HIF1A	
	 	 	 HIPK4	
	 	 	 HMMR	
	 	 	 HNF4A	
	 	 	 HOXA11	
	 	 	 HSP90AB1	
	 	 	 HSPA4	
	 	 	 HTATIP2	
	 	 	 ICAM1	
	 	 	 IER3	
	 	 	 IFI16	
	 	 	 IFNA1	
	 	 	 IGFBP1	
	 	 	 IL6	
	 	 	 IQCB1	
	 	 	 KAT2B	
	 	 	 KRT19	
	 	 	 KRT8	
	 	 	 LATS2	
	 	 	 LRDD	
	 	 	 LTF	
	 	 	 MAP4	
	 	 	 MAP4K4	
	 	 	 MAPK1	
	 	 	 MAPK14	
	 	 	 MAPK8	
	 	 	 MAPK9	
	 	 	 MCL1	
	 	 	 MCTS1	
	 	 	 MDM2	
	 	 	 MDM4	
	 	 	 MMP1	
	 	 	 MMP13	
	 	 	 MMP2	
	 	 	 MSH2	
	 	 	 MUC1	
	 	 	 MYC	
	 	 	 MYCN	
	 	 	 NCL	
	 	 	 NLRC4	
	 149	
	 	 	 NME1	
	 	 	 NOTCH1	
	 	 	 NOV	
	 	 	 NR2C1	
	 	 	 NTN1	
	 	 	 PADI4	
	 	 	 PARK2	
	 	 	 PCBP4	
	 	 	 PCNA	
	 	 	 PDGFRB	
	 	 	 PDRG1	
	 	 	 PERP	
	 	 	 PLAUR	
	 	 	 POU4F1	
	 	 	 PPM1A	
	 	 	 PPM1D	
	 	 	 PRC1	
	 	 	 PRKCA	
	 	 	 PRKD1	
	 	 	 PRKDC	
	 	 	 PRKG1	
	 	 	 PRSS50	
	 	 	 PSEN1	
	 	 	 PSMD10	
	 	 	 PTEN	
	 	 	 PTGS2	
	 	 	 PTTG1	
	 	 	 RAD51	
	 	 	 RAF1	
	 	 	 RAS	
	 	 	 RECQL4	
	 	 	 RGS16	
	 	 	 RREB1	
	 	 	 S100A6	
	 	 	 SERPINB5	
	 	 	 SESN2	
	 	 	 SGK1	
	 	 	 SIAH1	
	 	 	 SIVA1	
	 	 	 SLC2A1	
	 	 	 SLC2A4	
	 	 	 SLC6A6	
	 	 	 TCF7L2	
	 	 	 TFDP1	
	 150	
	 	 	 TGFA	
	 	 	 TGFB1	
	 	 	 TIAF1	
	 	 	 TLR3	
	 	 	 TP53AIP1	
	 	 	 TP53I13	
	 	 	 TP53INP1	
	 	 	 VEGFA	
	 	 	 VRK1	
	 	 	 WWP1	
	 	 	 XAF1	
	 	 	 YBX1	
	 	 	 ZMAT3	
U2OS	cells	untreated	vs.	SaOS2	cells	
untreated	
Upregulated	 Downregulated	 Unchanged	
	 Total	number	
	 18	 18	 166	
	 CDK5	 ABCB1	 AATF	
	 CDKN2A	 CCND1	 ABCC1	
	 CKM	 CD44	 AIFM2	
	 COL18A1	 CDC20	 APAF1	
	 DKK1	 CDKN1A	 AR	
	 IFITM2	 DDB2	 ARID3A	
	 IGF1R	 DFNA5	 ATF3	
	 IGFBP7	 DUSP2	 ATM	
	 ISG15	 FDXR	 ATR	
	 KAT2B	 FGF2	 AURKA	
	 KLF4	 MGMT	 AXIN1	
	 MAP4	 PEG3	 BAK1	
	 RPRM	 S100A2	 BAX	
	 S100A6	 SERPINF1	 BBC3	
	 SEMA3B	 SFN	 BCL2	
	 SOX4	 SLC2A1	 BCL3	
	 SP7	 THBS1	 BCL6	
	 TNFRSF10A	 TNFRSF10B	 BDKRB1	
	 	 	 BNIP3L	
	 	 	 BRCA1	
	 	 	 BTG2	
	 	 	 C12orf5	
	 	 	 C13orf15	
	 	 	 CALD1	
	 	 	 CASP8	
	 	 	 CCNA	
	 	 	 CCNB1	
	 	 	 CCNG1	
	 151	
	 	 	 CD58	
	 	 	 CD59	
	 	 	 CD82	
	 	 	 CDC25A	
	 	 	 CDK2	
	 	 	 CDK4	
	 	 	 CDK9	
	 	 	 CDKN1B	
	 	 	 CHEK1	
	 	 	 CHEK2	
	 	 	 CIAPIN1	
	 	 	 CKB	
	 	 	 CKS2	
	 	 	 CSNK2	
	 	 	 CXCR4	
	 	 	 DDIT4	
	 	 	 DDX5	
	 	 	 DUSP4	
	 	 	 DUSP5	
	 	 	 DYRK2	
	 	 	 E2F1	
	 	 	 ECT2	
	 	 	 EDA2R	
	 	 	 EGFR	
	 	 	 EIF2AK2	
	 	 	 ELAVL1	
	 	 	 EPHB4	
	 	 	 ERBB2	
	 	 	 ESR1	
	 	 	 EZH2	
	 	 	 FAS	
	 	 	 FEN1	
	 	 	 FHL2	
	 	 	 FOS	
	 	 	 FOXM1	
	 	 	 GADD45A	
	 	 	 GAPDH	
	 	 	 GSTP1	
	 	 	 GTSE1	
	 	 	 H2AFZ	
	 	 	 HDAC1	
	 	 	 HIC1	
	 	 	 HIF1A	
	 	 	 HIPK2	
	 152	
	 	 	 HIPK4	
	 	 	 HMMR	
	 	 	 HNF4A	
	 	 	 HOXA11	
	 	 	 HSP90AB1	
	 	 	 HSPA4	
	 	 	 HTATIP2	
	 	 	 ICAM1	
	 	 	 ID3	
	 	 	 IER3	
	 	 	 IFI16	
	 	 	 IFNA1	
	 	 	 IGFBP1	
	 	 	 IL6	
	 	 	 IQCB1	
	 	 	 KRT19	
	 	 	 KRT8	
	 	 	 LATS2	
	 	 	 LRDD	
	 	 	 LTF	
	 	 	 MAP4K4	
	 	 	 MAPK1	
	 	 	 MAPK14	
	 	 	 MAPK8	
	 	 	 MAPK9	
	 	 	 MCL1	
	 	 	 MCTS1	
	 	 	 MDM2	
	 	 	 MDM4	
	 	 	 MMP1	
	 	 	 MMP13	
	 	 	 MMP2	
	 	 	 MSH2	
	 	 	 MUC1	
	 	 	 MYC	
	 	 	 MYCN	
	 	 	 NCL	
	 	 	 NLRC4	
	 	 	 NME1	
	 	 	 NOTCH1	
	 	 	 NOV	
	 	 	 NR2C1	
	 	 	 NTN1	
	 	 	 PADI4	
	 153	
	 	 	 PARK2	
	 	 	 PCBP4	
	 	 	 PCNA	
	 	 	 PDGFRB	
	 	 	 PDRG1	
	 	 	 PERP	
	 	 	 PLAUR	
	 	 	 POU4F1	
	 	 	 PPM1A	
	 	 	 PPM1D	
	 	 	 PRC1	
	 	 	 PRKCA	
	 	 	 PRKD1	
	 	 	 PRKDC	
	 	 	 PRKG1	
	 	 	 PRSS50	
	 	 	 PSEN1	
	 	 	 PSMD10	
	 	 	 PTEN	
	 	 	 PTGS2	
	 	 	 PTTG1	
	 	 	 RAD51	
	 	 	 RAF1	
	 	 	 RAS	
	 	 	 RECQL4	
	 	 	 RGS16	
	 	 	 RREB1	
	 	 	 RRM2B	
	 	 	 SERPINB5	
	 	 	 SESN2	
	 	 	 SGK1	
	 	 	 SIAH1	
	 	 	 SIVA1	
	 	 	 SLC2A4	
	 	 	 SLC6A6	
	 	 	 TCF7L2	
	 	 	 TFDP1	
	 	 	 TGFA	
	 	 	 TGFB1	
	 	 	 TIAF1	
	 	 	 TLR3	
	 	 	 TP53AIP1	
	 	 	 TP53I13	
	 	 	 TP53INP1	
	 154	
	 	 	 VEGFA	
	 	 	 VRK1	
	 	 	 WWP1	
	 	 	 XAF1	
	 	 	 YBX1	
	 	 	 ZMAT3	
U2OS	cells	untreated	vs.	U2OS	cells	
with	DNA	damage	
Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 27	 22	 154	
	 ABCB1	 AR	 AATF	
	 BTG2	 AURKA	 ABCC1	
	 C12orf5	 CCNA	 AIFM2	
	 CD44	 CCNB1	 APAF1	
	 CD82	 CDC20	 ARID3A	
	 CDKN1A	 CDKN1B	 ATF3	
	 DDB2	 CDKN2A	 ATM	
	 DUSP2	 CHEK1	 ATR	
	 DUSP5	 CHEK2	 AXIN1	
	 FAS	 DDIT4	 BAK1	
	 FDXR	 ECT2	 BAX	
	 FHL2	 GTSE1	 BBC3	
	 FOS	 HMMR	 BCL2	
	 GADD45A	 HSP90AB1	 BCL3	
	 IER3	 ID3	 BCL6	
	 IL6	 MAPK9	 BDKRB1	
	 LRDD	 PEG3	 BNIP3L	
	 MAP4	 PRC1	 BRCA1	
	 MDM2	 SERPINF1	 C13orf15	
	 MMP1	 SIAH1	 CALD1	
	 PADI4	 TCF7L2	 CASP8	
	 PPM1D	 	 CCND1	
	 RRM2B	 	 CCNG1	
	 SFN	 	 CD58	
	 SGK1	 	 CD59	
	 TLR3	 	 CDC25A	
	 ZMAT3	 	 CDK2	
	 	 	 CDK4	
	 	 	 CDK5	
	 	 	 CDK9	
	 	 	 CIAPIN1	
	 	 	 CKB	
	 	 	 CKM	
	 	 	 CKS2	
	 	 	 COL18A1	
	 155	
	 	 	 CSNK2	
	 	 	 CXCR4	
	 	 	 DDX5	
	 	 	 DFNA5	
	 	 	 DKK1	
	 	 	 DUSP4	
	 	 	 DYRK2	
	 	 	 E2F1	
	 	 	 EDA2R	
	 	 	 EGFR	
	 	 	 EIF2AK2	
	 	 	 ELAVL1	
	 	 	 EPHB4	
	 	 	 ERBB2	
	 	 	 ESR1	
	 	 	 EZH2	
	 	 	 FEN1	
	 	 	 FGF2	
	 	 	 FOXM1	
	 	 	 GAPDH	
	 	 	 GSTP1	
	 	 	 H2AFZ	
	 	 	 HDAC1	
	 	 	 HIC1	
	 	 	 HIF1A	
	 	 	 HIPK2	
	 	 	 HIPK4	
	 	 	 HNF4A	
	 	 	 HOXA11	
	 	 	 HSPA4	
	 	 	 HTATIP2	
	 	 	 ICAM1	
	 	 	 IFI16	
	 	 	 IFITM2	
	 	 	 IFNA1	
	 	 	 IGF1R	
	 	 	 IGFBP1	
	 	 	 IGFBP7	
	 	 	 IQCB1	
	 	 	 ISG15	
	 	 	 KAT2B	
	 	 	 KLF4	
	 	 	 KRT19	
	 	 	 KRT8	
	 156	
	 	 	 LATS2	
	 	 	 LTF	
	 	 	 MAP4K4	
	 	 	 MAPK1	
	 	 	 MAPK14	
	 	 	 MAPK8	
	 	 	 MCL1	
	 	 	 MCTS1	
	 	 	 MDM4	
	 	 	 MGMT	
	 	 	 MMP13	
	 	 	 MMP2	
	 	 	 MSH2	
	 	 	 MUC1	
	 	 	 MYC	
	 	 	 MYCN	
	 	 	 NCL	
	 	 	 NLRC4	
	 	 	 NME1	
	 	 	 NOTCH1	
	 	 	 NOV	
	 	 	 NR2C1	
	 	 	 NTN1	
	 	 	 PARK2	
	 	 	 PCBP4	
	 	 	 PCNA	
	 	 	 PDGFRB	
	 	 	 PDRG1	
	 	 	 PERP	
	 	 	 PLAUR	
	 	 	 POU4F1	
	 	 	 PPM1A	
	 	 	 PRKCA	
	 	 	 PRKD1	
	 	 	 PRKDC	
	 	 	 PRKG1	
	 	 	 PRSS50	
	 	 	 PSEN1	
	 	 	 PSMD10	
	 	 	 PTEN	
	 	 	 PTGS2	
	 	 	 PTTG1	
	 	 	 RAD51	
	 	 	 RAF1	
	 157	
	 	 	 RAS	
	 	 	 RECQL4	
	 	 	 RGS16	
	 	 	 RPRM	
	 	 	 RREB1	
	 	 	 S100A2	
	 	 	 S100A6	
	 	 	 SEMA3B	
	 	 	 SERPINB5	
	 	 	 SESN2	
	 	 	 SIVA1	
	 	 	 SLC2A1	
	 	 	 SLC2A4	
	 	 	 SLC6A6	
	 	 	 SOX4	
	 	 	 SP7	
	 	 	 TFDP1	
	 	 	 TGFA	
	 	 	 TGFB1	
	 	 	 THBS1	
	 	 	 TIAF1	
	 	 	 TNFRSF10A	
	 	 	 TNFRSF10B	
	 	 	 TP53AIP1	
	 	 	 TP53I13	
	 	 	 TP53INP1	
	 	 	 VEGFA	
	 	 	 VRK1	
	 	 	 WWP1	
	 	 	 XAF1	
	 	 	 YBX1	
SaOS2	cells	untreated	vs	SaOS2	cells	
with	DNA	damage	
Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 30	 25	 147	
	 ATF3	 AURKA	 AATF	
	 BAX	 CCNB1	 ABCB1	
	 BBC3	 CCND1	 ABCC1	
	 BCL2	 CDC20	 AIFM2	
	 BRCA1	 CXCR4	 APAF1	
	 CDC25A	 ECT2	 AR	
	 CDK9	 FGF2	 ARID3A	
	 CDKN1A	 GADD45A	 ATM	
	 CHEK2	 HMMR	 ATR	
	 COL18A1	 IFNA1	 AXIN1	
	 158	
	 DDB2	 IL6	 BAK1	
	 DDIT4	 IQCB1	 BCL3	
	 DKK1	 KRT19	 BCL6	
	 EPHB4	 LTF	 BDKRB1	
	 HIPK2	 MAPK8	 BNIP3L	
	 IGF1R	 MAPK9	 BTG2	
	 IGFBP7	 MMP2	 C12orf5	
	 KLF4	 PARK2	 C13orf15	
	 MUC1	 PLAUR	 CALD1	
	 NOTCH1	 PRKCA	 CASP8	
	 PDGFRB	 PTTG1	 CCNA	
	 PRKDC	 S100A2	 CCNG1	
	 PTGS2	 SERPINF1	 CD44	
	 RAD51	 TGFA	 CD58	
	 SIVA1	 TP53INP1	 CD59	
	 TCF7L2	 	 CD82	
	 TLR3	 	 CDK2	
	 VRK1	 	 CDK4	
	 WWP1	 	 CDK5	
	 ZMAT3	 	 CDKN1B	
	 	 	 CDKN2A	
	 	 	 CHEK1	
	 	 	 CIAPIN1	
	 	 	 CKB	
	 	 	 CKM	
	 	 	 CKS2	
	 	 	 CSNK2	
	 	 	 DDX5	
	 	 	 DFNA5	
	 	 	 DUSP2	
	 	 	 DUSP4	
	 	 	 DUSP5	
	 	 	 DYRK2	
	 	 	 E2F1	
	 	 	 EDA2R	
	 	 	 EGFR	
	 	 	 EIF2AK2	
	 	 	 ELAVL1	
	 	 	 ERBB2	
	 	 	 ESR1	
	 	 	 EZH2	
	 	 	 FAS	
	 	 	 FDXR	
	 	 	 FEN1	
	 159	
	 	 	 FHL2	
	 	 	 FOS	
	 	 	 FOXM1	
	 	 	 GAPDH	
	 	 	 GSTP1	
	 	 	 GTSE1	
	 	 	 H2AFZ	
	 	 	 HDAC1	
	 	 	 HIC1	
	 	 	 HIF1A	
	 	 	 HIPK4	
	 	 	 HNF4A	
	 	 	 HOXA11	
	 	 	 HSP90AB1	
	 	 	 HSPA4	
	 	 	 HTATIP2	
	 	 	 ICAM1	
	 	 	 ID3	
	 	 	 IER3	
	 	 	 IFI16	
	 	 	 IFITM2	
	 	 	 IGFBP1	
	 	 	 ISG15	
	 	 	 KAT2B	
	 	 	 KRT8	
	 	 	 LATS2	
	 	 	 LRDD	
	 	 	 MAP4	
	 	 	 MAP4K4	
	 	 	 MAPK1	
	 	 	 MAPK14	
	 	 	 MCL1	
	 	 	 MCTS1	
	 	 	 MDM2	
	 	 	 MDM4	
	 	 	 MGMT	
	 	 	 MMP1	
	 	 	 MMP13	
	 	 	 MSH2	
	 	 	 MYC	
	 	 	 MYCN	
	 	 	 NCL	
	 	 	 NLRC4	
	 	 	 NME1	
	 160	
	 	 	 NOV	
	 	 	 NR2C1	
	 	 	 NTN1	
	 	 	 PADI4	
	 	 	 PCBP4	
	 	 	 PCNA	
	 	 	 PDRG1	
	 	 	 PEG3	
	 	 	 PERP	
	 	 	 POU4F1	
	 	 	 PPM1A	
	 	 	 PPM1D	
	 	 	 PRC1	
	 	 	 PRKD1	
	 	 	 PRKG1	
	 	 	 PRSS50	
	 	 	 PSEN1	
	 	 	 PSMD10	
	 	 	 PTEN	
	 	 	 RAF1	
	 	 	 RAS	
	 	 	 RECQL4	
	 	 	 RGS16	
	 	 	 RPRM	
	 	 	 RREB1	
	 	 	 RRM2B	
	 	 	 S100A6	
	 	 	 SEMA3B	
	 	 	 SERPINB5	
	 	 	 SESN2	
	 	 	 SFN	
	 	 	 SGK1	
	 	 	 SIAH1	
	 	 	 SLC2A1	
	 	 	 SLC2A4	
	 	 	 SLC6A6	
	 	 	 SOX4	
	 	 	 SP7	
	 	 	 TFDP1	
	 	 	 TGFB1	
	 	 	 THBS1	
	 	 	 TIAF1	
	 	 	 TNFRSF10A	
	 	 	 TNFRSF10B	
	 161	
	 	 	 TP53AIP1	
	 	 	 TP53I13	
	 	 	 VEGFA	
	 	 	 XAF1	
	 	 	 YBX1	
	
7.2.2.3	Dependency	matrix	changes	from	in	silico	knockout	analysis		
As	good	predictive	ratios	were	achieved	from	superimposition	of	in	vitro	transcriptome	
data	to	the	interactome,	we	further	explored	the	effect	of	in	silico	node	knockout	on	
the	PMH260	network.		The	in	silico	deletion	of	a	particular	node	can	mimic	in	vivo	loss	
of	functions	and	mutations,	and	as	such	represent	a	novel	tool	for	identifying	
deregulated	genes	or	pathways	from	their	loss.		To	investigate	network	perturbations	
from	absence	of	a	particular	node	in	PMH260,	3	in	silico	knockout	tests	of	highly	
connected	nodes	(MDM2,	p53	and	FGF2)	were	undertaken.	The	effect	of	a	node	
deletion	on	a	given	network	can	result	in	six	dependency	relationship	changes,	defined	
by	six	values	(1-	6)	described	in	detail	in	section	6,	material	and	methods,	summarised	
here	in	table	7.2.9.1.	
	
Table	7.2.9.1	Alterations	in	the	dependency	matrix	in	response	to	3	node	deletions	
3	nodes	were	deleted	from	the	PMH260	network.	The	numbers	of	six	types	of	effect	
elements	in	the	dependency	matrix	were	calculated	as	listed	below	which	represent	
the	6	relationships	described	in	effect	row.	The	value	“Null”	in	the	selected	gene	
column	indicates	the	p53	wild	type	network.	KO	=	knockout.		
Effect	
No	
Effect	
Ambival
ent	
Weak	
inhibitor	
Weak	
activator	
Strong	
inhibitor	
Strong	
activator	
Total	
Number	
effect	 1	 2	 3	 4	 5	 6	
	
In	silico	
KO	 	 	 	 	 	 	
	
Null	 40653	 20988	 2761	 3048	 48	 102	 67600	
p53	 59864	 6862	 38	 79	 71	 167	 67081	
MDM2	 40607	 20359	 2847	 3116	 48	 48	 67081	
FGF2	 40462	 20722	 2725	 3022	 48	 102	 67081	
	
The	total	number	of	dependencies	(n	=	67,600)	(260	×	260)	represents	elements	in	the	
dependency	matrix	of	the	PMH260	p53	wild	type	model	(null).	Of	these,	40653	
correspond	to	interactions	with	no	effect,	20988	are	ambivalent	factors,	2761	are	weak	
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inhibitors,	3048	are	weak	activators,	48	comprising	strong	inhibitors	and	102	strong	
activators.	For	each	in	silico	knockout	scenario	the	total	number	(n	=	67,081)	
represents	elements	within	the	network	after	node	deletion	(259	x	259).	We	focused	
on	changes	to	either	strong	activators	or	inhibitors	as	these	have	the	greatest	effect	on	
the	cell.		
	
The	majority	of	changes	were	derived	as	a	result	of	p53	deletion.	The	removal	of	p53	
resulted	in	a	two-fold	increase	from	the	number	of	strong	inhibitors	(48	in	p53	wild	
type	to	71	in	p53	knockout)	(table	7.2.9.1).	In	comparison,	p53s	negative	regulator,	
MDM2,	which	is	contained	within	an	intricate	feedback	loop	with	p53,	induced	only	
two	changes	when	deleted.		The	majority	of	the	dependency	changes	derived	from	in	
silico	p53	knockout	scenario	were	changes	to	strong	activators	(n	=	65)	and	strong	
inhibitors	(n	=	23),	from	ambivalent	factors	in	the	wild	type	model.	Interestingly,	
several	nodes	changed	from	having	no	influence	on	angiogenesis	in	the	wild	type	
scenario	to	having	a	strong	inhibitory	(COL181A,	PPARG	and	PML),	or	activating	
(MAPK14,	MMP2,	MMP13,	NTN1,	S100B,	SGK,	PRAK	and	STMN1)	angiogenic	effect	in	
the	absence	of	p53.		Similarly,	TFDP1,	GTSP1	and	EZH2	had	no	influence	on	cell	cycle	
arrest	in	the	presence	of	p53,	however	the	exclusion	of	p53	resulted	in	all	three	nodes	
changing	to	positive	regulators	of	cell	cycle	arrest	(table	7.2.9.2).	For	MDM2	KO,	one	
dependency	change	to	strong	activator	was	observed	(ATM	to	DYRK2).	No	changes	
were	observed	as	a	result	of	FGF2	deletion.		
	
As	a	result,	a	total	of	98	changes	were	derived	from	the	3	in	silico	knockout	tests,	of	
these,	the	majority	arose	from	p53	deletion.	To	validate	these	potential	predictions,	
scientific	literature	searches	were	undertaken.	As	a	consequence,	13	from	the	total	98	
were	confirmed	by	literature	or	experimentally	verified.		The	remaining	were	
considered	as	potential	novel	predictions	(PNPs).	Table	7.2.9.2	lists	all	predictions	with	
their	status	and	reference	if	validated	by	literature.	
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Table	7.2.9.2	Summary	of	predictions	derived	from	application	of	in	silico	knockout	tests	of	3	
nodes	(p53,	FGF2	and	MDM2)	to	dependency	matrix	elements.	98	predictions	were	obtained	
from	3	in	silico	deletions	of	highly	connected	nodes.	The	greatest	change	was	seen	in	the	
absence	of	p53.	Some	predictions	were	verified	from	literature	or	laboratory	experiments;	
others	are	potential	novel	predictions	(PNP).	Null	=	wildtype	model			
Deleted	
node	
Source	
node	 Target	 Null	 Knockout	 Prediction	
p53	 LATS2	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 Ke	et	al.	2004	
p53	 CCAR1	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 DAP	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 DYRK2	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 FAS	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 ING4	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 ING5	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 KAT2B	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 PAD4	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 UCHL1	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 Jin	et	al.	2013	
p53	 PPARG	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 Fjas	et	al.	2003	
p53	 PML	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 Yang	et	al.	2002	
p53	 TFAP2A	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	
Wajapeyee	and	
Somasundrum	2003	
p53	 ASSP1	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 ASSP2	 Apoptosis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 DAXX	 Apoptosis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 RB1CC1	 Apoptosis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 SGK	 Apoptosis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 STAT3	 Apoptosis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 PREP1	 Apoptosis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 CUL7	 Apoptosis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 PRAK	 Apoptosis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
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p53	 FOXM1	 CCNB1	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 KLF4	 CCNB1	
Ambivalent	
factor	
Strong	
inhibitor	 Yoon	et	al.	2004	
p53	 SFN	 CCNB1	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 FGF2	 CDK4	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 IFNA1	 CDK4	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 PTTG1	 CDK4	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 ATM	 CHK1	
Ambivalent	
factor	
Strong	
activator	 Tian	et	al.2013	
p53	 ATR	 CHK1	
Ambivalent	
factor	
Strong	
activator	 Tian	et	al.2013	
p53	 PPM1D	 CHK1	
Weak	
inhibitor	
Strong	
activator	 PNP	
p53	 IFNA1	 FAS	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 IFNA1	 TLR3	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 IFNA1	 FAS	
Ambivalent	
factor	
Strong	
inhibitor	 PNP		
p53	 PTTG1	 FGF2	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 MAPK14	 BAX	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 MAPK14	 MMP2	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 DYRK2	 p53AIP1	
Weak	
activator	
Strong	
activator	 PNP	
p53	 MAPK14	 SGK	
Weak	
activator	
Strong	
activator	 PNP	
p53	 RFC	 DNA	Repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 SOX4	 DNA	Repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 TP53BP1	 DNA	Repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 UBE2A	 DNA	Repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 YY1	 DNA	Repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 HOXA5	 DNA	Repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 PML	 DNA	Repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	
COL181
A	 Angiogenesis	 No	effect	
Strong	
inhibitor	 PNP	
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p53	 ING4	 Angiogenesis	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 PPARG	 Angiogenesis	 No	effect	
Strong	
inhibitor	 PNP	
p53	 PML	 Angiogenesis	 No	effect	
Strong	
inhibitor	 PNP	
p53	 JUN	 Angiogenesis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 MAPK14	 Angiogenesis	 No	effect	
Strong	
activator	 PNP	
p53	 MMP13	 Angiogenesis	 No	effect	
Strong	
activator	 PNP	
p53	 NTN1	 Angiogenesis	 No	effect	
Strong	
activator	 PNP	
p53	 S100B	 Angiogenesis	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 MMP2	 Angiogenesis	 No	effect	
Strong	
activator	 PNP	
p53	 SGK	 Angiogenesis	 No	effect	
Strong	
activator	 PNP	
p53	 PRAK	 Angiogenesis	 No	effect	
Strong	
activator	 PNP	
p53	 STMN1	 Angiogenesis	 No	effect	
Strong	
activator	 PNP	
p53	 JUN	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 ING5	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 IER3	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 BCCIP	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 DDX5	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 PITX1	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 RFC	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 SOX4	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 UBE2A	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 MYST4	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 ING4	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 KAT2B	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 PPARG	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
	 166	
p53	 TFAP2A	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 Scibetta	et	al.	2010	
p53	 TFAP2C	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 EZH2	
Cell	cycle	
arrest	 No	effect	
Strong	
activator	 PNP	
p53	 GSTP1	
Cell	cycle	
arrest	 No	effect	
Strong	
activator	 PNP	
p53	 RB1CC1	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 TFDP1	
Cell	cycle	
arrest	 No	effect	
Strong	
activator	 PNP	
p53	 CUL7	
Cell	cycle	
arrest	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 MAPK14	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 PPMID	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 DAXX	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 SGK	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	 LATS2	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
activator	 Tschop	et	al.	2011	
p53	 UCHL1	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 PPARG	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 PML	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
activator	 Scaglioni	et	al.	2012	
p53	 CUL7	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	 PRAK	
Cellular	
senescence	
Ambivalent	
factor	
Strong	
activator	 PNP	
	p53	 BCCIP	 DNA	repair	
Ambivalent	
factor	
Strong	
activator	 PNP	
	p53	
DNA	
damage	 CHK1	
Ambivalent	
factor	
Strong	
activator	 Reindhart	et	al.	2007	
p53	
DNA	
damage	 FAS	
Ambivalent	
factor	
Strong	
activator	 Manna	et	al.	2011	
p53	
DNA	
damage	 FGF2	
Ambivalent	
factor	
Strong	
inhibitor	 PNP	
p53	
DNA	
damage	 PML	
Ambivalent	
factor	
Strong	
activator	 PNP	
p53	
DNA	
damage	 TFAP2A	
Strong	
activator	 AF	 PNP	
p53	
DNA	
damage	 PRAK	 No	effect	
Strong	
inhibitor	 PNP	
MDM2	 ATM	 DYRK2	
Ambivalent	
factor	
Strong	
activator	 PNP	
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7.2.3	Conclusion		
The	tumour	suppressor	p53	has	a	well-defined	role	for	maintaining	genomic	integrity	
(Zilfou,	2009)	and	its	mutation	is	the	most	frequently	observed	in	over	half	of	all	
human	cancers.	p53	is	pivotal	to	anti-proliferative	processes,	critical	to	tumour	
suppression	and	typically	confers	sensitivity	to	chemo-therapeutic	intervention	(Lu	and	
El-Diery,	2009).	Thus,	p53	is	an	attractive	target	for	anti	-	cancer	drug	discovery	and	
targeted	strategies.	Nevertheless,	the	complexity	and	vast	literature	base	of	p53	and	its	
regulatory	pathways	makes	it	challenging	to	fully	elucidate	p53	–	cancer	dynamics.	
Thus	there	is	a	need	to	integrate	this	information	at	the	molecular	level	into	a	coherent	
framework.		
	
Systems	biology	teamed	with	traditional	reductionist	approaches	are	novel,	yet	
promising	tools	to	dissect	and	describe	the	complexity	of	disease	systems	such	as	
cancer	(Wang,	2010).		Boolean	networks	are	a	promising	predictive	framework	and	
have	been	applied	successfully	to	model	various	biological	phenomena.	In	particular,	
the	Boolean	model	-	PKT206	has	demonstrated	good	predictive	capability	when	
compared	to	transcriptome	data	for	p53	–	DNA	damage	pathways	(Tian	et	al.2013).	
Even	so,	the	p53	network	is	extensive,	with	a	plethora	of	p53	responsive	genes	
described	(Riley	et	al.2008).	To	capture	these,	a	larger	model	is	necessitated.	Extensive	
models	allow	for	a	global	system	overview	and	thus	better	representation	of	biological	
phenomena.			
	
With	this	in	mind,	we	expanded	the	PKT206	model	to	generate	the	preliminary	model	-	
PMH260	which	considers	980	interactions	of	activation	or	inhibition	amongst	254	
internal	nodes.	In	addition,	we	included	an	additional	3	outputs	of	DNA	repair,	
angiogenesis	and	cell	cycle	arrest	to	consider	the	heterogeneity	of	cancer	dynamics	
and	the	processes	that	govern	them.	We	undertook	in	silico	knock	out	tests	of	highly	
connected	nodes,	and	tested	the	predictive	efficiency	of	PMH260	on	a	genome	wide	
level	against	LSSA	data,	superimposing	exact	transcriptome	data	as	used	by	Tian	et	al.	
(2013)	to	determine	if	the	larger	Boolean	model	can	effectively	identify	p53	system	
attributes.	This	section	confirms	that	PMH260	can	effectively	identify	overall	system	
attributes.			
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Under	LSSA,	several	characteristic	nodes	were	differentially	expressed	strengthening	
the	models	capability	to	correctly	identify	system	attributes.	For	example,	in	response	
to	DNA	damage	and	p53	presence,	ATM	and	ATR	both	well-established	DNA	damage	
responsive	genes	were	upregulated	when	the	in	silico	DNA	damage	input	was	switched	
ON.	Similarly,	for	the	p53	target,	p21	was	upregulated.	With	regard	to	well	
characterised	p53	regulated	apoptotic	genes,	both	FAS	and	PUMA	were	upregulated	in	
p53	wildtype	backgrounds	(table	7.2.9).		
	
To	mimic	in	vivo	mutations	and	elucidate	the	role	of	deleted	nodes	on	the	PMH260	
network,	we	imposed	three	in	silico	knockout	tests	of	highly	connected	nodes	using	
CNA.	The	greatest	effect	was	observed	with	p53	exclusion,	resulting	in	98	changes.	
Conversely,	only	one	change	was	as	a	result	of	MDM2	removal,	and	no	strong	
dependency	changes	occurred	with	the	deletion	of	FGF2.	This	was	also	observed	in	the	
PKT206	model	using	the	same	in	silico	knockout	approach	(Tian	et	al.2013).	This	is	not	
surprising	considering	that	p53	is	the	most	highly	connected	‘hub’	node	in	the	network,	
and	participates	in	the	majority	of	feedback	loops	(>50	%)	and	interactions.		
The	effect	of	p53	on	network	stability	was	further	highlighted	by	the	fact	that	several	
nodes	altered	from	having	no	angiogenic	effect	to	a	positive	influence	on	angiogenesis	
in	the	absence	of	p53	(MAPK14,	MMP2,	MMP13,	NTN1,	S100B,	SGK,	PRAK	and	STMN1)	
(table	7.2.9.1).	These	are	interesting	findings	and	offer	potential	for	further	
investigation	in	p53	null	tumours.	Similarly,	two	nodes	changed	from	having	no	
influence	on	the	cell	cycle	in	the	wild	type	model	to	positive	cell	cycle	regulators	when	
p53	was	deleted	from	the	network.	All	these	genes	were	classified	as	PNPs,	however	
are	worthy	of	further	investigation,	in	particular	for	p53	mutated	tumours.		
We	performed	an	extensive	literature	search	for	potential	validations	of	the	98	
predictions	obtained	from	in	silico	tests.	Of	these,	13	were	confirmed	by	literature	or	
experimentally	verified	(table	7.2.9.1	provides	all	validated	references).	Of	the	24	
dependency	changes	described	in	PKT206	for	p53	in	silico	knockout,	22	(83	%)	in	
PMH260	were	in	agreement.	This	highlights	the	accuracy	and	reproducibility	of	the	p53	
interactome	when	enlarged.		Indeed,	majority	of	the	prediction	differences	from	
dependency	simulations	arose	from	new	nodes	introduced	into	PMH260.	This	is	
unsurprising,	as	additional	nodes	are	introduced,	dependencies	will	change.		
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As	PMH260	revealed	both	important	established	and	novel	predictions	that	could	be	of	
therapeutic	interest,	we	further	evaluated	its	predictive	potential.	We	superimposed	
the	exact	transcriptome	data	as	used	in	(Tian	et	al.2013),	and	compared	etoposide	
treated	and	untreated	human	osteosarcoma	and	HCT116	expression	profiles	to	the	
PMH260	interactome.	Good	prediction	ratios	were	derived	with	55-71	%	of	correct	
predictions	across	all	simulations.	This	number	significantly	exceeds	an	expected	
probability	of	33	%	for	a	random	model	which	has	three	possible	prediction	outcomes	
with	equal	probability	(Christensen	et	al.2009).		Predictive	ratios	here	are	similar	to	
those	obtained	from	the	PKT206	interactome.	This	is	promising,	as	the	model	increases	
so	does	network	complexity,	which	is	often	difficult	to	simulate	and	analyse.	
	
Comparing	differential	expression	profiles	of	apoptotic	and	angiogenic	factors	in	silico	
to	‘omics’	p53	wild	type	and	null	profiles	has	derived	several	important	predictions	of	
therapeutic	relevance.	For	example,	and	in	parallel	with	Tian	et	al.	(2013),	growth	
factors	were	also	uncovered	as	contributing	factors	to	osteosarcoma.	For	example,	the	
pro-angiogenic	and	apoptotic	ambivalent	factor	FGF2	was	down-regulated	in	SaOS2	
cells,	whilst	anti-apoptotic	PDFGRB	and	IGF1R,	along	with	growth	factor	regulated	
genes	EPHB4	and	PTGS2,	were	up-regulated	in	SaOS2	and	HCT116	cells,	suggestive	of	
cell	specific	regulation.	Indeed,	growth	factors	and	their	receptors	are	strongly	
implicated	in	osteosarcoma.	For	example;	PDGFRB	(McGary	et	al.2002)	and	EPHB4	
(Matsuo	and	Otaki,	2012).	Whilst,	Kujjier	et	al.	(2013)	has	shown	that	inhibition	of	
IGF1R	signalling	is	linked	to	reduced	proliferation	in	75	%	of	osteosarcoma	cell	lines,	
highlighting	that	inhibition	of	IGF1R	signalling	may	be	a	potential	anti-cancer	strategy	
in	high	grade	osteosarcoma	patients.	Proceeding	our	model	simulation	here	and	
implication	of	PTGS2	overexpression	in	osteosarcoma	cell	lines,	a	recent	study	by	Liu	et	
al.	(2015),	revealed	that	overexpression	of	PTGS2	is	linked	with	osteosarcoma	
metastasis.		These	results	strengthen	the	predictive	potential	of	the	expanded	model	
to	correctly	simulate	in	vitro	data,	and	along	with	previous	reports	our	results	highlight	
the	importance	of	growth	factors	in	p53	null	osteosarcoma	tumours.	Furthermore,	
several	novel	predictions	were	obtained	which	may	be	of	relevance	contributing	to	the	
p53	null	tumour	phenotype.	For	example,	8	genes	(described	above)	altered	to	pro-
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angiogenic	factors	when	p53	was	removed,	in	silico,	highlighting	their	potential	for	
further	investigation	for	putative	anti-cancer	targeted	strategies	in	osteosarcoma	p53	
null	tumours.			
	
In	summary,	PMH260	has	provided	increased	coverage	of	potential	expression	changes	
in	cancer,	and	validation	of	its	predictive	potential	through	comparison	to	in	vitro	
microarray	profiles	have	derived	good	results.	This	highlights	the	predictive	
performance	of	large-scale	Boolean	models	for	the	investigation	of	p53-DNA	damage	
inducible	pathways	and	offers	potential	to	further	expand	this	model	for	further	
increased	coverage	and	elucidation	of	p53	–	cancer	dynamics	using	logical	models.		
	
	
7.3	Generation	and	analyses	of	the	PMH302	model		
The	Boolean	p53	DNA	damage	inducible	models;	PMH260	(section	7.2)	and	the	earlier	
p53	model	generated	by	Tian	et	al.	(2013),	have	both	demonstrated	to	successfully	
predict	overall	p53	system	attributes.	For	example,	the	PMH260	Boolean	model,	
comprising	206	nodes	with	980	interactions	(Hussain	et	al.2015),	has	previously	
demonstrated	predictive	potential	of	p53	network	dynamics,	deriving	71	%	correct	
predictions	when	compared	to	various	in	vitro	microarray	profiles	of	etoposide	treated	
human	osteosarcoma	(p53	+/+),	(p53	-/-)	and	untreated	human	colon	cancer	(p53	+/+)	
and	(p53	-/-)	cell	lines.	Nevertheless,	as	previously	discussed,	the	p53	network	is	
extensive.	For	example,	1501	p53	responsive	genes	have	been	described	from	33615	
human	genes	on	cDNA	microarrays	by	Wang	et	al.	(2001)	also	in	(Riley	et	al.2008).	
Information	about	p53	interactions	at	the	molecular	level	must	be	integrated	with	the	
cell	environment	that	is	crucial	to	development	of	optimal	individualized	targeted	
therapies.	To	capture	these	and	depict	a	more	accurate	representation	of	the	
molecular	pathways	that	govern	p53	dynamics	a	larger	model	is	essential	to	dissect	the	
p53	–	cancer	network;	capture	mutation	drivers,	identify	perturbed	pathways	and	
create	sub	networks	of	cell/tissue	specific	models.	However,	larger	models	can	be	
difficult	to	simulate	due	to	network	complexity	and	size	(Klamt	et	al.2006).		
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In	addition,	whilst	the	PMH260	network	considers	five	biological	processes	that	
contribute	to	the	malignant	phenotype,	only	one	input	signal	of	DNA	damage	was	
included.	For	greater	clinical	representation,	models	must	incorporate	and	depict	
tumour	heterogeneity,	and	the	processes	that	regulate	and	govern	the	malignant	
phenotype.	Hypoxia	for	example	is	a	pathophysiological	feature	common	to	the	
majority	of	solid	tumours.	Genomic	instability	owing	to	hypoxic	conditions	allows	for	
the	activation	of	proliferative	signalling	pathways	involved	in,	for	example,	the	
regulation	of	angiogenesis	and	cell	death	contributing	to	tumour	progression	and	
survival.	Indeed,	tumour	hypoxia	has	been	associated	with	chemo-resistance	and	poor	
patient	survival	(Wilson	and	Hay,	2013).		
	
In	consideration	of	the	above,	and	given	the	fact	that	the	Boolean	PMH260	model	has	
successfully	identified	overall	system	attributes,	we	have	further	expanded	the	p53	
model	(PMH260)	to	generate	a	larger	model	designated	PMH302	(p53	Michelle	
Hussain	302	nodes).	In	addition,	to	capture	molecular	deviations	that	govern	tumour	
progression,	we	have	further	integrated	an	additional	input	of	hypoxia	into	PMH302.	
Thus	PMH302	may	be	more	representative	of	p53-cancer	dynamics	than	previous	
models.		
	
Given	the	fact	that	the	earlier	p53	logical	interactomes	have	all	derived	good	prediction	
percentages	when	compared	to	transcriptome	data,	we	used	the	same	mathematical	
principles	as	previously	applied	to	these	models.	We	aimed	to	evaluate	if	a	larger	
model	can	again	be	successfully	simulated	using	a	Boolean	framework	and,	
importantly,	if	greater	predictive	ratios	can	be	achieved.	In	addition,	as	the	earlier	
Boolean	p53	models	derived	good	predictive	potential	when	comparing	in	vitro	
expression	profiles,	we	aimed	to	extend	this	analyses	to	in	vivo	data	to	explore	the	
clinical	relevance	of	the	PMH302	model.		
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7.3.1	Results	
	
7.3.1.1	Generation	of	the	PMH302	model		
For	consistency,	we	followed	the	same	methodology	previously	used	for	generation	of	
all	earlier	p53	models	to	construct	the	PMH302	network.		All	potential	interactions	
direct	to	p53	and	indirect	(interactions	amongst	genes/proteins	surrounding	p53)	were	
extracted	from	the	STRING	database	(v9.1)	using	ULTRAEDIT,	filtered	in	accordance	
with	the	STRING	confidence	schema	of	a	0.7	threshold.		For	accuracy,	all	potential	
interactions	were	also	manually	curated	by	extensive	scientific	literature	search.	
Validation	of	all	interactions	were	additionally	confirmed	by	supervisor	(Prof.	M.	Krstic–	
Demonacos),	and	also	with	the	kind	help	of	Dr	Costas	Demonacos.		
	
Five	outputs	of	cell	cycle	arrest,	cellular	senescence,	DNA	repair,	angiogenesis	and	
apoptosis	are	considered	in	the	PMH302	model.		In	addition	to	the	DNA	damage	input	
already	included,	a	second	input	of	hypoxia	was	also	integrated.		Dependant	on	the	
biological	processes	they	regulate,	or	are	regulated	by,	all	internal	nodes	(n	=	295)	
were	linked	to	their	relevant	inputs	(n	=	2)	and	outputs	(n	=	5).	These	were	initially	
determined	by	their	GO	annotations	using	the	Gene	Ontology	database,	and	further	
confirmed	by	literature	evidence.		Table	7.3	summarises	all	interactions	between	nodes	
in	the	PMH302	model.	Figure	7.3	illustrates	the	PMH302	network	visualised	in	
Cytoscape	(v.28).	
	
7.3.1.2	Network	topology	of	PMH302	
Including	all	GO	annotations,	a	total	number	of	1398	interactions	of	activation	or	
inhibition	amongst	295	internal	nodes	(excluding	inputs	and	outputs,	n	=	7)	comprise	
the	PMH302	model.	Of	these,	898	comprised	activations,	the	remaining	(n	=	500)	are	
inhibitory	interactions.	295	nodes	were	linked	direct	to	p53.	Of	these,	p53	participated	
in	a	total	of	325	direct	interactions;	102	and	79	constituted	upstream	interactions	of	
p53	activating	or	inhibiting	target	nodes	respectively.	The	remaining	were	downstream	
of	p53;	activating	(n	=	92)	or	inhibiting	(n	=	52)	p53.	30	of	these	direct	interactions	with	
p53	were	ambivalent,	these	were	located	both	up	and	downstream	of	p53	in	the	
model.	Table	7.3	summarises	all	interactions	between	nodes	in	the	PMH302	model.	
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Figure	7.3	illustrates	the	PMH302	network	visualised	in	Cytoscape	(v.28).	Tables	7.3.1	
to	7.3.1.6	provides	GO	annotations	for	all	nodes	in	the	PMH302	network	
	
Image	7.3	The	PMH302	model	
The	PMH302	p53–DNA	damage	and	hypoxia	inducible	model.	Five	layers	are	observed	in	
accordance	with	node	function;	the	input	signals	of	DNA	damage	and	hypoxia	(green),	
upstream	of	p53	(yellow),	the	network	hub,	p53	contained	within	the	crucial	feedback	loop	
with	MDM2	(red),	downstream	of	p53	(turquoise)	and	five	downstream	outputs	(orange).	Red	
lines	signify	inhibition,	blue	activation.	Constructed	and	visualised	in	Cytoscape	(v.28).		
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Table	7.3	Total	interaction	list	of	nodes	and	interactions	considered	in	PMH302.	
A	total	of	1398	interactions	between	295	nodes	are	considered	in	the	PMH302	model.	Of	these	
557	are	activations	(excluding	GO	annotations).	PubMed	IDs	are	supplied.	Some	PMID/PMCIDs	
were	not	available,	for	these	their	DOI	are	provided.		This	table	does	not	consider	GO	
annotations.	These	are	described	in	separate	tables.		
Source	 Interaction	 Target		 PMID/PMC	
AATF	 Activates	 p53	 20708154	
AATF	 Activates	 CDK5	 18388733	
AIMP2	 Activates	 p53	 18695251	
APEX1	 Activates	 FEN1	 12200445	
APEX1	 Activates	 HIF1A	 11018583	
APEX1	 Activates	 HIF1A	 PMC2587278	
APP	 Inhibits	 p53	 10377452	
AR	 Inhibits	 MMP1	 8798622	
ASPP1	 Activates	 p53	 11684014	
ASPP1	 Activates	 p53	 22552744	
ASPP2	 Activates	 p53	 22552744	
ATF3	 Activates	 GDF15	 20110283	
ATF3	 Activates	 CCND1	 11375399	
ATF3	 Inhibits	 MMP2	 11792711	
ATF3	 Inhibits	 IL6	 16688168	
ATM	 Activates	 PRKDC	 23761041	
ATM	 Activates	 PCNA	 22362778	
ATM	 Activates	 p53	 10608806	
ATM	 Activates	 CHEK2	 16936775	
ATM	 Activates	 ATR	 17088261	
ATM	 Activates	 AATF	 17157788	
ATM	 Activates	 BRCA1	 12082091	
ATM	 Activates	 DYRK2	 19965871	
ATM	 Inhibits	 CCND1	 25486524	
ATM	 Inhibits	 CCND2	 19071090	
ATM	 Inhibits	 BCL6	 18346918	
ATM	 Inhibits	 MDM2	 16943424	
ATM	 Inhibits	 MDM4	 16943424	
ATR	 Activates	 p53	 16557269	
ATR	 Activates	 CHEK1	 16557269	
ATR	 Activates	 AATF	 17157788	
ATR	 Activates	 BRCA1	 12082091	
ATR	 Inhibits	 MDM2	 16943424	
AURKA	 Inhibits	 p53	 14702041	
AXIN1	 Activates	 HIPK2	 PMC533058	
AXIN1	 Activates	 p53	 19513548	
AXIN1	 Inhibits	 MYC	 PMC2657573	
AXIN1	 Inhibits	 CCND1	 11739413	
AXIN1	 Inhibits	 TCF7L2	 17768662	
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BAIAP2L1	 Inhibits	 p53	 21887275	
BAIAP2L1	 Inhibits	 p53	 PMC3160901	
BAIAP2L2	 Inhibits	 p53	 21887275	
BCCIP	 Activates	 p53	 15539944	
BCL2	 Activates	 MMP2	 19258038	
BCL2	 Activates	 CCND1	 11313702	
BCL2	 Activates	 FOS	 15326476	
BCL2	 Activates	 VEGFA	 12205045	
BCL2	 Activates	 SLC2A1	 15120582	
BCL2	 Activates	 RAS	 15326476	
BCL3	 Activates	 JUN	 10497212	
BCL3	 Activates	 EGFR	 17881446	
BCL6	 Activates	 p53	 18524763	
BCL6	 Inhibits	 STAT3	 17951530	
BCL6	 Inhibits	 JUN	 12165517	
BCL6	 Inhibits	 p53	 15577913	
BCL6	 Inhibits	 CDKN1B	 10981963	
BDKRB1	 Activates	 FGF2	 11387266	
BHLHE40	 Inhibits	 STAT3	 15223310	
BHLHE40	 Inhibits	 STAT3	 21761458	
BRCA1	 Activates	 p53	 11371136	
BRCA1	 Activates	 CCND1	 17278098	
BRCA1	 Inhibits	 ESR1	 PMC4030134	
BRCA1	 Inhibits	 ESR1	 PMC4030134	
BTG2	 Activates	 p53	 11814693	
BTG2	 Inhibits	 PIN1	 20569234	
BTG2	 Inhibits	 CCND1	 15378000	
CABLES	 Activates	 CDK5	 10896159	
CABLES	 Activates	 CDK5	 10896159	
CABLES	 Activates	 CDK5	 22898083	
CABLES	 Inhibits	 CDK2	 11585773	
CCAR1	 Activates	 p53	 18722177	
CCNA	 Activates	 CDC25A	 10926775	
CCNA	 Activates	 AXIN1	 15063782	
CCNA	 Inhibits	 CCNB1	 11018009	
CCNA	 Inhibits	 CKM	 8995365	
CCNA	 Inhibits	 FEN1	 12853968	
CCNA	 Inhibits	 E2F1	 7838523	
CCNB1	 Activates	 CDK2	 15818617	
CCNB1	 Activates	 CDK2	 15818617	
CCND1	 Activates	 ESR1	 9271411	
CCND1	 Activates	 HDAC1	 15713663	
CCND1	 Activates	 CDK2	 15355984	
CCND1	 Activates	 HSPA4	 9121772	
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CCND1	 Activates	 E2F1	 10504464	
CCND1	 Activates	 VEGFA	 16899623	
CCND1	 Inhibits	 CDK2	 9925749	
CCND1	 Inhibits	 MAPK1	 18722177	
CCND1	 Inhibits	 BCL6	 19307668	
CCND1	 Inhibits	 STAT3	 11279133	
CCND1	 Inhibits	 PPARG	 12917338	
CCND1	 Inhibits	 PPARG	 15713663	
CCND1	 Inhibits	 HNF4A	 PMC3409010	
CCND1	 Inhibits	 RB	 24305655	
CCND1	 Inhibits	 THBS1	 17020778	
CCNG1	 Activates	 CCNB1	 16322753	
CD44	 Inhibits	 CCND1	 17296798	
CD82	 Inhibits	 VEGFA	 20569234	
CD82	 Inhibits	 VEGFA	 16461284	
CD82	 Inhibits	 VEGFA	 15616196	
CD82	 Inhibits	 VEGFA	 17562791	
CD82	 Inhibits	 VEGFA	 22390300	
CDC25A	 Inhibits	 EGFR	 11912208	
CDK2	 Activates	 BRCA1	 19445729	
CDK2	 Activates	 FOXM1	 15654331	
CDK2	 Activates	 PTGS2	 16452236	
CDK2	 Activates	 CABLES	 11585773	
CDK2	 Activates	 p53	 11078726	
CDK2	 Activates	 CDC25A	 10926775	
CDK2	 Activates	 E2F1	 7969176	
CDK2	 Activates	 AXIN1	 15063782	
CDK2	 Activates	 CCNA	 10652300	
CDK2	 Inhibits	 BRCA1	 PMC84283	
CDK2	 Inhibits	 TFDP1	 10329431	
CDK2	 Inhibits	 RB	 24305655	
CDK2	 Inhibits	 CDKN1B	 8622855	
CDK2	 Inhibits	 MDM2	 21278451	
CDK4	 Activates	 RAD51	 PMC3436568	
CDK4	 Activates	 RAD51	 10918579	
CDK4	 Activates	 CCND1	 9099745	
CDK4	 Activates	 BRCA1	 10660629	
CDK4	 Inhibits	 BRCA1	 17334399	
CDK5	 Activates	 STAT3	 17145757	
CDK5	 Activates	 ATM	 19151707	
CDK5	 Activates	 p53	 17591690	
CDK5	 Activates	 MYC	 18408012	
CDK5	 Activates	 ERBB2	 16203963	
CDK5	 Activates	 CDKN1B	 16341208	
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CDK5	 Inhibits	 PPARG	 PMC2987584	
CDK5	 Inhibits	 PPARG	 20651683	
CDK5	 Inhibits	 PPARG	 23622515	
CDK9	 Activates	 p53	 16741955	
CDKN1A	 Activates	 ESR1	 15743834	
CDKN1A	 Inhibits	 CDK4	 15735718	
CDKN1A	 Inhibits	 CCNB1	 PMC2722839	
CDKN1A	 Inhibits	 STAT3	 20569234	
CDKN1A	 Inhibits	 E2F1	 10498892	
CDKN1A	 Inhibits	 MYC	 20569234	
CDKN1A	 Inhibits	 PCNA	 7885482	
CDKN1A	 Inhibits	 CDK2	 8756624	
CDKN1B	 Inhibits	 CDK2	 doi:10.1038/nrc2347	
CDKN1B	 Inhibits	 BCL2	 14676836	
CDKN1B	 Inhibits	 CCNA	 8547220	
CDKN1B	 Inhibits	 CDK2	 18354415	
CDKN2A	 Activates	 MDM4	 15907800	
CDKN2A	 Inhibits	 CDK4	 21170085+	
CDKN2A	 Inhibits	 CCND1	 15205322	
CDKN2A	 Inhibits	 MDM2	 20523835	
CDKN2A	 Inhibits	 MDM4	 20177397	
CHEK1	 Activates	 p53	 10673501	
CHEK1	 Inhibits	 CDC25A	 12759351	
CHEK1	 Inhibits	 MDM4	 16511572	
CHEK2	 Activates	 p53	 10673500	
CHEK2	 Activates	 MYC	 19812253	
CHEK2	 Activates	 BRCA1	 14701743	
CHEK2	 Activates	 E2F1	 12717439	
CHEK2	 Activates	 AATF	 17157788	
CHEK2	 Inhibits	 CDC25A	 12759351	
CHEK2	 Inhibits	 MDM4	 16943424	
CHK1	 Activates	 RAD51	 15665856	
CHK1	 Activates	 PRKDC	 24500207	
CHK1	 Inhibits	 CDK2	 12181445	
CIAPIN1	 Inhibits	 p53	 16410721	
CIAPIN1	 Inhibits	 BAX	 16410721	
CIAPIN1	 Inhibits	 BCL2	 18059532	
CSNK2	 Activates	 FOS	 1915270	
CSNK2	 Activates	 p53	 9244359	
CSNK2	 Activates	 MDM2	 16335531	
CSNK2	 Activates	 TCF7L2	 11711551	
CSNK2	 Activates	 PTEN	 11035045	
CSNK2	 Activates	 MYC	 2663470	
CSNK2	 Activates	 MYCN	 1425701	
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CSNK2	 Activates	 NCL	 3190709	
CSNK2	 Activates	 HDAC1	 11602581	
CSNK2	 Inhibits	 MDM2	 21769452	
CUL7	 Inhibits	 p53	 17586686	
CUL7	 Inhibits	 p53	 17229476	
CUL7	 Inhibits	 p53	 16547496	
CXCR4	 Activates	 VEGFA	 17559806	
CXCR4	 Activates	 TNFRSF10B	 15990565	
DAP	 Activates	 p53	 11146619	
DAP	 Inhibits	 PIN1	 21504826	
DAP	 Inhibits	 PIN1	 21497122	
DAXX	 Activates	 CCND1	 26205068	
DAXX	 Activates	 CCND1	 PMC373322	
DAXX	 Activates	 p53	 12482984	
DAXX	 Activates	 p53	 17210684	
DAXX	 Inhibits	 p53	 15364927	
DAXX	 Inhibits	 p53	 15339933	
DDX20	 Inhibits	 p53	 22335944	
DDX5	 Activates	 ESR1	 12738788	
DDX5	 Activates	 p53	 15660129	
DKK1	 Activates	 TGFB1	 20019166	
DNMT3A	 Inhibits	 p53	 16131836	
DUSP4	 Inhibits	 IL6	 PMC4090144	
DUSP4	 Inhibits	 MAPK1	 17473844	
DUSP5	 Inhibits	 MAPK1	 8221888	
DYRK2	 Activates	 p53	 17349958	
DYRK2	 Activates	 p53AIP1	 17349958	
E2F1	 Activates	 VRK1	 16547155	
E2F1	 Activates	 VRK1	 12629169	
E2F1	 Activates	 VRK1	 doi:10.1016/0006-291X(91)91760-A	
E2F1	 Activates	 p53	 12625370	
E2F1	 Activates	 HIC1	 19491197	
E2F1	 Activates	 SIVA1	 15105421	
E2F1	 Activates	 APAF1	 18056406	
E2F1	 Activates	 PCNA	 12468739	
E2F1	 Activates	 MYCN	 14645238	
E2F1	 Activates	 CHEK2	 15024084	
E2F1	 Activates	 SIAH1	 20187294	
E2F1	 Activates	 EZH2	 19893569	
E2F1	 Inhibits	 MDM2	 20837136	
E2F1	 Inhibits	 MCL1	 11857079	
E2F1	 Inhibits	 AR	 17178887	
EGFR	 Activates	 CCND1	 19935697	
EGFR	 Activates	 PTGS2	 15781636	
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EGFR	 Activates	 VEGFA	 21074412	
EGFR	 Activates	 ESR1	 19470835	
EGFR	 Inhibits	 NOTCH1	 18604200	
EIF2AK2	 Activates	 p53	 19210572	
EIF5A	 Activates	 p53	 15371445	
ELAVL1	 Activates	 CCNB1	 384372	
ELAVL1	 Activates	 THBS1	 3041167	
ELAVL1	 Activates	 VEGFA	 9497373	
ELAVL1	 Activates	 GDF15	 1369825	
ELAVL1	 Activates	 p53	 12821781	
ELAVL1	 Activates	 PTGS2	 14633672	
ELAVL1	 Inhibits	 VEGFA	 PMC3041167	
ELAVL1	 Inhibits	 CDKN1B	 18354415	
ELAVL1	 Inhibits	 MYC	 19574298	
ERBB2	 Activates	 STAT3	 14586404	
ERBB2	 Activates	 MCL1	 16467098	
ERBB2	 Activates	 VEGFA	 15582599	
ERBB2	 Activates	 CCND1	 17483350	
ERBB2	 Activates	 CXCR4	 15542424	
ERBB2	 Activates	 PTGS2	 11901151	
ERBB2	 Inhibits	 MUC1	 11410163	
ERBB2	 Inhibits	 p53	 8700512	
ERBB2	 Inhibits	 CDKN1B	 16951165	
ESR1	 Activates	 VEGFA	 2849827	
ESR1	 Activates	 BRCA1	 16229810	
ESR1	 Activates	 PCNA	 24283290	
ESR1	 Activates	 LTF	 15525592	
ESR1	 Activates	 CCND1	 15544931	
ESR1	 Activates	 CKB	 11746525	
ESR1	 Activates	 MYC	 19661132	
ESR1	 Inhibits	 CDKN1A	 16267837	
ESR1	 Inhibits	 IL6	 PMC146754	
ESR1	 Inhibits	 IL6	 16043358	
ESR1	 Inhibits	 EGFR	 9269899	
EXPORTIN1	 Inhibits	 CCND1	 DOI:	10.1186/s12885-015-1936-z	
EZH2	 Inhibits	 RAD51	 16331887	
FAS	 Activates	 p53	 9358752	
FGF2	 Activates	 YY1	 11487577	
FGF2	 Activates	 YY1	 19235591	
FGF2	 Activates	 STAT3	 PMC3307977	
FGF2	 Activates	 IL6	 PMC1220238	
FGF2	 Activates	 MMP13	 15564063	
FGF2	 Activates	 IGF1R	 1649391	
FGF2	 Activates	 MMP2	 19107653	
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FGF2	 Activates	 CDK4	 11889462	
FGF2	 Activates	 THBS1	 15927970	
FGF2	 Activates	 ABCB1	 17620438	
FGF2	 Activates	 FOS	 8783257	
FGF2	 Activates	 MMP1	 19107653	
FGF2	 Activates	 BCL2	 11380405	
FGF2	 Activates	 PTGS2	 9920767	
FGF2	 Activates	 VEGFA	 15485645	
FGF2	 Activates	 PCNA	 17003443	
FGF2	 Inhibits	 PRSS50	 20506264	
FGF2	 Inhibits	 CDKN1B	 12657588	
FGF2	 Inhibits	 CDKN1	 11726615	
FHL2	 Activates	 CCND1	 18378678	
FHL2	 Activates	 CCND1	 12124778	
FHL2	 Inhibits	 MAPK1	 I14729955	
FLI1	 Inhibits	 p53	 22266186	
FOS	 Activates	 PPARG	 10678274	
FOS	 Activates	 PPARG	 PMC4023468	
FOS	 Activates	 CCND1	 9710644	
FOS	 Activates	 MMP1	 21344389	
FOS	 Activates	 BCL2	 19079363	
FOS	 Inhibits	 ESR1	 14684847	
FOXM1	 Activates	 MMP2	 17804744	
FOXM1	 Activates	 VEGFA	 17804744	
FOXM1	 Activates	 CCNB1	 11682060	
GADD45A	 Inhibits	 AURKA	 16772293	
GAPDH	 Activates	 AR	 17553795	
GAPDH	 Activates	 SIAH1	 15951807	
GSK3B	 Activates	 BAX	 15525785	
GSK3B	 Inhibits	 CCND1	 9832503	
GSK3B	 Inhibits	 MYC	 1312697	
GSK3B	 Inhibits	 MYC	 9727977	
GSK3B	 Inhibits	 MYC	 14563837	
GSK3B	 Inhibits	 MYC	 11980918	
GSK3B	 Inhibits	 MYC	 PMC3719674	
H2AFZ	 Inhibits	 p53	 17671089	
HDAC1	 Inhibits	 ESR1	 14506733	
HDAC1	 Inhibits	 CDKN1A	 17412634	
HDAC1	 Inhibits	 PHB	 21152868	
HDAC1	 Inhibits	 TOP2A	 11062478			11136718	
HDAC1	 Inhibits	 p53	 12426395	
HF1A	 Activates	 CDKN1B	 19342889	
HIF1A	 Activates	 NOTCH1	 19293180	
HIF1A	 Activates	 SLC2A1	 16136514	
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HIF1A	 Activates	 BNIP3L	 19273585	
HIF1A	 Activates	 CD44	 22937154	
HIF1A	 Activates	 FLI1	 PMC2884367	
HIF1A	 Activates	 FOXM1	 19097132	
HIF1A	 Activates	 NANOG	 21712410	
HIF1A	 Activates	 CXCR4	 19212630	
HIF1A	 Activates	 IL6	 20600219	
HIF1A	 Activates	 MMP1	 17335808	
HIF1A	 Activates	 VEGFA	 17919812	
HIF1A	 Activates	 SLC2A1	 17387384	
HIF1A	 Activates	 PLAUR	 17335808	
HIF1A	 Inhibits	 AURKA	 23925655	
HIF1A	 Inhibits		 DUSP2	 21984126	
HIPK2	 Activates	 p53	 16601678	
HIPK2	 Inhibits	 DAXX	 doi:	10.1128/MCB.23.3.950-960.2003	
HIPK2	 Inhibits	 MDM2	 16212962	
HIPK2	 Inhibits	 HIF1A	 19046997	
HIPK2	 Inhibits	 POU4F1	 15492043	
HIPK4	 Activates	 p53	 18022393	
HNF4A	 Inhibits	 ESR1	 9794469	
HNF4A	 Inhibits	 CCND1	 22241473	
HOXA10	 Activates	 CDKN1A	 11040212	
HOXA10	 Activates	 p53	 15044858	
HOXA11	 Inhibits	 p53	 19372592	
HOXA5	 Activates	 p53	 12490103	
HOXA5	 Inhibits	 p53	 12490102	
HSP90AB1	 Inhibits	 MMP13	 18593760	
HSPA4	 Activates	 NQO1	 11821413	
HSPA4	 Activates	 p53	 17278883	
HSPA4	 Activates	 p53	 17278883	
HSPA4	 Inhibits	 FOS	 11189444	
HTATIP2	 Activates	 p53	 18519672	
HTATIP2	 Inhibits	 MMP2	 19349353	
HTATIP2	 Inhibits	 VEGFA	 19349353	
HTATIP2	 Inhibits	 MYC	 15073177	
iASPP	 Inhibits	 p53	 22552744	
iASPP	 Inhibits	 p53	 12524540	
ICAM1	 Activates	 FOS	 12097408	
ID3	 Inhibits	 p53	 19618124	
IFNA1	 Activates	 p53	 15254403	
IFNA1	 Activates	 MDM2	 15580300	
IFNA1	 Activates	 CXCR4	 18202009	
IFNA1	 Activates	 IL6	 12434062	
IFNA1	 Activates	 ICAM1	 11593644	
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IFNA1	 Activates	 EGFR	 1718587	
IFNA1	 Activates	 TLR3	 16087162	
IFNA1	 Activates	 FOS	 15970516	
IFNA1	 Activates	 PTGS2	 16685393	
IFNA1	 Activates	 FAS	 14616354	
IFNA1	 Activates	 MYC	 10068671	
IFNA1	 Activates	 TNFRSF10B	 12642868	
IFNA1	 Activates	 EIF2AK2	 15254208	
IFNA1	 Activates	 PRKCA	 17988665	
IFNA1	 Inhibits	 FGF2	 9485039	
IFNA1	 Inhibits	 ABCB1	 17331344	
IFNA1	 Inhibits	 BCL2	 12881711	
IFNA1	 Inhibits	 MYC	 11798827	
IFNA1	 Inhibits	 E2F1	 10208422	
IGF1R	 Activates	 PTGS2	 11114729	
IGF1R	 Activates	 p53	 8710868	
IGF1R	 Activates	 MDM2	 17846171	
IGF1R	 Activates	 RAS	 19174523	
IGF1R	 Activates	 VEGFA	 21264842	
IGFBP7	 Inhibits	 PTGS2	 19374835	
IGFBP7	 Inhibits	 VEGFA	 19374835	
IL6	 Activates	 MMP2	 16934628	
IL6	 Activates	 CXCR4	 9933168	
IL6	 Activates	 EGFR	 9459124	
IL6	 Activates	 TGFA	 11892999	
IL6	 Activates	 FOS	 11713282	
IL6	 Activates	 MMP1	 16934628	
IL6	 Activates	 MMP13	 15601621	
IL6	 Activates	 PTGS2	 16837651	
IL6	 Activates	 MYC	 20974848	
IL6	 Activates	 VEGFA	 8557680	
IL6	 Inhibits	 BAX	 12101271	
ING1	 Activates	 p53	 21731648	
ING2	 Activates	 p53	 PMC1190357	
ING4	 Activates	 p53	 12750254	
ING4	 Activates	 p53	 3742747	
ING5	 Activates	 p53	 12750254	
JAG1	 Activates	 p53	 24098521	
JUN	 Activates	 THBS1	 11216860	
JUN	 Activates	 CCND1	 12668975	
JUN	 Inhibits	 ESR1	 1906001	
JUN	 Inhibits	 p53	 10072388	
KAT2B	 Activates	 CCND1	 10318892	
KAT2B	 Activates	 E2F1	 20530585	
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KAT2B	 Activates	 E2F1	 doi:	10.1074/jbc.M402403200	
KAT2B	 Activates	 MYC	 15572685	
KAT2B	 Activates	 p53	 15153330	
KAT2B	 Inhibits	 PTEN	 doi:10.1074/jbc.M605391200	
KLF4	 Activates	 CDKN1A	 16372018	
KLF4	 Activates	 CDKN1A	 12087069	
KLF4	 Activates	 CDKN1	 PMC2668950	
KLF4	 Activates	 NOTCH1	 19717984	
KLF4	 Activates	 MUC1	 17908689	
KLF4	 Activates	 KRT19	 10859317	
KLF4	 Activates	 p53	 19696146	
KLF4	 Activates	 VEGFA	 PMC4467843	
KLF4	 Inhibits	 p53	 16244670	
KLF4	 Inhibits	 CCNB1	 14627709	
KLF4	 Inhibits	 NOTCH1	 20551324	
LATS2	 Activates	 p53	 17015431	
LTF	 Inhibits	 CCND1	 18697201	
MAPK1	 Activates	 PRAK	 9628874	
MAPK1	 Activates	 PRAK	 9628874	
MAPK1	 Activates	 STAT3	 15979846	
MAPK1	 Activates	 FOS	 16123044	
MAPK1	 Activates	 FOS	 DOI	10.1074/jbc.M204296200	
MAPK1	 Activates	 PTGS2	 20883667	
MAPK1	 Activates	 JUN	 22379036	
MAPK1	 Activates	 CCND1	 9618377	
MAPK1	 Activates	 p53	 11409876	
MAPK1	 Activates	 NR2C1	 18682553	
MAPK1	 Activates	 YBX1	 16198352	
MAPK1	 Activates	 RAF1	 1730637	
MAPK1	 Inhibits	 CCND1	 10952989	
MAPK1	 Inhibits	 CALD1	 PMC3084981	
MAPK14	 Activates	 MMP1	 18620911	
MAPK14	 Activates	 PTGS2	 doi.org/10.1016/j.cbi.2007.07.008	
MAPK14	 Activates	 ELAVL1	 PMC2725730	
MAPK14	 Activates	 MMP2	 15677464	
MAPK14	 Activates	 SGK	 12488318	
MAPK14	 Activates	 p53	 18265945	
MAPK14	 Inhibits	 JUN	 17468757	
MAPK8	 Activates	 TGFB1	 12760970	
MAPK8	 Activates	 MMP2	 16672691	
MAPK8	 Activates	 CCND1	 21135252	
MAPK8	 Activates	 ICAM1	 15389584	
MAPK8	 Activates	 FOS	 17085440	
MAPK8	 Activates	 ATF3	 18377912	
	 184	
MAPK8	 Activates	 PTGS2	 15546960	
MAPK8	 Activates	 p53	 11057897	
MAPK8	 Activates	 BAX	 16709574	
MAPK8	 Activates	 BCL2	 11323415	
MAPK8	 Inhibits	 E2F1	 10075927	
MAPK9	 Activates	 PTGS2	 9786861	
MAPK9	 Activates	 p53	 17525747	
MCTS1	 Activates	 CCND1	 11709712	
MCTS1	 Inhibits	 p53	 17416211	
MDM2	 Activates	 ESR1	 11178989	
MDM2	 Activates	 ABCB1	 8883415	
MDM2	 Activates	 HIF1A	 15024078	
MDM2	 Activates	 VEGFA	 21986500	
MDM2	 Inhibits	 CDKN1A	 14761977	
MDM2	 Inhibits	 KAT2B	 14769800	
MDM2	 Inhibits	 p53	 21423613	
MDM2	 Inhibits	 VEGFA	 18199551	
MDM2	 Inhibits	 MDM4	 16557269	
MDM2	 Inhibits	 DYRK2	 19965871	
MDM4	 Activates	 MDM2	 16557269	
MDM4	 Inhibits	 CDKN1A	 doi:	10.1128/MCB.01198-07		
MDM4	 Inhibits	 CDKN1A	 18086887	
MDM4	 Inhibits	 p53	 16557269	
MGMT	 Inhibits	 ESR1	 11564893	
MGMT	 Inhibits	 VEGFA	 20179017	
MMP2	 Activates	 BAX	 16857167	
MSH2	 Activates	 ESR1	 15886699	
MTA1	 Activates	 p53	 19837670	
MTA2	 Inhibits	 p53	 17914590	
MTA2	 Inhibits	 p53	 12920132	
MUC1	 Activates	 CCND1	 PMC2864713	
MUC1	 Activates	 CCND1	 14688481	
MUC1	 Activates	 EGFR	 16082192	
MUC1	 Activates	 VEGFA	 23108411	
MUC1	 Activates	 PDGFRB	 23108411	
MUC1	 Inhibits	 p53	 15710329	
MYC	 Activates	 CDK4	 10688915	
MYC	 Activates	 CCNB1	 11983916	
MYC	 Activates	 BRCA1	 11983916	
MYC	 Activates	 p53	 9839551	
MYC	 Activates	 MMP2	 19258038	
MYC	 Activates	 CCND1	 7526316	
MYC	 Activates	 MSH2	 15814658	
MYC	 Activates	 HSPA4	 1459202	
	 185	
MYC	 Activates	 CDC25A	 10205150	
MYC	 Activates	 BRCA1	 21668996	
MYC	 Activates	 VEGFA	 15580293	
MYC	 Activates	 NME1	 11960382	
MYC	 Activates	 TNFRSF10A	 17881904	
MYC	 Activates	 E2F1	 17784791	
MYC	 Activates	 CDK2	 8157956	
MYC	 Inhibits	 CDKN1A	 10319992	
MYC	 Inhibits	 BCL2	 11438662	
MYC	 Inhibits	 GADD45A	 15021909	
MYC	 Inhibits	 CDKN1A	 12408820	
MYCN	 Activates	 p53	 20145147	
MYCN	 Activates	 ABCC1	 14737110	
MYCN	 Activates	 ABCB1	 12819037	
MYCN	 Inhibits	 CD44	 11035936	
MYCN	 Inhibits	 MYC	 7529553	
MYCN	 Inhibits	 CDKN1B	 18198336	
MYST4	 Activates	 p53	 19001415	
NANOG	 Activates	 PTK2	 22493428	
NCL	 Activates	 BCL2	 21048921	
NCL	 Inhibits	 p53	 16213212	
NCL	 Inhibits	 MDM2	 16751805	
NFKB	 Activates	 p53	 8051093	
NME1	 Activates	 PTGS2	 16415009	
NME1	 Activates	 MYC	 19170058	
NOTCH1	 Activates	 STAT3	 19808903	
NOTCH1	 Activates	 NFKB2		 16546962	
NOTCH1	 Activates	 CCND1	 16546962	
NOTCH1	 Activates	 CCND1	 19915977	
NOTCH1	 Activates	 CCND1	 20887720	
NOTCH1	 Activates	 CDKN1A	 11432830	
NOTCH1	 Activates	 PIN1	 19151708	
NOTCH1	 Activates	 ESR1	 19838210	
NOTCH1	 Activates	 EGFR	 18359760	
NOTCH1	 Activates	 PTGS2	 19290049	
NOTCH1	 Inhibits	 PTEN	 21993533	
NOTCH1	 Inhibits	 CCNA	 14678992	
NOV	 Activates	 MMP1	 15611078	
NQO1	 Activates	 FOS	 20498278	
NQO1	 Activates	 FOS	 20498278	
NQO1	 Activates	 p53	 11867746	
NQO1	 Activates	 p53	 11867746	
NR2C1	 Inhibits	 ESR1	 12093804	
NTN1	 Inhibits	 p53	 18922894	
	 186	
p53	 Activates	 GDF15		 22723347	
p53	 Activates	 CASP2	 18418048	
p53	 Activates	 SERPINE1	 16862142	
p53	 Activates	 DUSP1	 18403641	
p53	 Activates	 BHLHE40	 18025081	
p53	 Activates	 S100B	 9632811	
p53	 Activates	 S100B	 10490652	
p53	 Activates	 PML	 1151544	
p53	 Activates	 UNC5A	 20372800	
p53	 Activates	 TFAP2A	 16636674	
p53	 Activates	 TFAP2C	 16636674	
p53	 Activates	 ABCC1	 12647018	
p53	 Activates	 GSTP1	 18505928	
p53	 Activates	 ESR1	 15012604	
p53	 Activates	 MMP2	 9343394	
p53	 Activates	 CKM	 7488858	
p53	 Activates	 CD82	 11212267	
p53	 Activates	 GAPDH	 18552833	
p53	 Activates	 MSH2	 10984493	
p53	 Activates	 CD58	 11812190	
p53	 Activates	 DUSP4	 16778175	
p53	 Activates	 RRM2B	 19010910	
p53	 Activates	 EDA2R	 20434500	
p53	 Activates	 DDB2	 12509284	
p53	 Activates	 MDM2	 11313969	
p53	 Activates	 NOV	 18418052	
p53	 Activates	 THBS1	 12609716	
p53	 Activates	 ARID3A	 12136662	
p53	 Activates	 KAT2B	 15153330	
p53	 Activates	 ICAM1	 15247038	
p53	 Activates	 ABCB1	 17666793	
p53	 Activates	 EGFR	 19597475	
p53	 Activates	 IGFBP1	 18056423	
p53	 Activates	 CDKN1A	 17585201	
p53	 Activates	 DUSP2	 16474395	
p53	 Activates	 FDXR	 12370809	
p53	 Activates	 BAX	 18949380	
p53	 Activates	 KRT8	 8615594	
p53	 Activates	 TGFA	 7651386	
p53	 Activates	 IFI16	 18974396	
p53	 Activates	 TLR3	 18779317	
p53	 Activates	 Tp53I13	 14767535	
p53	 Activates	 HSPA4	 20180806	
p53	 Activates	 FEN1	 16103874	
	 187	
p53	 Activates	 DDIT4	 19210572	
p53	 Activates	 MAP4K4	 15958553	
p53	 Activates	 HIC1	 7585125	
p53	 Activates	 SEMA3B	 11922394	
p53	 Activates	 RPRM	 11313928	
p53	 Activates	 PEG3	 11679586	
p53	 Activates	 SIVA1	 19240372	
p53	 Activates	 PCBP4	 11313928	
p53	 Activates	 DFNA5	 16897187	
p53	 Activates	 CD59	 11812190	
p53	 Activates	 Tp53INP1	 12438758	
p53	 Activates	 FHL2	 17352216	
p53	 Activates	 CCNG1	 21447558	
p53	 Activates	 CASP8	 12376477	
p53	 Activates	 CDKN1B	 12376477	
p53	 Activates	 COL18A1	 15958553	
p53	 Activates	 BBC3	 18657356	
p53	 Activates	 APAF1	 11559530	
p53	 Activates	 BAK1	 15105295	
p53	 Activates	 NLRC4	 15580302	
p53	 Activates	 GTSE1	 11313928	
p53	 Activates	 CALD1	 19349302	
p53	 Activates	 ATF3	 17108111	
p53	 Activates	 PTGS2	 15608668	
p53	 Activates	 RGS16	 16405749	
p53	 Activates	 SGK	 16619268	
p53	 Activates	 S100A2	 18388131	
p53	 Activates	 DUSP5	 12944906	
p53	 Activates	 IER3	 9781666	
p53	 Activates	 GADD45A	 18350249	
p53	 Activates	 NOTCH1	 17534448	
p53	 Activates	 FAS	 9841917	
p53	 Activates	 PTEN	 11729185	
p53	 Activates	 AIFM2	 15273740	
p53	 Activates	 CDKN1A	 17585201	
p53	 Activates	 DKK1	 15668788	
p53	 Activates	 PRKG1	 19955367	
p53	 Activates	 NME1	 12669312	
p53	 Activates	 PCNA	 11682006	
p53	 Activates	 C13orf15	 17146433	
p53	 Activates	 ISG15	 11462054	
p53	 Activates	 BNIP3L	 15607964	
p53	 Activates	 TNFRSF10A	 15289308	
p53	 Activates	 TNFRSF10B	 10942251	
	 188	
p53	 Activates	 IGFBP7	 19638426	
p53	 Activates	 LATS2	 19855428	
p53	 Activates	 SERPINB5	 15578720	
p53	 Activates	 RAS	 11574421	
p53	 Activates	 C12orf5	 16557269	
p53	 Activates	 PERP	 16557269	
p53	 Activates	 SIAH1	 16557269	
p53	 Activates	 LRDD	 16557269	
p53	 Activates	 p53AIP1	 16557269	
p53	 Activates	 SESN2	 16557269	
p53	 Activates	 SFN	 16557269	
p53	 Activates	 ZMAT3	 19805223	
p53	 Activates	 KLF4	 19826046	
p53	 Activates	 PPM1D	 18265945	
p53	 Activates	 TPT1	 24067374	
p53	 Activates	 EGR2	 21042708	
p53	 Inhibits	 APEX1	 11018583	
p53	 Inhibits	 CYP24A1	 25519225	
p53	 Inhibits	 NANOG		 15619621	
p53	 Inhibits	 RPA1	 8361542	
p53	 Inhibits	 WRN	 11427532	
p53	 Inhibits	 KLK3	 11791186	
p53	 Inhibits	 RPS27L	 21170087	
p53	 Inhibits	 SOD2	 15867370	
p53	 Inhibits	 TOP2A	 8972219	
p53	 Inhibits	 CA9	 480909	
p53	 Inhibits	 CA9	 18815219	
p53	 Inhibits	 STMN1	 11072234	
p53	 Inhibits	 STMN1	 10557083	
p53	 Inhibits	 APP	 19049493	
p53	 Inhibits	 APP	 23942195	
p53	 Inhibits	 EXPORTIN	1	 21683812	
p53	 Inhibits	 BCL3	 12808109	
p53	 Inhibits	 PDRG1	 20453924	
p53	 Inhibits	 BDKRB1	 11400161	
p53	 Inhibits	 CCND1	 12808109	
p53	 Inhibits	 ECT2	 16778203	
p53	 Inhibits	 CXCR4	 17130833	
p53	 Inhibits	 SLC6A6	 16734743	
p53	 Inhibits	 XAF1	 20198350	
p53	 Inhibits	 CDK4	 7851794	
p53	 Inhibits	 IL6	 11830554	
p53	 Inhibits	 THBS1	 9849855	
p53	 Inhibits	 PDGFRB	 18697203	
	 189	
p53	 Inhibits	 FGF2	 11313915	
p53	 Inhibits	 WWP1	 16924229	
p53	 Inhibits	 ABCB1	 11920581	
p53	 Inhibits	 IGF1R	 10023442	
p53	 Inhibits	 NR2C1	 8663350	
p53	 Inhibits	 EGFR	 18391986	
p53	 Inhibits	 CD44	 18614011	
p53	 Inhibits	 PRKCA	 15563462	
p53	 Inhibits	 CKB	 7969181	
p53	 Inhibits	 RECQL4	 15674334	
p53	 Inhibits	 MGMT	 19846904	
p53	 Inhibits	 SP7	 16380437	
p53	 Inhibits	 HSPA4	 8418500	
p53	 Inhibits	 CDC25A	 17001315	
p53	 Inhibits	 FOS	 1946467	
p53	 Inhibits	 CDC20	 17873905	
p53	 Inhibits	 IQCB1	 16322217	
p53	 Inhibits	 EZH2	 15208672	
p53	 Inhibits	 MMP1	 11850838	
p53	 Inhibits	 PSEN1	 18374905	
p53	 Inhibits	 PRSS50	 17283160	
p53	 Inhibits	 IFITM2	 19544527	
p53	 Inhibits	 HSP90AB1	 15284248	
p53	 Inhibits	 BCL2	 11313951	
p53	 Inhibits	 HIF1A	 18815219	
p53	 Inhibits	 MMP13	 11850838	
p53	 Inhibits	 FOXM1	 19806025	
p53	 Inhibits	 HNF4A	 16895524	
p53	 Inhibits	 TCF7L2	 14990988	
p53	 Inhibits	 BRCA1	 12802282	
p53	 Inhibits	 EPHB4	 16205642	
p53	 Inhibits	 HMMR	 18971636	
p53	 Inhibits	 MAP4	 10521394	
p53	 Inhibits	 PRC1	 15531928	
p53	 Inhibits	 KRT19	 7515894	
p53	 Inhibits	 PTGS2	 15921850	
p53	 Inhibits	 S100A6	 18714402	
p53	 Inhibits	 MCL1	 18208354	
p53	 Inhibits	 VEGFA	 11559575	
p53	 Inhibits	 SLC2A1	 21862591	
p53	 Inhibits	 AR	 18084622	
p53	 Inhibits	 TFDP1	 9556576	
p53	 Inhibits	 CKS2	 17336302	
p53	 Inhibits	 NME1	 12669312	
	 190	
p53	 Inhibits	 MYC	 8479742	
p53	 Inhibits	 PCNA	 8570655	
p53	 Inhibits	 SLC2A4	 20729871	
p53	 Inhibits	 CCNB1	 11162602	
p53	 Inhibits	 RAD51	 19942681	
p53	 Inhibits	 CCNA	 8270002	
p53	 Inhibits	 CDKN2A	 9774662	
p53	 Inhibits	 PPM1D	 20093361	
p53	 Inhibits	 PRSS50	 17283160	
p53	 Inhibits		 KIF23	 PMC3641139	
p53	 Activates	 COL1A2	 9764819	
p53	 Activates	 PPID	 	PMC3383624	
PAD4	 Inhibits	 p53	 2493360	
PAD4	 Inhibits	 p53	 18499678	
PARK2	 Inhibits	 AIMP2	 12783850	
PARK2	 Inhibits	 p53	 19801972	
PCNA	 Activates	 ESR1	 17636311	
PDGFRB	 Activates	 STAT3	 PMC84192	
PDGFRB	 Activates	 CCND1	 10688905	
PEG3	 Activates	 VEGFA	 PMC24782	
PHB	 Activates	 p53	 14500729	
PHB	 Inhibits	 E2F1	 10376528	
PHF20	 Activates	 p53	 22334668	
PIAS1	 Activates	 SUMO2	 23871671	
PIAS1	 Inhibits	 STAT1	 9724754	
PIAS1	 Inhibits	 p53	 PMC122440	
PIAS2	 Inhibits	 p53	 19901969	
PIN1	 Activates	 CDKN1B	 19584057	
PIN1	 Activates	 CCND1	 12540053	
PIN1	 Activates	 CCND1	 11805292	
PIN1	 Activates	 CCND1	 16865248	
PIN1	 Activates	 ERBB2	 19077306	
PIN1	 Activates	 NOTCH1	 19151708	
PIN1	 Activates	 FOS	 doi:	10.1074/jbc.C500353200	
PIN1	 Activates	 MCL1	 18676833	
PIN1	 Activates	 MYC	 PMC3719674	
PIN1	 Activates	 JUN	 11432833	
PIN1	 Activates	 VEGFA	 18294451	
PIN1	 Activates	 VEGFA	 doi:	10.1158/1535-7163.MCT-08-1061	
PIN1	 Activates	 p53	 12397362	
PIN1	 Inhibits	 FOS	 16123044	
PIN1	 Inhibits	 BCL6	 17828269	
PIN1	 Inhibits	 DAXX	 17938171	
PIN1	 Inhibits	 CDC25C	 9499405	
	 191	
PIN1	 Inhibits	 GSK3B	 22184106	
PIN1	 Inhibits	 MYC	 26655473	
PIN1	 Inhibits	 CREB	 23380442	
PIN1	 Inhibits	 CREB	 PMC2963389		
PIN1	 Inhibits	 AATF	 17468107	
PIRH2	 Activates	 p53	 doi:10.1016/S0092-8674(03)00193-4	
PIRH2	 Inhibits	 CDKN1B	 18006823	
PITX1	 Activates	 p53	 17762884	
PLA2G6	 Inhibits	 p53	 16492706	
PLAUR	 Inhibits	 p53	 17110957	
PML	 Activates	 p53	 12810724	
PML	 Activates	 p53	 14992722	
PML	 Inhibits	 MDM2	 22869143	
POU4F1	 Activates	 p53	 10329733	
POU4F1	 Activates	 BCL2	 9722627	
POU4F1	 Activates	 BRCA1	 11470235	
PPARG	 Activates	 CDKN1A	 15041706	
PPARG	 Activates	 p53	 16887883	
PPM1A	 Activates	 p53	 12514180	
PPM1A	 Inhibits	 PRKAB1	 23088624	
PPM1D	 Activates	 MDM4	 19808970	
PPM1D	 Inhibits	 p53	 15870257	
PPM1D	 Inhibits	 CHEK1	 15870257	
PPM1D	 Inhibits	 MAPK14	 18265945	
PRAK	 Activates	 p53	 17254968	
PREP1	 Activates	 p53	 2887940	
PREP1	 Activates	 p53	 20587415	
PRKAB1	 Inhibits	 p53	 15866171	
PRKCA	 Activates	 IL6	 9523575	
PRKCA	 Activates	 HSPA4	 17208995	
PRKCA	 Activates	 MMP1	 16368506	
PRKCA	 Activates	 VEGFA	 1511446	
PRKCA	 Activates	 ERBB2	 17545611	
PRKCA	 Activates	 ABCB1	 15563462	
PRKCA	 Activates	 RAF1	 8321321	
PRKCA	 Inhibits	 CCND1	 20141613	
PRKCA	 Inhibits	 ABCB1	 9823967	
PRKCA	 Inhibits	 MYC	 20141613	
PRKD1	 Activates	 PTGS2	 19794144	
PRKD1	 Activates	 p53	 12628923	
PRKDC	 Activates	 ESR1	 20219974	
PRKDC	 Activates	 ATM	 15753361	
PRKDC	 Activates	 p53	 11042698	
PRKDC	 Inhibits	 APEX1	 24466051	
	 192	
PRKDC	 Inhibits	 WRN	 11477099	
PRKG1	 Activates	 CDKN1A	 18593937	
PRKG1	 Activates	 CDKN1B	 18593937	
PRKG1	 Inhibits	 MAPK14	 16990590	
PSMD10	 Inhibits	 p53	 19287195	
PTEN	 Activates	 THBS1	 	doi:	10.1073/pnas.081063798	
PTEN	 Activates	 THBS1	 PMC2669036	
PTEN	 Inhibits	 CCND1	 16849370	
PTEN	 Inhibits	 HIF1A	 18158893	
PTEN	 Inhibits	 EPHB4	 15930280	
PTEN	 Inhibits	 VEGFA	 16527906	
PTEN	 Inhibits	 PCNA	 17826033	
PTGS2	 Activates	 CXCR4	 20110411	
PTGS2	 Activates	 ABCB1	 17510421	
PTGS2	 Activates	 CD44	 12393872	
PTGS2	 Activates	 HSPA4	 14717913	
PTGS2	 Activates	 FOS	 16685273	
PTGS2	 Activates	 MCL1	 16000874	
PTGS2	 Activates	 VEGFA	 18533784	
PTGS2	 Inhibits	 EGFR	 19671676	
PTGS2	 Inhibits	 CDKN1B	 14587561	
PTTG1	 Activates	 p53	 15242522	
PTTG1	 Activates	 MMP2	 19433493	
PTTG1	 Activates	 FGF2	 21858218	
PTTG1	 Activates	 BAX	 15242522	
PTTG1	 Activates	 MYC	 11115508	
PTTG1	 Inhibits	 AURKA	 18663361	
PTTG1	 Inhibits	 THBS1	 PMC2988648	
PTTG1	 Inhibits	 p53	 19477929	
RAF1	 Activates	 p53	 10732786	
RAS	 Activates	 GSTP1	 11606500	
RAS	 Activates	 MAPK14	 15677464	
RAS	 Activates	 CCND1	 10201372	
RAS	 Activates	 CD44	 8453616	
RAS	 Activates	 FOS	 7917786	
RAS	 Activates	 PTGS2	 19903783	
RAS	 Activates	 VEGFA	 11507052	
RAS	 Activates	 CDKN1A	 19440234	
RAS	 Activates	 CCNA	 15737994	
RAS	 Activates	 CDKN1B	 14504289	
RAS	 Activates	 RAF1	 9020159	
RAS	 Activates	 MAPK1	 9020159	
RAS	 Inhibits	 CKM	 3600660	
RAS	 Inhibits	 CCND1	 12081197	
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RAS	 Inhibits	 PTEN	 19000654	
RB	 Inhibits	 E2F1	 24305655	
RB	 Inhibits	 CCNA	 11018009	
RB1CC1	 Inhibits	 p53	 21775823	
RCHY1	 Inhibits	 p53	 12654245	
RFC	 Inhibits	 p53	 10910354	
RFC1	 Activates	 FEN1	 19208620	
RFWD3	 Activates	 p53	 PMC2842028	
RPA1	 Activates	 BLM	 10825162	
RREB1	 Activates	 p53	 19558368	
RRM2B	 Activates	 VEGFA	 19250552	
RRM2B	 Inhibits	 THBS1	 19250552	
RSK2	 Activates	 p53	 15867353	
S100A2	 Inhibits	 PTGS2	 16908593	
S100B	 Inhibits	 p53	 15572370	
SENP3	 Activates	 p53	 doi.org/10.1016/j.bbrc.2011.02.034	
SERPINB5	 Inhibits	 VEGFA	 19374835	
SERPINF1	 Activates	 p53	 17651710	
SERPINF1	 Inhibits	 VEGFA	 16901919	
SET	 Inhibits	 p53	 3245910	
SFN	 Activates	 MMP1	 19533306	
SFN	 Activates	 CDKN1B	 20642839	
SFN	 Inhibits	 CCNB1	 17573669	
SFN	 Inhibits	 CDK2	 10767298	
SGK	 Inhibits	 p53	 19756449	
SGK1	 Inhibits	 NOTCH1	 21147854	
SIAH1	 Activates	 HIF1A	 15210114	
SIRT1	 Activates	 WRN	 PMC2859066		
SIRT1	 Inhibits	 WRN	 17996922	
SIRT1	 Inhibits	 WRN	 PMC2859066	
SIRT1	 Inhibits	 WRN	 15317818	
SLC2A1	 Activates	 MMP2	 12122099	
SMYD2	 Inhibits	 p53	 17108971	
SOD1	 Activates	 p53	 20097285	
SOD2	 Activates	 MMP2	 11929863	
SOX4	 Activates	 p53	 19234109	
STAT3	 Activates	 CCND1	 10458605	
STAT3	 Activates	 FOS	 12600988	
STAT3	 Activates	 HIF1A	 18644974	
STAT3	 Activates	 HIF1A	 15919761	
STAT3	 Activates	 MUC1	 11084045	
STAT3	 Activates	 PTGS2	 20145033	
STAT3	 Activates	 JUN	 17951530	
STAT3	 Activates	 VEGFA	 11960372	
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STAT3	 Activates	 MYC	 DOI:	http://dx.doi.org/10.1182/blood-2007-04-
087734	
STAT3	 Activates	 BCL6	 23716595	
STAT3	 Activates	 BCL3	 23149915	
STAT3	 Inhibits	 BAX	 10374878	
STAT3	 Inhibits	 p53	 16107692	
SUB1	 Activates	 p53	 21586571	
SUMO2	 Activates	 p53	 21900752	
SUMO2	 Inhibits	 p53	 17012228	
SUMO3	 Activates	 p53	 17012228	
TCF7L2	 Activates	 MYC	 9727977	
TFAP2A	 Activates	 ESR1	 7846046	
TFAP2A	 Inhibits	 CDKN1A	 PMC4096794	
TFAP2A	 Inhibits	 p53	 16288208	
TFDP1	 Activates	 EZH2	 20565746	
TGFA	 Activates	 CCND1	 9407106	
TGFA	 Activates	 FOS	 8783257	
TGFA	 Activates	 PTGS2	 12930301	
TGFA	 Activates	 MYC	 10839631	
TGFB1	 Activates	 p53	 11741524	
TGFB1	 Activates	 IL6	 2265243	
TGFB1	 Activates	 THBS1	 11955611	
TGFB1	 Activates	 PRKCA	 14749204	
TGFB1	 Activates	 CCNG1	 9696022	
TGFB1	 Activates	 PTGS2	 10935498	
TGFB1	 Activates	 VEGFA	 12615726	
TGFB1	 Activates	 CDKN1A	 7696178	
TGFB1	 Activates	 IGFBP7	 18711401	
TGFB1	 Inhibits	 IL6	 2265243	
TGFB1	 Inhibits	 ICAM1	 14500551	
TGFB1	 Inhibits	 MMP1	 16911716	
TGFB1	 Inhibits	 MMP13	 9009143	
TGFB1	 Inhibits	 KRT19	 14732924	
TGFB1	 Inhibits	 PTEN	 19940030	
TGFB1	 Inhibits	 MYC	 12628347	
THBS1	 Activates	 TGFB1	 11021838	
THBS1	 Inhibits	 FGF2	 17996481	
TIAF1	 Activates	 p53	 14965474	
TLR3	 Activates	 HIF1A	 PMC2907580	
TLR3	 Inhibits	 CXCR4	 19652552	
Tp53BP1	 Activates	 p53	 9748285	
Tp53RK	 Activates	 p53	 16600182	
UBE2A	 Activates	 p53	 22083959	
UBE2A	 Inhibits	 p53	 22083959	
UBE3A	 Inhibits	 p53	 15567145	
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UCHL1	 Activates	 p53	 20395212	
UCHL1	 Activates	 p53	 22279545	
VDR	 Activates	 CYP24A1	 15601867	
VEGFA	 Activates	 SERPINF1	 12670505	
VEGFA	 Activates	 MMP2	 16584583	
VEGFA	 Activates	 CXCR4	 19391039	
VEGFA	 Activates	 CD44	 9242547	
VEGFA	 Activates	 FOS	 14741347	
VEGFA	 Activates	 BCL2	 11895790	
VEGFA	 Activates	 PTGS2	 21273371	
VEGFA	 Activates	 DUSP5	 19741200	
VEGFA	 Activates	 NOTCH1	 12482957	
VEGFA	 Activates	 ID3	 15494533	
VEGFA	 Activates	 MMP1	 1447317	
VEGFA	 Inhibits	 TGFB1	 19180561	
VEGFA	 Inhibits	 SERPINF1	 16901919	
VRK1	 Activates	 CCND1	 18713830	
VRK1	 Activates	 CCND1	 18286197	
VRK1	 Activates	 JUN	 15378002	
VRK1	 Activates	 CREB	 doi:	10.1242/jcs.026757	
VRK1	 Activates	 p53	 15542844	
WRN	 Activates	 ATM	 18596239	
WWOX	 Activates	 p53	 16219768	
XAF1	 Inhibits	 VEGFA	 24980821	
YBX1	 Activates	 CCND1	 24774443	
YBX1	 Activates	 CCND1	 12695516	
YBX1	 Activates	 p53	 11175333	
YBX1	 Activates	 MMP2	 9278454	
YBX1	 Activates	 ABCB1	 17038319	
YBX1	 Activates	 EGFR	 1967130	
YBX1	 Inhibits	 p53	 12835324	
YBX1	 Inhibits	 MMP13	 17822788	
YY1	 Activates	 ERBB2	 18218085	
YY1	 Activates	 PTGS2	 17220375	
YY1	 Activates	 p53	 PMC231595	
YY1	 Inhibits	 NOTCH1	 12913000	
YY1	 Inhibits	 CDKN1A	 17556661	
YY1	 Inhibits	 p53	 15295102	
ZMAT3	 Activates	 p53	 12196512	
ZMIZ2	 Activates	 p53	 PMC1935018	
ZNF148	 Activates	 p53	 PMC87140	
ZNF307	 Inhibits	 p53	 17910948	
	
	 196	
Amongst	the	five	outputs,	a	total	of	52	nodes	were	linked	to	angiogenesis;	35	of	these	
were	pro-angiogenic,	17	were	anti-angiogenic,	(table	7.3.1).	131	nodes	regulated	
apoptosis,	50	were	anti-apoptotic,	the	remaining	81	pro-apoptotic,	(table	7.3.1.1.).	Of	
the	total	37	nodes	regulating	DNA	repair;	8	were	considered	as	negative	regulators	and	
29	as	positive	regulators	of	DNA	repair,	(table	7.3.1.2).	A	total	of	66	nodes	regulated	
cell	cycle	arrest,	31	of	these	were	inhibitors,	the	remaining	35	positive	regulators	of	cell	
cycle	arrest,	(table	7.3.1.3).	74	nodes	regulated	cellular	senescence,	38	were	negative	
regulators,	36	positive	senescence	regulators	(table	7.3.1.4)	
	
Amongst	the	inputs	(hypoxia	and	DNA	damage),	a	total	of	62	nodes	are	influenced	by	
DNA	damage.	Of	these,	the	majority	are	activated	(n	=	57)	the	remaining	5	inhibited	
(table	7.3.1.5).	The	network	was	highly	connected	to	the	hypoxia	input	with	a	total	of	
90	nodes	regulated	by	hypoxia.	Of	these,	72	were	activated,	18	inhibited	(table	
7.3.1.6).		
	
Table	7.3.1	Nodes	that	regulate	angiogenesis	in	the	PMH302	model.		
A	total	of	52	angiogenic	nodes	are	considered.	Of	these;	35	are	pro	angiogenic,	17	anti-
angiogenic	nodes.	GO	IDs	and	terms	are	described	for	each	interaction.		Other	interactions	
were	confirmed	by	literature	search.	Some	PMID/PMCIDs	were	not	available.	For	these	DOI	or	
links	are	provided.		
Source	 Interaction	 Target	 GO	ID	 GO	TERM	 PMID/PMC	
BBC3	 Activates	 Angiogenesis	 	 	 23122957	
BCL2	 Activates	 Angiogenesis	 	 	 18490895	
BCL2	 Activates	 Angiogenesis	 	 	 11280784	
BDKRB1	 Activates	 Angiogenesis	 	 	 11387266	
CALD1	 Activates	 Angiogenesis	 GO:0001525	 Angiogenesis	 18980955	
CALD1	 Activates	 Angiogenesis	 GO:0001570	 Vasculogenesis	 15161654	
CCND1	 Activates	 Angiogenesis	 	 	 PMC1986788	
CD44	 Activates	 Angiogenesis	 	 	 1698758	
CDK2	 Activates	 Angiogenesis	 	 	 23042366	
CDK4	 Activates	 Angiogenesis	 	 	 20603602	
CDK5	 Activates	 Angiogenesis	 	 	 20826806	
JUN	 Activates	 Angiogenesis	 GO:0001525	 Angiogenesis	 25083991	
EGFR	 Activates	 Angiogenesis	 	 	 23856030	
ELAVL1	 Activates	 Angiogenesis	 	 	 25422430	
ELAVL1	 Activates	 Angiogenesis	 	 	 23516604	
ELAVL1	 Activates	 Angiogenesis	 	 	 25422430	
EPHB4	 Activates	 Angiogenesis	 GO:0002042	 Cell	migration	
involved	in	
12734395	
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sprouting	
angiogenesis	
EPHB4	 Activates	 Angiogenesis	 GO:0001525	 Angiogenesis	 10518221	
EPHB4	 Activates	 Angiogenesis	 GO:0035475	 Angioblast	cell	
migration	
involved	in	
selective	
angioblast	
sprouting	
19815777	
EPHB4	 Activates	 Angiogenesis	 	 	 14702107	
FGF2	 Activates	 Angiogenesis	 GO:0045766	 Positive	
regulation	of	
angiogenesis	
17187775	
FGF2	 Activates	 Angiogenesis	 GO:0002042	 Cell	migration	
involved	in	
sprouting	
angiogenesis	
23856030	
FGF2	 Activates	 Angiogenesis	 GO:0043536	 Positive	
regulation	of	
blood	vessel	
endothelial	cell	
migration	
18658046	
HIF1A	 Activates	 Angiogenesis	 GO:0030949	 Positive	
regulation	of	
vascular	
endothelial	
growth	factor	
receptor	
signaling	
pathway	
8756616	
HIF1A	 Activates	 Angiogenesis	 GO:0045766	 positive	
regulation	of	
angiogenesis	
12958148	
HIF1A	 Activates	 Angiogenesis	 	 positive	
regulation	
vascular	
endothelial	
growth	factor	
production	
18037992	
HIF1A	 Activates	 Angiogenesis	 GO:0001525	 Angiogenesis	 17636018	
HIF1A	 Activates	 Angiogenesis	 GO:2001214	 Positive	
regulation	of	
vasculogenesis	
22098710	
HSPA4	 Activates	 Angiogenesis	 GO:0004576
6	
Positive	
regulation	of	
angiogenesis	
15994930	
HSPA4	 Activates	 Angiogenesis	 	 	 15994930	
HSPA4	 Activates	 Angiogenesis	 	 	 PMC3980608	
MMP1	 Activates	 Angiogenesis	 	 	 7512058	
MMP13	 Activates	 Angiogenesis	 	 	 22992737	
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NTN1	 Activates	 Angiogenesis	 	 	 23824572	
NTN1	 Activates	 Angiogenesis	 	 	 20080097	
PDGFRB	 Activates	 Angiogenesis	 GO:0008543	 Fibroblast	
growth	factor	
receptor	
signalling	
pathway	
18827023	
PDGFRB	 Activates	 Angiogenesis	 GO:0038091	 positive	
regulation	of	
cell	
proliferation	
by	VEGF-
activated	
platelet	
derived	growth	
factor	receptor	
signalling	
pathway	
17470632	
PDGFRB	 Activates	 Angiogenesis	 GO:0060981	 Cell	migration	
involved	in	
coronary	
angiogenesis	
18555217	
PDGFRB	 Activates	 Angiogenesis	 GO:0035441	 Cell	migration	
involved	in	
vasculogenesis	
14998491	
PRKCA	 Activates	 Angiogenesis	 GO:0045786	 Positive	
regulation	of	
angiogenesis	
11909826	
PRKCA	 Activates	 Angiogenesis	 GO:0001525	 Angiogenesis	 11909826	
PRKCA	 Activates	 Angiogenesis	 GO:0001938	 Positive	
regulation	of	
endothelial	cell	
proliferation	
11909826	
PTGS2	 Activates	 Angiogenesis	 GO:0090050	 Positive	
regulation	of	
cell	migration	
involved	in	
sprouting	
angiogenesis	
9630216	
PTGS2	 Activates	 Angiogenesis	 GO:0010575	 Positive	
regulation	
vascular	
endothelial	
growth	factor	
production	
9630216	
PTGS2	 Activates	 Angiogenesis	 GO:0090271	 Positive	
regulation	of	
fibroblast	
growth	factor	
production	
9630216	
	 199	
S100B	 Activates	 Angiogenesis	 	 	 23719262	
SGK	 Activates	 Angiogenesis	 	 	 24265802	
SGK	 Activates	 Angiogenesis	 	 	 20568246	
STMN1	 Activates	 Angiogenesis	 	 	 15031128	
TGFA	 Activates	 Angiogenesis	 GO:0001938	 Angiogenesis	 14998491	
TGFA	 Activates	 Angiogenesis	 	 	 19481589	
VEGFA	 Activates	 Angiogenesis	 GO:0001525	 Angiogenesis	 11427521	
VEGFA	 Activates	 Angiogenesis	 GO:0001938	 Positive	
regulation	of	
endothelial	cell	
proliferation	
2575835	
VEGFA	 Activates	 Angiogenesis	 GO:0035148	 Tube	
formation	
21245381	
VEGFA	 Activates	 Angiogenesis	 GO:0048010	 vascular	
endothelial	
growth	factor	
receptor	
signaling	
pathway	
16109918	
VEGFA	 Activates	 Angiogenesis	 GO:0043117	 Positive	
regulation	of	
vascular	
permeability	
20497126	
VEGFA	 Activates	 Angiogenesis	 G0:0038033	 Positive	
regulation	of	
endothelial	cell	
chemotaxis	by	
VEGF-activated	
vascular	
endothelial	
growth	factor	
receptor	
signalling	
pathway	
16489009	
VEGFA	 Activates	 Angiogenesis	 GO:0035924	 Cellular	
response	to	
vascular	
endothelial	
growth	factor	
stimulus	
12714610	
VEGFA	 Activates	 Angiogenesis	 GO:0008083	 Growth	factor	
activity	
9202027	
VEGFA	 Activates	 Angiogenesis	 GO:0090050	 Positive	
regulation	of	
cell	migration	
involved	in	
sprouting	
angiogenesis	
18577655	
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VEGFA	 Activates	 Angiogenesis	 GO:0045766	 Positive	
regulation	of	
angiogenesis	
18440775	
VEGFA	 Activates	 Angiogenesis	 GO:0002042	 Cell	migration	
involved	in	
sprouting	
angiogenesis	
20497126	
VEGFA	 Activates	 Angiogenesis	 GO:0001974	 Blood	vessel	
remodelling	
20551324	
VEGFA	 Activates	 Angiogenesis	 GO:0001569	 Patterning	of	
blood	vessels	
7929439	
VEGFA	 Activates	 Angiogenesis	 	 	 17470632	
VEGFA	 Activates	 Angiogenesis	 	 	 18440775	
VEGFA	 Activates	 Angiogenesis	 	 	 20660291	
VEGFA	 Activates	 Angiogenesis	 	 	 19033661	
CD82	 Inhibits	 Angiogenesis	 	 	 25149363	
CD82	 Inhibits	 Angiogenesis	 	 	 PMC3313899	
IFI16	 Inhibits	 Angiogenesis	 	 	 21488755	
IFI16	 Inhibits	 Angiogenesis	 	 	 14729471	
CD59	 Inhibits	 Angiogenesis	 GO:0016525	 Negative	
regulation	of	
angiogenesis	
17237428	
COL18A1	 Inhibits	 Angiogenesis	 GO:0001525	 Angiogenesis	 15857886	
COL18A1	 Inhibits	 Angiogenesis	 	 	 10942434	
NOTCH1	 Inhibits	 Angiogenesis	 GO:0060979	 Vasculogenesis	
involved	in	
coronary	
vascular	
morphogenesi
s	
20616313	
NOTCH1	 Inhibits	 Angiogenesis	 GO:002040	 Sprouting	
angiogenesis	
20616313	
NOTCH1	 Inhibits	 Angiogenesis	 GO:008285	 Negative	
regulation	of	
cell	
proliferation	
20616313	
NOTCH1	 Inhibits	 Angiogenesis	 GO:0090051	 Negative	
regulation	of	
cell	migration	
involved	in	
sprouting	
angiogenesis	
20616313	
NOTCH1	 Inhibits	 Angiogenesis	 GO:0035924	 Cellular	
response	to	
vascular	
endothelial	
growth	factor	
stimulus	
20616313	
DKK1	 Inhibits	 Angiogenesis	 	 	 24091497	
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ING4	 Inhibits	 Angiogenesis	 	 	 15029197	
ING4	 Inhibits	 Angiogenesis	 	 	 19409049	
HOXA5	 Inhibits	 Angiogenesis	 GO:0016525	 Negative	
regulation	of	
angiogenesis	
17957028	
PPARG	 Inhibits	 Angiogenesis	 	 	 15041792	
PPARG	 Inhibits	 Angiogenesis	 	 	 16082179	
NQO1	 Inhibits	 Angiogenesis	 	 	 DOI:	
10.1158/0008
-5472	
PML	 Inhibits	 Angiogenesis	 	 	 22589541	
PML	 	 	 GO:0030308	 Negative	
regulation	of	
cell	growth	
PMC359216	
SERPINF1	 Inhibits	 Angiogenesis	 GO:0016525	 Negative	
regulation	of	
angiogenesis	
11562499	
SERPINF1	 Inhibits	 Angiogenesis	 	 	 24318110	
ELAVL1	 Inhibits	 Angiogenesis	 	 	 20724828	
TGFB1	 Inhibits	 Angiogenesis	 	 	 16373850	
BNIP3L	 Inhibits	 Angiogenesis	 	 	 17717605	
PTEN	 Inhibits	 Angiogenesis	 	 	 19437103	
NANOG	 Activates	 Angiogenesis	 	 	 21119109	
PHB	 Activates	 Angiogenesis	 	 	 PMC2213620	
SERPINE
1	
Activates	 Angiogenesis	 	 	 11454712	
SENP3	 Activates	 Angiogenesis	 	 	 19680224	
JAG1	 Activates	 Angiogenesis	 	 	 25767274	
MTA1	 Activates	 Angiogenesis	 	 	 16630134	
RSK2	 Activates	 Angiogenesis	 	 	 25014166	
MIC1	 Activates	 Angiogenesis	 	 	 22484283	
ING1	 Inhibits	 Angiogenesis	 	 	 20066899	
	
	
Table	7.3.1.1	Nodes	that	regulate	apoptosis	in	the	PMH302	model.		
A	total	of	131	apoptotic	nodes	are	considered.	Of	these;	81	are	pro-	apoptotic,	50	anti-
apoptotic.	GO	IDs	and	terms	are	described;	other	interactions	were	confirmed	by	literature	
search.	All	interactions	are	supplied	with	their	PMID	or	PMC	ID,	some	described	by	more	than	
one	literature	source.	Some	PMID/PMCIDs	were	not	available.	For	these	DOI	or	links	are	
supplied.	
Source	 Interacti
on	
Target	 GO	ID	 GO	Term	 PMID/PMC	
APEX1	 Inhibits	 Apoptosis	 	 	 15694346	
NANOG	 Inhibits	 Apoptosis	 	 	 21706347	
NANOG	 Inhibits	 Apoptosis	 	 	 19906868	
MIC1	 Activates	 Apoptosis	 	 	 25180886	
MIC1	 Activates	 Apoptosis	 	 	 19540205	
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TOP2A	 Activates	 Apoptosis	 GO:003
0263	
Apoptotic	
chromosome	
condensatio
n	
doi:10.1038/cddis.2013.2
87	
CASP2	 Activates	 Apoptosis	 GO:009
7194	
Execution	
phase	of	
apoptosis	
11832478	
MTA1	 Inhibits	 Apoptosis	 	 	 25502548	
FLI1	 Inhibits	 Apoptosis	 	 	 9178886	
ZNF148	 Activates	 Apoptosis	 	 	 17019648	
NFKB	 Activates	 Apoptosis	 	 	 10849002	
NFKB	 Inhibits	 Apoptosis	 	 	 11160126	
WWOX	 Activates	 Apoptosis	 	 	 PMC3380332	
SERPINE1	 Activates	 Apoptosis	 	 	 18483310	
CYP24A1	 Activates	 Apoptosis	 	 	 PMC3485377	
ESR1	 Activates	 Apoptosis	 GO:004
2981:	
regulation	of	
apoptotic	
process	
17615152	
ECT2	 Activates	 Apoptosis	 	 	 12787561	
MSH2	 Activates	 Apoptosis	 GO:004
3524:	
negative	
regulation	of	
neuron	
apoptosis	
20124482	
DUSP4	 Activates	 Apoptosis	 	 	 20860659	
CXCR4	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
15705741	
XAF1	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
21788101	
IL6	 Activates	 Apoptosis	 GO:004
3154:	
negative	
regulation	of	
cysteine-
type	
endopeptida
se	activity	
involved	in	
apoptotic	
process	
11751424	
IL7	 Activates	 Apoptosis	 GO:000
1781:	
neutrophil	
apoptosis	
12714376	
IL6	 Activates	 Apoptosis	 GO:004
2981:	
regulation	of	
apoptotic	
process	
21954875	
FGF2	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
15856005	
EGFR	 Activates	 Apoptosis	 	 	 20081577	
CD44	 Activates	 Apoptosis	 	 	 16208414	
PRKCA	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
10825394	
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PRKCA	 Activates	 Apoptosis	 	 	 DOI:10.1007/978-1-
59745-199-4_2	
DUSP2	 Activates	 Apoptosis	 GO:004
2981:	
regulation	of	
apoptotic	
process	
12673251	
DUSP2	 Activates	 Apoptosis	 	 	 9501207	
FDXR	 Activates	 Apoptosis	 	 	 12370809	
BAX	 Activates	 Apoptosis	 GO:004
2981:	
regulation	of	
apoptotic	
process	
19672311	
IFI16	 Activates	 Apoptosis	 GO:004
2771:	
DNA	damage	
response,	
signal	
transduction	
by	p53	class	
mediator	
resulting	in	
induction	of	
apoptosis	
14990579	
TLR3	 Activates	 Apoptosis	 GO:004
3065:	
positive	
regulation	of	
apoptotic	
process	
16585585	
CDC25A	 Activates	 Apoptosis	 	 	 15822194	;	
CDC25A	 Activates	 Apoptosis	 	 	 20368335	
FOS	 Activates	 Apoptosis	 	 	 8524298	
DDIT4	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
18796435	
MAP4K4	 Activates	 Apoptosis	 	 	 15958553	
SEMA3B	 Activates	 Apoptosis	 	 	 15273288	
PEG3	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
11050235	
PEG3	 Activates	 Apoptosis	 	 	 10681424	
PRSS50	 Activates	 Apoptosis	 	 	 21086474	
IFITM2	 Activates	 Apoptosis	 	 	 19544527	
SIVA1	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
20727854	
SIVA1	 Activates	 Apoptosis	 GO:000
6917:	
induction	of	
apoptosis	
20817677	
PCBP4	 Activates	 Apoptosis	 GO:000
8630:	
DNA	damage	
response,	
signal	
transduction	
resulting	in	
induction	of	
apoptosis	
21522185	
DFNA5	 Activates	 Apoptosis	 	 	 19835622	
HNF4A	 Activates	 Apoptosis	 	 	 21219856	
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TP53INP1	 Activates	 Apoptosis	 GO:000
6917:	
induction	of	
apoptosis	
24608790	
CCNG1	 Activates	 Apoptosis	 	 	 10467405	
CASP8	 Activates	 Apoptosis	 GO:004
2981:	
regulation	of	
apoptotic	
process	
15029256	
CDKN1B	 Activates	 Apoptosis	 	 	 10208428	
COL18A1	 Activates	 Apoptosis	 	 	 11158588	
BBC3	 Activates	 Apoptosis	 GO:000
8633:	
activation	of	
pro-
apoptotic	
gene	
products	
11572983	
BBC3	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
11572983	
BBC3	 Activates	 Apoptosis	 GO:000
6917:	
induction	of	
apoptosis	
11572983	
APAF1	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
10791976	
APAF1	 Activates	 Apoptosis	 GO:004
2981:	
regulation	of	
apoptotic	
process	
10791976	
BAK1	 Activates	 Apoptosis	 GO:004
2981:	
regulation	of	
apoptotic	
process	
20460378	
NLRC4	 Activates	 Apoptosis	 GO:004
3065:	
positive	
regulation	of	
apoptotic	
process	
11374873	
ATF3	 Activates	 Apoptosis	 	 	 18755691	
PTGS2	 Activates	 Apoptosis	 	 	 16544098	
GADD45A	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
17474084	
NOTCH1	 Activates	 Apoptosis	 GO:004
3065:	
positive	
regulation	of	
apoptotic	
process	
10227380	
FAS	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
7536620	
FAS	 Activates	 Apoptosis	 	 	 	
PTEN	 Activates	 Apoptosis	 GO:000
6917:	
induction	of	
apoptosis	
11159942	
AIFM2	 Activates	 Apoptosis	 GO:000
6917:	
induction	of	
apoptosis	
21943319	
DKK1	 Activates	 Apoptosis	 	 	 17026960;		
AR	 Activates	 Apoptosis	 	 	 16479009	
BNIP3L	 Activates	 Apoptosis	 GO:004
3065:	
positive	
regulation	of	
apoptotic	
process	
10381623	
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TNFRSF10
A	
Activates	 Apoptosis	 GO:000
6917:	
induction	of	
apoptosis	
21785270	
TNFRSF10
A	
Activates	 Apoptosis	 GO:000
8625:	
induction	of	
apoptosis	via	
death	
domain	
receptor	
21785270	
TNFRSF10
B	
Activates	 Apoptosis	 GO:000
8633:	
activation	of	
pro-
apoptotic	
gene	
products	
22046379	
IGFBP7	 Activates	 Apoptosis	 	 	 18267069	
LATS2	 Activates	 Apoptosis	 	 	 15265683	
SERPINB5	 Activates	 Apoptosis	 	 	 15713631	
PERP	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
10733530	
SIAH1	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
9403064	
SIAH1	 Activates	 Apoptosis	 GO:005
1402:	
neuron	
apoptosis	
9403064	
SIAH1	 Activates	 Apoptosis	 GO:000
43065	
:	positive	
regulation	of	
apoptotic	
process	
9403064	
LRDD	 Activates	 Apoptosis	 GO:004
3066:	
negative	
regulation	of	
apoptotic	
process	
16183742	
P53AIP1	 Activates	 Apoptosis	 GO:000
6915:	
apoptotic	
process	
16467208	
CDKN2A	 Activates	 Apoptosis	 GO:000
6917:	
induction	of	
apoptosis	
12660818	
KAT2B	 Activates	 Apoptosis	 	 	 PMC3847488	
PITX1	 Activates	 Apoptosis	 	 	 17762884	
PITX1	 Activates	 Apoptosis	 	 	 20563669	
DAXX	 Activates	 Apoptosis	 GO:000
8625	
Extrinsic	
apoptotic	
signalling	
pathway	via	
death	
domain	
receptors	
9215629	
DAXX	 Activates	 Apoptosis	 GO:200
1235	
Positive	
regulation	of	
apoptotic	
signalling	
pathway	
11193028	
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DAXX	 Activates	 Apoptosis	 GO:009
7190	
Apoptotic	
signalling	
pathway	
11003656	
DAXX	 Activates	 Apoptosis	 	 	 12407442	
DAXX	 Activates	 Apoptosis	 	 	 11773067	
DAXX	 Activates	 Apoptosis	 	 	 12407442	
DDX20	 Activates	 Apoptosis	 GO:004
3065	
Positive	
regulation	of	
apoptotic	
process	
16153597	
JUN	 Activates	 Apoptosis	 	 	 1169773	
ING5	 Activates	 Apoptosis	 GO:200
1235	
Positive	
regulation	of	
apoptotic	
signalling	
pathway	
12750254	
DAP	 Activates	 Apoptosis	 GO:000
6915	
Apoptotic	
process	
7828849	
DAP	 Activates	 Apoptosis	 GO:004
3605	
Positive	
regulation	of	
apoptotic	
process	
9118961	
DAP	 Activates	 Apoptosis	 GO:004
2981	
Regulation	of	
apoptotic	
process	
11709549	
HOXA10	 Activates	 Apoptosis	 	 	 	
UCHL1	 Activates	 Apoptosis	 	 	 18949367	
UCHL1	 Activates	 Apoptosis	 	 	 18949367	
UCHL1	 Activates	 Apoptosis	 	 	 24155778	
APP	 Activates	 Apoptosis	 GO:005
1402	
Neuron	
apoptotic	
process	
19225519	
PML	 Activates	 Apoptosis	 	 	 14663483	
PML	 Activates	 Apoptosis	 G0:006
0058	
Positive	
regulation	of	
apoptotic	
process	
involved	in	
mammary	
gland	
involution	
11080164	
TFAP2C	 Activates	 Apoptosis	 	 	 14573793	
TFAP2C	 Activates	 Apoptosis	 	 	 21779369	
TFAP2A		 Activates	 Apoptosis	 GO:000
8285	
Negative	
regulation	of	
cell	
proliferation	
20607706	
TFAP2A		 Activates	 Apoptosis	 	 	 14551210	
TFAP2A		 Activates	 Apoptosis	 	 	 12654297	
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ASPP1	 Activates	 Apoptosis	 GO:004
5786	
Negative	
regulation	of	
cell	cycle	
11684014	
ASPP1	 Activates	 Apoptosis	 	 	 14729977	
ASPP1	 Activates	 Apoptosis	 	 	 14729977	
ASPP1	 Activates	 Apoptosis	 GO:007
2332	
Intrinsic	
apoptotic	
signalling	
pathway	by	
p53	class	
mediator	
11684014	
ASSP2	 Activates	 Apoptosis	 	 	 14729977	
ASSP2	 Activates	 Apoptosis	 	 	 11684014	
ASPP2	 Activates	 Apoptosis	 	 	 14729977	
ING4	 Activates	 Apoptosis	 GO:004
5926	
Negative	
regulation	of	
growth	
16387653	
BCL3	 Inhibits	 Apoptosis	 GO:004
3066	
	 20800578	
GSTP1	 Inhibits	 Apoptosis	 	 	 21637416	
ESR1	 Inhibits	 Apoptosis	 GO:004
2981	
	 9118519	
DUSP4	 Inhibits	 Apoptosis	 	 	 20860659	
IL6	 Inhibits	 Apoptosis	 GO:004
3154	
	 11751424	
IL6	 Inhibits	 Apoptosis	 GO:000
1781	
	 11751424	
IL6	 Inhibits	 Apoptosis	 GO:004
2981	
	 11751424	
PDGFRB	 Inhibits	 Apoptosis	 	 	 21954875	
FGF2	 Inhibits	 Apoptosis	 GO:000
6915	
	 15856005	
WWP1	 Inhibits	 Apoptosis	 	 	 18806757	
IGF1R	 Inhibits	 Apoptosis	 GO:000
6916	
	 14726697	
IGF1R	 Inhibits	 Apoptosis	 GO:004
3066	
	 14726697	
IGF1R	 Inhibits	 Apoptosis	 GO:004
5768	
	 14726697	
EGFR	 Inhibits	 Apoptosis	 GO:004
3066	
	 15277479	
CD44	 Inhibits	 Apoptosis	 	 	 17045821	
PRKCA	 Inhibits	 Apoptosis	 GO:000
6915:	
	 DOI:10.1007/978-1-
59745-199-4_2	
DUSP2	 Inhibits	 Apoptosis	 GO:004
2981:	
	 12673251	
DUSP2	 Inhibits	 Apoptosis	 	 	 9501207	
TGFA	 Inhibits	 Apoptosis	 GO:000
6916:	
	 16079309	
	 208	
CDC25A	 Inhibits	 Apoptosis	 	 	 11416155	
FOS	 Inhibits	 Apoptosis	 	 	 19255142	
DDIT4	 Inhibits	 Apoptosis	 GO:000
6915:	
	 19221489	
MAP4K4	 Inhibits	 Apoptosis	 	 	 21196414	
EZH2	 Inhibits	 Apoptosis	 	 	 19893569;	
EZH2	 Inhibits	 Apoptosis	 	 	 19079346	
PSEN1	 Inhibits	 Apoptosis	 GO:000
6916:	
	 10805794	
BCL2	 Inhibits	 Apoptosis	 GO:000
6916:	
	 8617294	
FHL2	 Inhibits	 Apoptosis	 	 	 21377781	
CCNG1	 Inhibits	 Apoptosis	 GO:004
3066:	
	 18497347	
TCF7L2	 Inhibits	 Apoptosis	 	 	 21965303	
EPHB4	 Inhibits	 Apoptosis	 	 	 20133814	
CDKN1B	 Inhibits	 Apoptosis	 	 	 10050878	
ATF3	 Inhibits	 Apoptosis	 	 	 doi:10.1006/jmcc.2002.2
091	
PTGS2	 Inhibits	 Apoptosis	 	 	 20027603	
SGK	 Inhibits	 Apoptosis	 	 	 12488318	
MCL1	 Inhibits	 Apoptosis	 GO:004
2981:	
	 18550749	
IER3	 Inhibits	 Apoptosis	 GO:000
6916:	
	 14688131	
NOTCH1	 Inhibits	 Apoptosis	 GO:006
0548:	
	 10227380	
VEGFA	 Inhibits	 Apoptosis	 GO:000
6916:	
	 11891765	
CDKN1A	 Inhibits	 Apoptosis	 GO:000
8629:	
	 21815189	
AR	 Inhibits	 Apoptosis	 GO:004
3066:	
	 16479009	
CKS2	 Inhibits	 Apoptosis	 	 	 18498131	
C12orf5	 Inhibits	 Apoptosis	 	 	 16839880	
SFN	 Inhibits	 Apoptosis	 GO:000
6915:	
	 15857577		
SFN	 Inhibits	 Apoptosis	 GO:000
8630:	
	 10654934	
RB1CC1	 Inhibits	 Apoptosis	 GO:000
6916	
	 2064504	
RB1CC1	 Inhibits	 Apoptosis	 GO:200
1237	
	 PMC2064504	
STAT3	 Inhibits	 Apoptosis	 GO:006
0548	
	 20562100	
STAT3	 Inhibits	 Apoptosis	 GO:006
0548	
	 16540667	
STAT3	 Inhibits	 Apoptosis	 GO:000
8283	
	 11171987	
	 209	
DAXX	 Inhibits	 Apoptosis	 	 	 19017466	
DAXX	 Inhibits	 Apoptosis	 	 	 16088932	
TP53RK	 Inhibits	 Apoptosis	 	 	 20647325	
TPT1	 Inhibits	 Apoptosis	 GO:190
2230	
	 11598139	
TPT1	 Inhibits	 Apoptosis	 GO:004
3066	
	 16130169	
TPT1	 Inhibits	 Apoptosis	 G0:004
9281	
	 15162379	
TPT1	 Inhibits	 Apoptosis	 	 	 12149273	
TPT1	 Inhibits	 Apoptosis	 	 	 15262975	
PREP1	 Inhibits	 Apoptosis	 	 	 PMC2643814	
CUL7	 Inhibits	 Apoptosis	 	 	 17229476	
	
	
Table	7.3.1.2	Nodes	that	regulate	DNA	repair	in	the	PMH302	model.		
A	total	of	37	nodes	that	regulate	DNA	repair	are	considered.	Of	these;	29	are	positive	
regulators,	8	negative	regulators	of	DNA	repair.	GO	IDs	and	terms	are	described;	other	
interactions	were	confirmed	by	literature	search.	All	interactions	are	supplied	with	their	PMID	
or	PMCID.	Some	interactions	are	described	by	more	than	one	literature	source.		
Source	 Interaction	 Target	 GO	ID	 GO	Term	 PMID/PMC	
ATM	 Activates	 DNA	
repair	
GO:0006281	 DNA	repair	 18066086	
CD44	 Activates	 DNA	
repair	
	 	 16263582	
CDKN1A	 Activates	 DNA	
repair	
	 	 22735704	
DDB2	 Activates	 DNA	
repair	
GO:0070914	 UV-damage	
excision	repair	
22334663	
FEN1	 Activates	 DNA	
repair	
GO:0006302	 Double-strand	
break	repair	
8131753	
FGF2	 Activates	 DNA	
repair	
	 	 20681019	
HSPA4	 Activates	 DNA	
repair	
	 	 PMC4041939	
IFI16	 Activates	 DNA	
repair	
	 	 18472023	
MCL1	 Activates	 DNA	
repair	
	 	 20647761	
MGMT	 Activates	 DNA	
repair	
GO:0006307	 DNA	
dealkylation	
involved	in	
DNA	repair	
1554415	
MSH2	 Activates	 DNA	
repair	
GO:0006281	 DNA	repair	 8942985	
MSH2	 Activates	 DNA	
repair	
GO:0006298	 Mismatch	
repair	
1334021	
	 210	
MSH2	 Activates	 DNA	
repair	
GO:0006298	 Mismatch	
repair	
11555625	
MSH2	 Activates	 DNA	
repair	
GO:0006301	 Post	
replication	
repair	
17715146	
NME1	 Activates	 DNA	
repair	
	 	 25017017	
PCNA	 Activates	 DNA	
repair	
GO:0006281	 Positive	
regulation	of	
DNA	repair	
16227586	
PRKDC	 Activates	 DNA	
repair	
GO:0000724	 Double-strand	
break	repair	
via	
homologous	
recombination	
11418067	
RAD51	 Activates	 DNA	
repair	
GO:0000150	 	 PMC2430071	
ATM	 Activates	 DNA	
repair	
	 	 doi:10.1038/ncomms4347	
ATR	 Activates	 DNA	
repair	
	 	 PMC4176976	
BCCIP	 Activates	 DNA	
repair	
GO:0006281	 DNA	repair	 17947333	
BRCA1	 Activates	 DNA	
repair	
	 	 14636569	
GADD45A	 Activates	 DNA	
repair	
GO:0006281	 DNA	repair	 7973727	
YY1	 Activates	 DNA	
repair	
GO:0000724	 	Double	
strand	break	
repair	via	
homologous	
recombination	
18026119	
KLF4	 Inhibits	 DNA	
repair	
	 	 PMC3750599	
MDM4	 Inhibits	 DNA	
repair	
	 	 24608433	
MYC	 Inhibits	 DNA	
repair	
	 	 23308051	
PTTG1		 Inhibits	 DNA	
repair	
GO:0006281	 DNA	repair	 18663361	
SIAH1	 Inhibits	 DNA	
repair	
	 	 20682032	
PPMID	 Inhibits	 DNA	
repair	
	 	 15327777	
MDM2	 Inhibits	 DNA	
repair	
	 	 18541670	
APEX1	 Activates	 DNA	
Repair	
GO:0006284	 Base	Excision	
Repair	
25108836	
APEX1	 Activates	 DNA	
Repair	
GO:0000724	 Double-strand	
break	repair	
via	
19052983	
	 211	
homologous	
recombination	
APEX1	 Activates	 DNA	
Repair	
GO:0006281	 DNA	Repair	 9560228	
APEX1	 Activates	 DNA	
Repair	
GO:0045739	 	Positive	
regulation	of	
DNA	repair	
9207062	
PIN1	 Activates	 DNA	
Repair	
	 	 23623683	
PIAS1	 Activates	 DNA	
Repair	
	 	 20016603	
RPA1	 Activates	 DNA	
Repair	
GO:0006281	 DNA	Repair	 18469000	
	 	 	 GO:0000724	 Double-strand	
break	repair	
via	
homologous	
recombination	
17765923	
	 	 	 GO:0006284	 Base	excision	
repair	
9765279	
	 	 	 GO:0006298	 Mismatch	
repair	
							9430682	
ING1	 Activates	 DNA	
repair	
	 	 23459830	
SUMO3	 Activates	 DNA	
repair	
	 	 20016603	
RPS27L	 Activates	 DNA	
repair	
GO:0006281	 DNA	repair	 18056458	
MTA1	 Activates	 DNA	
repair	
GO:0006302	 Double	strand	
break	repair	
19805145	
RFWD3	 Activates	 DNA	
repair	
GO:0006281	 DNA	repair	 21558276	
SERPINE1	 Inhibits	 DNA	
repair	
	 	 23111469	
	
	
Table	7.3.1.3	Nodes	that	regulate	cell	cycle	arrest	in	the	PMH302	model.		
A	total	of	58	nodes	that	regulate	the	cell	cycle	are	considered.	Of	these;	28	are	positive	
regulators,	30	are	negative	regulators	of	cell	cycle	arrest.	GO	IDs	and	terms	are	described;	
other	interactions	were	confirmed	by	literature	search.	All	interactions	are	supplied	with	their	
PMID	or	PMCID.	Some	interactions	are	described	by	more	than	one	literature	source.	
Source	 Interaction	 Target	 GO	ID	 GO	Term	 PMID/PMC	
BRCA1	 Activates	 Cell	
cycle	
arrest	
GO:0071158	 Positive	
regulation	of	cell	
cycle	arrest	
21102443	
BRCA1	 Activates	 Cell	
cycle	
arrest	
	 	 10644742	
	 212	
BRCA1	 Activates	 Cell	
cycle	
arrest	
	 	 10644742	
BRCA1	 Activates	 Cell	
cycle	
arrest	
	 	 7954448	
CDKN1B	 Activates	 Cell	
cycle	
arrest	
GO:0007050	 Cell	cycle	arrest	 12093740	
CDKN1B	 Activates	 Cell	
cycle	
arrest	
GO:0000082	 G1/S	transition	
of	mitotic	cell	
cycle	
10208428	
CDKN1B	 Activates	 Cell	
cycle	
arrest	
GO:0000278	 Mitotic	cell	cycle	 19266349	
CDKN1B	 Activates	 Cell	
cycle	
arrest	
GO:0045736	 Negative	
regulation	of	
cyclin-
dependent	
protein	
serine/threonine	
kinase	activity	
15374880	
CDKN1B	 Activates	 Cell	
cycle	
arrest	
GO:006977	 DNA	damage	
response,	signal	
transduction	by	
p53	class	
mediator	
resulting	in	cell	
cycle	arrest	
8033213	
ATF3	 Activates	 Cell	
cycle	
arrest	
	 	 12386811	
PTGS2	 Activates	 Cell	
cycle	
arrest	
GO:0045786	 Negative	
regulation	of	cell	
cycle	
10567385	
PTGS2	 Activates	 Cell	
cycle	
arrest	
	 	 11606477	
GADD45A	 Activates	 Cell	
cycle	
arrest	
GO:0051726	 Regulation	of	
cell	cycle	
12124778	
GADD45A	 Activates	 Cell	
cycle	
arrest	
GO:0007050	 Cell	cycle	arrest	 10747892	
GADD45A	 Activates	 Cell	
cycle	
arrest	
GO:0000086	 G2/M	transition	
of	mitotic	cell	
cycle	
11964479	
DKK1	 Activates	 Cell	
cycle	
arrest	
	 	 20549706	
	 213	
DKK1	 Activates	 Cell	
cycle	
arrest	
	 	 12740383	
IGFBP7	 Activates	 Cell	
cycle	
arrest	
	 	 23388612	
RAS	 Activates	 Cell	
cycle	
arrest	
	 	 3510745	
RAS	 Activates	 Cell	
cycle	
arrest	
	 	 3049071	
KLF4	 Activates	 Cell	
cycle	
arrest	
	 	 PMC3750599	
E2F1	 Activates	 Cell	
cycle	
arrest	
	 	 9766435	
PAD4	 Activates	 Cell	
cycle	
arrest	
	 	 16502257	
CDK5	 Activates	 Cell	
cycle	
arrest	
GO:0071156	 Regulation	of	
cell	cycle	arrest	
21473899	
CDKN2A	 Activates	 Cell	
cycle	
arrest	
GO:0007050	 Cell	cycle	arrest	 23238983	
CDKN2A	 Activates	 Cell	
cycle	
arrest	
GO:0071158	 positive	
regulation	of	cell	
cycle	arrest	
9529249	
MAPK1	 Activates	 Cell	
cycle	
arrest	
	 	 11821415	
RAF1	 Activates	 Cell	
cycle	
arrest	
	 	 10022606	
RBC1CC1	 Activates	 Cell	
cycle	
arrest	
GO:0007049	 Cell	cycle	 16061648	
KAT2B	 Activates	 Cell	
cycle	
arrest	
GO:000825	 Negative	
regulation	of	cell	
proliferation	
8684459	
KAT2B	 Activates	 Cell	
cycle	
arrest	
G0:0006915	 	 20809119	
ING4	 Activates	 Cell	
cycle	
arrest	
	 Cell	cycle	 15251430	
STMN1	 Activates	 Cell	
cycle	
arrest	
	 	 15368352	
	 214	
STMN1	 Activates	 Cell	
cycle	
arrest	
	 	 15031128	
HOXA10	 Activates	 Cell	
cycle	
arrest	
	 	 2731304	
HOXA5	 Activates	 Cell	
cycle	
arrest	
	 	 25590986	
MYST4	 Activates	 Cell	
cycle	
arrest	
	 	 19001415	
PPARG	 Activates	 Cell	
cycle	
arrest	
	 	 15916743	
EXPORTIN1	 Activates	 Cell	
cycle	
arrest	
	 	 23615632	
EXPORTIN1	 Activates	 Cell	
cycle	
arrest	
	 	 22832492	
TFAP2C	 Activates	 Cell	
cycle	
arrest	
	 	 16867219	
ID3	 Activates	 Cell	
cycle	
arrest	
	 	 21498546	
CHEK2	 Activates	 Cell	
cycle	
arrest	
	 	 PMC316357	
BTG2	 Activates	 Cell	
cycle	
arrest	
GO:0006281	 DNA	repair	 10669755	
POU4F1	 Activates	 Cell	
cycle	
arrest	
	 	 18421303	
CHEK1	 Activates	 Cell	
cycle	
arrest	
	 	 21034966	
ATM	 Activates	 Cell	
cycle	
arrest	
GO:0007050	 cell	cycle	arrest	 11721054	
ATR	 Activates	 Cell	
cycle	
arrest	
	 	 11721054	
DUSP5	 Activates	 Cell	
cycle	
arrest	
	 	 12944906	
PARK2	 Activates	 Cell	
cycle	
arrest	
	 	 24793136	
	 215	
EPHB4	 Inhibits	 Cell	
cycle	
arrest	
	 	 15930280	
APAF1	 Inhibits	 Cell	
cycle	
arrest	
	 	 18309324	
APAF1	 Inhibits	 Cell	
cycle	
arrest	
	 	 18042457	
ATF3	 Inhibits	 Cell	
cycle	
arrest	
GO:0008284	 Positive	
regulation	of	cell	
proliferation	
15990869	
RGS16	 Inhibits	 Cell	
cycle	
arrest	
	 	 16405749	
S100A6	 Inhibits	 Cell	
cycle	
arrest	
GO:0048146	 Positive	
regulation	of	
fibroblast	
proliferation	
12577318	
S100A6	 Inhibits	 Cell	
cycle	
arrest	
	 	 20013795	
S100A6	 Inhibits	 Cell	
cycle	
arrest	
	 	 23095053	
IER3	 Inhibits	 Cell	
cycle	
arrest	
	 	 11311240	
SLC2A1	 Inhibits	 Cell	
cycle	
arrest	
	 	 22689530	
AR	 Inhibits	 Cell	
cycle	
arrest	
	 	 16877366	
AR	 Inhibits	 Cell	
cycle	
arrest	
	 	 6483690	
AR	 Inhibits	 Cell	
cycle	
arrest	
	 	 9685369	
MYCN	 Inhibits	 Cell	
cycle	
arrest	
	 	 17495526	
CCNB1	 Inhibits	 Cell	
cycle	
arrest	
	 	 2570636	
CCNB1	 Inhibits	 Cell	
cycle	
arrest	
	 	 1717476	
	 216	
CCNB1	 Inhibits	 Cell	
cycle	
arrest	
	 	 8797586	
MYC	 Inhibits	 Cell	
cycle	
arrest	
GO:0007050	 Cell	cycle	arrest	 10962037	
MUC1	 Inhibits	 Cell	
cycle	
arrest	
GO:0006977	 DNA	damage	
response,	signal	
transduction	by	
p53	class	
mediator	
resulting	in	cell	
cycle	arrest	
15710329	
YBX1	 Inhibits	 Cell	
cycle	
arrest	
	 	 20398058	
HDAC1	 Inhibits	 Cell	
cycle	
arrest	
	 	 20194438	
CDK2	 Inhibits	 Cell	
cycle	
arrest	
	 	 19445729	
VRK1	 Inhibits	 Cell	
cycle	
arrest	
	 	 18286197	
AURKA	 Inhibits	 Cell	
cycle	
arrest	
	 	 24841948	
JUN	 Inhibits	 Cell	
cycle	
arrest	
GO:0048146	 Positive	
regulation	of	
fibroblast	
proliferation	
1171114	
UBE2A	 Inhibits	 Cell	
cycle	
arrest	
GO:0008284	 Positive	
regulation	of	cell	
proliferation	
1748683	
ING5	 Inhibits	 Cell	
cycle	
arrest	
GO:0008285	 Negative	
regulation	of	cell	
proliferation	
12750254	
CUL7	 Inhibits	 Cell	
cycle	
arrest	
	 	 18498745	
PRAK	 Inhibits	 Cell	
cycle	
arrest	
	 	 DOI:	10.1007/s11684-
009-0073-y	
SIVA1	 Inhibits	 Cell	
cycle	
arrest	
	 	 23462994	
MCL1	 Inhibits	 Cell	
cycle	
arrest	
	 	 22378300	
	 217	
CKS2	 Inhibits	 Cell	
cycle	
arrest	
	 	 1862572	
ISG15	 Inhibits	 Cell	
cycle	
arrest	
	 	 PMC4226694	
RAD51	 Inhibits	 Cell	
cycle	
arrest	
	 	 19140342	
CCNA	 Inhibits	 Cell	
cycle	
arrest	
	 	 25615569	
PRKAB1	 Activates	 Cell	
cycle	
arrest	
GO:0007050	 Cell	cycle	arrest	 11554766	
PRKAB1	 Activates	 Cell	
cycle	
arrest	
	 	 15866171	
CASP2	 Activates	 Cell	
cycle	
arrest	
GO:0006977	 DNA	damage	
response,	signal	
transduction	by	
p53	class	
mediator	
resulting	in	cell	
cycle	arrest	
21726810	
CASP2	 Activates	 Cell	
cycle	
arrest	
	 	 19528949	
MTA1	 Inhibits	 Cell	
cycle	
arrest	
	 	 PMC3751420	
JAG1	 Inhibits	 Cell	
cycle	
arrest	
	 	 doi:10.1038/cddis.201
4.137	
E2F1	 Inhibits	 Cell	
cycle	
arrest	
	 	 11459832	
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Table	7.3.1.4	Nodes	that	regulate	cellular	senescence	in	the	PMH302	model.		
A	total	of	73	nodes	that	regulate	cellular	senescence	are	considered.	Of	these;	36	are	positive	
regulators,	37	are	negative	regulators	of	senescence.	GO	IDs	and	terms	are	described;	other	
interactions	were	confirmed	by	literature	search.	All	interactions	are	supplied	with	their	PMID	
or	PMC	ID.	Some	interactions	are	described	by	more	than	one	literature	source.		
Source	 Interact
ion	
Target	 GO	ID	 GO	TERM	 PMID/PMC	
GAPDH	 Activate
s	
Cellular	
senescence	
	 	 22847419	
MSH2	 Activate
s	
Cellular	
senescence	
	 	 18986375	
DDB2	 Activate
s	
Cellular	
senescence	
	 	 23109835	
IL6	 Activate
s	
Cellular	
senescence	
	 	 22374671	
IGF1R	 Activate
s	
Cellular	
senescence	
	 	 18216278	
CDKN1
A	
Activate
s	
Cellular	
senescence	
GO:0090
398	
Cellular	
senescen
ce	
15149599	
PRKCA	 Activate
s	
Cellular	
senescence	
	 	 18162471	
TGFA	 Activate
s	
Cellular	
senescence	
	 	 12593448	
IFI16	 Activate
s	
Cellular	
senescence	
	 	 15208661	
PSEN1	 Activate
s	
Cellular	
senescence	
	 	 19181896	
IFITM2	 Activate
s	
Cellular	
senescence	
	 	 19071156	
BCL2	 Activate
s	
Cellular	
senescence	
	 	 12670482	
CD59	 Activate
s	
Cellular	
senescence	
	 	 22918646	
CDKN1
B	
Activate
s	
Cellular	
senescence	
	 	 21795702	
BAK1	 Activate
s	
Cellular	
senescence	
	 	 19747230	
PTGS2	 Activate
s	
Cellular	
senescence	
	 	 23328527	
GADD4
5A	
Activate
s	
Cellular	
senescence	
	 	 16951155	
NOTCH
1	
Activate
s	
Cellular	
senescence	
	 	 23078884	
PTEN	 Activate
s	
Cellular	
senescence	
	 	 23314408	
DKK1	 Activate
s	
Cellular	
senescence	
	 	 22927647	
AR	 Activate
s	
Cellular	
senescence	
	 	 22403609	
	 219	
MYC	 Activate
s	
Cellular	
senescence	
	 	 20027199	
IGFBP7	 Activate
s	
Cellular	
senescence	
	 	 21997538	
LATS2	 Activate
s	
Cellular	
senescence	
	 	 21498571	
RAS	 Activate
s	
Cellular	
senescence	
GO:0090
398	
Cellular	
senescen
ce	
15489886	
C12orf
5	
Activate
s	
Cellular	
senescence	
	 	 19710698	
SFN	 Activate
s	
Cellular	
senescence	
	 	 19642975	
CDKN2
A	
Activate
s	
Cellular	
senescence	
GO:0090
398	
Cellular	
senescen
ce	
14966292	
CDKN2
A	
Activate
s	
Cellular	
senescence	
GO:2000
774	
Positive	
regulatio
n	of	
cellular	
senescen
ce	
14966292	
APP	 Activate
s	
Cellular	
senescence	
	 	 24232259	
PML	 Activate
s	
Cellular	
senescence	
GO:0032
211	
Negative	
regulatio
n	of	
telomere	
maintena
nce	via	
telomera
se	
10950866	
PML	 Activate
s	
Cellular	
senescence	
GO:0032
211	
Negative	
regulatio
n	of	
telomere	
maintena
nce	via	
telomera
se	
10910364	
PML	 Activate
s	
Cellular	
senescence	
	 	 12093737	
PRAK	 Activate
s	
Cellular	
senescence	
	 	 17254968	
GAPDH	 Inhibits	 Cellular	
senescence	
	 	 21749859	
MSH2	 Inhibits	 Cellular	
senescence	
	 	 23213348	
RRM2B	 Inhibits	 Cellular	
senescence	
	 	 23139867	
	 220	
CDK4	 Inhibits	 Cellular	
senescence	
	 	 12435633	
ARID3A	 Inhibits	 Cellular	
senescence	
	 	 22010578	
FGF2	 Inhibits	 Cellular	
senescence	
	 	 17532297	
FGF2	 Inhibits	 Cellular	
senescence	
	 	 21990129	
WWP1	 Inhibits	 Cellular	
senescence	
	 	 22051607	
WWP1	 Inhibits	 Cellular	
senescence	
	 	 21795702	
EGFR	 Inhibits	 Cellular	
senescence	
	 	 21852385	
CKB	 Inhibits	 Cellular	
senescence	
	 	 21980054	
DDIT4	 Inhibits	 Cellular	
senescence	
	 	 22629318	
EZH2	 Inhibits	 Cellular	
senescence	
	 	 15208672	
EZH2	 Inhibits	 Cellular	
senescence	
	 	 21383005	
BCL2	 Inhibits	 Cellular	
senescence	
	 	 19855432	
PCBP4	 Inhibits	 Cellular	
senescence	
	 	 20817677	
HIF1A	 Inhibits	 Cellular	
senescence	
	 	 18645006	
CD59	 Inhibits	 Cellular	
senescence	
	 	 17188915	
FOXM1	 Inhibits	 Cellular	
senescence	
	 	 23262037	
HNF4A	 Inhibits	 Cellular	
senescence	
	 	 21385945	
FHL2	 Inhibits	 Cellular	
senescence	
	 	 19018287	
BRCA1	 Inhibits	 Cellular	
senescence	
	 	 12533509	
APAF1	 Inhibits	 Cellular	
senescence	
	 	 17652622	
BAK1	 Inhibits	 Cellular	
senescence	
	 	 11557285	
SGK	 Inhibits	 Cellular	
senescence	
	 	 15068796	
S100A6	 Inhibits	 Cellular	
senescence	
	 	 23095053	
MCL1	 Inhibits	 Cellular	
senescence	
	 	 22451485	
GADD4
5A	
Inhibits	 Cellular	
senescence	
	 	 21986581	
	 221	
PTEN	 Inhibits	 Cellular	
senescence	
	 	 21072054	
VEGFA	 Inhibits	 Cellular	
senescence	
	 	 21618508	
DKK1	 Inhibits	 Cellular	
senescence	
	 	 21712954	
TFDP1	 Inhibits	 Cellular	
senescence	
	 	 15716376	
NME1	 Inhibits	 Cellular	
senescence	
	 	 20713695	
MYC	 Inhibits	 Cellular	
senescence	
	 	 17664422	
SESN2	 Inhibits	 Cellular	
senescence	
	 	 20606249	
PPM1D	 Inhibits	 Cellular	
senescence	
	 	 22201816	
DAXX	 Inhibits	 Cellular	
Senescence	
	 	 23542781	
CUL7	 Inhibits	 Cellular	
senescence	
	 	 18498745	
ELAVL1	 Inhibits	 Cellular	
senescence	
	 	 23028944	
PIN1	 Activate
s	
Cellular	
senescence	
	 	 24375406	
MIC1	 Activate
s	
Cellular	
senescence	
	 	 PMC117570	
BHLHE
40	
Activate
s	
Cellular	
senescence	
	 	 18025081	
ING1	 Activate
s	
Cellular	
senescence	
	 	 19121449	
ING1	 Activate
s	
Cellular	
senescence	
	 	 19442113	
SOD2	 Inhibits	 Cellular	
senescence	
	 	 22278880	
PAI1	 Activate
s	
Cellular	
senescence	
	 	 16862142	
JAG1	 Inhibits	 Cellular	
senescence	
	 	 doi.org/10.1371/journal.pone
.0100359	
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Table	7.3.1.5	Nodes	that	are	regulated	by	DNA	damage	in	the	PMH302	model.		
A	total	of	57	nodes	are	regulated	by	the	DNA	damage	input	in	the	302	model.	Of	these;	52	are	
activated,	5	are	inhibited	by	DNA	damage.	GO	IDs	and	terms	are	described;	other	interactions	
were	confirmed	by	literature	search.	All	interactions	are	supplied	with	their	PMID	or	PMC	ID.	
Some	interactions	are	described	by	more	than	one	literature	source.	For	some	interactions	
PMID/PMC	ID	was	not	available,	thus	links	are	provided.	
Source	 Interaction	 Target	 GO	ID	 GO	Term	 PMID/PMC	
DNA	
damage	
Inhibits	 STMN1	 	 	 16909102	
DNA	
damage	
Inhibits	 MDM2	 GO:0006977:	 Positive	regulation	of	
cell	cycle	arrest	by	
p53-mediated	DNA	
damage	response.	
11960904	
DNA	
damage	
Inhibits	 MDM2	 	 	 16227609	
DNA	
damage	
Inhibits	 PTTG1	 	 	 18047793	
DNA	
damage	
Inhibits	 MYC	 GO:0034644:	 cellular	response	to	
UV	
12761495	
DNA	
damage	
Inhibits	 AURKA	 	 	 21099343	
DNA	
damage	
Activates	 YY1	 GO:0034644	 Cellular	response	to	
UV	
18026119	
DNA	
damage	
Activates	 YY1	 GO:0006974	 Cellular	response	to	
DNA	damage	
stimulus	
18026119	
DNA	
damage	
Activates	 STAT3	 	 	 20456494	
DNA	
damage	
Activates	 ICAM1	 G0:0010212	 Response	to	ionizing	
radiation	
7963663	
DNA	
damage	
Activates	 SUB1	 	 	 19047459	
DNA	
damage	
Activates	 PITX1	 	 	 20563669	
DNA	
damage	
Activates	 CCAR1	 	 	 12816952	
DNA	
damage	
Activates	 DAXX	 	 	 23539629	
DNA	
damage	
Activates	 JUN	 	 	 16733206	
DNA	
damage	
Activates	 UBE2A	 GO:0009411	 Response	to	UV	 1717990	
DNA	
damage	
Activates	 UBE2A	 	 	 23525009	
DNA	
damage	
Activates	 TP53RK	 	 	 20647325	
DNA	
damage	
Activates	 RFC	 	 	 11336696	
DNA	
damage	
Activates	 RFC	 	 	 18245774	
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DNA	
damage	
Activates	 RFC	 	 	 PMC87010	
DNA	
damage	
Activates	 PHF20	 	 	 PMC3454513	
DNA	
damage	
Activates	 ING5	 	 	 23576563	
DNA	
damage	
Activates	 DAP	 	 	 15608685	
DNA	
damage	
Activates	 MYST4	 	 	 19001415	
DNA	
damage	
Activates	 PML	 	 	 PMC156140	
DNA	
damage	
Activates	 TFAP2A	 	 	 8962096	
DNA	
damage	
Activates	 TGFB1	 	 GO:0001666:	
response	to	hypoxia	
15652459	
DNA	
damage	
Activates	 SOX4	 	 GO:0042769:	DNA	
damage	response,	
detection	of	DNA	
damage	
19234109	
DNA	
damage	
Activates	 ERBB2	 	 	 19406993	
DNA	
damage	
Activates	 NCL	 	 	 12000845	
DNA	
damage	
Activates	 HTATIP2	 	 	 21376742	
DNA	
damage	
Activates	 BTG2	 GO:0006974	 response	to	DNA	
damage	stimulus	
8944033	
DNA	
damage	
Activates	 MCTS1	 GO:0006974	 response	to	DNA	
damage	stimulus	
17016429	
DNA	
damage	
Activates	 FAS	 	 	 9660938	
DNA	
damage	
Activates	 YBX1	 GO:0006355	 regulation	of	
transcription,	DNA-
dependent	
12080043	
DNA	
damage	
Activates	 MYC	 GO:0034644	 cellular	response	to	
UV	
2687769	
DNA	
damage	
Activates	 CDK5	 	 	 19151707	
DNA	
damage	
Activates	 PRKD1	 	 	 16911582	
DNA	
damage	
Activates	 MAPK9	 	 	 17306896	
DNA	
damage	
Activates	 MAPK8	 GO:0008624	 induction	of	
apoptosis	by	
extracellular	signals	
15696159	
DNA	
damage	
Activates	 MAPK8	 GO:0008624	 induction	of	
apoptosis	by	
intracellular	signals	
15696159	
DNA	
damage	
Activates	 MAPK8	 GO:0009411	 response	to	UV	 15696159	
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DNA	
damage	
Activates	 ATM	 GO:0008630	 DNA	damage	
response,	signal	
transduction	
resulting	in	induction	
of	apoptosis	
15279774	
DNA	
damage	
Activates	 ATM	 GO:	0010212	 response	to	ionizing	
radiation	
15322239	
DNA	
damage	
Activates	 ATR	 GO:0034644	 cellular	response	to	
UV	
15322239	
DNA	
damage	
Activates	 PRKDC	 	 	 16908529	
DNA	
damage	
Activates	 TP53BP1	 	 	 14695167	
DNA	
damage	
Activates	 TP53BP1	 	 	 PMC150747	
DNA	
damage	
Activates	 CUL7	 	 	 17586686	
DNA	
damage	
Activates	 APP	 	 	 18421302	
DNA	
damage	
Activates	 PIAS1	 	 	 22976298	
DNA	
damage	
Activates	 RPA1	 GO:0042769	 DNA	damage	
response,	detection	
of	DNA	damage	
7876222	
DNA	
damage	
Activates	 RPA2	 	 	 10653628	
DNA	
damage	
Activates	 WRN	 GO:0006974	 Cellular	response	to	
DNA	damage	
stimulus	
18203716	
DNA	
damage	
Activates	 ING2	 GO:2001020	 Regulation	of	
response	to	DNA	
damage	stimulus	
23823870	
DNA	
damage	
Activates	 ING4	 	 	 PMC3705588	
DNA	
damage	
Activates	 TOP2A	 GO:0006974	 Cellular	response	to	
DNA	damage	
stimulus	
16611985	
DNA	
damage	
Activates	 PIRH2	 	 	 12654245	
DNA	
damage	
Activates	 PIRH3	 GO:0006974	 Cellular	response	to	
DNA	damage	
stimulus	
18056458	
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Table	7.3.1.6	Nodes	that	are	regulated	by	hypoxia	in	the	PMH302	model.		
A	total	of	90	nodes	are	regulated	by	the	hypoxia	input	in	the	302	model.	Of	these;	72	are	
activated	and	18	are	inhibited	by	hypoxia.	GO	IDs	and	terms	are	described;	other	interactions	
were	confirmed	by	literature	search.	All	interactions	are	supplied	with	their	PMID	or	PMC	ID.	
Some	interactions	are	described	by	more	than	one	literature	source.	For	some	interactions	
PMID/PMC	ID	was	not	available,	thus	links	are	provided.	
Source	 Interactio
n	
Target	 GO	ID	 GO	Term	 PMID/PMC	
Hypoxia	 Activates	 APP	 	 	 21640074	
Hypoxia	 Activates	 AR	 	 	 16707435	
Hypoxia	 Activates	 ICAM1	 GO:007145
6	
Cellular	
response	to	
hypoxia	
20631551	
Hypoxia	 Activates	 ICAM1	 	 	 24626595	
Hypoxia	 Activates	 ABCB1	 	 	 22946104	
Hypoxia	 Inhibits	 AIMP2	 	 	 24626595	
Hypoxia	 Activates	 AIMP2	 GO:000166
6	
Response	
to	hypoxia	
12507893	
Hypoxia	 Activates	 APAF1	 GO:000166
6	
Response	
to	hypoxia	
PMC3973202	
Hypoxia	 Inhibits	 APEX1	 	 	 doi:	10.1161/hh1201.093162	
Hypoxia	 Activates	 ATF3	 	 	 18377912	
Hypoxia	 Activates	 ATF4	 	 	 doi:10.1038/sj.onc.1209781	
Hypoxia	 Activates	 ATM	 	 	 PMC2612523	
Hypoxia	 Activates	 ATR	 	 	 PMC2612523	
Hypoxia	 Inhibits	 BAK1	 	 	 18366759	
Hypoxia	 Activates	 BCL2	 GO:007145
6	
Cellular	
response	to	
hypoxia	
20307495	
Hypoxia	 Activates	 BCL3	 	 	 12173346	
Hypoxia	 Activates	 BCL6	 	 `	 PMC3834117	
Hypoxia	 Activates	 BHLHE4
0	
	 	 25963661	
Hypoxia	 Activates	 BHLHE4
0	
	 	 15221940	
Hypoxia	 Activates	 BTG2	 	 	 doi:10.1152/ajpcell.00180.20
11	
Hypoxia	 Activates	 CA9	 GO:006141
8	
Regulation	
of	
transcriptio
n	from	RNA	
polymerase	
II	promoter	
in	response	
to	hypoxia	
19564335	
Hypoxia	 Activates	 CASP8	 	 	 12396104	
Hypoxia		 Inhibits	 CCNB1	 	 	 22264882	
Hypoxia		 Activates	 CCNG1	 	 	 11112789	
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Hypoxia	 Activates	 CD59	 	 	 PMC1779384	
Hypoxia	 Inhibits	 CDC25A	 	 	 19738433	
Hypoxia	 Inhibits	 CDC25A	 	 	 17671423	
Hypoxia	 Activates	 CDK5	 	 	 20977891	
Hypoxia	 Inhibits	 CDKN2A	 	 	 doi:	10.1158/1538-
7445.AM2012-178	
Hypoxia	 Activates	 CHEK1	 	 	 DOI:	
10.4161/cc.9.13.12059	
Hypoxia	 Inhibits	 CUL7	 	 	 22524683	
Hypoxia	 Activates	 CXCR4	 GO:000166
6	
Response	
to	hypoxia	
15174142	
Hypoxia	 Activates	 DDIT4	 GO:000166
6	
Response	
to	hypoxia	
20166753	
Hypoxia	 Inhibits	 DDX5	 	 	 24517586	
Hypoxia	 Activates	 DKK1	 	 	 24770633	
Hypoxia	 Activates	 DUSP1	 	 	 24267255	
Hypoxia	 Activates	 EGFR	 	 	 17670948	
Hypoxia	 Activates	 EGFR	 	 	 23185433	
Hypoxia	 Activates	 EPHB4	 	 	 16081502	
Hypoxia	 Inhibits	 ERBB2	 	 	 22792252	
Hypoxia	 Inhibits	 ESR1	 	 	 21458421	
Hypoxia	 Activates	 EZH2	 	 	 25189741	
Hypoxia	 Activates	 UNC5A	 	 	 PMC3793633	
Hypoxia	 Activates	 FGF2	 	 	 12088755	
hypoxia	 Activates	 FOS	 GO:003461
4	
	Cellular	
response	to	
reactive	
oxygen	
species		
19241444	
Hypoxia	 Activates	 GAPDH	 	 	 doi:10.1006/bbrc.1999.1798	
hypoxia	 Activates	 GLUT1	 	 	 10572068	
Hypoxia	 Activates	 GLUT4	 GO:003461
4	
Cellular	
response	to	
hypoxia	
20868366	
Hypoxia	 Activates	 GLUT4	 	 	 15631691	
Hypoxia	 Activates	 GLUT4	 	 Response	
to	Hypoxia	
12482987	
Hypoxia	 Activates	 GLUT4	 	 Cellular	
response	to	
hypoxia	
16081502	
Hypoxia	 Inhibits	 HNF4A	 	 	 11553861	
Hypoxia	 Activates	 HSPA4	 	 	 24660549	
Hypoxia	 Inhibits	 ID3	 	 	 doi:10.1136/heartjnl-2012-
302920y.9	
Hypoxia	 Activates	 IER3	 	 	 24758227	
Hypoxia	 Activates	 IGFBP1	 	 	 23748030	
Hypoxia	 Activates	 IGFBP1	 	 	 15644436	
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Hypoxia	 Activates	 JUN	 GO:000166
6	
Response	
to	hypoxia	
11909946	
Hypoxia	 Activates	 JUL	 GO:003461
4	
Cellular	
response	to	
hypoxia	
	
Hypoxia	 Activates	 JUN	 	 	 19241444	
Hypoxia	 Activates	 MAP4	 	 	 PMC4540186	
Hypoxia	 Activates	 MAPK1	 	 	 24555431	
Hypoxia	 Activates	 MAPK8	 	 	 11062137	
Hypoxia	 Activates	 MAPK9	 	 	 10428063	
Hypoxia	 Activates	 MCTS1	 	 	 19876643	
Hypoxia	 Activates	 MDM2	 GO:003461
4	
Cellular	
response	to	
hypoxia	
15205329	
Hypoxia	 Activates	 MDM2	 	 	 20810912	
Hypoxia	 Activates	 MDM4	 GO:003461
4	
Cellular	
response	to	
hypoxia	
22556425	
Hypoxia	 Activates	 MDM4	 	 	 20810912	
Hypoxia	 Activates	 MMP1	 	 	 26343184	
Hypoxia	 Inhibits	 MMP1	 	 	 12817301	
Hypoxia	 Activates	 MMP13	 GO:000166
6	
Response	
to	hypoxia	
19241444	
Hypoxia	 Activates	 MMP13	 	 	 16965566	
Hypoxia	 Activates	 MMP2	 	 	 16210427	
Hypoxia	 Activates	 MMP2	 	 	 16980344	
Hypoxia	 Inhibits	 MSH2	 	 	 17275176	
Hypoxia	 Activates	 MUC1	 GO:000166
6	
Response	
to	hypoxia	
23108411	
Hypoxia	 Inhibits	 MYC	 GO:003461
4	
Cellular	
response	to	
hypoxia	
PMC3753854	
Hypoxia	 Activates	 NFKB	 	 	 20696840	
Hypoxia	 Activates	 NME1	 	 	 21912348	
Hypoxia	 Activates	 NOTCH1	 GO:006141
9	
Positive	
regulation	
of	
transcriptio
n	from	RNA	
polymerase	
II	promoter	
in	response	
to	hypoxia	
DOI:	10.1186/1756-8722-6-3	
Hypoxia	 Activates	 NTN1	 	 	 PMC3793633	
Hypoxia	 Activates	 PLAUR	 GO:000166
6	
Response	
to	hypoxia	
25509186	
Hypoxia	 Activates	 PRKDC	 	 	 15272235	
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Hypoxia	 Activates	 PTGS2	 GO:003461
4	
Cellular	
response	to	
hypoxia	
16818642	
Hypoxia	 Inhibits	 RAD51	 	 	 15367671	
Hypoxia	 Activates	 RAF1	 	 	 8603510	
Hypoxia	 Activates	 SERPINE
1	
GO:003461
4	
Cellular	
response	to	
hypoxia	
247582271	
	
Hypoxia	 Activates	 SERPINE
1	
	 	 10590062	
Hypoxia	 Activates	 SGK	 	 	 19910698	
Hypoxia	 Inhibits	 SLC6A6	 	 	 23381576	
Hypoxia	 Activates	 SOX4	 GO:000166
6	
Response	
to	hypoxia	
doi.org/10.1155/2012/41692
7	
Hypoxia	 Activates	 SP7	 	 	 23805815	
Hypoxia	 Activates	 STAT3	 	 	 24525913	
Hypoxia	 Activates	 TCF7L2	 	 	 19644051	
Hypoxia	 Activates	 TGFA	 	 	 22863020	
Hypoxia	 Activates	 TGFB	 GO:000166
6	
Response	
to	hypoxia	
24626595	
Hypoxia	 Activates	 TGFB	 	 	 17213961	
Hypoxia	 Activates	 THBS1	 GO:000166
6	
Response	
to	hypoxia	
24195060	
Hypoxia	 Activates	 THBS1	 	 	 9304800	
Hypoxia	 Activates	 TPT1	 	 	 12817301	
Hypoxia	 Activates	 VEGFA	 GO:006141
8	
Regulation	
of	
transcriptio
n	from	RNA	
polymerase	
II	promoter	
in	response	
to	hypoxia	
7641334	
Hypoxia	 Activates	 VEGFA	 GO:006141
9	
Positive	
regulation	
of	
transcriptio
n	from	RNA	
polymerase	
II	promoter	
in	response	
to	hypoxia	
16081502	
Hypoxia	 Activates	 VRK1	 	 	 PMC3493170	
Hypoxia	 Activates	 XAF1	 	 	 18485100	
Hypoxia	 Activates	 YY1	 	 	 23580145	
Hypoxia	 Activates	 CCND1	 	 	 16155412	
Hypoxia	 Activates	 ID3	 	 	 20881097	
Hypoxia	 Activates	 RAS	 	 	 20532039	
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Hypoxia	 Inhibits	 WWP1	 	 	 22227207	
	
	
7.3.2	Analysis	and	validation	of	the	PMH302	model		
The	PMH260	model	was	expanded	to	provide	a	greater	overview	of	p53	–	cancer	
dynamics,	generating	the	model	designated	as	PMH302.	For	a	more	accurate	
representation	of	tumour	characteristics,	an	additional	input	of	hypoxia	was	also	
integrated,	and	its	effect	on	the	network	explored.	This	established	a	network	of	1389	
interactions	between	295	internal	nodes	(excluding	2	inputs	and	5	outputs).	To	
investigate	network	perturbations	of	the	p53-PMH302	interactome	in	response	to	in	
silico	manipulation	of	different	node	states	and	inputs	(hypoxia	and	DNA	damage)	two	
methods	were	undertaken;	Logical	Steady	State	Analysis	(LSSA)	and	in	silico	knockout	
analysis	using	dependency	matrix	calculations.	Both	applications	are	provided	in	
CellNetAnalyzer	(v.2015.1)	(CNA).	In	silico	methods	and	analyses	of	the	Boolean	
PMH302	network	using	CNA	(v.2015.1)	were	undertaken	in	accordance	with	Klamt	et	
al.	(2007).		Full	methodology	is	provided	in	section	6,	sub	section	6.2.		
	
7.3.2.1	Application	of	logical	steady	state	analysis		
For	investigation	of	potential	network	perturbation	arising	from	the	in	silico	effect	of	
node	state	changes	under	LSSA	in	response	to	loss	of	p53	and	different	input	stresses,	
four	in	silico	comparisons	were	generated	(section	6,	tables	6	–	6.3)	comprising	
different	statuses	of	DNA	damage	or	hypoxia	(ON	or	OFF)	and	p53	(knockout	or	wild	
type).	All	nodes	in	the	PMH302	network	were	subsequently	filtered	dependant	on	the	
biological	processes	that	they	regulate	(cell	cycle	arrest,	DNA	repair,	apoptosis,	cellular	
senescence,	and	angiogenesis)	and	their	effect	on	the	network	explored.	Of	the	
different	in	silico	conditions,	we	created	four	comparative	scenarios	and	explored	the	
effects	of	all	node	state	changes	regulating	their	outputs	to	ascertain	if	the	PMH302	
interactome	can	identify	overall	system	attributes.	Global	list	of	node	state	changes	
under	LSSA	are	provided	in	tables	7.3.1.7	and	7.3.1.8	for	p53	-	DNA	damage	and	
hypoxia	simulations	respectively.		
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7.3.2.2	DNA	damage	and	p53	simulations		
All	nodes	that	regulate	the	five	outputs	in	the	PMH302	model	(cell	cycle	arrest,	DNA	
repair,	apoptosis,	cellular	senescence,	and	angiogenesis)	were	filtered,	and	their	effect	
on	the	network	explored.	Of	these	different	in	silico	conditions,	we	further	created	four	
comparative	scenarios	and	explored	the	effects	of	all	node	state	changes	regulating	
their	outputs	to	ascertain	if	the	PMH302	interactome	can	identify	potential	
perturbations	and	overall	system	attributes.	Global	list	of	node	state	changes	is	
provided	in	table	7.3.1.7	
	
Table	7.3.1.7	Global	list	of	node	state	changes	under	LSSA	in	PMH302	in	response	to	different	
DNA	damage	and	p53	status	simulations.	Distribution	of	all	nodes	(n	=	302	in	PMH302	under	
LSSA	in	response	to	the	four	different	simulations	of	different	p53	(WT=wild	type,	
KO=knockout),	and	DNA	damage	statuses	(section	2,	material	and	methods).	In	accordance	
with	CNA,	three	states	exist;	1	=	upregulated,	0	=	downregulated,	NaN	=	undetermined.		
Node	ID	 p53	WT	with	DD	
ON	
p53	WT	with	DD	
OFF	
p53	KO	with	DD	
ON	
p53	KO	with	DD	
OFF	
AATF	 1	 1	 1	 1	
ABCB1	 1	 1	 1	 1	
ABCC1	 1	 1	 1	 1	
AIFM2	 1	 1	 0	 NaN	
AIMP2	 1	 1	 NaN	 1	
Angiogenesis	 1	 1	 1	 1	
APAF1	 1	 1	 1	 1	
APEX1	 1	 1	 NaN	 1	
Apoptosis	 1	 1	 1	 1	
APP	 1	 0	 1	 0	
AR	 0	 0	 1	 0	
ARID3A	 1	 1	 0	 NaN	
ASPP1	 NaN	 NaN	 NaN	 NaN	
ASPP2	 NaN	 NaN	 NaN	 NaN	
ATF3	 1	 1	 1	 1	
ATM	 1	 0	 1	 0	
ATR	 1	 0	 1	 0	
AURKA	 NaN	 NaN	 NaN	 NaN	
AXIN1	 1	 1	 1	 1	
BAIAP2L1	 NaN	 NaN	 NaN	 NaN	
BAIAP2L2	 0	 0	 NaN	 NaN	
BAK1	 1	 1	 NaN	 1	
BAX	 1	 1	 1	 1	
BBC3	 1	 1	 0	 NaN	
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BCCIP	 NaN	 NaN	 NaN	 NaN	
BCL2	 1	 1	 1	 1	
BCL3	 0	 0	 1	 NaN	
BCL6	 0	 1	 NaN	 1	
BDKRB1	 0	 0	 1	 NaN	
BHLHE40	 0	 0	 NaN	 0	
BNIP3L	 1	 1	 0	 NaN	
BRCA1	 1	 1	 1	 1	
BTG2	 1	 0	 1	 0	
C12orf5	 1	 1	 0	 NaN	
C13orf15	 1	 1	 0	 NaN	
CA9	 0	 0	 1	 0	
CALD1	 1	 1	 0	 NaN	
CASP2	 NaN	 NaN	 NaN	 NaN	
CASP8	 1	 1	 NaN	 0	
CCAR1	 1	 0	 1	 0	
CCNA	 1	 1	 1	 1	
CCNB1	 1	 1	 1	 1	
CCND1	 1	 1	 1	 1	
CCNG1	 1	 1	 1	 1	
CD44	 1	 1	 1	 1	
CD58	 1	 1	 0	 NaN	
CD59	 1	 1	 NaN	 0	
CD82	 1	 1	 0	 NaN	
CDC20	 0	 0	 1	 NaN	
CDC25A	 1	 1	 1	 1	
CDK2	 1	 1	 1	 1	
CDK4	 NaN	 1	 1	 1	
CDK5	 1	 1	 1	 1	
CDK9	 NaN	 NaN	 NaN	 NaN	
CDKN1A	 1	 1	 1	 1	
CDKN1B	 1	 1	 1	 1	
CDKN2A	 1	 1	 1	 1	
Cell	Cycle	
Arrest	
1	 1	 1	 1	
Cellular	
Senescence	
1	 1	 1	 1	
CHEK1	 1	 0	 1	 NaN	
CHEK2	 1	 1	 1	 1	
CIAPIN1	 NaN	 NaN	 NaN	 NaN	
CKB	 1	 1	 1	 1	
CKM	 1	 1	 0	 0	
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CKS2	 0	 0	 1	 NaN	
COL18A1	 1	 1	 0	 NaN	
COL1A2	 NaN	 NaN	 NaN	 NaN	
CSNK2	 NaN	 NaN	 NaN	 NaN	
CUL7	 1	 1	 1	 1	
CXCR4	 1	 1	 1	 1	
CYP24A1	 NaN	 NaN	 NaN	 NaN	
DAP	 1	 0	 1	 0	
DAXX	 1	 0	 1	 0	
DDB2	 1	 1	 0	 NaN	
DDIT4	 1	 1	 NaN	 0	
DDX20	 NaN	 NaN	 NaN	 NaN	
DDX5	 1	 1	 NaN	 1	
DFNA5	 1	 1	 0	 NaN	
DKK1	 1	 1	 NaN	 0	
DNA	damage	 1	 0	 1	 0	
DNA	Repair	 1	 1	 1	 1	
DNMT3A	 NaN	 NaN	 NaN	 NaN	
DUSP1	 1	 0	 1	 0	
DUSP2	 1	 1	 0	 NaN	
DUSP4	 1	 1	 0	 NaN	
DUSP5	 1	 1	 1	 1	
DYRK2	 1	 0	 1	 0	
E2F1	 1	 1	 1	 1	
ECT2	 0	 0	 1	 NaN	
EDA2R	 1	 1	 0	 NaN	
EGFR	 1	 1	 1	 1	
EGR2	 1	 1	 0	 NaN	
EIF2AK2	 NaN	 NaN	 NaN	 NaN	
EIF5A	 NaN	 NaN	 NaN	 NaN	
ELAVL1	 NaN	 NaN	 NaN	 NaN	
EPHB4	 0	 0	 1	 NaN	
ERBB2	 1	 1	 1	 1	
ESR1	 1	 1	 1	 1	
EXPORTIN1	 0	 0	 1	 NaN	
EZH2	 1	 1	 1	 1	
FAS	 1	 1	 1	 NaN	
FDXR	 1	 1	 0	 NaN	
FEN1	 1	 1	 0	 0	
FGF2	 NaN	 1	 1	 1	
FHL2	 1	 1	 0	 NaN	
FLI1	 1	 0	 1	 0	
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FOS	 1	 1	 1	 1	
FOXM1	 0	 0	 1	 NaN	
GADD45A	 1	 1	 0	 0	
GAPDH	 1	 1	 NaN	 0	
GSTP1	 1	 1	 1	 1	
GTSE1	 1	 1	 0	 NaN	
H2AFZ	 NaN	 NaN	 NaN	 NaN	
HDAC1	 NaN	 NaN	 NaN	 NaN	
HIC1	 1	 1	 1	 1	
HIF1A	 1	 1	 1	 1	
HIPK2	 NaN	 NaN	 NaN	 NaN	
HIPK4	 NaN	 NaN	 NaN	 NaN	
HMMR	 0	 0	 1	 NaN	
HNF4A	 1	 1	 1	 1	
HOXA10	 NaN	 NaN	 NaN	 NaN	
HOXA11	 NaN	 NaN	 NaN	 NaN	
HOXA5	 NaN	 NaN	 NaN	 NaN	
HSP90AB1	 0	 0	 1	 NaN	
HSPA4	 1	 1	 1	 1	
HTATIP2	 1	 0	 1	 0	
Hypoxia	 0	 0	 0	 0	
ICAM1	 1	 1	 1	 1	
ID3	 1	 1	 1	 1	
IER3	 1	 1	 NaN	 0	
IFI16	 1	 1	 0	 NaN	
IFITM2	 0	 0	 1	 NaN	
IFNA1	 NaN	 NaN	 NaN	 NaN	
IGF1R	 0	 0	 1	 NaN	
IGFBP1	 1	 1	 NaN	 0	
IGFBP7	 1	 1	 0	 NaN	
IL6	 1	 1	 1	 1	
ING1	 NaN	 NaN	 NaN	 NaN	
ING2	 1	 0	 1	 0	
ING4	 NaN	 NaN	 NaN	 NaN	
ING5	 1	 0	 1	 0	
IQCB1	 0	 0	 1	 NaN	
ISG15	 1	 1	 0	 NaN	
JAG1	 NaN	 NaN	 NaN	 NaN	
JUN	 1	 1	 1	 1	
KAT2B	 1	 1	 0	 NaN	
KIF23	 0	 0	 1	 NaN	
KLF4	 1	 1	 NaN	 0	
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KLK3	 NaN	 NaN	 NaN	 NaN	
KRT19	 0	 0	 1	 0	
KRT8	 1	 1	 0	 NaN	
LATS2	 1	 1	 0	 NaN	
LRDD	 1	 1	 0	 NaN	
LTF	 1	 1	 1	 1	
MAP4	 0	 0	 1	 0	
MAP4K4	 1	 1	 0	 NaN	
MAPK1	 1	 1	 1	 1	
MAPK14	 1	 1	 1	 1	
MAPK8	 1	 1	 1	 1	
MAPK9	 1	 0	 1	 0	
MCL1	 1	 1	 1	 1	
MCTS1	 1	 0	 1	 0	
MDM2	 1	 1	 1	 1	
MDM4	 1	 1	 1	 1	
MGMT	 0	 0	 1	 NaN	
MIC1	 NaN	 NaN	 NaN	 NaN	
MMP1	 1	 1	 1	 1	
MMP13	 1	 1	 1	 1	
MMP2	 1	 1	 1	 1	
MSH2	 1	 1	 1	 1	
MTA1	 1	 0	 1	 0	
MTA2	 NaN	 NaN	 NaN	 NaN	
MUC1	 0	 0	 NaN	 0	
MYC	 1	 1	 1	 1	
MYCN	 1	 1	 1	 1	
MYST4	 1	 0	 1	 0	
NANOG	 NaN	 NaN	 NaN	 NaN	
NCL	 1	 NaN	 1	 NaN	
NFKB2	 1	 0	 1	 0	
NLRC4	 1	 1	 0	 NaN	
NME1	 1	 1	 1	 1	
NOTCH1	 1	 1	 1	 1	
NOV	 1	 1	 0	 NaN	
NQO1	 NaN	 NaN	 NaN	 NaN	
NR2C1	 1	 1	 1	 1	
NTN1	 0	 0	 NaN	 0	
P53	 1	 1	 0	 0	
P53AIP1	 1	 1	 1	 0	
PAD4	 NaN	 NaN	 NaN	 NaN	
PARK2	 NaN	 NaN	 NaN	 NaN	
	 235	
PCBP4	 1	 1	 0	 NaN	
PCNA	 1	 1	 1	 1	
PDGFRB	 0	 0	 1	 NaN	
PDRG1	 0	 0	 1	 NaN	
PEG3	 1	 1	 0	 NaN	
PERP	 1	 1	 0	 NaN	
PHB	 NaN	 NaN	 NaN	 NaN	
PHF20	 NaN	 NaN	 NaN	 NaN	
PIAS1	 1	 0	 1	 0	
PIAS2	 NaN	 NaN	 NaN	 NaN	
PIN1	 NaN	 NaN	 NaN	 NaN	
PIRH2	 1	 0	 1	 0	
PITX1	 1	 0	 1	 0	
PLA2G6	 NaN	 NaN	 NaN	 NaN	
PLAUR	 1	 1	 1	 1	
PML	 1	 1	 1	 0	
POU4F1	 NaN	 NaN	 NaN	 NaN	
PPARG	 NaN	 NaN	 NaN	 NaN	
PPID	 NaN	 NaN	 NaN	 NaN	
PPM1A	 NaN	 NaN	 NaN	 NaN	
PPM1D	 1	 1	 1	 NaN	
PRAK	 NaN	 NaN	 NaN	 NaN	
PRC1	 0	 0	 1	 NaN	
PREP1	 NaN	 NaN	 NaN	 NaN	
PRKAB1	 NaN	 NaN	 NaN	 NaN	
PRKCA	 1	 1	 1	 1	
PRKD1	 1	 0	 1	 0	
PRKDC	 1	 0	 1	 0	
PRKG1	 1	 1	 0	 NaN	
PRSS50	 0	 0	 1	 NaN	
PSEN1	 0	 0	 1	 NaN	
PSMD10	 NaN	 NaN	 NaN	 NaN	
PTEN	 1	 1	 NaN	 NaN	
PTGS2	 1	 1	 1	 1	
PTTG1	 0	 1	 0	 1	
RAD51	 1	 1	 1	 1	
RAF1	 1	 1	 1	 1	
RAS	 1	 1	 1	 1	
RB	 NaN	 NaN	 NaN	 NaN	
RB1CC1	 NaN	 NaN	 NaN	 NaN	
RECQL4	 0	 0	 1	 NaN	
RFC	 NaN	 NaN	 NaN	 NaN	
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RFWD3	 1	 0	 1	 0	
RGS16	 1	 1	 0	 NaN	
RPA1	 1	 0	 1	 0	
RPRM	 1	 1	 0	 NaN	
RPS27L	 1	 0	 1	 0	
RREB1	 NaN	 NaN	 NaN	 NaN	
RRM2B	 1	 1	 0	 NaN	
RSK2	 1	 0	 1	 0	
S100A2	 1	 1	 0	 NaN	
S100A6	 0	 0	 1	 NaN	
S100B	 NaN	 NaN	 NaN	 NaN	
SEMA3B	 1	 1	 0	 NaN	
SENP3	 NaN	 NaN	 NaN	 NaN	
SERPINB5	 1	 1	 0	 NaN	
SERPINE1	 0	 0	 NaN	 0	
SERPINF1	 1	 1	 1	 1	
SESN2	 1	 1	 0	 NaN	
SET	 NaN	 NaN	 NaN	 NaN	
SFN	 1	 1	 0	 NaN	
SGK	 1	 1	 1	 1	
SIAH1	 1	 1	 1	 1	
SIVA1	 1	 1	 1	 1	
SKIL	 NaN	 NaN	 NaN	 NaN	
SLC2A1	 1	 1	 1	 1	
SLC2A4	 0	 0	 1	 0	
SLC6A6	 1	 1	 1	 1	
SMYD2	 NaN	 NaN	 NaN	 NaN	
SOD1	 NaN	 NaN	 NaN	 NaN	
SOD2	 NaN	 NaN	 NaN	 NaN	
SOX4	 1	 0	 1	 0	
SP1	 1	 0	 NaN	 0	
SP7	 0	 0	 1	 0	
STAT3	 1	 1	 1	 1	
STMN1	 0	 1	 0	 1	
SUB1	 1	 0	 1	 0	
SUMO2	 NaN	 NaN	 NaN	 NaN	
SUMO3	 NaN	 NaN	 NaN	 NaN	
TCF7L2	 NaN	 NaN	 1	 NaN	
TFAP2A	 1	 1	 1	 0	
TFAP2C	 1	 1	 0	 NaN	
TFDP1	 0	 0	 1	 NaN	
TGFA	 1	 1	 1	 1	
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TGFB1	 1	 1	 1	 1	
THBS1	 1	 1	 1	 1	
TIAF1	 NaN	 NaN	 NaN	 NaN	
TLR3	 1	 1	 NaN	 NaN	
TNFRSF10A	 1	 1	 1	 1	
TNFRSF10B	 1	 1	 1	 1	
TOP2A	 1	 0	 1	 0	
TP53BP1	 1	 0	 1	 0	
TP53I13	 1	 1	 0	 0	
TP53INP1	 1	 1	 0	 0	
TP53RK	 NaN	 NaN	 NaN	 NaN	
TPT1	 1	 1	 NaN	 0	
UBE2A	 1	 0	 1	 0	
UBE3A	 NaN	 NaN	 NaN	 NaN	
UCHL1	 NaN	 NaN	 NaN	 NaN	
UNC5A	 1	 1	 NaN	 0	
VEGFA	 1	 1	 1	 1	
VRK1	 0	 0	 NaN	 0	
WRN	 1	 0	 1	 0	
WWOX	 1	 0	 1	 0	
WWP1	 1	 1	 1	 1	
XAF1	 0	 0	 1	 0	
YBX1	 1	 1	 1	 1	
YY1	 0	 0	 NaN	 0	
ZMAT3	 1	 1	 0	 NaN	
ZMIZ2	 NaN	 NaN	 NaN	 NaN	
ZNF148	 NaN	 NaN	 NaN	 NaN	
ZNF307	 NaN	 NaN	 NaN	 NaN	
	
	
7.3.2.2.1	Nodes	regulating	apoptosis	under	LSSA	
We	filtered	all	nodes	that	regulate	apoptosis	from	the	PMH302	network.	Of	the	total	
131	nodes	regulating	apoptosis	in	the	PMH302	model,	globally,	a	greater	number	of	
pro-apoptotic	nodes	were	upregulated	in	the	p53	wild	type	backgrounds	compared	to	
p53	knockouts	backgrounds,	with	a	slight	increase	in	the	total	number	when	DNA	
damage	was	switched	ON.	Comparable,	a	greater	number	of	anti-apoptotic	nodes	were	
downregulated	in	the	p53	wild	type	backgrounds	globally,	compared	to	p53	knockout	
backgrounds	(table	7.3.1.8,	figure	7.3).		
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Table.	7.3.1.8	Distribution	of	anti-apoptotic	nodes	under	LSSA	in	the	PMH302	model.		
Total	number	of	anti-apoptotic	node	with	three	possible	state	changes;	upregulated,	
downregulated	or	undetermined.	A	total	of	50	anti-apoptotic	nodes	are	considered	in	the	
PMH302	network.		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	DNA	damage	ON	 37	 7	 6	
	 NFKB2	 AR	 FGF2	
	 APEX1	 BCL3	 NANOG	
	 FLI1	 CKS2	 PREP1	
	 MTA1	 EPHB4	 TCF7L2	
	 ATF3	 IGF1R	 TP53RK	
	 BCL2	 PDGFRB	 RB1CC1	
	 C12orf5	 PSEN1	 	
 CCNG1	 	  
 CD44	 	  
 CDC25A	 	  
 CDKN1A	 	  
 CDKN1B	 	  
 CUL7	 	  
 DAXX	 	  
 DDIT4	 	  
 DUSP2	 	  
 DUSP4	 	  
 EGFR	 	  
 ESR1	 	  
 EZH2	 	  
 FHL2	 	  
 FOS	 	  
 GSTP1	 	  
 IER3	 	  
 IL6	 	  
 MAP4K4	 	  
 MCL1	 	  
 NOTCH1	 	  
 PRKCA	 	  
 PTGS2	 	  
 SFN	 	  
 SGK	 	  
 STAT3	 	  
 TGFA	 	  
 TPT1	 	  
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 VEGFA	 	  
 WWP1	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 34	 11	 5	
	 APEX1	 AR	 NANOG	
	 ATF3	 BCL3	 PREP1	
	 BCL2	 CKS2	 TCF7L2	
	 C12orf5	 DAXX	 TP53RK	
	 CCNG1	 EPHB4	 RB1CC1	
	 CD44	 FLI1	 	
 CDC25A	 IGF1R	 	
 CDKN1A	 MTA1	 	
 CDKN1B	 PDGFRB	 	
 CUL7	 PSEN1	 	
 DDIT4	 NFKB2	 	
 DUSP2	 	  
 DUSP4	 	  
 EGFR	 	  
 ESR1	 	  
 EZH2	 	  
 FGF2	 	  
 FHL2	 	  
 FOS	 	  
 GSTP1	 	  
 IER3	 	  
 IL6	 	  
 MAP4K4	 	  
 MCL1	 	  
 NOTCH1	 	  
 PRKCA	 	  
 PTGS2	 	  
 SFN	 	  
 SGK	 	  
 STAT3	 	  
 TGFA	 	  
 TPT1	 	  
 VEGFA	 	  
 WWP1	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 36	 6	 8	
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	 NFKB2	 C12ORF5	 NANOG	
	 AR	 DUSP2	 PREP1	
	 FLI1	 DUSP4	 TP53RK	
	 MTA1	 FHL2	 RB1CC1	
	 ATF3	 MAP4K4	 APEX1	
	 BCL2	 SFN	 DDIT4	
	 CCNG1	 	 IER3	
	 CD44	 	 TPT1	
	 CDC25A	 	  
 CDKN1A	 	  
 CDKN1B	 	  
 CUL7	 	  
 DAXX	 	  
 EGFR	 	  
 ESR1	 	  
 EZH2	 	  
 FOS	 	  
 GSTP1	 	  
 IL6	 	  
 MCL1	 	  
 NOTCH1	 	  
 PRKCA	 	  
 PTGS2	 	  
 SGK	 	  
 STAT3	 	  
 TGFA	 	  
 VEGFA	 	  
 WWP1	 	  
 BCL3	 	  
 CKS2	 	  
 EPHB4	 	  
 FGF2	 	  
 IGF1R	 	  
 PDGFRB	 	  
 PSEN1	 	  
 TCF7L2	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	  Total	number	 	
 25	 8	 17	
	 APEX1	 FLI1	 BCL3	
	 ATF3	 MTA1	 C12orf5	
	 BCL2	 AR	 CKS2	
	 241	
	 CCNG1	 DAXX	 DUSP2	
	 CD44	 DDIT4	 DUSP4	
	 CDC25A	 IER3	 EPHB4	
	 CDKN1A	 TPT1	 FHL2	
	 CDKN1B	 NFKB2	 IGF1R	
	 CUL7	 	 MAP4K4	
	 EGFR	 	 NANOG	
	 ESR1	 	 PDGFRB	
	 EZH2	 	 PREP1	
	 FGF2	 	 PSEN1	
	 FOS	 	 SFN	
	 GSTP1	 	 TCF7L2	
	 IL6	 	 TP53RK	
	 MCL1	 	 RB1CC1	
	 NOTCH1	 	  
 PRKCA	 	  
 PTGS2	 	  
 SGK	 	  
 STAT3	 	  
 TGFA	 	  
 VEGFA	 	  
 WWP1	 	  
	
	
Table	7.3.1.9	Distribution	of	pro	-	apoptotic	nodes	under	LSSA	in	PMH302.		
Total	number	of	pro-apoptotic	node	with	three	possible	state	changes	of	upregulated,	
downregulated	or	undetermined.	A	total	of	81	pro	apoptotic	nodes	were	described	in	the	
PMH302	network.	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	DNA	damage	ON	 64	 6	 11	
	 TOP2A	 SERPINE1	 ASPP1	
	 WWOX	 AR	 ASPP2	
	 AIFM2	 ECT2	 CASP2	
	 APAF1	 IFITM2	 DDX20	
	 APP	 PRSS50	 FGF2	
	 ATF3	 XAF1	 HOXA10	
	 BAK1	 	 ING4	
	 BAX	 	 MIC1	
	 BBC3	 	 UCHL1	
	 BNIP3L	 	 ZNF148	
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	 CASP8	 	 CYP24A1	
	 CCNG1	 	  
 CD44	 	  
 CDC25A	 	  
 CDKN1B	 	  
 CDKN2A	 	  
 COL18A1	 	  
 CXCR4	 	  
 DAP	 	  
 DAXX	 	  
 DDIT4	 	  
 DFNA5	 	  
 DKK1	 	  
 DUSP2	 	  
 DUSP4	 	  
 EGFR	 	  
 ESR1	 	  
 FAS	 	  
 FDXR	 	  
 FOS	 	  
 GADD45A	 	  
 HNF4A	 	  
 IFI16	 	  
 IGFBP7	 	  
 IL6	 	  
 ING5	 	  
 JUN	 	  
 KAT2B	 	  
 LATS2	 	  
 LRDD	 	  
 MAP4K4	 	  
 MSH2	 	  
 NLRC4	 	  
 NOTCH1	 	  
 P53AIP1	 	  
 PCBP4	 	  
 PEG3	 	  
 PERP	 	  
 PITX1	 	  
 PML	 	  
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 PRKCA	 	  
 PTEN	 	  
 PTGS2	 	  
 SEMA3B	 	  
 SERPINB5	 	  
 SIAH1	 	  
 SIVA1	 	  
 TFAP2C	 	  
 TLR3	 	  
 TNFRSF10A	 	  
 TNFRSF10B	 	  
 TP53INP1	 	  
 NFKB2	 	  
 TFAP2A	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 57	 14	 10	
	 AIFM2	 APP	 ASPP1	
	 APAF1	 AR	 ASPP2	
	 ATF3	 DAP	 CASP2	
	 BAK1	 DAXX	 DDX20	
	 BAX	 ECT2	 HOXA10	
	 BBC3	 IFITM2	 ING4	
	 BNIP3L	 ING5	 MIC1	
	 CASP8	 PITX1	 UCHL1	
	 CCNG1	 PRSS50	 CYP24A1	
	 CD44	 SERPINE1	 ZNF148	
	 CDC25A	 TOP2A	 	
 CDKN1B	 WWOX	 	
 CDKN2A	 XAF1	 	
 COL18A1	 NFKB2	 	
 CXCR4	 	  
 DDIT4	 	  
 DFNA5	 	  
 DKK1	 	  
 DUSP2	 	  
 DUSP4	 	  
 EGFR	 	  
 ESR1	 	  
 FAS	 	  
 FDXR	 	  
 FGF2	 	  
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 FOS	 	  
 GADD45A	 	  
 HNF4A	 	  
 IFI16	 	  
 IGFBP7	 	  
 IL6	 	  
 JUN	 	  
 KAT2B	 	  
 LATS2	 	  
 LRDD	 	  
 MAP4K4	 	  
 MSH2	 	  
 NLRC4	 	  
 NOTCH1	 	  
 P53AIP1	 	  
 PCBP4	 	  
 PEG3	 	  
 PERP	 	  
 PML	 	  
 PRKCA	 	  
 PTEN	 	  
 PTGS2	 	  
 SEMA3B	 	  
 SERPINB5	 	  
 SIAH1	 	  
 SIVA1	 	  
 TFAP2C	 	  
 TLR3	 	  
 TNFRSF10A	 	  
 TNFRSF10B	 	  
 TP53INP1	 	  
 TFAP2A	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 42	 23	 16	
	 TOP2A	 SERPINE1	 ASPP1	
	 WWOX	 AIFM2	 ASPP2	
	 APAF1	 BBC3	 CASP2	
	 APP	 BNIP3L	 DDX20	
	 ATF3	 COL18A1	 HOXA10	
	 AR	 GADD45A	 ING4	
	 BAX	 DFNA5	 MIC1	
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	 CCNG1	 TP53NP1	 PTEN	
	 CD44	 DUSP2	 TLR3	
	 CDC25A	 DUSP4	 UCHL1	
	 CDKN1B	 FDXR	 CYP24A1	
	 CDKN2A	 IFI16	 ZNF148	
	 CXCR4	 IGFBP7	 BAK1	
	 DAP	 KAT2B	 CASP8	
	 DAXX	 LATS2	 DDIT4	
	 EGFR	 LRDD	 DKK1	
	 ESR1	 MAP4K4	 	
 FAS	 NLRC4	 	
 FOS	 PCBP4	 	
 HNF4A	 PEG3	 	
 IL6	 TFAP2C	 	
 ING5	 SERPINB5	 	
 JUN	 SEMA3B	 	
 MSH2	 	  
 NOTCH1	 	  
 P53AIP1	 	  
 PITX1	 	  
 PML	 	  
 PRKCA	 	  
 PTGS2	 	  
 SIAH1	 	  
 SIVA1	 	  
 TNFRSF10A	 	  
 TNFRSF10B	 	  
 XAF1	 	  
 NFKB2	 	  
 TFAP2A	 	  
 ECT2	 	  
 FGF2	 	  
 IFITM2	 	  
 PERP	 	  
 PRSS50	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 25	 19	 37	
	 APAF1	 SERPINE1	 AIFM2	
	 ATF3	 TOP2A	 ASPP1	
	 BAK1	 WWOX	 ASPP2	
	 BAX	 APP	 BBC3	
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	 CCNG1	 AR	 BNIP3L	
	 CD44	 CASP8	 CASP2	
	 CDC25A	 DAP	 CYP24A1	
	 CDKN1B	 DAXX	 COL18A1	
	 CDKN2A	 DDIT4	 DDX20	
	 CXCR4	 DKK1	 DFNA5	
	 EGFR	 GADD45A	 DUSP2	
	 ESR1	 ING5	 DUSP4	
	 FGF2	 P53AIP1	 ECT2	
	 FOS	 PITX1	 FAS	
	 HNF4A	 PML	 FDXR	
	 IL6	 TP53INP1	 HOXA10	
	 JUN	 XAF1	 IFI16	
	 MSH2	 NFKB2	 IFITM2	
	 NOTCH1	 TFAP2A	 IGFBP7	
	 PRKCA	 	 ING4	
	 PTGS2	 	 KAT2B	
	 SIAH1	 	 LATS2	
	 SIVA1	 	 LRDD	
	 TNFRSF10A	 	 MAP4K4	
	 TNFRSF10B	 	 MIC1	
	   NLRC4	
	   PCBP4	
	   PEG3	
	   PERP	
	   PRSS50	
	   PTEN	
	   SEMA3B	
	   SERPINB5	
	   TFAP2C	
	   TLR3	
	   UCHL1	
	   ZNF148	
	
Nearly	a	twofold	upregulation	was	observed	in	pro-	apoptotic	nodes	(n=64)	in	the	
presence	of	p53	under	DNA	damage,	compared	to	pro-	apoptotic	nodes	in	the	absence	
of	p53	with	no	DNA	damage	(n=42)	(compare	lanes	1	and	3	fig.	7.3).	These	node	IDs	are	
given	in	table	7.3.1.2.		
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Surprisingly,	the	number	of	anti-apoptotic	nodes	upregulated	was	greater	in	the	
presence	of	p53	than	when	p53	was	deleted	from	the	network	when	in	silico	DNA	
damage	was	ON	(compare	lanes	13	and	15	in	fig.7.3).	However,	the	majority	of	those	
upregulated	also	have	anti-proliferative	roles	in	apoptosis	and	cellular	senescence	and	
include,	SFN,	MAP4K4,	DUSP2/4,	DDIT4	and	C12Orf5	(table	7.3.1.8).		
	
	
Figure	7.3	Total	number	and	distribution	of	nodes	regulating	apoptosis	under	LSSA	in	
PMH302.	A	total	of	131	nodes	that	regulated	apoptosis	are	considered	in	PMH302.	A	greater	
shift	towards	pro-apoptotic	nodes	upregulated	compared	to	anti-apoptotic	nodes	upregulated	
in	p53	wild	type	backgrounds	were	observed	(see	lanes	1	and	2	to	lanes	13	and	14)	
	
7.3.2.2.2	Nodes	regulating	angiogenesis	under	LSSA.	
Globally,	of	the	total	52	angiogenic	nodes	described	in	PMH302,	a	greater	number	of	
pro-	angiogenic	nodes	(41)	were	upregulated	than	anti-	angiogenic	(22)	nodes	in	the	
p53	wild	type	backgrounds.	A	similar	number	of	total	pro-angiogenic	nodes	were	
upregulated	when	comparing	p53	backgrounds;	41	and	42	for	p53	wild	type	aand	p53	
deletion	backgrounds	respectively.	A	descriptive	list	of	angiogenic	nodes	and	their	
state	changes	under	LSSA	are	summarised	in	tables	7.3.2	and	7.3.2.1	for	anti	and	pro	
angiogenic	respectively,	and	graphically	in	figure	7.3.1.		
	
Comparing	the	p53	wildtype	backgrounds	with	DNA	damage	OFF	and	ON,	a	similar	
number	of	upregulated	pro-angiogenic	nodes	were	observed,	regardless	of	the	DNA	
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damage	effect	(compare	lanes	1	and	2,	figure	7.3.1).	Of	the	20	upregulated	when	DNA	
damage	was	ON,	to	21	upregulated	when	DNA	damage	was	OFF	(compare	lanes	1	and	
2	in	fig.	7.3.1),	BBC3	and	CALD1,	along	with	MTA1,	RSK2,	and	CCND1	were	differentially	
in	silico	expressed	when	the	in	silico	DNA	damage	input	was	ON	(table	7.3.2.1).	The	
number	of	anti-angiogenic	nodes	upregulated	were	identical,	11	for	both	DNA	damage	
conditions	in	p53	wild	type	backgrounds	(compare	lanes	13	and	14).	No	anti-	
angiogenic	nodes	were	downregulated	(see	lanes	17	and	18).		
	
A	comparable	number	of	pro-angiogenic	nodes	was	also	noted	in	DNA	damage	ON	
backgrounds;	20	upregulated	in	the	presence	of	p53	compared	to	23	upregulated	in	
the	absence	of	p53	(compare	lanes	1	and	3,	figure	7.3.1).	Of	these,	all	nodes	were	
identical	(table	7.3.2.1)	apart	from	the	upregulation	of	BBC3	and	CALD1	in	the	presence	
of	p53.	Conversely,	a	greater	number	of	anti-angiogenic	nodes	were	upregulated	
(nearly	three-fold)	in	the	p53	wild	type	background	(n=11),	compared	to	when	p53	was	
deleted	(n=4)	both	under	DNA	damage	(compare	lanes	13	and	15)	BNIP3L,	CD59,	
COL18A1,	DKK1,	IFI16,	and	PTEN	were	considered	as	in	silico	p53	responsive	nodes	
regardless	of	the	DNA	damage	effect	(table	7.3.2).	
	
Table	7.3.2	Distribution	of	anti	angiogenic	nodes	under	LSSA	in	PMH302.	A	total	of	17	anti-
angiogenic	nodes	were	considered	in	the	PMH302	model.	Three	node	state	changes	are	
possible;	upregulated,	downregulated	or	undetermined.		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes 
p53	wild	type	with	DNA	damage	ON	 11	 0	 6	
	 BNIP3L	 	 ELAVL1	
	 CD59	 	 HOXA5	
	 CD82	 	 ING1	
	 COL18A1	 	 ING4	
	 DKK1	 	 NQO1	
	 IFI16	 	 PPARG	
	 NOTCH1	 	  
 PML	 	  
 PTEN	 	  
 SERPINF1	 	  
 TGFB1	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
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	 Total	number 
 11	 0	 6	
	 BNIP3L	 	 ELAVL1	
	 CD59	 	 HOXA5	
	 CD82	 	 ING1	
	 COL18A1	 	 ING4	
	 DKK1	 	 NQO1	
	 IFI16	 	 PPARG	
	 NOTCH1	 	  
 PML	 	  
 PTEN	 	  
 SERPINF1	 	  
 TGFB1	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 4	 4	 9	
	 NOTCH1	 BNIP3L	 CD59	
	 PML	 CD82	 DKK1	
	 SERPINF1	 COL18A1	 ELAVL1	
	 TGFB1	 IFI16	 HOXA5	
	   ING1	
	   ING4	
	   NQO1	
	   PPARG	
	   PTEN	
	    
    
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 No	change	
	 Total	number 
 3	 3	 11	
	 NOTCH1	 CD59	 BNIP3L	
	 SERPINF1	 DKK1	 CD82	
	 TGFB1	 PML	 COL18A1	
	   ELAVL1	
	   HOXA5	
	   IFI16	
	   ING1	
	   ING4	
	   NQO1	
	   PPARG	
	   PTEN	
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Table	7.3.2.1	Distribution	of	pro	-	angiogenic	nodes	under	LSSA	in	PMH302.		
A	total	of	35	pro	angiogenic	nodes	are	considered	in	the	PMH302	model		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
p53	wild	type	with	DNA	damage	ON	 Total	number	of	nodes 
 20	 6	 9	
	 MTA1	 STMN1	 CDK4	
	 RSK2	 NTN1	 FGF2	
	 BBC3	 PDGFRB	 JAG1	
	 BCL2	 EPHB4	 MIC1	
	 CALD1	 EPHB4	 NANOG	
	 CCND1	 SERPINE1	 PHB	
	 CD44	 	 S100B	
	 CDK2	 	 SENP3	
	 CDK5	 	 ELAVL1	
	 EGFR	 	  
 HIF1A	 	  
 HSPA4	 	  
 JUN	 	  
 MMP1	 	  
 MMP13	 	  
 PRKCA	 	  
 PTGS2	 	  
 SGK	 	  
 TGFA	 	  
 VEGFA	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 21	 7	 7	
	 BBC3	 BDKRB1	 ELAVL1	
	 BCL2	 EPHB4	 JAG1	
	 CALD1	 MTA1	 MIC1	
	 CCND1	 NTN1	 NANOG	
	 CD44	 PDGFRB	 PHB	
	 CDK2	 RSK2	 S100B	
	 CDK4	 SERPINE1	 SENP3	
	 CDK5	 	  
 EGFR	 	  
 FGF2	 	  
 HIF1A	 	  
 HSPA4	 	  
 JUN	 	  
 MMP1	 	  
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 MMP13	 	  
 PRKCA	 	  
 PTGS2	 	  
 SGK	 	  
 STMN1	 	  
 TGFA	 	  
 VEGFA	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 23	 3	 9	
	 MTA1	 BBC3	 SERPIN1	
	 RSK2	 CALD1	 NTN1	
	 BCL2	 STMN1	 ELAVL1	
	 CCND1	 	 JAG1	
	 CD44	 	 MIC1	
	 CDK2	 	 NANOG	
	 CDK5	 	 PHB	
	 EGFR	 	 S100B	
	 HIF1A	 	 SENP3	
	 HSPA4	 	  
 JUN	 	  
 MMP1	 	  
 MMP13	 	  
 PRKCA	 	  
 PTGS2	 	  
 SGK	 	  
 TGFA	 	  
 VEGFA	 	  
 BDKRB1	 	  
 CDK4	 	  
 EPHB4	 	  
 FGF2	 	  
 PDGFRB	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 19	 4	 12	
	 BCL2	 MTA1	 BBC3	
	 CCND1	 RSK2	 BDKRB1	
	 CD44	 SERPINE1	 CALD1	
	 CDK2	 NTN1	 ELAVL1	
	 CDK4	 	 EPHB4	
	 CDK5	 	 JAG1	
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	 EGFR	 	 MIC1	
	 FGF2	 	 NANOG	
	 HIF1A	 	 PDGFRB	
	 HSPA4	 	 PHB	
	 JUN	 	 S100B	
	 MMP1	 	 SENP3	
	 MMP13	 	  
 PRKCA	 	  
 PTGS2	 	  
 SGK	 	  
 STMN1	 	  
 TGFA	 	  
 VEGFA	 	  
	
	
Figure	7.3.1	Total	number	and	distribution	of	nodes	regulating	angiogenesis	under	LSSA	in	
PMH302.	Globally,	an	increased	upregulation	of	pro-angiogenic	nodes	is	observed	compared	to	
anti-angiogenic	nodes	in	both	p53	wild	type	and	p53	knockout	backgrounds	
	
	
7.3.2.2.3	Nodes	regulating	DNA	repair	under	LSSA	
A	total	of	37	nodes	that	regulate	DNA	repair	are	described	in	PMH302.	Of	these,	only	a	
small	minority	(n	=	8)	were	negative	regulators,	with	the	remaining	positively	
regulating	DNA	repair	(n	=	29).			
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Investigating	the	effect	of	p53	in	the	presence	of	DNA	damage;	an	increase	in	the	
upregulation	of	positive	regulators	of	DNA	repair	was	observed	in	the	presence	of	p53	
(n=22)	compared	to	when	p53	was	deleted	(n=19)	(compare	lanes	1	and	3	of	fig.	
7.3.1.1).	No	major	change	in	node	states	was	observed	of	those	downregulated	in	
response	to	DNA	damage;	2	and	4	for	p53	wild	type	and	p53	knockout	backgrounds	
respectively	(compare	lanes	2	and	7,	figure	7.3.1.1).		
	
Comparing	node	state	changes	between	negative	regulators	of	DNA	repair	in	response	
to	different	DNA	damage	inputs;	a	twofold	increase	in	nodes	upregulated	was	
observed	from	6	to	3	in	the	presence	and	absence	of	p53	respectively	(compare	lanes	
13	and	15,	figure	7.3.1.1).	However,	when	DNA	damage	was	ON,	and	in	the	presence	of	
p53,	unsurprisingly,	increased	pro-DNA	repair	nodes	were	upregulated	compared	to	all	
other	conditions	(see	lane	1,	figure	7.3.1.1).	Identical	numbers	and	nodes	that	
negatively	regulate	DNA	repair	was	noted	when	DNA	damage	was	ON	and	OFF	in	p53	
wild	type	backgrounds	(n	=	6)	(lanes	13	and	14,	figure	7.3.1.1).		In	comparison,	5	anti-
DNA	repair	nodes	were	upregulated	in	p53	deletion	backgrounds	compared	to	the	6	as	
described	for	p53	wild	type	backgrounds,	this	was	regardless	of	DNA	damage	effect	
(compare	lanes	13	and	14	to	lanes	15	and	16,	figure	7.3.1.1).		
	
Table	7.3.2.2	Distribution	of	nodes	that	negatively	regulate	DNA	repair	under	LSSA	in	
PMH302.		A	total	of	8	anti	-	DNA	repair	nodes	are	considered	in	the	PMH302	model.		
In	silico	condition		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes 
p53	wild	type	with	DNA	damage	ON	 6	 2	 0	
	 KLF4	 SERPINE1	 	
 MDM2	 PTTG1	 	
 MDM4	 	  
 MYC	 	  
 SIAH1	 	  
 PPMID	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 6	 1	 1	
	 KLF4	 SERPINE1	 PTTG1	
	 MDM2	 	  
 MDM4	 	  
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 MYC	 	  
 SIAH1	 	  
 PPMID	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 5	 1	 2	
	 MDM2	 PTTG1	 KLF4	
	 MYC	 	 SERPINE1	
	 SIAH1	 	  
 MDM4	 	  
 PPMID	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 5	 2	 1	
	 MDM2	 SERPINE1	 PPM1D	
	 MDM4	 KLF4	 	
 MYC	 	  
 SIAH1	 	  
 PTTG1	 	  
	
Table	7.3.2.3	Distribution	of	nodes	that	positively	regulate	DNA	repair	under	LSSA	in	
PMH302.	A	total	of	29	pro	DNA	repair	nodes	are	considered	in	the	PMH302	model.		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes 
p53	wild	type	with	DNA	damage	ON	 22	 2	 5	
	 APEX1	 MGMT	 BCCIP	
	 MTA1	 YY1	 FGF2	
	 PIAS1	 	 ING1	
	 RFWD3	 	 PIN1	
	 RPA1	 	 SUMO3	
	 RPS27L	 	  
 ATM	 	  
 ATR	 	  
 BRCA1	 	  
 CD44	 	  
 CDKN1A	 	  
 DDB2	 	  
 FEN1	 	  
 GADD45A	 	  
 HSPA4	 	  
 IFI16	 	  
 MCL1	 	  
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 MSH2	 	  
 NME1	 	  
 PCNA	 	  
 PRKDC	 	  
 RAD51	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 15	 10	 4	
	 APEX1	 ATM	 BCCIP	
	 BRCA1	 ATR	 ING1	
	 CD44	 MGMT	 PIN1	
	 CDKN1A	 MTA1	 SUMO3	
	 DDB2	 PIAS1	 	
 FEN1	 PRKDC	 	
 FGF2	 RFWD3	 	
 GADD45A	 RPA1	 	
 HSPA4	 RPS27L	 	
 IFI16	 YY1	 	
 MCL1	 	  
 MSH2	 	  
 NME1	 	  
 PCNA	 	  
 RAD51	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 19	 4	 6	
	 FGF2	 FEN1	 BCCIP	
	 MTA1	 GADD45A	 APEX1	
	 PIAS1	 DDB2	 YY1	
	 RFWD3	 IFI16	 ING1	
	 RPA1	 	 PIN1	
	 RPS27L	 	 SUMO3	
	 ATM	 	  
 ATR	 	  
 BRCA1	 	  
 CD44	 	  
 CDKN1A	 	  
 HSPA4	 	  
 MCL1	 	  
 MSH2	 	  
 NME1	 	  
 PCNA	 	  
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 PRKDC	 	  
 RAD51	 	  
 MGMT	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 11	 11	 7	
	 APEX1	 MTA1	 BCCIP	
	 BRCA1	 PIAS1	 DDB2	
	 CD44	 RFWD3	 IFI16	
	 CDKN1A	 RPA1	 ING1	
	 FGF2	 RPS27L	 MGMT	
	 HSPA4	 ATM	 PIN1	
	 MCL1	 ATR	 SUMO3	
	 MSH2	 FEN1	 	
 NME1	 GADD45A	 	
 PCNA	 PRKDC	 	
 RAD51	 YY1	 	
	
	
	
Figure	7.3.1.1	Total	number	and	distribution	of	nodes	regulating	DNA	repair	under	LSSA	in	
PMH302	A	greater	number	of	pro-DNA	repair	nodes	were	upregulated	in	the	presence	of	p53	
(lanes	1	and	2).	However,	only	a	minority	of	anti-repair	nodes	are	considered	(n	=	8)		
	
7.3.2.2.4	Nodes	regulating	cell	cycle	arrest	under	LSSA	
Globally,	increased	upregulation	of	nodes	that	activate	cell	cycle	arrest	was	observed	in	
p53	wild	type	backgrounds	compared	to	p53	deletion	backgrounds.	However	identical	
numbers	of	upregulated	pro-cell	cycle	arrest	nodes	were	noted	when	compared	to	
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those	that	negatively	regulate	cell	cycle	arrest.		In	the	absence	of	p53,	the	majority	of	
nodes	shifted	to	an	undetermined	state	(compare	lanes	9	and	10	to	11	and	12,	and	
lanes	21	and	22	to	lanes	23	and	24,	fig.	7.3.1.2).	Descriptive	summary	of	node	state	
changes	and	their	IDs	are	given	in	tables	7.3.2.4	and	7.3.2.5.		
	
Under	DNA	damage	and	in	the	presence	of	p53	increased	numbers	of	positive	
regulators	of	cell	cycle	arrest	was	observed	(n=24)	compared	to	when	p53	was	absent	
with	DNA	damage	ON	(n=19)	(compare	lanes	1	and	3	in	fig.	7.3.1.2).	DKK1,	GADD45A,	
IGFBP7,	KAT2B	and	TFAP2C	were	differentially	in	silico	expressed,	downregulated	or	
undetermined	in	the	absence	of	p53.	Of	the	positive	regulators	of	cell	cycle	arrest,	only	
2	were	downregulated	in	the	presence	of	p53,	compared	to	5	when	p53	was	removed	
in	silico	with	DNA	damage	ON	respectively	(compare	lanes	5	and	7).		
	
Of	the	nodes	which	inhibit	cell	cycle	arrest,	there	was	a	slight	increase	in	nodes	
upregulated	in	the	absence	of	p53	when	DNA	damage	was	ON	(n=22)	than	in	p53	
absence	(n=21)	(compare	lanes	13	and	15,	fig.	7.3.1.2).	Of	these,	the	majority	were	
identical	apart	from	ISG15,	IER3	and	RGS16	upregulated	in	the	presence	of	p53	(table	
7.3.2.5).		
	
22	anti-cell	cycle	arrest	nodes	were	upregulated	in	when	DNA	damage	was	ON,	
compared	to	only	15	when	DNA	damage	was	OFF	in	p53	deletion	backgrounds	
(compare	lanes	15	and	16,	fig.	7.3.1.2)	with	MTA1,	ING5,	UBE2A,	AR,	CKS2,	EPHB4	and	
S100A6	the	additional	anti	–	cell	cycle	arrest	nodes	upregulated	when	DNA	damage	
was	ON	(table	7.3.2.4).		
	
Table	7.3.2.4	Distribution	of	nodes	that	negatively	regulate	cell	cycle	arrest	under	LSSA	in	
PMH302.	A	total	of	31	anti-cell	cycle	arrest	nodes	are	considered	in	the	PMH302	model	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes 
p53	wild	type	with	DNA	damage	ON	 21	 6	 4	
	 MTA1	 AR	 AURKA	
	 APAF1	 CKS2	 HDAC1	
	 ATF3	 EPHB4	 JAG1	
	 CCNA	 MUC1	 PRAK	
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	 CCNB1	 S100A6	 	
 CDK2	 VRK1	 	
 CUL7	 	  
 E2F1	 	  
 IER3	 	  
 ING5	 	  
 ISG15	 	  
 JUN	 	  
 MCL1	 	  
 MYC	 	  
 RAD51	 	  
 RGS16	 	  
 SIVA1	 	  
 SLC2A1	 	  
 UBE2A	 	  
 YBX1	 	  
 MYCN	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 18	 9	 4	
	 APAF1	 AR	 AURKA	
	 ATF3	 CKS2	 HDAC1	
	 CCNA	 EPHB4	 JAG1	
	 CCNB1	 ING5	 PRAK	
	 CDK2	 MTA1	 	
 CUL7	 MUC1	 	
 E2F1	 S100A6	 	
 IER3	 UBE2A	 	
 ISG15	 VRK1	 	
 JUN	 	  
 MCL1	 	  
 MYC	 	  
 RAD51	 	  
 RGS16	 	  
 SIVA1	 	  
 SLC2A1	 	  
 YBX1	 	  
 MYCN	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 22	 2	 7	
	 MTA1	 ISG15	 AURKA	
	 259	
	 APAF1	 RSG16	 HDAC1	
	 ATF3	 	 JAG1	
	 CCNA	 	 PRAK	
	 CCNB1	 	 IER3	
	 CDK2	 	 MUC1	
	 CUL7	 	 VRK1	
	 E2F1	 	  
 ING5	 	  
 JUN	 	  
 MCL1	 	  
 MYC	 	  
 RAD51	 	  
 SIVA1	 	  
 SLC2A1	 	  
 UBE2A	 	  
 YBX1	 	  
 MYCN	 	  
 AR	 	  
 CKS2	 	  
 EPHB4	 	  
 S100A6	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 15	 7	 9	
	 APAF1	 MTA1	 AURKA	
	 ATF3	 AR	 CKS2	
	 CCNA	 IER3	 EPHB4	
	 CCNB1	 ING5	 HDAC1	
	 CDK2	 MUC1	 ISG15	
	 CUL7	 UBE2A	 JAG1	
	 E2F1	 VRK1	 PRAK	
	 JUN	 	 RGS16	
	 MCL1	 	 S100A6	
	 MYC	 	  
 RAD51	 	  
 SIVA1	 	  
 SLC2A1	 	  
 YBX1	 	  
 MYCN	 	  
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Table	7.3.2.5	Distribution	of	nodes	that	positively	regulate	cell	cycle	arrest	under	LSSA	in	
PMH302.	A	total	of	35	pro-cell	cycle	arrest	nodes	are	considered	in	the	PMH302	model	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes 
p53	wild	type	with	DNA	damage	ON	 24	 2	 9	
	 ATF3	 EXPORTIN1	 HOXA10	
	 ATM	 STMN1	 HOXA5	
	 ATR	 	 ING4	
	 BTG2	 	 PPARG	
	 CDK5	 	 PRKAB1	
	 CHEK1	 	 CASP2	
	 CHEK2	 	 PADI4	
	 DKK1	 	 POU4F1	
	 DUSP5	 	 PARK2	
	 E2F1	 	  
 GADD45A	 	  
 ID3	 	  
 IGFBP7	 	  
 KAT2B	 	  
 KLF4	 	  
 MAPK1	 	  
 MYST4	 	  
 PTGS2	 	  
 RAF1	 	  
 RAS	 	  
 TFAP2C	 	  
 BRCA1	 	  
 CDKN1B	 	  
 CDKN2A	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 20	 6	 9	
 ATF3	 ATM	 HOXA10	
	 CDK5	 ATR	 HOXA5	
	 CHEK2	 BTG2	 ING4	
	 DKK1	 CHEK1	 PPARG	
	 DUSP5	 EXPORTIN1	 PRKAB1	
	 E2F1	 MYST4	 CASP2	
	 GADD45A	 	 PADI4	
	 ID3	 	 POU4F1	
	 IGFBP7	 	 PARK2	
	 KAT2B	 	  
	 261	
 KLF4	 	  
 MAPK1	 	  
 PTGS2	 	  
 RAF1	 	  
 RAS	 	  
 STMN1	 	  
 TFAP2C	 	  
 BRCA1	 	  
 CDKN1B	 	  
 CDKN2A	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	 
 19	 5	 11	
	 ATF3	 IGFBP7	 KLF4	
	 ATM	 GADD45A	 HOXA10	
	 ATR	 STMN1	 HOXA5	
	 BTG2	 KAT2B	 DKK1	
	 CDK5	 TFAP2C	 ING4	
	 CHEK1	 	 PPARG	
	 CHEK2	 	 PRKAB1	
	 DUSP5	 	 CASP2	
	 E2F1	 	 PADI4	
	 ID3	 	 PARK2	
	 EXPORTIN1	 	 POU4F1	
	 MAPK1	 	  
 MYST4	 	  
 PTGS2	 	  
 RAF1	 	  
 RAS	 	  
 BRCA1	 	  
 CDKN1B	 	  
 CDKN2A	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	 
 14	 7	 14	
	 ATF3	 ATM	 CHEK1	
	 CDK5	 ATR	 EXPORTIN1	
	 CHEK2	 BTG2	 HOXA10	
	 DUSP5	 DKK1	 HOXA5	
	 E2F1	 GADD45A	 IGFBP7	
	 ID3	 KLF4	 ING4	
	 MAPK1	 MYST4	 KAT2B	
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	 PTGS2	 	 PPARG	
	 RAF1	 	 PRKAB1	
	 RAS	 	 TFAP2C	
	 BRCA1	 	 CASP2	
	 CDKN1B	 	 PADI4	
	 CDKN2A	 	 PARK2	
	   POU4FA	
	
	
	
Figure	7.3.1.2	Total	number	and	distribution	of	nodes	regulating	cell	cycle	arrest	under	LSSA	
in	PMH302.	Nodes	that	regulate	cell	cycle	arrest	under	LSSA	in	response	to	the	4	different	DNA	
damage	and	p53	simulations.	The	majority	of	pro-cell	cycle	arrest	nodes	were	upregulated	in	
p53	wild	type	(WT)	backgrounds	compared	to	knockout	(KO).			
	
7.3.2.2.5	Nodes	regulating	cellular	senescence	under	LSSA	
Of	the	total	73	nodes	that	regulate	cellular	senescence	and	globally,	a	greater	shift	
towards	nodes	that	activate	cellular	senescence	was	observed	in	p53	wild	type	
backgrounds	than	in	p53	deletion	backgrounds.	Conversely,	a	larger	number	of	nodes	
that	inhibit	cellular	senescence	was	also	noted	in	p53	backgrounds	compared	to	pro	-	
senescence	nodes	in	p53	presence.		However,	to	note,	the	majority	(>	90	%)	of	these	
anti-cell	cycle	arrest	nodes	also	have	other	anti-proliferative	roles.	Tables	7.3.2.6	and	
7.3.2.7	summarise	node	IDs	and	their	state	changes	for	anti	and	pro	-	cell	cycle	arrest	
nodes	respectively,	graphically	represented	in	figure	7.3.1.3.	
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30	anti	-	senescence	nodes	were	upregulated	in	the	presence	of	p53	compared	to	23	in	
the	absence	of	p53	under	DNA	damage	(compare	lanes	13	and	15,	fig.	7.3.1.3),	
however	of	these,	only	5	nodes	solely	negatively	regulated	senescence,	several	others	
had	additional	anti-proliferative	roles	(DDIT4,	DKK1,	GADD45A,	GAPDH,	NME1,	PCBP4,	
and	PTEN).		
	
Unsurprisingly,	an	increase	in	the	number	of	pro-senescence	nodes	upregulated	was	
observed	in	the	p53	wild	type	background	(n	=	26)	compared	to	when	p53	was	deleted	
from	the	network	(n=18)	under	in	silico	DNA	damage	(compare	lanes	1	and	3,	fig.	
7.3.1.3).	This	was	similarly	noted	when	DNA	damage	was	OFF,	the	majority	of	nodes	
that	inhibit	cellular	senescence	was	greater	in	the	p53	wild	type	background	(n=31)	
compared	to	the	p53	deleted	background	(n=18)	(compare	lanes	14	and	16,	fig	7.3.1.3).		
	
Of	the	pro-senescence	nodes	downregulated,	8	for	p53	deletion	and	6	for	p53	wild	
type	backgrounds,	CD59,	DKK1,	GADD45A,	GAPDH	and	PML	were	downregulated	in	the	
absence	of	p53,	whilst	IFITM2,	IGF1R	and	PSEN1	were	downregulated	in	the	presence	
of	p53	with	in	silico	DNA	damage	OFF	(table	7.3.2.7).		
	
Table	7.3.2.6	Nodes	that	negatively	regulate	cellular	senescence	in	PMH302.	
A	total	of	38	anti-cellular	senescence	nodes	are	described	in	PMH302.	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes 
p53	wild	type	with	DNA	damage	ON	 30	 3	 5	
	 APAF1	 FOXM1	 CDK4	
	 ARID3A	 S100A6	 ELAVL1	
	 BAK1	 TFDP1	 FGF2	
	 BCL2	 	 JAG1	
	 BRCA1	 	 SOD2	
	 CD59	 	  
 CKB	 	  
 CUL7	 	  
 DAXX	 	  
 DDIT4	 	  
 DKK1	 	  
 EGFR	 	  
 EZH2	 	  
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 FHL2	 	  
 GADD45A	 	  
 GAPDH	 	  
 HIF1A	 	  
 HNF4A	 	  
 MCL1	 	  
 MSH2	 	  
 MYC	 	  
 NME1	 	  
 PCBP4	 	  
 PPM1D	 	  
 PTEN	 	  
 RRM2B	 	  
 SESN2	 	  
 SGK	 	  
 VEGFA	 	  
 WWP1	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
 31	 4	 3	
	 APAF1	 DAXX	 ELAVL1	
	 ARID3A	 FOXM1	 JAG1	
	 BAK1	 S100A6	 SOD2	
	 BCL2	 TFDP1	 	
 BRCA1	 	  
 CD59	 	  
 CDK4	 	  
 CKB	 	  
 CUL7	 	  
 DDIT4	 	  
 DKK1	 	  
 EGFR	 	  
 EZH2	 	  
 FGF2	 	  
 FHL2	 	  
 GADD45A	 	  
 GAPDH	 	  
 HIF1A	 	  
 HNF4A	 	  
 MCL1	 	  
 MSH2	 	  
 MYC	 	  
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 NME1	 	  
 PCBP4	 	  
 PPM1D	 	  
 PTEN	 	  
 RRM2B	 	  
 SESN2	 	  
 SGK	 	  
 VEGFA	 	  
 WWP1	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 23	 6	 9	
	 APAF1	 GADD45A	 ELAVL1	
	 BCL2	 ARID3A	 JAG1	
	 BRCA1	 FHL2	 PTEN	
	 CKB	 PCBP4	 SOD2	
	 CUL7	 RRM2B	 BAK1	
	 DAXX	 SESN2	 CD59	
	 EGFR	 	 DDIT4	
	 EZH2	 	 DKK1	
	 HIF1A	 	 GAPDH	
	 HNF4A	 	  
 MCL1	 	  
 MSH2	 	  
 MYC	 	  
 NME1	 	  
 SGK	 	  
 VEGFA	 	  
 WWP1	 	  
 CDK4	 	  
 FGF2	 	  
 FOXM1	 	  
 PPM1D	 	  
 S100A6	 	  
 TFDP1	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 19	 6	 13	
	 APAF1	 CD59	 ARID3A	
	 BAK1	 DAXX	 ELAVL1	
	 BCL2	 DDIT4	 FHL2	
	 BRCA1	 DKK1	 FOXM1	
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	 CDK4	 GADD45A	 JAG1	
	 CKB	 GAPDH	 PCBP4	
	 CUL7	 	 PPM1D	
	 EGFR	 	 PTEN	
	 EZH2	 	 RRM2B	
	 FGF2	 	 S100A6	
	 HIF1A	 	 SESN2	
	 HNF4A	 	 SOD2	
	 MCL1	 	 TFDP1	
	 MSH2	 	  
 MYC	 	  
 NME1	 	  
 SGK	 	  
 VEGFA	 	  
 WWP1	 	  
	
	
Table	7.3.2.7	Nodes	that	positively	regulate	cellular	senescence	in	PMH302.	
A	total	of	35	pro	-cellular	senescence	nodes	are	described	in	the	PMH302	model.		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes 
p53	wild	type	with	DNA	damage	ON	 26	 5	 4	
	 APP	 BHLHE40	 ING1	
	 BAK1	 AR	 MIC1	
	 BCL2	 IFITM2	 PIN1	
	 C12orf5	 IGF1R	 PRAK	
	 CD59	 PSEN1	 	
 CDKN1A	 	  
 CDKN1B	 	  
 CDKN2A	 	  
 DDB2	 	  
 DKK1	 	  
 GADD45A	 	  
 GAPDH	 	  
 IFI16	 	  
 IGFBP7	 	  
 IL6	 	  
 LATS2	 	  
 MSH2	 	  
 MYC	 	  
 NOTCH1	 	  
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 PML	 	  
 PRKCA	 	  
 PTEN	 	  
 PTGS2	 	  
 RAS	 	  
 SFN	 	  
 TGFA	 	  
p53	wild	type	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 25	 6	 4	
	 BAK1	 APP	 ING1	
	 BCL2	 AR	 MIC1	
	 CD59	 BHLHE40	 PIN1	
	 DKK1	 IFITM2	 PRAK	
	 GADD45A	 IGF1R	 	
 GAPDH	 PSEN1	 	
 MSH2	 	  
 MYC	 	  
 PTEN	 	  
 C12orf5	 	  
 CDKN1A	 	  
 CDKN1B	 	  
 CDKN2A	 	  
 DDB2	 	  
 IFI16	 	  
 IGFBP7	 	  
 IL6	 	  
 LATS2	 	  
 NOTCH1	 	  
 PML	 	  
 PRKCA	 	  
 PTGS2	 	  
 RAS	 	  
 SFN	 	  
 TGFA	 	  
p53	knockout	with	DNA	damage	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 18	 7	 10	
	 APP	 GADD45A	 ING1	
	 BCL2	 C12ORF5	 MIC1	
	 CDKN1A	 DDB2	 PIN1	
	 CDKN1B	 IFI16	 PRAK	
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	 CDKN2A	 IGFBP7	 PTEN	
	 IL6	 LATS2	 BAK1	
	 MSH2	 SFN	 BHLHE40	
	 MYC	 	 CD59	
	 NOTCH1	 	 DKK1	
	 PML	 	 GAPDH	
	 PRKCA	 	  
 PTGS2	 	  
 RAS	 	  
 TGFA	 	  
 AR	 	  
 IFITM2	 	  
 IGF1R	 	  
 PSEN1	 	  
p53	knockout	with	DNA	damage	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number 
 13	 8	 14	
	 BAK1	 BHLHE40	 C12orf5	
	 BCL2	 APP	 DDB2	
	 CDKN1A	 AR	 IFI16	
	 CDKN1B	 CD59	 IFITM2	
	 CDKN2A	 DKK1	 IGF1R	
	 IL6	 GADD45A	 IGFBP7	
	 MSH2	 GAPDH	 ING1	
	 MYC	 PML	 LATS2	
	 NOTCH1	 	 MIC1	
	 PRKCA	 	 PIN1	
	 PTGS2	 	 PRAK	
	 RAS	 	 PSEN1	
	 TGFA	 	 PTEN	
	   SFN	
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Figure	7.3.1.3	Total	number	and	distribution	of	nodes	regulating	cellular	senescence	under	
LSSA	
	
7.3.2.3	Hypoxia	and	p53	LSSA	simulations	
As	hypoxia	was	included	into	the	302	model	as	another	input,	a	further	four	in	silico	
conditions	were	generated	of	different	hypoxia	inputs	(ON/OFF),	and	p53	statuses	
(wild	type	/	knockout).	Their	response	to	these	conditions	onto	cellular	fate	were	
investigated	under	LSSA.	The	four	comparative	scenarios	and	conditions	are	
summarised	in	section	6	of	material	and	methods.	A	global	list	of	all	nodes	under	LSSA	
is	given	in	table	7.3.2.8.	
	
Table	7.3.2.8	Global	list	of	node	state	changes	under	LSSA	in	PMH302	in	response	to	different	
hypoxia	and	p53	status	simulations.	Distribution	of	all	nodes	(n	=	302)	in	PMH302	under	LSSA	
in	response	to	the	four	different	simulations	of	different	p53	(WT=wild	type,	KO=knockout),	
and	hypoxia	statuses	(section	2,	material	and	methods).	In	accordance	with	CNA,	three	states	
exist;	1	=	upregulated,	0	=	downregulated,	NaN	=	undetermined.		
Node	ID	 p53	WT	with	
Hypoxia	ON	
p53	WT	with	
Hypoxia	OFF	
p53	KO	with	
Hypoxia	ON	
p53	KO	with	
Hypoxia	OFF	
AATF	 1	 1	 1	 1	
ABCB1	 1	 1	 1	 1	
ABCC1	 1	 1	 1	 1	
AIFM2	 1	 1	 NaN	 NaN	
AIMP2	 1	 1	 1	 1	
Angiogenesis	 1	 1	 1	 1	
APAF1	 1	 1	 1	 1	
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Nodes	that	regulate	cellular	senesence	under	LSSA
p53	wildtype	with	DNA	damage	ON p53	wildtype	with	DNA	damage	OFF
p53	knockout	with	DNA	damage	ON p53	knockout	with	DNA	damage	OFF
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APEX1	 0	 1	 0	 1	
Apoptosis	 1	 1	 1	 1	
APP	 1	 0	 1	 0	
AR	 1	 0	 1	 0	
ARID3A	 1	 1	 NaN	 NaN	
ASPP1	 NaN	 NaN	 NaN	 NaN	
ASPP2	 NaN	 NaN	 NaN	 NaN	
ATF3	 1	 1	 1	 1	
ATM	 1	 0	 1	 0	
ATR	 1	 0	 1	 0	
AURKA	 NaN	 NaN	 NaN	 NaN	
AXIN1	 1	 1	 1	 1	
BAIAP2L1	 NaN	 NaN	 NaN	 NaN	
BAIAP2L2	 0	 0	 NaN	 NaN	
BAK1	 1	 1	 0	 1	
BAX	 1	 1	 1	 1	
BBC3	 1	 1	 NaN	 NaN	
BCCIP	 NaN	 NaN	 NaN	 NaN	
BCL2	 1	 1	 1	 1	
BCL3	 0	 0	 NaN	 NaN	
BCL6	 1	 1	 1	 1	
BDKRB1	 0	 0	 NaN	 NaN	
BHLHE40	 1	 0	 1	 0	
BNIP3L	 1	 1	 NaN	 NaN	
BRCA1	 1	 1	 1	 1	
BTG2	 1	 0	 1	 0	
C12orf5	 1	 1	 NaN	 NaN	
C13orf15	 1	 1	 NaN	 NaN	
CA9	 1	 0	 1	 0	
CALD1	 1	 1	 NaN	 NaN	
CASP2	 NaN	 NaN	 NaN	 NaN	
CASP8	 1	 1	 1	 0	
CCAR1	 0	 0	 0	 0	
CCNA	 1	 1	 1	 1	
CCNB1	 0	 1	 1	 1	
CCND1	 1	 1	 1	 1	
CCNG1	 1	 1	 1	 1	
CD44	 1	 1	 1	 1	
CD58	 1	 1	 NaN	 NaN	
CD59	 1	 1	 1	 0	
CD82	 1	 1	 NaN	 NaN	
CDC20	 0	 0	 NaN	 NaN	
CDC25A	 1	 1	 1	 1	
CDK2	 1	 1	 1	 1	
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CDK4	 1	 1	 1	 1	
CDK5	 1	 1	 1	 1	
CDK9	 NaN	 NaN	 NaN	 NaN	
CDKN1A	 1	 1	 1	 1	
CDKN1B	 1	 1	 1	 1	
CDKN2A	 0	 1	 0	 1	
Cell	Cycle	
Arrest	
1	 1	 1	 1	
Cellular	
Senescence	
1	 1	 1	 1	
CHEK1	 1	 0	 1	 NaN	
CHEK2	 1	 1	 1	 1	
CIAPIN1	 NaN	 NaN	 NaN	 NaN	
CKB	 1	 1	 1	 1	
CKM	 1	 1	 0	 0	
CKS2	 0	 0	 NaN	 NaN	
COL18A1	 1	 1	 NaN	 NaN	
COL1A2	 NaN	 NaN	 NaN	 NaN	
CSNK2	 NaN	 NaN	 NaN	 NaN	
CUL7	 0	 1	 0	 1	
CXCR4	 1	 1	 1	 1	
CYP24A1	 NaN	 NaN	 NaN	 NaN	
DAP	 0	 0	 0	 0	
DAXX	 0	 0	 0	 0	
DDB2	 1	 1	 NaN	 NaN	
DDIT4	 1	 1	 1	 0	
DDX20	 NaN	 NaN	 NaN	 NaN	
DDX5	 0	 1	 0	 1	
DFNA5	 1	 1	 NaN	 NaN	
DKK1	 1	 1	 1	 0	
DNA	damage	 0	 0	 0	 0	
DNA	Repair	 1	 1	 1	 1	
DNMT3A	 NaN	 NaN	 NaN	 NaN	
DUSP1	 1	 0	 1	 0	
DUSP2	 1	 1	 NaN	 NaN	
DUSP4	 1	 1	 NaN	 NaN	
DUSP5	 1	 1	 1	 1	
DYRK2	 1	 0	 1	 0	
E2F1	 1	 1	 1	 1	
ECT2	 0	 0	 NaN	 NaN	
EDA2R	 1	 1	 NaN	 NaN	
EGFR	 1	 1	 1	 1	
EGR2	 1	 1	 NaN	 NaN	
EIF2AK2	 NaN	 NaN	 NaN	 NaN	
EIF5A	 NaN	 NaN	 NaN	 NaN	
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ELAVL1	 NaN	 NaN	 NaN	 NaN	
EPHB4	 1	 0	 1	 NaN	
ERBB2	 1	 1	 1	 1	
ESR1	 1	 1	 1	 1	
EXPORTIN1	 0	 0	 NaN	 NaN	
EZH2	 1	 1	 1	 1	
FAS	 1	 1	 NaN	 NaN	
FDXR	 1	 1	 NaN	 NaN	
FEN1	 1	 1	 0	 0	
FGF2	 1	 1	 1	 1	
FHL2	 1	 1	 NaN	 NaN	
FLI1	 0	 0	 0	 0	
FOS	 1	 1	 1	 1	
FOXM1	 0	 0	 NaN	 NaN	
GADD45A	 1	 1	 0	 0	
GAPDH	 1	 1	 1	 0	
GSTP1	 1	 1	 1	 1	
GTSE1	 1	 1	 NaN	 NaN	
H2AFZ	 NaN	 NaN	 NaN	 NaN	
HDAC1	 NaN	 NaN	 NaN	 NaN	
HIC1	 1	 1	 1	 1	
HIF1A	 1	 1	 1	 1	
HIPK2	 NaN	 NaN	 NaN	 NaN	
HIPK4	 NaN	 NaN	 NaN	 NaN	
HMMR	 0	 0	 NaN	 NaN	
HNF4A	 0	 1	 0	 1	
HOXA10	 NaN	 NaN	 NaN	 NaN	
HOXA11	 NaN	 NaN	 NaN	 NaN	
HOXA5	 NaN	 NaN	 NaN	 NaN	
HSP90AB1	 0	 0	 NaN	 NaN	
HSPA4	 1	 1	 1	 1	
HTATIP2	 0	 0	 0	 0	
Hypoxia	 1	 0	 1	 0	
ICAM1	 1	 1	 1	 1	
ID3	 1	 1	 1	 1	
IER3	 1	 1	 1	 0	
IFI16	 1	 1	 NaN	 NaN	
IFITM2	 0	 0	 NaN	 NaN	
IFNA1	 NaN	 NaN	 NaN	 NaN	
IGF1R	 0	 0	 NaN	 NaN	
IGFBP1	 1	 1	 1	 0	
IGFBP7	 1	 1	 NaN	 NaN	
IL6	 1	 1	 1	 1	
ING1	 NaN	 NaN	 NaN	 NaN	
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ING2	 0	 0	 0	 0	
ING4	 NaN	 NaN	 NaN	 NaN	
ING5	 0	 0	 0	 0	
IQCB1	 0	 0	 NaN	 NaN	
ISG15	 1	 1	 NaN	 NaN	
JAG1	 NaN	 NaN	 NaN	 NaN	
JUN	 1	 1	 1	 1	
KAT2B	 1	 1	 NaN	 NaN	
KIF23	 0	 0	 NaN	 NaN	
KLF4	 1	 1	 0	 0	
KLK3	 NaN	 NaN	 NaN	 NaN	
KRT19	 0	 0	 0	 0	
KRT8	 1	 1	 NaN	 NaN	
LATS2	 1	 1	 NaN	 NaN	
LRDD	 1	 1	 NaN	 NaN	
LTF	 1	 1	 1	 1	
MAP4	 1	 0	 1	 0	
MAP4K4	 1	 1	 NaN	 NaN	
MAPK1	 1	 1	 1	 1	
MAPK14	 1	 1	 1	 1	
MAPK8	 1	 1	 1	 1	
MAPK9	 1	 0	 1	 0	
MCL1	 1	 1	 1	 1	
MCTS1	 1	 0	 1	 0	
MDM2	 1	 1	 1	 1	
MDM4	 1	 1	 1	 1	
MGMT	 0	 0	 NaN	 NaN	
MIC1	 NaN	 NaN	 NaN	 NaN	
MMP1	 1	 1	 1	 1	
MMP13	 1	 1	 1	 1	
MMP2	 1	 1	 1	 1	
MSH2	 1	 1	 1	 1	
MTA1	 0	 0	 0	 0	
MTA2	 NaN	 NaN	 NaN	 NaN	
MUC1	 1	 0	 1	 0	
MYC	 1	 1	 1	 1	
MYCN	 1	 1	 1	 1	
MYST4	 0	 0	 0	 0	
NANOG	 NaN	 NaN	 NaN	 NaN	
NCL	 NaN	 NaN	 NaN	 NaN	
NFKB2	 1	 0	 1	 0	
NLRC4	 1	 1	 NaN	 NaN	
NME1	 1	 1	 1	 1	
NOTCH1	 1	 1	 1	 1	
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NOV	 1	 1	 NaN	 NaN	
NQO1	 NaN	 NaN	 NaN	 NaN	
NR2C1	 1	 1	 1	 1	
NTN1	 1	 0	 1	 0	
P53	 1	 1	 0	 0	
P53AIP1	 1	 1	 1	 0	
PAD4	 NaN	 NaN	 NaN	 NaN	
PARK2	 NaN	 NaN	 NaN	 NaN	
PCBP4	 1	 1	 NaN	 NaN	
PCNA	 1	 1	 1	 1	
PDGFRB	 0	 0	 NaN	 NaN	
PDRG1	 0	 0	 NaN	 NaN	
PEG3	 1	 1	 NaN	 NaN	
PERP	 1	 1	 NaN	 NaN	
PHB	 NaN	 NaN	 NaN	 NaN	
PHF20	 NaN	 NaN	 NaN	 NaN	
PIAS1	 0	 0	 0	 0	
PIAS2	 NaN	 NaN	 NaN	 NaN	
PIN1	 NaN	 NaN	 NaN	 NaN	
PIRH2	 0	 0	 0	 0	
PITX1	 0	 0	 0	 0	
PLA2G6	 NaN	 NaN	 NaN	 NaN	
PLAUR	 1	 1	 1	 1	
PML	 1	 1	 0	 0	
POU4F1	 NaN	 NaN	 NaN	 NaN	
PPARG	 NaN	 NaN	 NaN	 NaN	
PPID	 NaN	 NaN	 NaN	 NaN	
PPM1A	 NaN	 NaN	 NaN	 NaN	
PPM1D	 1	 1	 NaN	 NaN	
PRAK	 NaN	 NaN	 NaN	 NaN	
PRC1	 0	 0	 NaN	 NaN	
PREP1	 NaN	 NaN	 NaN	 NaN	
PRKAB1	 NaN	 NaN	 NaN	 NaN	
PRKCA	 1	 1	 1	 1	
PRKD1	 0	 0	 0	 0	
PRKDC	 1	 0	 1	 0	
PRKG1	 1	 1	 NaN	 NaN	
PRSS50	 0	 0	 NaN	 NaN	
PSEN1	 0	 0	 NaN	 NaN	
PSMD10	 NaN	 NaN	 NaN	 NaN	
PTEN	 1	 1	 NaN	 NaN	
PTGS2	 1	 1	 1	 1	
PTTG1	 1	 1	 1	 1	
RAD51	 0	 1	 0	 1	
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RAF1	 1	 1	 1	 1	
RAS	 1	 1	 1	 1	
RB	 NaN	 NaN	 NaN	 NaN	
RB1CC1	 NaN	 NaN	 NaN	 NaN	
RECQL4	 0	 0	 NaN	 NaN	
RFC	 NaN	 NaN	 NaN	 NaN	
RFWD3	 0	 0	 0	 0	
RGS16	 1	 1	 NaN	 NaN	
RPA1	 0	 0	 0	 0	
RPRM	 1	 1	 NaN	 NaN	
RPS27L	 0	 0	 0	 0	
RREB1	 NaN	 NaN	 NaN	 NaN	
RRM2B	 1	 1	 NaN	 NaN	
RSK2	 0	 0	 0	 0	
S100A2	 1	 1	 NaN	 NaN	
S100A6	 0	 0	 NaN	 NaN	
S100B	 NaN	 NaN	 NaN	 NaN	
SEMA3B	 1	 1	 NaN	 NaN	
SENP3	 NaN	 NaN	 NaN	 NaN	
SERPINB5	 1	 1	 NaN	 NaN	
SERPINE1	 1	 0	 1	 0	
SERPINF1	 1	 1	 1	 1	
SESN2	 1	 1	 NaN	 NaN	
SET	 NaN	 NaN	 NaN	 NaN	
SFN	 1	 1	 NaN	 NaN	
SGK	 1	 1	 1	 1	
SIAH1	 1	 1	 1	 1	
SIVA1	 1	 1	 1	 1	
SKIL	 NaN	 NaN	 NaN	 NaN	
SLC2A1	 1	 1	 1	 1	
SLC2A4	 1	 0	 1	 0	
SLC6A6	 0	 1	 0	 1	
SMYD2	 NaN	 NaN	 NaN	 NaN	
SOD1	 NaN	 NaN	 NaN	 NaN	
SOD2	 NaN	 NaN	 NaN	 NaN	
SOX4	 1	 0	 1	 0	
SP1	 0	 0	 0	 0	
SP7	 1	 0	 1	 0	
STAT3	 1	 1	 1	 1	
STMN1	 1	 1	 1	 1	
SUB1	 0	 0	 0	 0	
SUMO2	 NaN	 NaN	 NaN	 NaN	
SUMO3	 NaN	 NaN	 NaN	 NaN	
TCF7L2	 1	 NaN	 1	 NaN	
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TFAP2A	 1	 1	 0	 0	
TFAP2C	 1	 1	 NaN	 NaN	
TFDP1	 0	 0	 NaN	 NaN	
TGFA	 1	 1	 1	 1	
TGFB1	 1	 1	 1	 1	
THBS1	 1	 1	 1	 1	
TIAF1	 NaN	 NaN	 NaN	 NaN	
TLR3	 1	 1	 NaN	 NaN	
TNFRSF10A	 1	 1	 1	 1	
TNFRSF10B	 1	 1	 1	 1	
TOP2A	 0	 0	 0	 0	
TP53BP1	 0	 0	 0	 0	
TP53I13	 1	 1	 0	 0	
TP53INP1	 1	 1	 0	 0	
TP53RK	 NaN	 NaN	 NaN	 NaN	
TPT1	 1	 1	 1	 0	
UBE2A	 0	 0	 0	 0	
UBE3A	 NaN	 NaN	 NaN	 NaN	
UCHL1	 NaN	 NaN	 NaN	 NaN	
UNC5A	 1	 1	 1	 0	
VEGFA	 1	 1	 1	 1	
VRK1	 1	 0	 1	 0	
WRN	 0	 0	 0	 0	
WWOX	 0	 0	 0	 0	
WWP1	 0	 1	 0	 1	
XAF1	 1	 0	 1	 0	
YBX1	 1	 1	 1	 1	
YY1	 1	 0	 1	 0	
ZMAT3	 1	 1	 NaN	 NaN	
ZMIZ2	 NaN	 NaN	 NaN	 NaN	
ZNF148	 NaN	 NaN	 NaN	 NaN	
ZNF307	 NaN	 NaN	 NaN	 NaN	
	
	
7.3.2.3.1	Nodes	regulating	angiogenesis	under	LSSA.		
Under	conditions	of	hypoxia	ON	and	OFF,	and	globally,	nearly	a	three-fold	increase	in	
anti	-	angiogenic	nodes	upregulated	was	seen	in	the	p53	wild	type	backgrounds	(n=22)	
compared	to	p53	wild	type	backgrounds	(n=8).	Conversely,	a	slight	increase	in	pro-	
angiogenic	nodes	upregulated	was	seen	in	the	p53	wild	type	backgrounds	(n=45),	
compared	to	p53	deleted	backgrounds	(n=41).	A	descriptive	summary	of	node	IDs	and	
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their	LSS	changes	under	these	conditions	are	given	in	tables	7.3.2.9	and	7.3.3	for	anti	
and	pro	–	angiogenic	nodes	respectively.		
	
No	major	differences	were	noted	in	upregulated	pro-angiogenic	node	state	changes	
between	different	p53	status	under	hypoxias;	24	in	the	presence	of	p53,	22	in	the	p53	
deleted	background	(compare	lanes	1	and	3	in	fig.	7.3.1.4)	all	these	nodes	were	
identical	(table	7.3.3)	apart	from	BBC3	and	CALD1	upregulated	in	the	p53	wild	type	
background.	A	two-fold	upregulation	of	these	anti-angiogenic	nodes	was	observed	
when	p53	was	present	(n=11),	to	when	p53	was	deleted	(n=5)	(compare	lanes	13	and	
15)	the	difference	being	BNIP3L,	CD82,	COL18A1,	IFI16,	PTEN,	and	PML,	all	shifted	to	an	
undetermined	state	when	p53	was	removed	from	the	network,	apart	from	PML	which	
was	downregulated.	No	anti-angiogenic	nodes	were	downregulated	in	the	presence	of	
p53	under	hypoxia,	in	fact,	all	(n	=	11)	were	upregulated	(table	7.3.2.9).		
	
Comparing	the	in	silico	hypoxia	effect	in	the	presence	of	p53,	nearly	a	two-fold	increase	
of	pro-	angiogenic	nodes	downregulated	was	observed	in	the	presence	of	p53	(n=7),	
compared	to	when	p53	was	deleted	(n=4)	(compare	lanes	6	and	8).	EPHB4,	NTN1	and	
SERPINE1	were	hypoxia	responsive,	upregulated	when	in	silico	hypoxia	was	ON,	
downregulated	when	OFF,	this	was	regardless	of	p53	status	(table	7.3.3)		
	
	
Table	7.3.2.9	Anti	-	angiogenic	nodes	under	LSSA	in	PMH302	hypoxia	simulations.		
A	total	of	15	anti-angiogenic	nodes	are	described.	Three	node	state	changes	are	possible;	
upregulated,	downregulated	or	undetermined	(no	change)	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 11	 0	 6	
	 BNIP3L	 	 ELAVL1	
	 CD59	 	 HOXA5	
	 CD82	 	 ING1	
	 COL18A1	 	 ING4	
	 DKK1	 	 NQO1	
	 IFI16	 	 PPARG	
	 NOTCH1	 	 	
	 PML	 	 	
	 PTEN	 	 	
	 SERPINF1	 	 	
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	 TGFB1	 	 	
p53	wild	type	with	DNA	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 11	 0	 6	
	 BNIP3L	 	 ELAVL1	
	 CD59	 	 HOXA5	
	 CD82	 	 ING1	
	 COL18A1	 	 ING4	
	 DKK1	 	 NQO1	
	 IFI16	 	 PPARG	
	 NOTCH1	 	 	
	 PML	 	 	
	 PTEN	 	 	
	 SERPINF1	 	 	
	 TGFB1	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 5	 1	 11	
	 CD59	 PML	 BNIP3L	
	 DKK1	 	 CD82	
	 NOTCH1	 	 COL18A1	
	 SERPINF1	 	 ELAVL1	
	 TGFB1	 	 HOXA5	
	 	 	 IFI16	
	 	 	 ING1	
	 	 	 ING4	
	 	 	 NQO1	
	 	 	 PPARG	
	 	 	 PTEN	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 3	 3	 11	
	 NOTCH1	 CD59	 BNIP3L	
	 SERPINF1	 DKK1	 CD82	
	 TGFB1	 PML	 COL18A1	
	 	 	 ELAVL1	
	 	 	 HOXA5	
	 	 	 IFI16	
	 	 	 ING1	
	 	 	 ING4	
	 	 	 NQO1	
	 	 	 PPARG	
	 	 	 PTEN	
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Table	7.3.3	Pro-	angiogenic	nodes	under	LSSA	in	PMH302	hypoxia	simulations		
A	total	of	35	pro-angiogenic	nodes	are	described	in	the	PMH302	model	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 24	 4	 7	
	 BBC3	 BDKRB1	 ELAVL1	
	 BCL2	 MTA1	 JAG1	
	 CALD1	 PDGFRB	 MIC1	
	 CCND1	 RSK2	 NANOG	
	 CD44	 	 PHB	
	 CDK2	 	 S100B	
	 CDK4	 	 SENP3	
	 CDK5	 	 	
	 EGFR	 	 	
	 EPHB4	 	 	
	 FGF2	 	 	
	 HIF1A	 	 	
	 HSPA4	 	 	
	 JUN	 	 	
	 MMP1	 	 	
	 MMP13	 	 	
	 NTN1	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SERPINE1	 	 	
	 SGK	 	 	
	 STMN1	 	 	
	 TGFA	 	 	
	 VEGFA	 	 	
p53	wild	type	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 21	 7	 7	
	 BBC3	 BDKRB1	 ELAVL1	
	 BCL2	 EPHB4	 JAG1	
	 CALD1	 MTA1	 MIC1	
	 CCND1	 NTN1	 NANOG	
	 CD44	 PDGFRB	 PHB	
	 CDK2	 RSK2	 S100B	
	 CDK4	 SERPINE1	 SENP3	
	 CDK5	 	 	
	 EGFR	 	 	
	 FGF2	 	 	
	 HIF1A	 	 	
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	 HSPA4	 	 	
	 JUN	 	 	
	 MMP1	 	 	
	 MMP13	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SGK	 	 	
	 STMN1	 	 	
	 TGFA	 	 	
	 VEGFA	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 22	 2	 11	
	 BCL2	 MTA1	 BBC3	
	 CCND1	 RSK2	 BDKRB1	
	 CD44	 	 CALD1	
	 CDK2	 	 ELAVL1	
	 CDK4	 	 JAG1	
	 CDK5	 	 MIC1	
	 EGFR	 	 NANOG	
	 EPHB4	 	 PDGFRB	
	 FGF2	 	 PHB	
	 HIF1A	 	 S100B	
	 HSPA4	 	 SENP3	
	 JUN	 	 	
	 MMP1	 	 	
	 MMP13	 	 	
	 NTN1	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SERPINE1	 	 	
	 SGK	 	 	
	 STMN1	 	 	
	 TGFA	 	 	
	 VEGFA	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 19	 4	 12	
	 BCL2	 MTA1	 BBC3	
	 CCND1	 NTN1	 BDKRB1	
	 CD44	 RSK2	 CALD1	
	 CDK2	 SERPINE1	 ELAVL1	
	 CDK4	 	 EPHB4	
	 CDK5	 	 JAG1	
	 281	
	 EGFR	 	 MIC1	
	 FGF2	 	 NANOG	
	 HIF1A	 	 PDGFRB	
	 HSPA4	 	 PHB	
	 JUN	 	 S100B	
	 MMP1	 	 SENP3	
	 MMP13	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SGK	 	 	
	 STMN1	 	 	
	 TGFA	 	 	
	 VEGFA	 	 	
	
	
Figure	7.3.1.4	Total	number	and	distribution	of	nodes	regulating	angiogenesis	under	LSSA	in	
PMH302	hypoxia	simulations	
	
	
7.3.2.3.2	Nodes	regulating	apoptosis	under	LSSA	
A	total	of	131	apoptotic	nodes	were	described	in	the	302	model,	of	these	50	were	
considered	as	anti-apoptotic	and	81	pro-apoptotic.	Globally	for	these	apoptotic	nodes	
under	differential	in	silico	hypoxic	conditions	a	greater	number	of	pro-apoptotic	nodes	
were	upregulated	in	the	presence	of	p53,	compared	to	pro-apoptotic	nodes	
upregulated	in	the	absence	of	p53.	However,	an	increase	in	anti-apoptotic	nodes	
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upregulated	in	p53	wild	type	backgrounds	compared	to	p53	deleted	backgrounds	
under	in	silico	hypoxia	was	also	observed.	A	list	of	node	IDs	and	their	LSS	changes	in	
response	to	the	four	conditions	are	summarised	in	tables	7.3.3.1	and	7.3.3.2	for	pro	
and	anti-apoptotic	nodes	respectively.	Figure	7.3.1.5	provides	a	graphical	
representation,	globally.			
	
Nearly	a	two	–	fold	increase	was	observed	in	pro-apoptotic	nodes	upregulated	in	the	
presence	of	p53	(n=60)	compared	to	31	in	the	p53	deleted	background	under	hypoxia	
(compare	lanes	1	and	3	in	fig.	7.3.1.5).	Of	the	anti-apoptotic	nodes,	35	were	
upregulated	in	the	presence	of	p53	compared	to	only	29	in	p53	absence	under	in	silico	
hypoxia.	Of	these	nodes,	all	were	identical	(table	7.3.3.2)	apart	from,	C12orf5,	
DUSP2/4,	MAP4K4,	PTGS2	and	SFN	upregulated	in	the	presence	of	p53	under	in	silico	
hypoxia.	Another	major	change	noted	was	the	number	of	nodes	that	shifted	to	an	
undetermined	state	when	p53	was	deleted	from	the	network;	10	for	p53	wild	type	and	
37	for	p53	knockout.		
	
No	major	difference	in	the	number	of	anti-apoptotic	nodes	upregulated	in	p53	wild	
type	backgrounds	when	hypoxia	was	OFF	and	ON;	35	and	34	for	hypoxia	ON	and	OFF	
respectively	(compare	lanes	13	and	14	fig.	7.3.1.5)	however,	of	these,	AR,	EPHB4,	
NFKB2,	TCF7L2	and	WWP1	were	all	upregulated	when	hypoxia	was	ON	(table	7.3.3.2).			
	
29	and	25	anti-apoptotic	nodes	were	upregulated	when	hypoxia	was	ON	compared	to	
when	it	was	OFF	respectively	in	p53	deletion	backgrounds.	Of	these,	AR,	IER3,	NFKB2,	
TCF7L2,	TPT1	were	all	upregulated	in	response	to	in	silico	hypoxia	ON	(table	7.3.3.2).	
Whilst,	WWP1,	APEX1	and	CUL7	were	upregulated	when	OFF		
	
Table	7.3.3.1	Pro	apoptotic	nodes	under	LSSA	in	PMH302	hypoxia	simulations.	
A	total	of	81	pro	–	apoptotic	nodes	are	described	in	PMH302.		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 60	 11	 10	
	 AIFM2	 DAP	 ASPP1	
	 APAF1	 DAXX	 ASPP2	
	 APP	 ECT2	 CASP2	
	 283	
	 AR	 IFITM2	 CYP24A1	
	 ATF3	 ING5	 DDX20	
	 BAK1	 PITX1	 HOXA10	
	 BAX	 PRSS50	 ING4	
	 BBC3	 SERPINE1	 MIC1	
	 BNIP3L	 TOP2A	 UCHL1	
	 CASP8	 WWOX	 ZNF148	
	 CCNG1	 XAF1	 	
	 CD44	 	 	
	 CDC25A	 	 	
	 CDKN1B	 	 	
	 COL18A1	 	 	
	 CXCR4	 	 	
	 DDIT4	 	 	
	 DFNA5	 	 	
	 DKK1	 	 	
	 DUSP2	 	 	
	 DUSP4	 	 	
	 EGFR	 	 	
	 ESR1	 	 	
	 FAS	 	 	
	 FDXR	 	 	
	 FGF2	 	 	
	 FOS	 	 	
	 GADD45A	 	 	
	 IFI16	 	 	
	 IGFBP7	 	 	
	 IL6	 	 	
	 JUN	 	 	
	 KAT2B	 	 	
	 LATS2	 	 	
	 LRDD	 	 	
	 MAP4K4	 	 	
	 MSH2	 	 	
	 NLRC4	 	 	
	 NOTCH1	 	 	
	 P53AIP1	 	 	
	 PCBP4	 	 	
	 PEG3	 	 	
	 PERP	 	 	
	 PML	 	 	
	 PRKCA	 	 	
	 PTEN	 	 	
	 PTGS2	 	 	
	 SEMA3B	 	 	
	 SERPINB5	 	 	
	 SERPINE1	 	 	
	 SIAH1	 	 	
	 SIVA1	 	 	
	 TFAP2C	 	 	
	 284	
	 TLR3	 	 	
	 TNFRSF10A	 	 	
	 TNFRSF10B	 	 	
	 TP53INP1	 	 	
	 XAF1	 	 	
	 TFAP2A	 	 	
	 NFKB2	 	 	
p53	wild	type	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 57	 14	 10	
	 AIFM2	 APP	 ASPP1	
	 APAF1	 AR	 ASPP2	
	 ATF3	 DAP	 CASP2	
	 BAK1	 DAXX	 CYP24A1	
	 BAX	 ECT2	 DDX20	
	 BBC3	 IFITM2	 HOXA10	
	 BNIP3L	 ING5	 ING4	
	 CASP8	 PITX1	 MIC1	
	 CCNG1	 PRSS50	 UCHL1	
	 CD44	 SERPINE1	 ZNF148	
	 CDC25A	 TOP2A	 	
	 CDKN1B	 WWOX	 	
	 CDKN2A	 XAF1	 	
	 COL18A1	 NFKB2	 	
	 CXCR4	 	 	
	 DDIT4	 	 	
	 DFNA5	 	 	
	 DKK1	 	 	
	 DUSP2	 	 	
	 DUSP4	 	 	
	 EGFR	 	 	
	 ESR1	 	 	
	 FAS	 	 	
	 FDXR	 	 	
	 FGF2	 	 	
	 FOS	 	 	
	 GADD45A	 	 	
	 HNF4A	 	 	
	 IFI16	 	 	
	 IGFBP7	 	 	
	 IL6	 	 	
	 JUN	 	 	
	 KAT2B	 	 	
	 LATS2	 	 	
	 LRDD	 	 	
	 MAP4K4	 	 	
	 MSH2	 	 	
	 NLRC4	 	 	
	 NOTCH1	 	 	
	 P53AIP1	 	 	
	 285	
	 PCBP4	 	 	
	 PEG3	 	 	
	 PERP	 	 	
	 PML	 	 	
	 PRKCA	 	 	
	 PTEN	 	 	
	 PTGS2	 	 	
	 SEMA3B	 	 	
	 SERPINB5	 	 	
	 SIAH1	 	 	
	 SIVA1	 	 	
	 TFAP2C	 	 	
	 TLR3	 	 	
	 TNFRSF10A	 	 	
	 TNFRSF10B	 	 	
	 TP53INP1	 	 	
	 TFAP2A	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 31	 13	 37	
	 APAF1	 BAK1	 AIFM2	
	 APP	 CDKN2A	 ASPP1	
	 AR	 DAP	 ASPP2	
	 ATF3	 DAXX	 BBC3	
	 BAX	 GADD45A	 BNIP3L	
	 CASP8	 HNF4A	 CASP2	
	 CCNG1	 ING5	 COL18A1	
	 CD44	 PITX1	 CYP24A1	
	 CDC25A	 PML	 DDX20	
	 CDKN1B	 TOP2A	 DFNA5	
	 CXCR4	 TP53INP1	 DUSP2	
	 DDIT4	 WWOX	 DUSP4	
	 DKK1	 TFAP2A	 ECT2	
	 EGFR	 	 FAS	
	 ESR1	 	 FDXR	
	 FGF2	 	 HOXA10	
	 FOS	 	 IFI16	
	 IL6	 	 IFITM2	
	 JUN	 	 IGFBP7	
	 MSH2	 	 ING4	
	 NOTCH1	 	 KAT2B	
	 P53AIP1	 	 LATS2	
	 PRKCA	 	 LRDD	
	 PTGS2	 	 MAP4K4	
	 SERPINE1	 	 MIC1	
	 SIAH1	 	 NLRC4	
	 SIVA1	 	 PCBP4	
	 TNFRSF10A	 	 PEG3	
	 TNFRSF10B	 	 PERP	
	 XAF1	 	 PRSS50	
	 286	
	 NFKB2	 	 PTEN	
	 	 	 SEMA3B	
	 	 	 SERPINB5	
	 	 	 TFAP2C	
	 	 	 TLR3	
	 	 	 UCHL1	
	 	 	 ZNF148	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 25	 19	 37	
	 APAF1	 APP	 ASPP1	
	 ATF3	 AR	 ASPP2	
	 BAK1	 CASP8	 BBC3	
	 BAX	 DAP	 BNIP3L	
	 CCNG1	 DAXX	 CASP2	
	 CD44	 DDIT4	 COL18A1	
	 CDC25A	 DKK1	 CYP24A1	
	 CDKN1B	 GADD45A	 DDX20	
	 CDKN2A	 ING5	 DFNA5	
	 CXCR4	 P53AIP1	 DUSP2	
	 EGFR	 PITX1	 DUSP4	
	 ESR1	 PML	 ECT2	
	 FGF2	 SERPINE1	 FAS	
	 FOS	 TOP2A	 FDXR	
	 HNF4A	 TP53INP1	 HOXA10	
	 IL6	 WWOX	 IFI16	
	 JUN	 XAF1	 IFITM2	
	 MSH2	 NFKB2	 IGFBP7	
	 NOTCH1	 TFAP2A	 ING4	
	 PRKCA	 	 KAT2B	
	 PTGS2	 	 LATS2	
	 SIAH1	 	 LRDD	
	 SIVA1	 	 MAP4K4	
	 TNFRSF10A	 	 MIC1	
	 TNFRSF10B	 	 NLRC4	
	 	 	 PCBP4	
	 	 	 PEG3	
	 	 	 PERP	
	 	 	 PRSS50	
	 	 	 PTEN	
	 	 	 SEMA3B	
	 	 	 SERPINB5	
	 	 	 TFAP2C	
	 	 	 TLR3	
	 	 	 UCHL1	
	 	 	 ZNF148	
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Table	7.3.3.2	Anti	-apoptotic	nodes	under	LSSA	in	PMH302	hypoxia	simulations.	
A	total	of	50	anti	–	apoptotic	nodes	are	described	in	PMH302.		
In	silico	scenario	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 35	 11	 4	
	 AR	 APEX1	 NANOG	
	 ATF3	 BCL3	 PREP1	
	 BCL2	 CKS2	 RB1CC1	
	 C12orf5	 CUL7	 TP53RK	
	 CCNG1	 DAXX	 	
	 CD44	 FLI1	 	
	 CDC25A	 IGF1R	 	
	 CDKN1A	 MTA1	 	
	 CDKN1B	 PDGFRB	 	
	 DDIT4	 PSEN1	 	
	 DUSP2	 WWP1	 	
	 DUSP4	 	 	
	 EGFR	 	 	
	 EPHB4	 	 	
	 ESR1	 	 	
	 EZH2	 	 	
	 FGF2	 	 	
	 FHL2	 	 	
	 FOS	 	 	
	 GSTP1	 	 	
	 IER3	 	 	
	 IL6	 	 	
	 MAP4K4	 	 	
	 MCL1	 	 	
	 NFKB2	 	 	
	 NOTCH1	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SFN	 	 	
	 SGK	 	 	
	 STAT3	 	 	
	 TCF7L2	 	 	
	 TGFA	 	 	
	 TPT1	 	 	
	 VEGFA	 	 	
p53	wild	type	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
	 34	 11	 4	
	 APEX1	 AR	 NANOG	
	 ATF3	 BCL3	 PREP1	
	 288	
	 BCL2	 CKS2	 RB1CC1	
	 C12orf5	 DAXX	 TCF7L2	
	 CCNG1	 EPHB4	 TP53RK	
	 CD44	 FLI1	 	
	 CDC25A	 IGF1R	 	
	 CDKN1A	 MTA1	 	
	 CDKN1B	 NFKB2	 	
	 CUL7	 PDGFRB	 	
	 DDIT4	 PSEN1	 	
	 DUSP2	 	 	
	 DUSP4	 	 	
	 EGFR	 	 	
	 ESR1	 	 	
	 EZH2	 	 	
	 FGF2	 	 	
	 FHL2	 	 	
	 FOS	 	 	
	 GSTP1	 	 	
	 IER3	 	 	
	 IL6	 	 	
	 MAP4K4	 	 	
	 MCL1	 	 	
	 NOTCH1	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SFN	 	 	
	 SGK	 	 	
	 STAT3	 	 	
	 TGFA	 	 	
	 TPT1	 	 	
	 VEGFA	 	 	
	 WWP1	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
	 29	 6	 15	
	 AR	 APEX1	 BCL3	
	 ATF3	 CUL7	 C12orf5	
	 BCL2	 DAXX	 CKS2	
	 CCNG1	 FLI1	 DUSP2	
	 CD44	 MTA1	 DUSP4	
	 CDC25A	 WWP1	 FHL2	
	 CDKN1A	 	 IGF1R	
	 CDKN1B	 	 MAP4K4	
	 DDIT4	 	 NANOG	
	 289	
	 EGFR	 	 PDGFRB	
	 EPHB4	 	 PREP1	
	 ESR1	 	 PSEN1	
	 EZH2	 	 RB1CC1	
	 FGF2	 	 SFN	
	 FOS	 	 TP53RK	
	 GSTP1	 	 	
	 IER3	 	 	
	 IL6	 	 	
	 MCL1	 	 	
	 NFKB2	 	 	
	 NOTCH1	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SGK	 	 	
	 STAT3	 	 	
	 TCF7L2	 	 	
	 TGFA	 	 	
	 TPT1	 	 	
	 VEGFA	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
	 25	 8	 17	
	 APEX1	 AR	 BCL3	
	 ATF3	 DAXX	 C12orf5	
	 BCL2	 DDIT4	 CKS2	
	 CCNG1	 FLI1	 DUSP2	
	 CD44	 IER3	 DUSP4	
	 CDC25A	 MTA1	 EPHB4	
	 CDKN1A	 NFKB2	 FHL2	
	 CDKN1B	 TPT1	 IGF1R	
	 CUL7	 	 MAP4K4	
	 EGFR	 	 NANOG	
	 ESR1	 	 PDGFRB	
	 EZH2	 	 PREP1	
	 FGF2	 	 PSEN1	
	 FOS	 	 RB1CC1	
	 GSTP1	 	 SFN	
	 IL6	 	 TCF7L2	
	 MCL1	 	 TP53RK	
	 NOTCH1	 	 	
	 PRKCA	 	 	
	 PTGS2	 	 	
	 SGK	 	 	
	 290	
	 STAT3	 	 	
	 TGFA	 	 	
	 VEGFA	 	 	
	 WWP1	 	 	
	
	
	
Figure	7.3.1.5	Total	number	and	distribution	of	nodes	regulating	apoptosis	in	PMH302	
hypoxia	simulations	under	LSSA.		
	
	
7.3.2.3.3	Nodes	regulating	cell	cycle	arrest	under	LSSA.		
A	total	of	66	nodes	regulating	cell	cycle	arrest	are	described	in	PMH302.	Globally,	
comparing	pro	and	anti-cell	cycle	arrest	nodes	and	under	differential	in	silico	hypoxic	
conditions	a	greater	shift	to	nodes	upregulated	that	activate	cell	cycle	arrest	was	noted	
compared	to	nodes	upregulated	that	inhibit	cell	cycle	arrest	in	the	p53	wild	type	
backgrounds	
	
Under	in	silico	hypoxia,	in	the	presence	of	p53	there	was	an	increase	of	pro-cell	cycle	
arrest	upregulated	(n=23)	compared	to	the	p53	deletion	background	(n=18)	(compare	
lanes	1	and	3	in	fig.	7.3.1.6).	A	similar	number	of	anti-cell	cycle	arrest	nodes	were	
upregulated	regardless	of	p53	status;	19	upregulated	for	p53	wild	type	and	18	
upregulated	for	p53	knockout	under	hypoxia	(compare	lanes	13	and	15).	Of	these,	
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CCNB1	was	exclusively	upregulated	in	the	absence	of	p53	under	hypoxia,	whilst	ISG15	
and	RGS16	were	upregulated	in	the	presence	of	p53	(table	7.3.3.3).	In	fact,	ISG15,	
RGS16	were	exclusively	p53	responsive.	Tables	7.3.3.3	and	7.3.3.4	summarise	node	
state	changes	for	anti	and	pro-	cell	cycle	arrest	nodes	respectively.		
	
Table	7.3.3.3	Nodes	that	negatively	regulate	cell	cycle	arrest	under	LSSA	in	PMH302	hypoxia	
simulations.	A	total	of	31	anti-cell	cycle	arrest	nodes	are	described.		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 19	 8	 4	
	 APAF1	 CCNB1	 AURKA	
	 AR	 CKS2	 HDAC1	
	 ATF3	 CUL7	 JAG1	
	 CCNA	 ING5	 PRAK	
	 CDK2	 MTA1	 	
	 E2F1	 RAD51	 	
	 EPHB4	 S100A6	 	
	 IER3	 UBE2A	 	
	 ISG15	 	 	
	 JUN	 	 	
	 MCL1	 	 	
	 MUC1	 	 	
	 MYC	 	 	
	 RGS16	 	 	
	 SIVA1	 	 	
	 SLC2A1	 	 	
	 VRK1	 	 	
	 YBX1	 	 	
	 MYC	 	 	
p53	wild	type	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 18	 9	 4	
	 APAF1	 AR	 AURKA	
	 ATF3	 CKS2	 HDAC1	
	 CCNA	 EPHB4	 JAG1	
	 CCNB1	 ING5	 PRAK	
	 CDK2	 MTA1	 	
	 CUL7	 MUC1	 	
	 E2F1	 S100A6	 	
	 IER3	 UBE2A	 	
	 ISG15	 VRK1	 	
	 JUN	 	 	
	 MCL1	 	 	
	 292	
	 MYC	 	 	
	 RAD51	 	 	
	 RGS16	 	 	
	 SIVA1	 	 	
	 SLC2A1	 	 	
	 YBX1	 	 	
	 MYCN	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 18	 5	 8	
	 APAF1	 CUL7	 AURKA	
	 AR	 ING5	 CKS2	
	 ATF3	 MTA1	 HDAC1	
	 CCNA	 RAD51	 ISG15	
	 CCNB1	 UBE2A	 JAG1	
	 CDK2	 	 PRAK	
	 E2F1	 	 RGS16	
	 EPHB4	 	 S100A6	
	 IER3	 	 	
	 JUN	 	 	
	 MCL1	 	 	
	 MUC1	 	 	
	 MYC	 	 	
	 SIVA1	 	 	
	 SLC2A1	 	 	
	 VRK1	 	 	
	 YBX1	 	 	
	 MYCN	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 15	 7	 9	
	 APAF1	 AR	 AURKA	
	 ATF3	 IER3	 CKS2	
	 CCNA	 ING5	 EPHB4	
	 CCNB1	 MTA1	 HDAC1	
	 CDK2	 MUC1	 ISG15	
	 CUL7	 UBE2A	 JAG1	
	 E2F1	 VRK1	 PRAK	
	 JUN	 	 RGS16	
	 MCL1	 	 S100A6	
	 MYC	 	 	
	 RAD51	 	 	
	 SIVA1	 	 	
	 SLC2A1	 	 	
	 293	
	 YBX1	 	 	
	 MYCN	 	 	
	
	
	
Table	7.3.3.4	Nodes	that	positively	regulate	cell	cycle	arrest	under	LSSA	in	PMH302	hypoxia	
simulations.	A	total	of	35	pro-cell	cycle	arrest	nodes	are	described	in	PMH302.	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 23	 3	 9	
	 ATF3	 EXPORTIN1	 HOXA10	
	 ATM	 MYST4	 HOXA5	
	 ATR	 CDKN2A	 ING4	
	 BTG2	 	 PPARG	
	 CDK5	 	 PRKAB1	
	 CHEK1	 	 CASP2	
	 CHEK2	 	 PADI4	
	 DKK1	 	 PARK2	
	 DUSP5	 	 POU4F1	
	 E2F1	 	 	
	 GADD45A	 	 	
	 ID3	 	 	
	 IGFBP7	 	 	
	 KAT2B	 	 	
	 KLF4	 	 	
	 MAPK1	 	 	
	 PTGS2	 	 	
	 RAF1	 	 	
	 RAS	 	 	
	 STMN1	 	 	
	 TFAP2C	 	 	
	 CDKN1B	 	 	
	 BRCA1	 	 	
p53	wild	type	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 20	 6	 9	
	 ATF3	 ATM	 HOXA10	
	 E2F1	 ATR	 HOXA5	
	 CDK5	 BTG2	 ING4	
	 CHEK2	 CHEK1	 PPARG	
	 DKK1	 EXPORTIN1	 PRKAB1	
	 DUSP5	 MYST4	 CASP2	
	 GADD45A	 	 PADI4	
	 294	
	 ID3	 	 PARK2	
	 IGFBP7	 	 POU4F1	
	 KAT2B	 	 	
	 KLF4	 	 	
	 MAPK1	 	 	
	 PTGS2	 	 	
	 RAF1	 	 	
	 RAS	 	 	
	 STMN1	 	 	
	 TFAP2C	 	 	
	 BRCA1	 	 	
	 CDKN1B	 	 	
	 CDKN2A	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 18	 4	 9	
	 ATF3	 GADD45A	 EXPORTIN1	
	 ATM	 KLF4	 HOXA10	
	 ATR	 MYST4	 HOXA5	
	 BTG2	 CDKN2A	 IGFBP7	
	 CDK5	 	 ING4	
	 CHEK1	 	 KAT2B	
	 CHEK2	 	 PPARG	
	 DKK1	 	 PRKAB1	
	 DUSP5	 	 TFAP2C	
	 E2F1	 	 POU4F1	
	 ID3	 	 PARK2	
	 MAPK1	 	 PADI4	
	 PTGS2	 	 CASP2	
	 RAF1	 	 	
	 RAS	 	 	
	 STMN1	 	 	
	 BRCA1	 	 	
	 CDKN1B	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 14	 7	 14	
	 ATF3	 ATM	 CHEK1	
	 CDK5	 ATR	 EXPORTIN1	
	 CHEK2	 BTG2	 HOXA10	
	 DUSP5	 DKK1	 HOXA5	
	 E2F1	 GADD45A	 IGFBP7	
	 ID3	 KLF4	 ING4	
	 MAPK1	 MYST4	 KAT2B	
	 295	
	 PTGS2	 	 PPARG	
	 RAF1	 	 PRKAB1	
	 RAS	 	 TFAP2C	
	 STMN1	 	 POU4F1	
	 BRCA1	 	 PARK2	
	 CDKN1B	 	 PADI4	
	 CDKN2A	 	 CASP2	
	
	
	
Figure	7.3.1.6	Total	number	and	distribution	of	nodes	regulating	cell	cycle	arrest	under	LSSA	
in	PMH302	hypoxia	simulations.	A	total	of	66	nodes	that	regulated	cell	cycle	arrest	were	
considered	in	PMH302.	The	majority	of	pro-cell	cycle	arrest	nodes	were	upregulated	in	
p53	wild	type	compared	to	knockout	backgrounds.		
	
	
7.3.2.3.4	Nodes	regulating	cellular	senescence	under	LSSA	
A	total	of	73	nodes	that	regulate	cellular	senescence	are	described	in	PMH302.	Of	
these,	35	are	positive	regulators,	38	negative	regulators	of	senescence.	Globally	across	
all	conditions	under	differential	in	silico	hypoxic	conditions,	a	greater	number	of	pro	-
cellular	senescence	nodes	were	upregulated	in	the	presence	of	p53,	than	in	p53s	
absence.		
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Investigating	the	effect	of	p53	status	when	the	hypoxic	input	was	switched	OFF,	nearly	
a	two-fold	increase	in	pro-senescence	nodes	upregulated	was	observed	in	the	presence	
of	p53	(n=25)	than	in	its	absence	(n=13)	(compare	lanes	2	and	4	in	fig.	7.3.1.7).	
Comparable	to	this,	31	anti	–senescence	nodes	were	upregulated	in	p53	wild	type	
background	compared	to	19	in	the	p53	deleted	background	(compare	lanes	14	and	16).	
Of	the	pro-senescence	nodes	downregulated,	8	in	the	absence	of	p53	compared	to	6	in	
p53	presence,	PML,	GAPDH,	GADD45A,	DKK1	and	CD59	were	exclusively	
downregulated	in	the	absence	of	p53,	whilst	IFITM2,	IGF1R	and	PSEN1	were	
downregulated	when	p53	was	present	(table	7.3.3.6).		
	
In	the	p53	wild	type	backgrounds,	31	anti-senescence	nodes	upregulated	when	hypoxia	
was	OFF,	compared	to	28	upregulated	when	hypoxia	was	ON.	Of	these,	CUL7,	DKK1	
and	HNF4A	were	the	differential	nodes	upregulated	in	the	absence	of	hypoxia	(table	
7.3.3.5).		
	
The	number	of	anti-senescence	nodes	upregulated	and	downregulated	were	identical	
regardless	of	hypoxic	input	in	p53	knockout	backgrounds;	19	upregulated	for	both	
hypoxia	ON	and	OFF	(compare	lanes	13	and	16	fig.	7.3.1.7).	Even	so,	of	these	anti-
senescence	nodes,	CD59,	DDIT4	and	DKK1	were	upregulated	in	response	to	in	silico	
hypoxia,	whilst	BAK1,	CUL7	and	HNF4A	were	upregulated	when	hypoxia	was	switched	
OFF	(table	7.3.3.5).	The	number	of	pro-senescence	nodes	downregulated	was	identical	
(n=4)	for	both	conditions,	however	BAK1,	CDKN2A	and	PML	were	downregulated	when	
hypoxia	was	ON,	whilst	CD59,	DKK1	and	GAPDH	were	downregulated	when	hypoxia	
was	OFF	in	p53	deletion	backgrounds.	GADD45A	was	p53	responsive,	downregulated	in	
both	conditions,	regardless	of	hypoxia	(table	7.3.3.6).	As	in	all	other	p53	deleted	
conditions,	majority	of	nodes	shifted	to	an	undetermined	state	when	p53	was	removed	
from	the	network.	Tables	7.3.3.5	and	7.3.3.6	summarise	their	node	state	changes	in	
response	to	the	four	conditions	of	different	hypoxia	input	and	p53	statuses	under	LSSA.		
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Table	7.3.3.5	Nodes	that	negatively	regulate	cellular	senescence	under	LSSA	in	PMH302	
hypoxia	simulations.		A	total	of	38	anti	–	senescence	nodes	are	described	in	PMH302.	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 28	 7	 3	
	 APAF1	 CUL7	 ELAVL1	
	 ARID3A	 DAXX	 JAG1	
	 BAK1	 FOXM1	 SOD2	
	 BCL2	 HNF4A	 	
	 BRCA1	 S100A6	 	
	 CD59	 TFDP1	 	
	 CDK4	 WWP1	 	
	 CKB	 	 	
	 DDIT4	 	 	
	 DKK1	 	 	
	 EGFR	 	 	
	 EZH2	 	 	
	 FGF2	 	 	
	 FHL2	 	 	
	 GADD45A	 	 	
	 GAPDH	 	 	
	 HIF1A	 	 	
	 MCL1	 	 	
	 MSH2	 	 	
	 MYC	 	 	
	 NME1	 	 	
	 PCBP4	 	 	
	 PPM1D	 	 	
	 PTEN	 	 	
	 RRM2B	 	 	
	 SESN2	 	 	
	 SGK	 	 	
	 VEGFA	 	 	
p53	wild	type	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 31	 4	 3	
	 APAF1	 DAXX	 ELAVL1	
	 ARID3A	 FOXM1	 JAG1	
	 BAK1	 S100A6	 SOD2	
	 BCL2	 TFDP1	 	
	 BRCA1	 	 	
	 CD59	 	 	
	 CDK4	 	 	
	 CKB	 	 	
	 CUL7	 	 	
	 DDIT4	 	 	
	 DKK1	 	 	
	 EGFR	 	 	
	 EZH2	 	 	
	 298	
	 FGF2	 	 	
	 FHL2	 	 	
	 GADD45A	 	 	
	 GAPDH	 	 	
	 HIF1A	 	 	
	 HNF4A	 	 	
	 MCL1	 	 	
	 MSH2	 	 	
	 MYC	 	 	
	 NME1	 	 	
	 PCBP4	 	 	
	 PPM1D	 	 	
	 PTEN	 	 	
	 RRM2B	 	 	
	 SESN2	 	 	
	 SGK	 	 	
	 VEGFA	 	 	
	 WWP1	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 19	 6	 13	
	 APAF1	 BAK1	 ARID3A	
	 BCL2	 CUL7	 ELAVL1	
	 BRCA1	 DAXX	 FHL2	
	 CD59	 GADD45A	 FOXM1	
	 CDK4	 HNF4A	 JAG1	
	 CKB	 WWP1	 PCBP4	
	 DDIT4	 	 PPM1D	
	 DKK1	 	 PTEN	
	 EGFR	 	 RRM2B	
	 EZH2	 	 S100A6	
	 FGF2	 	 SESN2	
	 GAPDH	 	 SOD2	
	 HIF1A	 	 TFDP1	
	 MCL1	 	 	
	 MSH2	 	 	
	 MYC	 	 	
	 NME1	 	 	
	 SGK	 	 	
	 VEGFA	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 19	 6	 13	
	 APAF1	 CD59	 ARID3A	
	 BAK1	 DAXX	 ELAVL1	
	 BCL2	 DDIT4	 FHL2	
	 BRCA1	 DKK1	 FOXM1	
	 CDK4	 GADD45A	 JAG1	
	 CKB	 GAPDH	 PCBP4	
	 CUL7	 	 PPM1D	
	 299	
	 EGFR	 	 PTEN	
	 EZH2	 	 RRM2B	
	 FGF2	 	 S100A6	
	 HIF1A	 	 SESN2	
	 HNF4A	 	 SOD2	
	 MCL1	 	 TFDP1	
	 MSH2	 	 	
	 MYC	 	 	
	 NME1	 	 	
	 SGK	 	 	
	 VEGFA	 	 	
	 WWP1	 	 	
	
	
Table	7.3.3.6	Nodes	that	positively	regulate	cellular	senescence	under	LSSA	in	PMH302	
hypoxia	simulations.		A	total	of	35	pro	–	senescence	nodes	are	described	in	PMH302.		
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 27	 4	 4	
	 APP	 CDKN2A	 ING1	
	 AR	 IFITM2	 MIC1	
	 BAK1	 IGF1R	 PIN1	
	 BCL2	 PSEN1	 PRAK	
	 BHLHE40	 	 	
	 C12orf5	 	 	
	 CD59	 	 	
	 CDKN1A	 	 	
	 CDKN1B	 	 	
	 DDB2	 	 	
	 DKK1	 	 	
	 GADD45A	 	 	
	 GAPDH	 	 	
	 IFI16	 	 	
	 IGFBP7	 	 	
	 IL6	 	 	
	 LATS2	 	 	
	 MSH2	 	 	
	 MYC	 	 	
	 NOTCH1	 	 	
	 PML	 	 	
	 PRKCA	 	 	
	 PTEN	 	 	
	 PTGS2	 	 	
	 RAS	 	 	
	 SFN	 	 	
	 300	
	 TGFA	 	 	
p53	wild	type	with	DNA	
hypoxia	OFF	
Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 25	 6	 4	
	 BAK1	 APP	 ING1	
	 BCL2	 AR	 MIC1	
	 C12orf5	 BHLHE40	 PIN1	
	 CD59	 IFITM2	 PRAK	
	 CDKN1A	 IGF1R	 	
	 CDKN1B	 PSEN1	 	
	 CDKN2A	 	 	
	 DDB2	 	 	
	 DKK1	 	 	
	 GADD45A	 	 	
	 GAPDH	 	 	
	 IFI16	 	 	
	 IGFBP7	 	 	
	 IL6	 	 	
	 LATS2	 	 	
	 MSH2	 	 	
	 MYC	 	 	
	 NOTCH1	 	 	
	 PML	 	 	
	 PRKCA	 	 	
	 PTEN	 	 	
	 PTGS2	 	 	
	 RAS	 	 	
	 SFN	 	 	
	 TGFA	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 	 Total	number	 	
	 17	 4	 14	
	 APP	 BAK1	 C12orf5	
	 AR	 CDKN2A	 DDB2	
	 BCL2	 GADD45A	 IFI16	
	 BHLHE40	 PML	 IFITM2	
	 CD59	 	 IGF1R	
	 CDKN1A	 	 IGFBP7	
	 CDKN1B	 	 ING1	
	 DKK1	 	 LATS2	
	 GAPDH	 	 MIC1	
	 IL6	 	 PIN1	
	 MSH2	 	 PRAK	
	 MYC	 	 PSEN1	
	 301	
	 NOTCH1	 	 PTEN	
	 PRKCA	 	 SFN	
	 PTGS2	 	 	
	 RAS	 	 	
	 TGFA	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 	 Total	number	 	
	 13	 8	 14	
	 BAK1	 CD59	 PTEN	
	 BCL2	 DKK1	 C12orf5	
	 MSH2	 GADD45A	 DDB2	
	 MYC	 GAPDH	 IFI16	
	 CDKN1A	 APP	 IFITM2	
	 CDKN1B	 AR	 IGF1R	
	 CDKN2A	 BHLHE40	 IGFBP7	
	 IL6	 PML	 ING1	
	 NOTCH1	 	 LATS2	
	 PRKCA	 	 MIC1	
	 PTGS2	 	 PIN1	
	 RAS	 	 PRAK	
	 TGFA	 	 PSEN1	
	 	 	 SFN	
	
	
	
	
Figure	7.3.1.7	Total	number	and	distribution	of	nodes	regulating	cellular	senescence	under	
LSSA	in	PMH302	hypoxia	simulations.	
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7.3.2.3.5	Nodes	regulating	DNA	repair	under	LSSA	
investigating	the	effect	of	p53	under	hypoxia,	an	increase	in	pro-	DNA	repair	nodes	
upregulated	in	the	presence	of	p53	(n=17)	was	noted,	compared	to	the	p53	deleted	
background	(n=13)	(compare	lanes	1	and	3	in	fig.7.3.1.8).	The	number	of	upregulated	
anti	-DNA	repair	nodes	were	similar	regardless	of	p53	status;	6	for	p53	wild	type	and	5	
for	p53	knockout	background	(compare	lanes	13	and	15)	with	PPM1D	and	KLF4	the	
difference,	upregulated	when	p53	was	present	(table	7.3.3.7).	Of	the	pro-DNA	repair	
nodes	downregulated,	MGMT	was	exclusively	downregulated	in	the	presence	of	p53,	
whilst	FEN1	and	GADD45A	were	downregulated	in	the	absence	of	p53	(table	7.3.3.8).		
	
In	p53	wild	type	backgrounds,	nearly	all	anti	-	DNA	repair	nodes	were	upregulated	
regardless	of	hypoxia	effect,	8	when	hypoxia	was	switched	ON,	7	when	switched	OFF	
(compare	lanes	13	and	14)	all	nodes	were	identical,	apart	from	SERPINE1	upregulated	
in	response	to	hypoxia	switched	ON	(table	7.3.3.7).		
	
In	p53	deletion	backgrounds,	9	pro	-	DNA	repair	nodes	were	downregulated	when	
hypoxia	was	ON	compared	to	11	pro-DNA	repair	nodes	downregulated	when	hypoxia	
was	OFF	(compare	lanes	7	and	8).	Of	these,	ATM,	ATR,	PRKDC	and	YY1	were	
downregulated	when	hypoxia	was	OFF,	whilst	APEX1	and	RAD51	were	downregulated	
in	response	to	hypoxia	ON	(table	7.3.3.8).	The	upregulation	of	SERPINE1	in	response	to	
in	silico	hypoxia	was	the	only	difference	in	p53	deletion	backgrounds	(table	7.3.3.7).		
	
	
Table	7.3.3.7	Nodes	that	negatively	regulate	DNA	repair	under	LSSA	in	PMH302	hypoxia	
simulations.		Only	a	minority	of	nodes	(n	=	8)	that	negatively	regulate	DNA	repair	are	described	
in	the	PMH302	model	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 8	 0	 0	
	 KLF4	 	 	
	 MDM2	 	 	
	 MDM4	 	 	
	 MYC	 	 	
	 SERPINE1	 	 	
	 SIAH1	 	 	
	 303	
	 PPM1D	 	 	
	 PTTG1	 	 	
p53	wild	type	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 7	 1	 0	
	 KLF4	 SERPINE1	 	
	 MDM2	 	 	
	 MDM4	 	 	
	 MYC	 	 	
	 SIAH1	 	 	
	 PPM1D	 	 	
	 PTTG1	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 6	 1	 1	
	 MDM2	 KLF4	 PPMID	
	 MDM4	 	 	
	 MYC	 	 	
	 SERPINE1	 	 	
	 SIAH1	 	 	
	 PTTG1	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 5	 2	 1	
	 MDM2	 KLF4	 PPMID	
	 MDM4	 SERPINE1	 	
	 MYC	 	 	
	 SIAH1	 	 	
	 PTTG1	 	 	
.		
	
Table	7.3.3.8	Nodes	that	positively	regulate	DNA	repair	under	LSSA	in	PMH302	hypoxia	
simulations.		A	total	of	29	pro	–DNA	repair	nodes	are	described	in	PMH302	
In	silico	simulation		 Upregulated	 Downregulated	 Undetermined	
	 Total	number	of	nodes	
p53	wild	type	with	hypoxia	ON	 17	 8	 4	
	 ATM	 APEX1	 BCCIP	
	 ATR	 MGMT	 ING1	
	 BRCA1	 MTA1	 PIN1	
	 CD44	 PIAS1	 SUMO3	
	 CDKN1A	 RAD51	 	
	 DDB2	 RFWD3	 	
	 FEN1	 RPA1	 	
	 FGF2	 RPS27L	 	
	 304	
	 GADD45A	 	 	
	 HSPA4	 	 	
	 IFI16	 	 	
	 MCL1	 	 	
	 MSH2	 	 	
	 NME1	 	 	
	 PCNA	 	 	
	 PRKDC	 	 	
	 YY1	 	 	
p53	wild	type	with	DNA	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 15	 10	 4	
	 APEX1	 ATM	 BCCIP	
	 BRCA1	 ATR	 ING1	
	 CD44	 MGMT	 PIN1	
	 CDKN1A	 MTA1	 SUMO3	
	 DDB2	 PIAS1	 	
	 FEN1	 PRKDC	 	
	 FGF2	 RFWD3	 	
	 GADD45A	 RPA1	 	
	 HSPA4	 RPS27L	 	
	 IFI16	 YY1	 	
	 MCL1	 	 	
	 MSH2	 	 	
	 NME1	 	 	
	 PCNA	 	 	
	 RAD51	 	 	
p53	knockout	with	hypoxia	ON	 Upregulated	 Downregulated	 Undetermined	
	 Total	number	
	 13	 9	 7	
	 ATM	 APEX1	 BCCIP	
	 ATR	 FEN1	 DDB2	
	 BRCA1	 GADD45A	 IFI16	
	 CD44	 MTA1	 ING1	
	 CDKN1A	 PIAS1	 MGMT	
	 FGF2	 RAD51	 PIN1	
	 HSPA4	 RFWD3	 SUMO3	
	 MCL1	 RPA1	 	
	 MSH2	 RPS27L	 	
	 NME1	 	 	
	 PCNA	 	 	
	 PRKDC	 	 	
	 YY1	 	 	
p53	knockout	with	hypoxia	OFF	 Upregulated	 Downregulated	 Undetermined	
	 305	
	 Total	number	
	 11	 11	 7	
	 APEX1	 ATM	 BCCIP	
	 BRCA1	 ATR	 DDB2	
	 CD44	 FEN1	 IFI16	
	 CDKN1A	 GADD45A	 ING1	
	 FGF2	 MTA1	 MGMT	
	 HSPA4	 PIAS1	 PIN1	
	 MCL1	 PRKDC	 SUMO3	
	 MSH2	 RFWD3	 	
	 NME1	 RPA1	 	
	 PCNA	 RPS27L	 	
	 RAD51	 YY1	 	
	
	
Figure	7.3.1.8	Total	number	and	distribution	of	nodes	regulating	DNA	repair	under	LSSA	in	
PMH302	hypoxia	simulations.	Only	a	small	number	of	anti-DNA	repair	nodes	are	considered	in	
the	PMH302	network	(n=8).		
	
	
7.3.3	In	silico	node	knockout	analysis	using	dependency	matrix	calculations		
Logical	dependencies	between	genes	/	proteins	are	represented	by	the	dependency	
matrix,	(Klamt	et	al.2006;2011).	This	denotes	the	effects	between	all	binary	nodes	in	
the	PMH302	model.	In	accordance	with	Klamt	et	al.	(2006:2011)	six	types	of	
relationships	are	defined	by	CellNetAnalyzer.	This	is	based	upon	whether	positive	and	
negative	paths	exist	between	pairwise	nodes.	These	six	relationships	are	described	in	
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detail	in	material	and	methods,	section	6.	2.1	and	table	7.3.3.9	where	the	numbers	1-	6	
correspond	to;	no	effect,	ambivalent,	weak	inhibitor,	weak	activator,	strong	inhibitor	
and	strong	activator	respectively.		
	
To	investigate	node	dependency	relationships	in	response	to	various	in	silico	knockouts	
(KOs),	the	connectivity	degree	of	all	nodes	were	determined	in	the	PMH302	network.	
As	expected,	the	hub	of	the	network	–	p53	was	connected	to	over	300	interactions,	65	
nodes	were	connected	to	10	–	100	interactions,	the	remaining	were	connected	to	10	or	
less	(figure	7.3.1.9).	Of	the	highly	connected,	seven	nodes	connected	to	over	10	%	of	all	
other	nodes	(>30	nodes),	were	chosen	for	in	silico	deletion.	Selected	nodes	and	
corresponding	edges	were	deleted	from	the	model	to	represent	in	vivo	KO	or	mutation.	
Depending	on	the	effect	of	a	particular	node	KO,	the	relationships	between	remaining	
nodes	within	the	network	are	defined	by	these	six	dependency	relationships.		
	
The	total	number	of	dependencies	(n	=	91204)	(302×302)	represents	elements	in	the	
dependency	matrix	of	the	p53	wild-type	model	(null).	Of	these,	61336	correspond	to	
interactions	with	no	effect,	23590	are	ambivalent	factors,	2946	are	weak	inhibitors,	
3147	are	weak	activators,	59	are	strong	inhibitors	and	126	strong	activators.	For	any	
knockout	scenario	the	total	number	(n	=	90601)	represents	the	elements	within	the	
network	after	a	particular	node	deletion	(301x301).	We	focused	on	changes	in	strong	
activators	or	strong	inhibitors	as	these	typically	have	the	greatest	effect	on	the	cell.		
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Figure	7.3.1.9	Connectivity	degree	distribution	of	all	nodes	in	PMH302.		
Axes	are	in	logarithmic	scale.	As	expected,	the	only	node	with	over	300	interactions	was	p53	
(far	right	of	figure)	
	
	
The	greatest	effect	was	seen	when	p53	was	deleted	from	the	network,	with	nearly	a	
two-fold	increase	in	strong	activators	and	strong	inhibitors	from	the	null	model	(table	
7.3.3.9).	514	potential	novel	predictions	(PNPs)	were	obtained	from	dependency	
changes	in	response	to	in	silico	deletion	of	the	seven	highly	connected	nodes	(table	
7.3.4).	Of	these,	the	removal	of	p53	and	E2F1	from	the	network	resulted	in	the	
majority	of	changes,	deriving	134	and	124	dependency	changes	(predictions)	
respectively.		66	and	70	changes	were	as	a	result	of	FGF2	and	HIF1A	removal	
respectively.	VEGFA,	MDM2	and	MYC	resulted	in	the	least	changes;	32,	48	and	41	
respectively	when	deleted	from	the	network.	These	predictions	are	summarised	in	
table	7.3.4.	
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Table	7.3.3.9	Alterations	in	the	dependency	matrix	upon	node	deletions	
A	single	node	was	deleted	from	the	PMH302	network.	The	numbers	of	six	types	of	effect	
elements	in	the	dependency	matrix	were	calculated	as	listed	below.	The	value	“Null”	in	the	
selected	node	column	indicates	p53	wild	type.	
Effect	
No	
Effect	 Ambivalent	
Weak	
inhibitor	
Weak	
activator	
Strong	
inhibitor	
Strong	
activator	 Total	
Number	
effect	 1	 2	 3	 4	 5	 6	 	
In	silico	
KO	 	 	 	 	 	 	 	
Null	 61336	 23590	 2946	 3147	 59	 126	 91204	
p53	 82300	 7883	 38	 94	 91	 195	 90601	
E2F1	 61233	 22539	 3193	 3450	 59	 127	 90601	
FGF2	 61263	 23123	 2911	 3118	 59	 127	 90601	
MDM2	 61078	 23147	 3007	 3184	 59	 126	 90601	
MYC	 61265	 22867	 3030	 3253	 60	 126	 90601	
HIF1A	 61601	 22719	 2949	 3141	 61	 130	 90601	
VEGFA	 62123	 22134	 2972	 3177	 63	 132	 90601	
	
	
Table	7.3.4	Summary	of	predictions	derived	from	application	of	in	silico	KOs	of	7	nodes	to	
dependency	matrix	elements.	514	predictions	were	obtained	from	various	in	silico	deletions	of	
highly	connected	nodes.	The	greatest	change	was	in	the	absence	of	p53.	Some	predictions	
were	verified	from	literature	or	laboratory	experiments;	others	are	novel	predictions	(PNP).			
Deleted	
node	
Source	
node	
Target	
node	
Wild	type	 Knockout	 Prediction	
status	
Reference	
p53	 ASPP1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 ASPP2	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 BCCIP	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 BDKRB
1	
CDK4	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 BDKRB
1	
FGF2	 Weak	
activator	
Strong	
activator	
PNP	 	
p53	 BHLHE
40	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 BHLHE
40	
STAT3	 Weak	
inhibitor	
Strong	
inhibitor	
PNP	 	
p53	 CUL7	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 CUL7	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 DAP	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 DAXX	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
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p53	 DAXX	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 DDX20	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 DNA	
damag
e	
PML	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 DNA	
damag
e	
TFAP2A	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 DNA	
damag
e	
APP	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 DNA	
damag
e	
CDK4	 Ambivale
nt	factor	
Strong	
inhibitor	
Laboratory	
verified	
here	
Inconsistent	with	
prediction	
p53	 DNA	
damag
e	
FAS	 Ambivale
nt	factor	
Strong	
activator	
Literature	
verified	
Manna	et.al	2011	
p53	 DYRK2	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 DYRK2	 P53AIP1	 Weak	
activator	
Strong	
activator	
PNP	 	
p53	 FAS	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 FGF2	 CDK4	 Ambivale
nt	factor	
Strong	
activator	
Laboratory	
verified	
here	
Confirmed	
p53	 FLI1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 HOXA
5	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
BAK1	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 Hypox
ia	
CA9	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
CASP8	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
CD59	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
CDK4	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
CDKN2A	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 Hypox
ia	
DDIT4	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
DDX5	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
FGF2	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
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p53	 Hypox
ia	
GAPDH	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
HNF4A	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
IER3	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
IGFBP1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
MAP4	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
SLC2A4	 Ambivale
nt	factor	
Weak	
activator	
PNP	 	
p53	 Hypox
ia	
SLC6A6	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 Hypox
ia	
SP7	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
TPT1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
UNC5A	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 Hypox
ia	
WWP1	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 Hypox
ia	
XAF1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 ID3	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 IFNA1	 CDK4	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 IFNA1	 FAS	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 IFNA1	 TLR3	 Ambivale
nt	factor	
Strong	
activator	
Opposite	to	
prediction	
Taura	et	al.2004	
p53	 IGFBP
7	
CDK4	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 ING4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 ING4	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 ING5	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 ING5	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 JUN	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 JUN	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 JUN	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 KAT2B	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
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p53	 KAT2B	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 KLF4	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 KLF4	 CCNB1	 Ambivale
nt	factor	
Strong	
inhibitor	
Literature	
verified	
Yoon	and	Yang,	
2004	
p53	 KLF4	 DNA	
repair	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 LATS2	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
Literature	
verified	
Ke	at	al.2004	
p53	 LATS2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
activator	
Literature	
verified	
Tschop	et	al.	2011	
p53	 MAPK
14	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 MAPK
14	
BAX	 Ambivale
nt	factor	
Strong	
activator	
Literature	
verified	
Gomez	et	al.2008	
p53	 MAPK
14	
MMP2	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 MAPK
14	
SGK	 Weak	
activator	
Strong	
activator	
PNP	 	
p53	 MAPK
14	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 MYST
4	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 NTN1	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 P53AI
P1	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PADI4	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PARK2	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PCBP4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PCBP4	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 PEG3	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
p53	 PHB	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
p53	 PIAS1	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PITX1	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
p53	 PML	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 PML	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
Literature	
verified	
Yang	et	al.2002	
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p53	 PML	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
activator	
Literature	
verified	
Scaglioni	et	al.2012	
p53	 PPAR
G	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 PPAR
G	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PRAK	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PREP1	 Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
p53	 PRKAB
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PRSS5
0	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PSEN1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
p53	 PTTG1	 CDK4	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 PTTG1	 FGF2	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 RAD51	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 RB1CC
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
p53	 RB1CC
1	
Cell	cycle	
arrest	
No	effect	 Strong	
activator	
PNP	 	
p53	 RGS16	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
p53	 RPA1	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
p53	 RPS27
L	
DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
p53	 RSK2	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 S100A
6	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 S100A
6	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 S100B	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
p53	 SEMA
3B	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 SENP3	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
p53	 SERPI
NB5	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
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p53	 SERPI
NE1	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
p53	 SERPI
NE1	
DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
p53	 SESN2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 SGK	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 SGK	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 SGK	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 SIVA1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 SLC2A
1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
p53	 SLC2A
1	
BAX	 No	effect	 Strong	
activator	
PNP	 	
p53	 SOD2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 STAT3	 Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
p53	 STMN
1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 STMN
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 SUMO
3	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 TFAP2
A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
Literature	
verified	
Wajapeyee	and	
Somasundara,	2002	
p53	 TFAP2
C	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 TFAP2
C	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 TFDP1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
p53	 TFDP1	 DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
p53	 TNFRS
F10A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
p53	 TP53I
NP1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
p53	 TPT1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
p53	 UBE2A	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
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p53	 UCHL1	 Apoptosis	 No	effect	 Strong	
activator	
Literature	
verified	
Jin	et	al.2013	
p53	 WWP
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
p53	 WWP
1	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
p53	 YY1	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 HSP90
AB1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 IFI16	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 ING1	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 JAG1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 MIC1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 MMP1
3	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 MTA1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 NANO
G	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 NQO1	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 PHB	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 RSK2	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 SENP3	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 SERPI
NE1	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 STMN
1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
APEX1	 No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 AIFM2	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 APAF1	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 APEX1	 Apoptosis	 Strong	
inhibitor	
Strong	
inhibitor	
PNP	 	
E2F1	 APP	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 BAK1	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 BAX	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
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E2F1	 BBC3	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 BNIP3
L	
Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 C12orf
5	
Apoptosis	 Strong	
inhibitor	
Strong	
inhibitor	
PNP	 	
E2F1	 CASP8	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 CKS2	 Apoptosis	 Strong	
inhibitor	
Strong	
inhibitor	
PNP	 	
E2F1	 COL18
A1	
Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 DFNA
5	
Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 ECT2	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 EPHB4	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 EZH2	 Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 FDXR	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 GADD
45A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 GSTP1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 HNF4
A	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 HOXA
10	
Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 IER3	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 IFI16	 Apoptosis	 Strong	
inhibitor	
Strong	
activator	
PNP	 	
E2F1	 IFITM
2	
Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 LRDD	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 MCL1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 MMP2	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 MSH2	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 MTA1	 Apoptosis	 Strong	
activator	
Strong	
inhibitor	
PNP	 	
E2F1	 NANO
G	
Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 NFKB2	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
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E2F1	 NLRC4	 Apoptosis	 Strong	
inhibitor	
Strong	
activator	
PNP	 	
E2F1	 P53AI
P1	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 PCBP4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 PEG3	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 PERP	 Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 PRSS5
0	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 PSEN1	 Apoptosis	 Strong	
activator	
Strong	
inhibitor	
PNP	 	
E2F1	 SEMA
3B	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 SERPI
NB5	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 SIVA1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 SLC2A
1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 TFAP2
C	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 TFDP1	 Apoptosis	 Strong	
activator	
Strong	
inhibitor	
PNP	 	
E2F1	 TNFRS
F10A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 TNFRS
F10B	
Apoptosis	 Strong	
activator	
Strong	
activator	
PNP	 	
E2F1	 TP53I
NP1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 TPT1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 WWP
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 XAF1	 Apoptosis	 Strong	
inhibitor	
Strong	
activator	
PNP	 	
E2F1	 MMP2	 BAX	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 SLC2A
1	
BAX	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 		DNA	
damag
e	
AATF	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 DNA	
damag
e	
CDK5	 Ambivale
nt	factor	
Strong	
activator	
	 Verified	here		
E2F1	 EPHB4	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
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E2F1	 EXPOR
TIN1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 IER3	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 JAG1	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 MTA1	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 PRKAB
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 RGS16	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 S100A
6	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 STMN
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 TFAP2
C	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 EZH2	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 HNF4
A	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 IFI16	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 JAG1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 MCL1	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 MIC1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 PCBP4	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 PSEN1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 S100A
6	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 SESN2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 SOD2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
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E2F1	 TFDP1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 WWP
1	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 Hypox
ia	
CUL7	 No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 EZH2	 DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 FEN1	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 IFI16	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 ING1	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 MGM
T	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 MSH2	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 RAD51	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 RPA1	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 RPS27
L	
DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
E2F1	 SERPI
NE1	
DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 SUMO
3	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 TFDP1	 DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 Hypox
ia	
DUSP1	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 IFNA1	 EIF2AK2	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 TFDP1	 EZH2	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
MAPK9	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
MCTS1	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 NOV	 MMP1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 HSP90
AB1	
MMP13	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
E2F1	 SLC2A
1	
MMP2	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
MUC1	 No	effect	 Strong	
activator	
PNP	 	
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E2F1	 CSNK2	 MYCN	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
NFKB2	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
NTN1	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 HIPK2	 POU4F1	 No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 Hypox
ia	
PRKDC	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
SERPINE1	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
SOX4	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 Hypox
ia	
VRK1	 No	effect	 Strong	
activator	
PNP	 	
E2F1	 EZH2	 RAD51	 No	effect	 Strong	
inhibitor	
PNP	 	
E2F1	 TFDP1	 RAD51	 No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 BDKRB
1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 HSP90
AB1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 IFI16	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 ING1	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 JAG1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 MIC1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 MMP1
3	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 MTA1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 NANO
G	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 NQO1	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 PHB	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 RSK2	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 SENP3	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 SERPI
NE1	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 STMN
1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
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FGF2	 GADD
45A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 GSTP1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 HNF4
A	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
FGF2	 IER3	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 LRDD	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 MCL1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 MMP2	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
FGF2	 NANO
G	
Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 NFKB2	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 P53AI
P1	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 PCBP4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 PEG3	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
FGF2	 PRSS5
0	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 SEMA
3B	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 SERPI
NB5	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
FGF2	 SIVA1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 SLC2A
1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
FGF2	 TFAP2
C	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 TNFRS
F10A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 TP53I
NP1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
FGF2	 TPT1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 WWP
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 IER3	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 JAG1	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 MTA1	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
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FGF2	 PRKAB
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 RGS16	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 S100A
6	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 STMN
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 TFAP2
C	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 HNF4
A	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 IFI16	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 JAG1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 MCL1	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 MIC1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 PCBP4	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 PSEN1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 S100A
6	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 SESN2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 SOD2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
FGF2	 TFDP1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 WWP
1	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 IFI16	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 ING1	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
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FGF2	 MGM
T	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 MSH2	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 RAD51	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 RPA1	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 RPS27
L	
DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
FGF2	 SERPI
NE1	
DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
FGF2	 SUMO
3	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
FGF2	 TFDP1	 DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
VEGFA	 CXCR4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 CXCR4	 TOP2A	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
PIAS2	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
PLA2G6	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
PRKG1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
RAD51	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
VEGFA	 DNA	
damag
e	
RGS16	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
RPRM	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
RREB1	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
S100A2	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
SP7	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
SUB1	 Strong	
activator	
Strong	
inhibitor	
PNP	 	
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VEGFA	 DNA	
damag
e	
SUMO2	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
TP53I13	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 DNA	
damag
e	
UBE3A	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 EZH2	 RAF1	 No	effect	 Strong	
inhibitor	
PNP	 	
VEGFA	 FOXM
1	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 FOXM
1	
BAX	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 FOXM
1	
CCNB1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 FOXM
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
VEGFA	 FOXM
1	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
VEGFA	 FOXM
1	
MMP2	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 FOXM
1	
MMP2	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 Hypox
ia	
PRKG1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 Hypox
ia	
SERPINF1	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 Hypox
ia	
SP7	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 RSK2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
VEGFA	 SESN2	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
VEGFA	 SLC2A
4	
BAX	 No	effect	 Strong	
activator	
PNP	 	
VEGFA	 TGFA	 EZH2	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
VEGFA	 TGFA	 RAF1	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
VEGFA	 WWP
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 NANO
G	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 NQO1	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 PHB	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
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MYC	 RSK2	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 SENP3	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
MYC	 SERPI
NE1	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
MYC	 STMN
1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 NANO
G	
Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 NFKB2	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 P53AI
P1	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 PCBP4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 PEG3	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MYC	 PRSS5
0	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 SEMA
3B	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 SERPI
NB5	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MYC	 SIVA1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 SLC2A
1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MYC	 TCF7L
2	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 TFAP2
C	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 TNFRS
F10A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 TP53I
NP1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MYC	 TPT1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 WWP
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 PRKAB
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 RGS16	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 S100A
6	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 STMN
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 TFAP2
C	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
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MYC	 PCBP4	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 PSEN1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
MYC	 S100A
6	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 SESN2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 SOD2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MYC	 TFDP1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 WWP
1	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 RAD51	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 RPA1	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
MYC	 RPS27
L	
DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
MYC	 SERPI
NE1	
DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
MYC	 SUMO
3	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MYC	 TFDP1	 DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 MIC1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 MMP1
3	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 MTA1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 NANO
G	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 NQO1	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 PHB	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 RSK2	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 SENP3	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 SERPI
NE1	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
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MDM2	 STMN
1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 MMP2	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MDM2	 NANO
G	
Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 NFKB2	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 P53AI
P1	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 PCBP4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 PEG3	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MDM2	 PRSS5
0	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 SEMA
3B	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 SERPI
NB5	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MDM2	 SIVA1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 SLC2A
1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MDM2	 TFAP2
C	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 TNFRS
F10A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 TP53I
NP1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
MDM2	 TPT1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 WWP
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 MTA1	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 PRKAB
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 RGS16	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 S100A
6	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 STMN
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 TFAP2
C	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 MIC1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
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MDM2	 PCBP4	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 PSEN1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 S100A
6	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 SESN2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 SOD2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
MDM2	 TFDP1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 WWP
1	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 MGM
T	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 MSH2	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 RAD51	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 RPA1	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 RPS27
L	
DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
MDM2	 SERPI
NE1	
DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
MDM2	 SUMO
3	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
MDM2	 TFDP1	 DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 HSP90
AB1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 IFI16	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 ING1	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 JAG1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 MIC1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 MMP1
3	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 MTA1	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
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HIF1A	 NANO
G	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 NQO1	 Angiogene
sis	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 PHB	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 RSK2	 Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 SENP3	 Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 SERPI
NE1	
Angiogene
sis	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 STMN
1	
Angiogene
sis	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 IER3	 Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 JAG1	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 MTA1	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 PRKAB
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 RGS16	 Cell	cycle	
arrest	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 S100A
6	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 STMN
1	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 TFAP2
C	
Cell	cycle	
arrest	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 HNF4
A	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 IFI16	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 JAG1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 MCL1	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 MIC1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 PCBP4	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 PSEN1	 Cellular	
senescenc
e	
No	effect	 Strong	
activator	
PNP	 	
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HIF1A	 S100A
6	
Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 SESN2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 SOD2	 Cellular	
senescenc
e	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 TFDP1	 Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 WWP
1	
Cellular	
senescenc
e	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 GAPD
H	
DNA	
repair	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 IFI16	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 ING1	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 MGM
T	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 MSH2	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 RAD51	 DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 RPA1	 DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 RPS27
L	
DNA	
repair	
No	effect	 Strong	
activator	
PNP	 	
HIF1A	 SERPI
NE1	
DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 SIAH1	 DNA	
repair	
Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 SUMO
3	
DNA	
repair	
Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 TFDP1	 DNA	
repair	
No	effect	 Strong	
inhibitor	
PNP	 	
HIF1A	 Hypox
ia	
PLAUR	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 GAPD
H	
SIAH1	 Weak	
activator	
Strong	
activator	
PNP	 	
HIF1A	 GAPD
H	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 HNF4
A	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
HIF1A	 IER3	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 LRDD	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
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HIF1A	 MCL1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 MMP2	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
HIF1A	 NANO
G	
Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 NFKB2	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 P53AI
P1	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 PCBP4	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 PEG3	 Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
HIF1A	 PRSS5
0	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 SEMA
3B	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 SERPI
NB5	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
HIF1A	 SIAH1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 SIVA1	 Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 SLC2A
1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
HIF1A	 TFAP2
C	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 TNFRS
F10A	
Apoptosis	 Ambivale
nt	factor	
Strong	
activator	
PNP	 	
HIF1A	 TP53I
NP1	
Apoptosis	 No	effect	 Strong	
activator	
PNP	 	
HIF1A	 TPT1	 Apoptosis	 Ambivale
nt	factor	
Strong	
inhibitor	
PNP	 	
HIF1A	 WWP
1	
Apoptosis	 No	effect	 Strong	
inhibitor	
PNP	 	
	
	
The	majority	of	dependency	changes	from	a	given	knockout	scenario	were	altered	from	
ambivalent	factors	to	strong	activators	and	strong	inhibitors.	A	large	majority	of	nodes	
(n	=	199),	changed	from	having	no	influence	(no	effect),	on	a	target	node	to	a	strong	
activating	(n	=126),	or	strong	inhibitory	effect	(n	=	73).		
	
To	evaluate	the	models	predictive	capacity	to	detect	perturbations	from	in	silico	node	
knockout,	extensive	literature	search	was	undertaken	for	validation	of	changes	derived	
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from	the	various	knockout	tests	(n=7).	Of	the	514	predictions	(table	7.3.4)	15	were	
confirmed	as	true	by	literature	verification	or	laboratory	verified.	Four	of	these	
predictions	were	verified	here	in	our	laboratory.	However,	an	important	note	to	
consider	is	that	not	all	predictions	were	literature	searched	for	validation	due	to	time	
constraints.		
	
7.3.4	Genome	wide	analysis	and	validation	of	the	PMH302	model	
In	order	to	evaluate	the	capability	of	the	Boolean	PMH302	model	to	predict	differential	
gene	expression	changes,	we	performed	LSSA	(tables	7.3.1.7	and	7.3.2.8)	and	
compared	the	results	on	a	genome	wide	level	gene	using	transcriptome	in	vitro	and	in	
vivo	data.	For	comparison	of	model	to	experimental	data,	we	used	the	formula	in	
accordance	with	Christensen	et	al.	(2009)	and	Tian	et	al.	(2013)	also	described	in	detail	
in	section	6.3.		
	
7.3.4.1	Superimposition	of	U2OS	cell	line	(p53	+/+)	gene	expression	profiles	to	
PMH302.		
Tian	et	al.	(2013)	and	Hussain	et	al.	(2015)	(section	7.2)	previously	superimposed	
human	osteosarcoma	cell	lines;	SaoS2	(p53	-/-)	and	U2OS	p53	+/+)	to	the	earlier	p53	
models;	PKT206	and	PMH260	respectively.	Good	predictive	ratios	were	obtained	of	
over	70	%	for	both.	As	we	have	generated	a	larger	model,	we	again	superimposed	
U2OS	cells	treated	with	etoposide	and	untreated	to	PMH302	to	explore	and	compare	
the	predictive	ratios	of	the	larger	model.		203	genes	were	filtered	from	U2OS	
expression	profiles	and	compared	to	the	302	model	using	the	same	formula	as	
described	by	Christensen	et	al.	(2009).		Correct	predictions	remained	the	same	as	
previously	obtained	for	PMH260	of	141	(70	%),	similarly	small	errors	were	in	the	
minority	(1	%).	Total	number	and	percentage	of	predictions	are	summarised	in	table	
7.3.4.1.	
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Table	7.3.4.1	Correct	predictions	for	superimposition	of	U2OS	(p53	+/+)	gene	expression	
profiles	to	in	silico	LSSA	results	of	PMH302.	Identical	microarray	profiles	of	human	
osteosarcoma	cell	lines	compared	against	PKT206	and	PMH260	were	again	superimposed	to	
the	larger	model	-	PMH302.		The	same	prediction	ratios	were	obtained	as	those	derived	from	
PMH260.	Total	number	and	percentages	are	shown.		
Experimental	condition	 in	silico	condition	 Correct	 Small	error	 Large	error	
U2OS	cells	treated	with	
etoposide	vs.	U2OS	cells	
untreated		
p53	wild	type	with	
DNA	damage	ON	vs.	
p53	wild	type	with	
DNA	damage	OFF	
142	(70	%)	 59	(29	%)	 2	(1	%)	
	
	
7.3.4.2	Superimposition	of	mesothelioma	in	vitro	transcriptome	data	to	the	PMH302	
model	
For	comparison	to	in	vitro	data,	microarray	profiles	of	human	Mero-14	malignant	
mesothelioma	cell	lines	treated	under	a	hypoxic	environment	of	1	%	oxygen	(24	h)	and	
DNA	damage	conditions	with	10	µM	etoposide	(24	h)	and	a	control	of	untreated	(37	⁰	C	
with	5%	CO2)	were	superimposed	against	PMH302.	Using	these	in	vitro	conditions	to	
compare	in	silico	results	derived	from	the	LSSA,	the	in	silico	hypoxia	and	DNA	damage	
input	was	switched	‘ON’	to	mimic	conditions	of	cells	treated	with	hypoxia	or	etoposide,	
and	‘OFF’	to	mimic	cells	untreated.		No	p53	knockout	scenario	was	generated	as	no	p53	
null	cell	lines	were	used	to	create	a	p53	wild	type	vs.	p53	knockout	scenario.		
	
Log	fold	changes	of	>1.5,	<-1.5	and	P	values	of	<	0.05	were	used	to	obtain	significantly	
differentially	expressed	genes	from	mesothelioma	gene	expression	profiles	using	
Affymetrix	expression	platform.	Simulations	for	experimental	comparisons	were	
undertaken	in	the	Affymetrix	expression	platform	and	also	Bioconductor,	available	in	R	
with	the	kind	help	of	Dr	Tian	for	Bioconductor.	From	these	profiles,	247	genes	were	
described	for	hypoxia	and	210	genes	for	etoposide	in	the	302	model.		
	
The	total	number	of	correct	predictions,	small	and	large	errors	are	summarised	in	table	
7.3.4.2	and	their	percentages	in	figure	7.3.2.	Correct	predictions	were	in	the	majority	
globally	(see	lanes	1-3	figure	7.3.2)	with	an	average	of	75.5	%	when	considering	all	3	
scenarios.	For	the	simulation	of	mesothelioma	cells	treated	with	10	µM	etoposide	vs.	
cells	untreated	a	total	of	144	correct	predictions,	(68.5	%)	were	obtained	with	64	small	
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errors	(30.5	%).	Large	errors	occupied	the	minority	of	all	these	predictions	comprising	a	
total	number	of	2	(1	%).		The	greatest	number	of	correct	predictions	were	obtained	for	
hypoxia	simulations,	with	a	total	of	175	predictions	correctly	predicted	(83	%)	from	the	
total	210	genes	analysed	in	mesothelioma	cells	treated	with	10	µM	etoposide	vs.	cells	
under	1	%	O2.	No	large	errors	were	obtained	for	this	simulation.	184	(75%)	correct	
predictions	were	obtained	from	cells	under	hypoxic	conditions	vs.	cells	untreated	from	
the	total	247	genes	analysed	(table	7.3.4.2).		
	
Concerning	the	experimental	data,	the	differential	gene	expression	of	malignant	
mesothelioma	cells	untreated	and	treated	with	1	%	02	and	10	µM	etoposide	for	24	h	
were	further	explored	in	accordance	with	the	formula	described	by	Christensen	et	al.	
(2009)	(table	7.3.4.3).	In	general,	the	majority	of	genes	across	the	three	conditions	
remained	unchanged	in	response	these	conditions.		
	
	
Table.	7.3.4.2	Total	number	of	correct,	small	and	large	error	predictions	from	
superimposition	of	mesothelioma	‘omics’	data	to	PMH302	interactome.	Three	outcomes	are	
possible	in	accordance	with	Christensen	et	al.	(2009)	Correct,	small	error	and	large	error.		
Experimental	to	in	silico	comparison		 Predictions	
	 	 Correct	
Small	
error	
Large	
error	
In	vitro	condition	 in	silico	simulation	 Total	number	
Cells	treated	with	etoposide	vs	cells	
untreated		
DNA	damage	ON	vs.	
DNA	damage	OFF	 144	 64	 2	
Cells	treated	with	hypoxia	vs.	cells	
untreated	
Hypoxia	ON	vs.	hypoxia	
OFF	 184	 61	 2	
Cells	treated	with	etoposide	vs	cells	
treated	with	hypoxia	
DNA	damage	ON	vs.	
hypoxia	ON	 175	 35	 0	
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Figure	7.3.2	Percentage	of	correct,	small	and	large	error	predictions	between	in	vitro	and	in	
silico	data	in	PMH302.	Gene	expression	profiles	of	malignant	mesothelioma	cell	lines	
untreated	and	treated	with	1	%	O2	and	10	µM	etoposide	(24	h)	were	superimposed	and	
compared	to	in	silico	LSSA	results.	Correct	predictions	were	in	the	majority	for	all	comparisons	
(see	lanes	1-3).	Percentage	data	labels	are	shown.		
	
	
Table	7.3.4.3	Global	list	of	genes	differentially	expressed	in	human	mesothelioma	cancer	cell	
lines	under	the	3	comparative	scenarios.	In	accordance	with	Christensen	et	al.	(2009),	three	
different	changes	were	possible;	1	=	upregulated,	-1	=	downregulated	or	0	=	unchanged	
comparing	in	vitro	data	to	in	silico	data.	Total	number	of	genes,	247	for	hypoxia	and	210	for	
DNA	damage	simulations.			
Experimental	condition	 Upregulated	 Downregulated	 No	change	
	
Total	number		
Mesothelioma	cells	treated	with	
etoposide	vs.	cells	untreated		 19	 23	 168	
	 AURKA	 ATF3	 APEX1	
	 BNIP3L	 BRCA1	 APP	
	 CA9	 CDKN1A	 ARID3A	
	 CCNB1	 DDX20	 ATM	
	 CDC20	 DKK1	 ATR	
	 COL18A1	 DUSP2	 AXIN1	
	 EPHB4	 EZH2	 BAIAP2L1	
	 FOS	 FAS	 BAK1	
	 KRT19	 FEN1	 BAX	
	 MGMT	 GADD45A	 BBC3	
	 MMP2	 JAG1	 BCCIP	
	 MYCN	 JUN	 BCL2	
	 PDGFRB	 KLF4	 BCL6	
	 PTEN	 MSH2	 BDKRB1	
	 PTTG1	 MUC1	 BHLHE40	
	 TP53BP1	 MYC	 CALD1	
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Prediction
DNA	damage	ON	vs	DNA	damage	OFF Hypoxia	On	vs.	hypoxia	OFF DNA	damage	ON	vs	hypoxia	ON
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	 WWOX	 PCNA	 CASP2	
	 YY1	 PDRG1	 CASP8	
	 ZNF148	 PTGS2	 CCAR1	
	 	 RFWD3	 CCND1	
	 	 SESN2	 CCNG1	
	 	 TLR3	 CD44	
	 	 TNFRSF10B	 CD58	
	 	 	 CD59	
	 	 	 CD82	
	 	 	 CDC25A	
	 	 	 CDK2	
	 	 	 CDK4	
	 	 	 CDKN1B	
	 	 	 CDKN2A	
	 	 	 CHEK1	
	 	 	 CHEK2	
	 	 	 CIAPIN1	
	 	 	 CKM	
	 	 	 CKS2	
	 	 	 CUL7	
	 	 	 CXCR4	
	 	 	 CYP24A1	
	 	 	 DAP	
	 	 	 DAXX	
	 	 	 DDB2	
	 	 	 DFNA5	
	 	 	 DNMT3A	
	 	 	 DUSP1	
	 	 	 DUSP4	
	 	 	 E2F1	
	 	 	 ECT2	
	 	 	 EDA2R	
	 	 	 EGFR	
	 	 	 EIF2AK2	
	 	 	 ELAVL1	
	 	 	 ERBB2	
	 	 	 ESR1	
	 	 	 FDXR	
	 	 	 FHL2	
	 	 	 FOXM1	
	 	 	 GAPDH	
	 	 	 GSTP1	
	 	 	 GTSE1	
	 	 	 H2AFZ	
	 336	
	 	 	 HDAC1	
	 	 	 HIC1	
	 	 	 HIF1A	
	 	 	 HIPK4	
	 	 	 HMMR	
	 	 	 HOXA10	
	 	 	 HOXA11	
	 	 	 HOXA5	
	 	 	 HSP90AB1	
	 	 	 HSPA4	
	 	 	 HTATIP2	
	 	 	 ICAM1	
	 	 	 ID3	
	 	 	 IER3	
	 	 	 IFITM2	
	 	 	 IFNA1	
	 	 	 IGF1R	
	 	 	 IGFBP7	
	 	 	 ING1	
	 	 	 ING2	
	 	 	 ING4	
	 	 	 ING5	
	 	 	 ISG15	
	 	 	 KAT2B	
	 	 	 KIF23	
	 	 	 LATS2	
	 	 	 LTF	
	 	 	 MAPK8	
	 	 	 MAPK9	
	 	 	 MCL1	
	 	 	 MDM4	
	 	 	 MMP1	
	 	 	 MMP13	
	 	 	 MTA1	
	 	 	 NCL	
	 	 	 NFKB2	
	 	 	 NLRC4	
	 	 	 NOTCH1	
	 	 	 NOV	
	 	 	 NQO1	
	 	 	 NR2C1	
	 	 	 NTN1	
	 	 	 P53	
	 	 	 PADI4	
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	 	 	 PARK2	
	 	 	 PCBP4	
	 	 	 PERP	
	 	 	 PHB	
	 	 	 PHF20	
	 	 	 PIAS2	
	 	 	 PIN1	
	 	 	 PITX1	
	 	 	 PLA2G6	
	 	 	 PLAUR	
	 	 	 PML	
	 	 	 PPARG	
	 	 	 PPM1A	
	 	 	 PPM1D	
	 	 	 PRC1	
	 	 	 PRKAB1	
	 	 	 PRKCA	
	 	 	 PRKD1	
	 	 	 PRKG1	
	 	 	 PSEN1	
	 	 	 PSMD10	
	 	 	 RAF1	
	 	 	 RB1CC1	
	 	 	 RGS16	
	 	 	 RPA1	
	 	 	 RPRM	
	 	 	 RPS27L	
	 	 	 RREB1	
	 	 	 RRM2B	
	 	 	 S100A2	
	 	 	 S100A6	
	 	 	 S100B	
	 	 	 SERPINB5	
	 	 	 SERPINF1	
	 	 	 SFN	
	 	 	 SIAH1	
	 	 	 SIVA1	
	 	 	 SKIL	
	 	 	 SLC6A6	
	 	 	 SMYD2	
	 	 	 SOD1	
	 	 	 SOD2	
	 	 	 SOX4	
	 	 	 STAT3	
	 338	
	 	 	 STMN1	
	 	 	 SUB1	
	 	 	 SUMO3	
	 	 	 TFAP2A	
	 	 	 TFAP2C	
	 	 	 TFDP1	
	 	 	 TGFA	
	 	 	 TGFB1	
	 	 	 THBS1	
	 	 	 TNFRSF10
A	
	 	 	 TP53I13	
	 	 	 TP53INP1	
	 	 	 TP53RK	
	 	 	 UBE2A	
	 	 	 UBE3A	
	 	 	 UCHL1	
	 	 	 UNC5A	
	 	 	 WRN	
	 	 	 ZMAT3	
	 	 	 ZMIZ2	
Mesothelioma	cells	treated	with	
hypoxia	vs.	cells	untreated		
Upregulated	 Downregulated	 No	change	
	 24	 28	 195	
	 ABCC1	 ATF3	 AIMP2	
	 AIFM2	 BBC3	 APAF1	
	 APEX1	 CDK2	 APP	
	 AURKA	 CDKN1A	 AR	
	 CCNB1	 CXCR4	 ARID3A	
	 CD82	 DDX5	 ATM	
	 COL18A1	 DKK1	 ATR	
	 HIF1A	 DUSP2	 AXIN1	
	 HIPK2	 DUSP5	 BAIAP2L1	
	 IFITM2	 EZH2	 BAK1	
	 KAT2B	 FEN1	 BAX	
	 KRT19	 FHL2	 BCCIP	
	 MGMT	 GADD45A	 BCL2	
	 MYCN	 ID3	 BCL3	
	 NME1	 IER3	 BCL6	
	 NQO1	 ING2	 BDKRB1	
	 NTN1	 JUN	 BNIP3L	
	 PDGFRB	 KLF4	 BRCA1	
	 PRKCA	 MYC	 CA9	
	 PRKD1	 PPM1D	 CALD1	
	 PRKDC	 RECQL4	 CASP2	
	 339	
	 PTEN	 SESN2	 CASP8	
	 TLR3	 TFAP2C	 CCAR1	
	 WWOX	 TGFB1	 CCND1	
	 	 TP53INP1	 CCNG1	
	 	 VEGFA	 CD44	
	 	 BHLHE40	 CD58	
	 	 GDF15	 CD59	
	 	 	 CDC20	
	 	 	 CDC25A	
	 	 	 CDK4	
	 	 	 CDK5	
	 	 	 CDK9	
	 	 	 CDKN1B	
	 	 	 CDKN2A	
	 	 	 CHEK1	
	 	 	 CHEK2	
	 	 	 CIAPIN1	
	 	 	 CKM	
	 	 	 CKS2	
	 	 	 CUL7	
	 	 	 CYP24A1	
	 	 	 DAP	
	 	 	 DAXX	
	 	 	 DDB2	
	 	 	 DDIT4	
	 	 	 DDX20	
	 	 	 DNMT3A	
	 	 	 DUSP1	
	 	 	 DUSP4	
	 	 	 E2F1	
	 	 	 ECT2	
	 	 	 EDA2R	
	 	 	 EGFR	
	 	 	 EIF2AK2	
	 	 	 ELAVL1	
	 	 	 EPHB4	
	 	 	 ERBB2	
	 	 	 ESR1	
	 	 	 FAS	
	 	 	 FDXR	
	 	 	 FGF2	
	 	 	 FLI1	
	 	 	 FOS	
	 	 	 FOXM1	
	 340	
	 	 	 GAPDH	
	 	 	 GSTP1	
	 	 	 GTSE1	
	 	 	 H2AFZ	
	 	 	 HDAC1	
	 	 	 HIC1	
	 	 	 HIPK4	
	 	 	 HMMR	
	 	 	 HOXA10	
	 	 	 HOXA11	
	 	 	 HOXA5	
	 	 	 HSP90AB1	
	 	 	 HSPA4	
	 	 	 HTATIP2	
	 	 	 ICAM1	
	 	 	 IFI16	
	 	 	 IFNA1	
	 	 	 IGF1R	
	 	 	 IGFBP1	
	 	 	 IGFBP7	
	 	 	 IL6	
	 	 	 ING1	
	 	 	 ING4	
	 	 	 ING5	
	 	 	 IQCB1	
	 	 	 ISG15	
	 	 	 JAG1	
	 	 	 KIF23	
	 	 	 KLK3	
	 	 	 KRT8	
	 	 	 LATS2	
	 	 	 LTF	
	 	 	 MAP4K4	
	 	 	 MAPK1	
	 	 	 MAPK14	
	 	 	 MAPK8	
	 	 	 MAPK9	
	 	 	 MCL1	
	 	 	 MDM2	
	 	 	 MDM4	
	 	 	 MMP1	
	 	 	 MMP13	
	 	 	 MMP2	
	 	 	 MSH2	
	 341	
	 	 	 MTA1	
	 	 	 MTA2	
	 	 	 NCL	
	 	 	 NFKB2	
	 	 	 NLRC4	
	 	 	 NOTCH1	
	 	 	 NOV	
	 	 	 NR2C1	
	 	 	 PADI4	
	 	 	 PARK2	
	 	 	 PCBP4	
	 	 	 PCNA	
	 	 	 PDRG1	
	 	 	 PEG3	
	 	 	 PERP	
	 	 	 PHB	
	 	 	 PHF20	
	 	 	 PIAS1	
	 	 	 PIAS2	
	 	 	 PIN1	
	 	 	 PITX1	
	 	 	 PLA2G6	
	 	 	 PLAUR	
	 	 	 PML	
	 	 	 POU4F1	
	 	 	 PPARG	
	 	 	 PPM1A	
	 	 	 PRC1	
	 	 	 PRKAB1	
	 	 	 PRKG1	
	 	 	 PRSS50	
	 	 	 PSEN1	
	 	 	 PSMD10	
	 	 	 PTGS2	
	 	 	 PTTG1	
	 	 	 RAF1	
	 	 	 RB1CC1	
	 	 	 RFWD3	
	 	 	 RGS16	
	 	 	 RPA1	
	 	 	 RPRM	
	 	 	 RPS27L	
	 	 	 RREB1	
	 	 	 RRM2B	
	 342	
	 	 	 S100A2	
	 	 	 S100A6	
	 	 	 S100B	
	 	 	 SEMA3B	
	 	 	 SENP3	
	 	 	 SERPINB5	
	 	 	 SERPINF1	
	 	 	 SFN	
	 	 	 SIAH1	
	 	 	 SIVA1	
	 	 	 SKIL	
	 	 	 SLC2A1	
	 	 	 SLC2A4	
	 	 	 SLC6A6	
	 	 	 SMYD2	
	 	 	 SOD1	
	 	 	 SOD2	
	 	 	 STAT3	
	 	 	 STMN1	
	 	 	 SUB1	
	 	 	 SUMO2	
	 	 	 SUMO3	
	 	 	 TFAP2A	
	 	 	 TFDP1	
	 	 	 TGFA	
	 	 	 THBS1	
	 	 	 TNFRSF10
A	
	 	 	 TNFRSF10
B	
	 	 	 TOP2A	
	 	 	 TP53	
	 	 	 TP53BP1	
	 	 	 TP53I13	
	 	 	 TP53RK	
	 	 	 UBE2A	
	 	 	 UBE3A	
	 	 	 UCHL1	
	 	 	 UNC5A	
	 	 	 WRN	
	 	 	 YY1	
	 	 	 ZMAT3	
	 	 	 ZMIZ2	
	 	 	 ZNF148	
	 343	
Mesothelioma	cells	treated	with	
etoposide	vs.	cells	treated	with	hypoxia		
Upregulated	 Downregulated	 No	change	
	 0	 2	 208	
	 	 BCL2	 APEX1	
	 	 PPARG	 APP	
	 	 	 ARID3A	
	 	 	 ATF3	
	 	 	 ATM	
	 	 	 ATR	
	 	 	 AURKA	
	 	 	 AXIN1	
	 	 	 BAIAP2L1	
	 	 	 BAK1	
	 	 	 BAX	
	 	 	 BBC3	
	 	 	 BCCIP	
	 	 	 BCL6	
	 	 	 BDKRB1	
	 	 	 BNIP3L	
	 	 	 BRCA1	
	 	 	 CA9	
	 	 	 CALD1	
	 	 	 CASP2	
	 	 	 CASP8	
	 	 	 CCAR1	
	 	 	 CCNB1	
	 	 	 CCND1	
	 	 	 CCNG1	
	 	 	 CD44	
	 	 	 CD58	
	 	 	 CD59	
	 	 	 CD82	
	 	 	 CDC20	
	 	 	 CDC25A	
	 	 	 CDK2	
	 	 	 CDK4	
	 	 	 CDKN1A	
	 	 	 CDKN1B	
	 	 	 CDKN2A	
	 	 	 CHEK1	
	 	 	 CHEK2	
	 	 	 CIAPIN1	
	 	 	 CKM	
	 	 	 CKS2	
	 	 	 COL18A1	
	 344	
	 	 	 CUL7	
	 	 	 CXCR4	
	 	 	 CYP24A1	
	 	 	 DAP	
	 	 	 DAXX	
	 	 	 DDB2	
	 	 	 DDX20	
	 	 	 DFNA5	
	 	 	 DKK1	
	 	 	 DNMT3A	
	 	 	 DUSP1	
	 	 	 DUSP2	
	 	 	 DUSP4	
	 	 	 E2F1	
	 	 	 ECT2	
	 	 	 EDA2R	
	 	 	 EGFR	
	 	 	 EIF2AK2	
	 	 	 ELAVL1	
	 	 	 EPHB4	
	 	 	 ERBB2	
	 	 	 ESR1	
	 	 	 EZH2	
	 	 	 FAS	
	 	 	 FDXR	
	 	 	 FEN1	
	 	 	 FHL2	
	 	 	 FOS	
	 	 	 FOXM1	
	 	 	 GADD45A	
	 	 	 GAPDH	
	 	 	 GSTP1	
	 	 	 GTSE1	
	 	 	 H2AFZ	
	 	 	 HDAC1	
	 	 	 HIC1	
	 	 	 HIF1A	
	 	 	 HIPK4	
	 	 	 HMMR	
	 	 	 HOXA10	
	 	 	 HOXA11	
	 	 	 HOXA5	
	 	 	 HSP90AB1	
	 	 	 HSPA4	
	 345	
	 	 	 HTATIP2	
	 	 	 ICAM1	
	 	 	 ID3	
	 	 	 IER3	
	 	 	 IFITM2	
	 	 	 IFNA1	
	 	 	 IGF1R	
	 	 	 IGFBP7	
	 	 	 ING1	
	 	 	 ING2	
	 	 	 ING4	
	 	 	 ING5	
	 	 	 ISG15	
	 	 	 JAG1	
	 	 	 JUN	
	 	 	 KAT2B	
	 	 	 KIF23	
	 	 	 KLF4	
	 	 	 KRT19	
	 	 	 LATS2	
	 	 	 LTF	
	 	 	 MAPK8	
	 	 	 MAPK9	
	 	 	 MCL1	
	 	 	 MDM4	
	 	 	 MGMT	
	 	 	 MMP1	
	 	 	 MMP13	
	 	 	 MMP2	
	 	 	 MSH2	
	 	 	 MTA1	
	 	 	 MYC	
	 	 	 MYCN	
	 	 	 NCL	
	 	 	 NFKB2	
	 	 	 NLRC4	
	 	 	 NOTCH1	
	 	 	 NOV	
	 	 	 NQO1	
	 	 	 NR2C1	
	 	 	 NTN1	
	 	 	 PADI4	
	 	 	 PARK2	
	 	 	 PCBP4	
	 346	
	 	 	 PCNA	
	 	 	 PDGFRB	
	 	 	 PDRG1	
	 	 	 PERP	
	 	 	 PHB	
	 	 	 PHF20	
	 	 	 PIAS2	
	 	 	 PIN1	
	 	 	 PITX1	
	 	 	 PLA2G6	
	 	 	 PLAUR	
	 	 	 PML	
	 	 	 PPM1A	
	 	 	 PPM1D	
	 	 	 PRC1	
	 	 	 PRKAB1	
	 	 	 PRKCA	
	 	 	 PRKD1	
	 	 	 PRKG1	
	 	 	 PSEN1	
	 	 	 PSMD10	
	 	 	 PTEN	
	 	 	 PTGS2	
	 	 	 PTTG1	
	 	 	 RAF1	
	 	 	 RB1CC1	
	 	 	 RFWD3	
	 	 	 RGS16	
	 	 	 RPA1	
	 	 	 RPRM	
	 	 	 RPS27L	
	 	 	 RREB1	
	 	 	 RRM2B	
	 	 	 S100A2	
	 	 	 S100A6	
	 	 	 S100B	
	 	 	 SERPINB5	
	 	 	 SERPINF1	
	 	 	 SESN2	
	 	 	 SFN	
	 	 	 SIAH1	
	 	 	 SIVA1	
	 	 	 SKIL	
	 	 	 SLC6A6	
	 347	
	 	 	 SMYD2	
	 	 	 SOD1	
	 	 	 SOD2	
	 	 	 STAT3	
	 	 	 STMN1	
	 	 	 SUB1	
	 	 	 SUMO3	
	 	 	 TFAP2A	
	 	 	 TFAP2C	
	 	 	 TFDP1	
	 	 	 TGFA	
	 	 	 TGFB1	
	 	 	 THBS1	
	 	 	 TLR3	
	 	 	 TNFRSF10
A	
	 	 	 TNFRSF10
B	
	 	 	 TP53BP1	
	 	 	 TP53I13	
	 	 	 TP53INP1	
	 	 	 TP53RK	
	 	 	 UBE2A	
	 	 	 UBE3A	
	 	 	 UCHL1	
	 	 	 UNC5A	
	 	 	 WRN	
	 	 	 WWOX	
	 	 	 YY1	
	 	 	 ZMAT3	
	 	 	 ZMIZ2	
	 	 	 ZNF148	
	 	 	 BHLHE40	
	 	 	 MUC1	
	 	 	 P53	
	 	 	 SOX4	
	
	
	
	
